title,datetime,impact_score,sentiment,summary,article
Motorola Solutions Joins Forces with Google Cloud to Advance Safety and Security,2024-02-18T22:47:00.000Z,Low,Positive,"Motorola Solutions (NYSE: MSI) partners with Google Cloud to enhance safety and security technologies through assistive intelligence, video content delivery, mapping, and AI capabilities. The collaboration aims to make safety and security more accessible and actionable by leveraging sensors, data, and AI.","Motorola Solutions Joins Forces with Google Cloud to Advance Safety and Security Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary Motorola Solutions (NYSE: MSI) partners with Google Cloud to enhance safety and security technologies through assistive intelligence, video content delivery, mapping, and AI capabilities. The collaboration aims to make safety and security more accessible and actionable by leveraging sensors, data, and AI. Positive None. Negative None. Technology Analyst The strategic partnership between Motorola Solutions and Google Cloud represents a significant development in the realm of public safety and enterprise security technology. By utilizing Google Cloud's robust infrastructure, Motorola Solutions is positioning itself to enhance its assistive intelligence capabilities. This includes the delivery of high-quality video content, improved mapping and advanced AI features. The integration of these technologies aims to address the increasing demand for sophisticated safety solutions in real-time scenarios.From an industry perspective, the collaboration underscores a growing trend where traditional hardware-focused companies are shifting towards cloud-based services. This transition allows for the leveraging of big data analytics and AI to provide more proactive and predictive security solutions. The partnership also indicates a competitive response to the market's demand for innovative and integrated security solutions.For stakeholders, the immediate benefit lies in the potential for enhanced security products that could lead to increased market share and customer satisfaction for Motorola Solutions. Over the long term, the reliance on Google Cloud's infrastructure could yield cost efficiencies and scalability benefits. However, the success of this initiative will largely depend on the seamless integration of Google's AI capabilities with Motorola's existing security systems and the ability to deliver on the promised advancements without compromising data privacy and security. Market Analyst The announcement is noteworthy for investors as it signals Motorola Solutions' commitment to innovation and growth within the cloud security sector. The partnership with a tech giant like Google provides Motorola with a competitive edge in terms of technological advancement and could potentially open up new revenue streams. The focus on cloud-native solutions like Avigilon Alta indicates a strategic pivot towards subscription-based models, which can provide a more predictable and stable source of revenue compared to one-time hardware sales.Investors should monitor the adoption rate of these cloud-based solutions and the impact on Motorola's financials. The market for enterprise security is vast and Motorola's ability to capture a larger market share through these innovations could positively influence its stock performance. However, it's important to consider the investment required for such a technological shift and whether the returns justify the expenditure. Additionally, the collaboration with Google Cloud could also lead to concerns regarding vendor lock-in and the implications it may have on Motorola's operational flexibility. Cybersecurity Expert From a cybersecurity standpoint, the partnership has the potential to significantly enhance the security posture of organizations by providing advanced tools for threat detection and response. The application of AI in security systems can lead to more effective identification of anomalies and potential threats. However, the increased reliance on cloud infrastructure and AI also introduces new challenges and risks, particularly in terms of data privacy and vulnerability to cyberattacks.It is crucial for Motorola Solutions to ensure that their cloud-based solutions adhere to stringent cybersecurity standards to protect sensitive data. The collaboration with Google Cloud, which has substantial expertise and resources in managing cloud security, could be advantageous in this regard. Nevertheless, customers and stakeholders will expect transparency regarding how data is handled and the measures in place to safeguard against breaches. The effectiveness of these security measures will be a determining factor in the success of the partnership and the trustworthiness of the solutions provided. 02/18/2024 - 05:47 PM Motorola Solutions to leverage Google Cloud to help accelerate innovation for public safety and enterprise security CHICAGO & SUNNYVALE, Calif.--(BUSINESS WIRE)-- Motorola Solutions (NYSE: MSI) and Google Cloud today announced a strategic, multi-year agreement that will focus on innovating cloud solutions across Motorola Solutions’ safety and security technologies. With Google Cloud’s infrastructure, Motorola Solutions will prioritize the advancement of assistive intelligence, including highly accurate and reliable video content delivery, mapping and AI capabilities, to help address real-world safety challenges. “From communities to businesses, our customers rely on us to help create a safer future,” said Mahesh Saptharishi, executive vice president and chief technology officer of Motorola Solutions. “This collaboration will leverage the power of sensors, data and AI to help make safety and security more accessible and actionable.” Motorola Solutions expects to deploy the newly developed capabilities across its rapidly growing cloud security solutions, including Avigilon Alta, an entirely cloud-native video suite that enables enterprise security for organizations of all sizes. “Whether it’s enabling better protection for schools, identifying unusual activity at businesses or more effectively securing large-scale events, real-time visibility and awareness are foundational for both public safety and enterprise security outcomes,” Saptharishi said. “Motorola Solutions has long demonstrated leadership in innovating the technologies that safeguard communities and enterprises,“ said Will Grannis, vice president and chief technology officer of Google Cloud. “Together we will channel our latest cloud advancements to support Motorola Solutions’ sharpened focus on safety and security innovations via the cloud.” About Motorola Solutions Motorola Solutions is solving for safer. We build and connect technologies to help protect people, property and places. Our solutions enable the collaboration between public safety agencies and enterprises that’s critical for a proactive approach to safety and security. Learn more about how we’re solving for safer communities, safer schools, safer hospitals, safer businesses – safer everywhere – at www.motorolasolutions.com. Motorola Solutions Forward-Looking Statements This press release contains ""forward-looking statements"" within the meaning of applicable federal securities law. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and generally include words such as “believes,” “expects,” “intends,” “anticipates,” “estimates” and similar expressions. The company can give no assurance that any actual or future results or events discussed in these statements will be achieved. Any forward-looking statements represent the company’s views only as of today and should not be relied upon as representing the company’s views as of any subsequent date. Readers are cautioned that such forward-looking statements are subject to a variety of risks and uncertainties that could cause the company’s actual results or events discussed in these statements to differ materially from the statements contained in this release. Such forward-looking statements include, but are not limited to, the growth of our video cloud solutions and the ability to develop and deploy new capabilities across our products. Motorola Solutions cautions the reader that the risks and uncertainties below, as well as those in Part I Item 1A of Motorola Solutions’ 2022 Annual Report on Form 10-K, Part II Item 1A of Motorola Solutions’ 2023 Third Quarter Report on Form 10-Q and in its other SEC filings available for free on the SEC’s website at www.sec.gov and on Motorola Solutions’ website at www.motorolasolutions.com, could cause Motorola Solutions’ actual results or events discussed in these statements to differ materially from those estimated or predicted in the forward-looking statements. Many of these risks and uncertainties cannot be controlled by Motorola Solutions and factors that may impact forward-looking statements include, but are not limited to, Motorola Solutions’ ability to successfully leverage Google’s cloud infrastructure to accelerate innovation and deploy any new capabilities. Motorola Solutions undertakes no obligation to publicly update any forward-looking statement or risk factor, whether as a result of new information, future events or otherwise. About Google Cloud Google Cloud accelerates every organization's ability to digitally transform its business and industry. We deliver enterprise-grade solutions that leverage Google's cutting-edge technology, and tools that help developers build more sustainably. Customers in more than 200 countries and territories turn to Google Cloud as their trusted partner to enable growth and solve their most critical business problems. View source version on businesswire.com: https://www.businesswire.com/news/home/20240218667089/en/ Media Contact Rebecca Benson rebecca.benson@motorolasolutions.com +1 312-919-1645 Google Cloud Media Contact press@google.com Source: Motorola Solutions What is the partnership between Motorola Solutions and Google Cloud about? The partnership focuses on innovating cloud solutions across Motorola Solutions’ safety and security technologies, prioritizing the advancement of assistive intelligence, video content delivery, mapping, and AI capabilities. What are the key areas of innovation in the collaboration between Motorola Solutions and Google Cloud? The collaboration aims to enhance safety and security through highly accurate and reliable video content delivery, mapping, and AI capabilities to address real-world safety challenges. Which cloud solutions will Motorola Solutions deploy the newly developed capabilities in? Motorola Solutions expects to deploy the newly developed capabilities across its rapidly growing cloud security solutions, including Avigilon Alta, a cloud-native video suite. How will the partnership benefit public safety and enterprise security? The collaboration will provide real-time visibility and awareness to enable better protection for schools, identify unusual activity at businesses, and more effectively secure large-scale events."
Media Alert: BrainChip CEO Hosts Virtual Investor Roadshow,2024-02-18T22:30:00.000Z,Low,Positive,"BrainChip Holdings Ltd (BRCHF) announces a Virtual Investor Roadshow on February 26, 3 p.m. PST, hosted by CEO Sean Hehir. The event aims to update investors on the company's commercial strategy, recent achievements, and upcoming product rollouts. Shareholders can participate by pre-registering at the provided link.","Media Alert: BrainChip CEO Hosts Virtual Investor Roadshow Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary BrainChip Holdings Ltd (BRCHF) announces a Virtual Investor Roadshow on February 26, 3 p.m. PST, hosted by CEO Sean Hehir. The event aims to update investors on the company's commercial strategy, recent achievements, and upcoming product rollouts. Shareholders can participate by pre-registering at the provided link. Positive None. Negative None. 02/18/2024 - 05:30 PM LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI IP, invites current and potential investors to participate in a Virtual Investor Roadshow February 26 at 3 p.m. PST. Those wishing to participate in the event are required to pre-register at https://my.eu.lumiconnect.com/279287038 BrainChip CEO Sean Hehir will serve as the host of the 1-hour presentation. Among the topics planned for discussion are: Update on the execution of the Company’s commercial strategy, Recap of the recent CES2024 event in Las Vegas where BrainChip demonstrated some of its next-generation neuromorphic technology products, Video showcase of some of those product demonstrations, Discussion of upcoming neuromorphic product rollouts, Q&A session with shareholders. “BrainChip is constantly looking for creative ways to keep our shareholders informed of our strategy, operations, and recent achievements. While we already provide ASX announcements, quarterly filings, and many forms of PR via social media, we are now adding this Virtual Investor Roadshow to our shareholder communications efforts,” said Hehir. “After attending this virtual event, our shareholders should have a deeper understanding of the market opportunity and why BrainChip is uniquely positioned to capitalize on the market. I look forward to meeting virtually with our shareholders and taking as many questions as possible.” Those interested in learning more about how BrainChip is proving that on-chip AI, close to the sensor, is the future for its customers’ products and that planet are invited to the company’s library of investment tools at https://investors.brainchip.com/ About BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY) BrainChip is the worldwide leader in Edge AI on-chip processing and learning. The company’s first-to-market, fully digital, event-based AI processor, AkidaTM, uses neuromorphic principles to mimic the human brain, analyzing only essential sensor inputs at the point of acquisition, processing data with unparalleled efficiency, precision, and economy of energy. Akida uniquely enables Edge learning local to the chip, independent of the cloud, dramatically reducing latency while improving privacy and data security. Akida Neural processor IP, which can be integrated into SoCs on any process technology, has shown substantial benefits on today’s workloads and networks, and offers a platform for developers to create, tune and run their models using standard AI workflows like Tensorflow/Keras. In enabling effective Edge compute to be universally deployable across real world applications such as connected cars, consumer electronics, and industrial IoT, BrainChip is proving that on-chip AI, close to the sensor, is the future, for its customers’ products, as well as the planet. Explore the benefits of Essential AI at www.brainchip.com. Follow BrainChip on Twitter: https://www.twitter.com/BrainChip_inc Follow BrainChip on LinkedIn: https://www.linkedin.com/company/7792006 View source version on businesswire.com: https://www.businesswire.com/news/home/20240218683452/en/ Media Contact: Mark Smith JPR Communications 818-398-1424 Investor Relations: Tony Dawe Director, Global Investor Relations tdawe@brainchip.com Source: BrainChip Holdings Ltd When is BrainChip Holdings Ltd hosting the Virtual Investor Roadshow? BrainChip Holdings Ltd is hosting the Virtual Investor Roadshow on February 26 at 3 p.m. PST. Who will be hosting the Virtual Investor Roadshow? CEO Sean Hehir will serve as the host of the 1-hour presentation during the Virtual Investor Roadshow. How can investors participate in the Virtual Investor Roadshow? Investors can participate in the Virtual Investor Roadshow by pre-registering at https://my.eu.lumiconnect.com/279287038 What topics are planned for discussion during the Virtual Investor Roadshow? The topics planned for discussion during the Virtual Investor Roadshow include an update on the company's commercial strategy, a recap of the recent CES2024 event, upcoming product rollouts, and a Q&A session with shareholders. Why is BrainChip Holdings Ltd hosting the Virtual Investor Roadshow? BrainChip Holdings Ltd is hosting the Virtual Investor Roadshow to keep shareholders informed of the company's strategy, operations, recent achievements, and market opportunities."
Quhuo Limited Announces Change of Venue for 2023 Annual General Meeting,2024-02-18T03:00:00.000Z,Low,Very Positive,"Quhuo Limited changes venue for upcoming annual general meeting of shareholders in Beijing, China.","Quhuo Limited Announces Change of Venue for 2023 Annual General Meeting Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Quhuo Limited changes venue for upcoming annual general meeting of shareholders in Beijing, China. Positive None. Negative None. 02/17/2024 - 10:00 PM BEIJING, Feb. 17, 2024 /PRNewswire/ -- Quhuo Limited (""Quhuo"" or the ""Company"") (NASDAQ: QH), a leading gig economy platform focusing on local life services in China, announces a change of venue for its upcoming annual general meeting of shareholders scheduled to be held on February 19, 2024. The location of the meeting will now be changed to 3F, Building A, Xin'anmen, No. 1 South Bank, Huihe South Street, Chaoyang District, Beijing 100020, The People's Republic of China. As previously published, the meeting will be held at 10:00 a.m. (local time) on February 19, 2024. About Quhuo Quhuo Limited (NASDAQ: QH) is a leading economy platform focusing on local life services in China. Leveraging Quhuo+, its proprietary technology infrastructure, Quhuo is dedicated to empowering and linking workers and local life service providers and providing end-to-end operation solutions for the life service market. The Company currently provides multiple industry-tailored operational solutions, primarily including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services, meeting the living needs of hundreds of millions of families in the communities. With the vision of promoting employment, stabilizing income and empowering entrepreneurship, Quhuo explores multiple scenarios to promote employment of workers, provides, among others, safety and security and vocational training to protect workers, and helps workers plan their career development paths to realize their self-worth. For more information about Quhuo, please visit https://ir.quhuo.cn/. View original content:https://www.prnewswire.com/news-releases/quhuo-limited-announces-change-of-venue-for-2023-annual-general-meeting-302064655.html SOURCE Quhuo Limited Where is Quhuo Limited's upcoming annual general meeting of shareholders being held? Quhuo Limited's upcoming annual general meeting of shareholders is now being held at 3F, Building A, Xin'anmen, No. 1 South Bank, Huihe South Street, Chaoyang District, Beijing 100020, The People's Republic of China. When is Quhuo Limited's upcoming annual general meeting of shareholders scheduled? Quhuo Limited's upcoming annual general meeting of shareholders is scheduled to be held at 10:00 a.m. (local time) on February 19, 2024."
Cessna Grand Caravan EX Amphibian extends reach in Southeast Asia with delivery in Malaysia,2024-02-18T00:00:00.000Z,Low,Neutral,"Textron Aviation delivers a Cessna Grand Caravan EX Amphibian turboprop to Malaysian developer Ikhasas Sdn Bhd for passenger transport to Perhentian Islands. The aircraft, managed by SAS, marks Malaysia's first amphibious plane operation. Textron Inc. subsidiary, Textron Aviation, highlights the aircraft's efficiency and suitability for sustainable tourism in Malaysia.","Cessna Grand Caravan EX Amphibian extends reach in Southeast Asia with delivery in Malaysia Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Textron Aviation delivers a Cessna Grand Caravan EX Amphibian turboprop to Malaysian developer Ikhasas Sdn Bhd for passenger transport to Perhentian Islands. The aircraft, managed by SAS, marks Malaysia's first amphibious plane operation. Textron Inc. subsidiary, Textron Aviation, highlights the aircraft's efficiency and suitability for sustainable tourism in Malaysia. Positive None. Negative None. Market Research Analyst The introduction of the Cessna Grand Caravan EX Amphibian into Malaysia's domestic travel sector represents a significant development in regional transportation. The ability to connect the capital to remote tourist destinations without the need for traditional airport infrastructure could set a precedent for future transportation models in similar markets. By reducing travel time from a combined seven hours to a direct flight, the value proposition for tourists is substantially increased. This could result in a boost for the local tourism industry, potentially increasing demand for such services and encouraging competitors to consider similar investments.For Textron Aviation, capturing over 40% of Malaysia's general aviation aircraft market signifies a strong foothold. This strategic move may enhance their market share and brand presence in the Asia-Pacific region. The specific mention of the aircraft's environmental benefits aligns with growing global trends towards sustainable tourism, which may resonate with eco-conscious consumers and investors alike. Environmental Sustainability Analyst The emphasis on preserving the Perhentian Islands' natural environment by opting for an amphibious aircraft over constructing an airport is a noteworthy approach to sustainable development. The environmental impact of traditional airport construction can be substantial, often involving deforestation and disruption of local ecosystems. By choosing an aircraft that can land on water, Ikhasas Sdn Bhd demonstrates a commitment to minimizing ecological footprints, which could serve as a case study for other developers considering eco-friendly transportation solutions.The Grand Caravan EX Amphibian's role in supporting sustainable tourism initiatives is an example of how aviation technology can be leveraged to balance economic development with environmental stewardship. This approach could influence industry norms, encouraging other companies to adopt similar strategies and technologies that prioritize ecological considerations. Financial Analyst Textron Inc.'s (NYSE:TXT) delivery of its Cessna Grand Caravan EX Amphibian aircraft to a Malaysian property developer could have positive implications for the company's financial performance. The successful entry into a new operational niche—country's first amphibious airplane operation—may lead to increased sales in the region. Additionally, the diversification of the aircraft's use cases, including VIP transport, tourism and special missions, indicates a versatile revenue stream that can adapt to market demands.Investors should monitor the utilization rates and customer satisfaction of the new service, as these factors will be critical in determining the long-term success and profitability of this venture. A successful implementation could encourage further orders, not only in Malaysia but potentially in other countries with similar geographical and infrastructural challenges. 02/17/2024 - 07:00 PM WICHITA, Kan.--(BUSINESS WIRE)-- Textron Aviation today announced the delivery of a new Cessna Grand Caravan EX Amphibian turboprop to Malaysian property developer, Ikhasas Sdn Bhd, via its subsidiary company Oriental Sky Sdn Bhd. The aircraft, to be managed and operated by local charter operator Systematic Aviation Services (SAS), will be used for passenger transport between the capital city of Kuala Lumpur and a new waterfront resort on Perhentian islands, off the northern east coast of Malaysia. This will be the country’s first amphibious airplane operation in recent history after it gained necessary approvals from the Civil Aviation Authority of Malaysia to launch domestic operations in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216837400/en/Oriental Sky’s Grand Caravan EX Amphibian (Photo: Business Wire) The Cessna Grand Caravan EX Amphibian is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Ikhasas group managing director, Ir. Tan Chee Kian, said, “Seaplanes will be the most convenient way to reach the Perhentian Islands. Currently, it takes a time-consuming 6-hour road journey followed by a one-hour ferry ride from the port in Kuala Besut. With our 11-seater aircraft, travelers will benefit from time savings as it will transport passengers from Kuala Lumpur to land directly in the waters near the beachside resort. At the same time, we preserve the islands’ pristine environment and natural forests which would otherwise be felled for airport construction.” “We are honored for Grand Caravan EX Amphibian to be selected. The versatility and excellent operating economics make it the perfect partner for Ikhasas to develop sustainable tourism. The comfortable cabin, large windows for sightseeing, and floats allowing it to take off and land anywhere are ideal for their missions,” said Tony Jones, vice president, International Sales (Asia-Pacific). “Malaysia is also an important market to Textron Aviation. Our products lead the installed base and make up over 40% of the country’s general aviation aircraft. Our customers in Malaysia use our products for a variety of operations including VIP transport, tourism, as well as other special missions such as air ambulances, and skydiving.” About the Cessna Grand Caravan EX The Cessna Caravan platform has seen more than 3,000 aircraft delivered that are certified in 100 countries with nearly 24 million flight hours amassed worldwide since the aircraft was introduced. Caravans fulfill roles for multiple missions, ranging from flight training to recreation, commuter airlines to VIP transport, cargo carriers and humanitarian missions. The Grand Caravan EX aircraft is known for its dependable and efficient performance by regional airlines, charter operators, cargo carriers and special missions operators worldwide. The aircraft offers an impressive output of 867 horsepower and a rate of climb of 1,275 feet per minute. Endless Special Missions Possibilities When government, military and commercial customers want airborne solutions for critical missions, they turn to Textron Aviation. The company’s aviation solutions provide the high performance and flight characteristics required to address the unique challenges of special missions operations. With unparalleled quality, versatility and low operating costs, Textron Aviation products are chosen for air ambulance, ISR, utility transport, aerial survey, flight inspection, training and a number of other special operations. About Textron Aviation We inspire the journey of flight. For more than 95 years, Textron Aviation has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special missions, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight. For more information, visit www.txtav.com | defense.txtav.com | scorpion.txtav.com. About Textron Textron is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, and Textron Systems. For more information, visit: www.textron.com. Certain statements in this press release are forward-looking statements which may project revenues or describe strategies, goals, outlook or other non-historical matters; these statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, changes in aircraft delivery schedules or cancellations or deferrals of orders. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216837400/en/ Media: Doug Scott +1.316.347.0116 dscott2@txtav.com txtav.com Source: Textron Aviation What type of aircraft was delivered by Textron Aviation to Ikhasas Sdn Bhd? Textron Aviation delivered a Cessna Grand Caravan EX Amphibian turboprop to Ikhasas Sdn Bhd. Who will manage and operate the aircraft for passenger transport to Perhentian Islands? Local charter operator Systematic Aviation Services (SAS) will manage and operate the aircraft for passenger transport to Perhentian Islands. What is significant about this delivery in Malaysia's aviation history? This marks Malaysia's first amphibious airplane operation in recent history, gaining necessary approvals from the Civil Aviation Authority of Malaysia to launch domestic operations in 2024. Which Textron Inc. subsidiary designed and manufactured the Cessna Grand Caravan EX Amphibian? Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, designed and manufactured the Cessna Grand Caravan EX Amphibian. What benefits does the Grand Caravan EX Amphibian offer for travelers to Perhentian Islands? The Grand Caravan EX Amphibian offers time savings by transporting passengers directly from Kuala Lumpur to the waters near the beachside resort, avoiding the need for a time-consuming road journey and ferry ride."
NVIDIA Accelerates Quantum Computing Exploration at Australia’s Pawsey Supercomputing Centre,2024-02-18T21:00:00.000Z,Neutral,Neutral,"NVIDIA partners with Australia's Pawsey Supercomputing Research Centre to utilize the CUDA Quantum platform accelerated by NVIDIA Grace Hopper Superchips, aiming to drive breakthroughs in quantum computing. The collaboration will enable researchers to run high-fidelity quantum simulations and develop hybrid algorithms for various scientific applications, potentially creating new jobs and revenue opportunities in the quantum computing sector.","NVIDIA Accelerates Quantum Computing Exploration at Australia’s Pawsey Supercomputing Centre Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary NVIDIA partners with Australia's Pawsey Supercomputing Research Centre to utilize the CUDA Quantum platform accelerated by NVIDIA Grace Hopper Superchips, aiming to drive breakthroughs in quantum computing. The collaboration will enable researchers to run high-fidelity quantum simulations and develop hybrid algorithms for various scientific applications, potentially creating new jobs and revenue opportunities in the quantum computing sector. Positive None. Negative None. Market Research Analyst The integration of NVIDIA's CUDA Quantum platform and Grace Hopper Superchips into Pawsey Supercomputing Research Centre's infrastructure represents a significant advancement in quantum computing capabilities. From a market perspective, this collaboration is poised to enhance Australia's position in the global quantum computing market, which is projected to grow substantially. The anticipated domestic market opportunity estimated by CSIRO at $2.5 billion annually, along with the creation of 10,000 new jobs by 2040, underscores the economic potential of quantum computing integration across various industries.Furthermore, the deployment of NVIDIA Grace Hopper Superchip nodes at Pawsey indicates an increased demand for high-performance computing solutions. NVIDIA's stock could see a positive impact as the company continues to solidify its role in the burgeoning field of quantum computing, potentially leading to increased investor confidence in NVIDIA's growth trajectory and innovation capabilities. Technology Analyst The technical implications of NVIDIA's CUDA Quantum and Grace Hopper Superchips for quantum computing are substantial. The Grace Hopper Superchip's architecture, which eliminates the need for traditional CPU-to-GPU PCIe connections, offers a 7x increase in bandwidth. This technical enhancement is critical for high-fidelity quantum simulations that require immense data processing capabilities. The ability to perform scalable simulations and interface with future quantum hardware infrastructure could lead to more rapid advancements in quantum algorithm development and error correction techniques.For stakeholders, the long-term benefits include potential breakthroughs in fields such as quantum machine learning, chemistry and bioinformatics, which could translate into significant commercial applications. However, the high costs associated with cutting-edge quantum computing research and infrastructure development could present financial risks. Nonetheless, the strategic move by Pawsey to adopt NVIDIA's technology could catalyze further innovation and partnerships within the quantum computing sector. Financial Analyst The financial implications of NVIDIA's announcement are multifaceted. On one hand, the investment in NVIDIA's technology by a prominent research center like Pawsey could signal to investors the company's strong position in the high-performance computing market. This could potentially lead to an uptick in NVIDIA's stock as the market reacts to the company's expanding influence in quantum computing research and infrastructure.On the other hand, investors must also consider the long-term capital requirements and R&D expenses associated with developing and maintaining such advanced technologies. While the initial costs may be high, the potential revenue from a market opportunity of $2.5 billion annually suggests a favorable cost-benefit analysis. Investors will need to weigh the immediate financial impact of the deal against the projected growth in the quantum computing market and NVIDIA's potential to capture a significant share of that market. 02/18/2024 - 04:00 PM Scientists to Run State-of-the-Art Quantum Computing Simulations Using NVIDIA CUDA Quantum Platform, Turbocharged by NVIDIA Grace Hopper SuperchipsSYDNEY, Australia, Feb. 18, 2024 (GLOBE NEWSWIRE) -- SCA2024 -- NVIDIA today announced that Australia’s Pawsey Supercomputing Research Centre will add the NVIDIA® CUDA Quantum platform accelerated by NVIDIA Grace Hopper™ Superchips to its National Supercomputing and Quantum Computing Innovation Hub, furthering its work driving breakthroughs in quantum computing. Researchers at the Perth-based center will leverage CUDA Quantum — an open-source hybrid quantum computing platform that features powerful simulation tools, and capabilities to program hybrid CPU, GPU and QPU systems — as well as, the NVIDIA cuQuantum software development kit of optimized libraries and tools for accelerating quantum computing workflows. The NVIDIA Grace Hopper Superchip — which combines the NVIDIA Grace CPU and Hopper GPU architectures — provides extreme performance to run high-fidelity and scalable quantum simulations on accelerators and seamlessly interface with future quantum hardware infrastructure. “High-performance simulation is essential for researchers to address the biggest challenges in quantum computing — from algorithm discovery and device design to the invention of powerful methods for error correction, calibration and control,” said Tim Costa, director of HPC and quantum computing at NVIDIA. “CUDA Quantum, together with the NVIDIA Grace Hopper Superchip, allows innovators such as Pawsey Supercomputing Research Centre to achieve these essential breakthroughs and accelerate the timeline to useful quantum-integrated supercomputing.” “Pawsey Supercomputing Centre’s research and test-bed facility is helping to advance scientific exploration for all of Australia as well as the world,” said Mark Stickells, executive director at the Pawsey Supercomputing Research Centre. “NVIDIA’s CUDA Quantum platform will allow our scientists to push the boundaries of what’s possible in quantum computing research.” Australia’s national science agency, CSIRO (Commonwealth Scientific and Industrial Research Organisation), estimates the domestic market opportunity from quantum computing to be worth $2.5 billion annually in revenue, with the potential to create 10,000 new jobs by 2040. Achieving this will require quantum computing to be embedded in other scientific domains, with applications in astronomy, life sciences, medicine, finance and more. Pushing the Boundaries of Quantum Computing Pawsey will deploy the system to run quantum workloads directly from traditional high performance computing systems, leveraging their processing power and developing hybrid algorithms that intelligently divide calculations into classical and quantum kernels, using the quantum device to improve computing efficiency. Quantum machine learning, chemistry simulations, image processing for radio astronomy, financial analysis, bioinformatics and specialized quantum simulators will be studied, starting with various quantum variational algorithms. Pawsey is deploying eight NVIDIA Grace Hopper Superchip nodes based on NVIDIA MGX™ modular architecture. GH200 Superchips eliminate the need for a traditional CPU-to-GPU PCIe connection by combining an Arm-based NVIDIA Grace™ CPU with an NVIDIA H100 Tensor Core GPU in the same package, using NVIDIA NVLink™-C2C chip interconnects. This increases the bandwidth between GPU and CPU by 7x compared with the latest PCIe technology. It delivers up to 10x higher performance for applications running terabytes of data, giving quantum-classical researchers unprecedented power to solve the world’s most complex problems. Pawsey is committed to making the NVIDIA Grace Hopper platform available to the Australian quantum community, as well as its international partners. About NVIDIASince its founding in 1993, NVIDIA (NASDAQ: NVDA) has been a pioneer in accelerated computing. The company’s invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined computer graphics, ignited the era of modern AI and is fueling industrial digitalization across markets. NVIDIA is now a full-stack computing infrastructure company with data-center-scale offerings that are reshaping industry. More information at https://nvidianews.nvidia.com/. For further information, contact:Alex ShapiroPublic RelationsNVIDIA Corporation+1-415-608-5044ashapiro@nvidia.com Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, performance, features, and availability of NVIDIA’s products and technologies, including NVIDIA CUDA Quantum platform, NVIDIA Grace Hopper Superchips, NVIDIA cuQuantum, NVIDIA MGX modular architecture, NVIDIA Grace CPU, NVIDIA H100 Tensor Core GPU, and NVIDIA NVLink-C2C chip interconnects; the benefits, impact, features, and timing of our collaborations with third parties and their strategies; and the estimated domestic market opportunity from quantum computing and its potential to create new jobs are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances. © 2024 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, CUDA, NVIDIA Grace, NVIDIA Grace Hopper, NVIDIA MGX, and NVLink are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6959336e-dc31-4fae-975f-1e1ce5e0e073 What is the collaboration between NVIDIA and Pawsey Supercomputing Research Centre about? The collaboration involves utilizing the NVIDIA CUDA Quantum platform accelerated by NVIDIA Grace Hopper Superchips for quantum computing research. What are the key features of the NVIDIA CUDA Quantum platform? The platform features powerful simulation tools, capabilities to program hybrid CPU, GPU, and QPU systems, and the NVIDIA cuQuantum software development kit. What is the potential market opportunity from quantum computing according to CSIRO? CSIRO estimates the domestic market opportunity from quantum computing to be worth $2.5 billion annually in revenue, with the potential to create 10,000 new jobs by 2040. How will Pawsey Supercomputing Research Centre leverage the NVIDIA Grace Hopper Superchips? Pawsey will deploy eight NVIDIA Grace Hopper Superchip nodes based on NVIDIA MGX modular architecture to run quantum workloads directly from traditional high-performance computing systems. What is the unique feature of the NVIDIA Grace Hopper Superchips in terms of CPU-to-GPU connection? The GH200 Superchips eliminate the need for a traditional CPU-to-GPU PCIe connection by combining an Arm-based NVIDIA Grace CPU with an NVIDIA H100 Tensor Core GPU in the same package."
"Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market",2024-02-17T05:17:00.000Z,Neutral,Neutral,"Tevogen Bio Holdings Inc. (TVGN) commenced public trading on Nasdaq, emphasizing its focus on developing affordable T cell therapies for virology, oncology, and neurology. The CEO highlighted the company's dedication to shareholders and mission.","Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Tevogen Bio Holdings Inc. (TVGN) commenced public trading on Nasdaq, emphasizing its focus on developing affordable T cell therapies for virology, oncology, and neurology. The CEO highlighted the company's dedication to shareholders and mission. Positive None. Negative None. 02/17/2024 - 12:17 AM WARREN, N.J.--(BUSINESS WIRE)-- Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024. This major milestone underscored the company's commitment to its valued shareholders and its mission to develop commercially attractive, affordable, genetically unmodified off-the-shelf T cell therapies for large patient populations in virology, oncology, and neurology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216782434/en/Team Tevogen celebrating listing with Nasdaq (Photo: Business Wire) “We are deeply honored to become part of the Nasdaq family, a significant milestone that highlighted the commitment and dedication of our team,” remarked Ryan Saadi, MD, MPH, Chief Executive Officer of Tevogen Bio. “This event not only reconfirmed company’s growth strategy but also reinforced our commitment to our mission. As we embark on this new chapter, we look forward to contributing to the market's vibrancy and delivering value to our shareholders and patients.” About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward-Looking Statements This press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws, including without limitation statements regarding the anticipated benefits of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”), the future financial condition and performance of Tevogen Bio, and the product candidates, products, markets, and expected future performance and market opportunities of Tevogen Bio. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Factors that could cause actual future events to differ materially from the forward-looking statements in this communication include without limitation: (i) the effect of the announcement of the Business Combination on Tevogen Bio’s business relationships, operating results, and business generally; (ii) the outcome of any legal proceedings that may be instituted against Tevogen Bio related to the Merger Agreement or the Business Combination ; (iii) changes in the markets in which Tevogen Bio competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (iv) changes in domestic and global general economic conditions; (v) risk that Tevogen Bio may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; (vi) risk that Tevogen Bio may not be able to develop and maintain effective internal controls; (vii) costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination or to realize estimated pro forma results and underlying assumptions, including with respect to estimated shareholder redemptions; (viii) the failure to recognize the anticipated benefits of the Business Combination and to achieve Tevogen Bio’s commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen Bio to grow and manage growth economically and hire and retain key employees; (ix) the risk that Tevogen Bio may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (x) the ability to develop, license or acquire new therapeutics; (xi) the risk that Tevogen Bio will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xii) the risk of product liability or regulatory lawsuits or proceedings relating to Tevogen Bio’s business; (xiii) uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; (xiv) risks associated with intellectual property protection; (xv) Tevogen Bio’s limited operating history; and (xvi) those factors discussed in Tevogen Bio’s filings with the SEC and that that are contained in the Proxy Statement/Prospectus relating to the Business Combination. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Proxy Statement/Prospectus and other documents to be filed by Tevogen Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Tevogen Bio may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216782434/en/ Tevogen Communications T: 1 877 TEVOGEN, Ext 701 communications@Tevogen.com Source: Tevogen Bio When did Tevogen Bio Holdings Inc. start public trading on Nasdaq? Tevogen Bio Holdings Inc. started public trading on Nasdaq on February 15th, 2024. What is Tevogen Bio Holdings Inc.'s ticker symbol? Tevogen Bio Holdings Inc.'s ticker symbol is TVGN. What are the focus areas of Tevogen Bio Holdings Inc.'s therapies? Tevogen Bio Holdings Inc. focuses on developing genetically unmodified off-the-shelf T cell therapies for virology, oncology, and neurology. Who is the Chief Executive Officer of Tevogen Bio Holdings Inc.? Ryan Saadi, MD, MPH, is the Chief Executive Officer of Tevogen Bio Holdings Inc. What was the significance of Tevogen Bio Holdings Inc. ringing the opening bell at Nasdaq? Ringing the opening bell at Nasdaq was a significant milestone highlighting Tevogen Bio Holdings Inc.'s commitment to shareholders and its mission."
Rocket Lab Successfully Launches Mission Designed to Investigate Removing Space Junk from Orbit,2024-02-18T17:24:00.000Z,Neutral,Neutral,"Rocket Lab successfully launches Electron rocket deploying ADRAS-J satellite for Astroscale Japan Inc for orbital debris inspection. The mission aims to test technologies for approaching and monitoring space junk, supporting space sustainability. The satellite will observe a derelict rocket stage left in orbit and assess methods for deorbiting. The launch required precise timing and orbital deployment parameters, showcasing Rocket Lab's advanced capabilities.","Rocket Lab Successfully Launches Mission Designed to Investigate Removing Space Junk from Orbit Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Rocket Lab successfully launches Electron rocket deploying ADRAS-J satellite for Astroscale Japan Inc for orbital debris inspection. The mission aims to test technologies for approaching and monitoring space junk, supporting space sustainability. The satellite will observe a derelict rocket stage left in orbit and assess methods for deorbiting. The launch required precise timing and orbital deployment parameters, showcasing Rocket Lab's advanced capabilities. Positive None. Negative None. Aerospace Engineer The successful deployment of the ADRAS-J satellite by Rocket Lab's Electron rocket signifies a critical advancement in orbital debris mitigation, a growing concern within the aerospace community. The ability to rendezvous with and potentially de-orbit defunct satellites and rocket stages is a milestone in space sustainability efforts. As space becomes increasingly congested, the risk of collisions, which can generate further debris, poses a significant threat to both current and future missions. The technology demonstrated by Astroscale Japan Inc could become a cornerstone in the emerging field of on-orbit servicing and debris removal, with implications for satellite operators, space agencies and companies involved in space logistics and infrastructure.Moreover, the mission's demand for high precision in orbital insertion and the tight launch timing showcases Rocket Lab's technical capabilities. This level of precision is essential for the intricate maneuvers required for debris monitoring and removal, setting a precedent for future missions. The success of such missions could lead to increased demand for Rocket Lab's services, potentially impacting the company's market position and financial performance positively. Financial Analyst From a financial perspective, Rocket Lab's successful launch and deployment of the ADRAS-J satellite may have favorable implications for the company's stock valuation. Investors often look for consistent performance and innovation as indicators of a company's growth potential. This launch demonstrates Rocket Lab's ability to execute complex missions with stringent requirements, which could enhance its reputation and lead to new contracts. The growing concern over space debris and the need for sustainable space operations could translate into a new revenue stream for companies like Rocket Lab, as the demand for debris removal services is expected to increase.However, investors should also consider the costs associated with developing such advanced technologies and the competitive landscape of the space industry. While the successful mission could be seen as a positive signal, the long-term financial benefits will depend on the company's ability to secure further contracts and effectively manage the costs of its advanced space services. Environmental Policy Expert The environmental impact of space debris is an issue that extends beyond the aerospace industry, affecting global policy and environmental sustainability. The successful deployment of the ADRAS-J satellite represents a proactive approach to addressing the growing problem of space debris, which is an encouraging sign for policymakers and environmentalists advocating for responsible space utilization. The mission aligns with international efforts, such as the United Nations' guidelines for the long-term sustainability of outer space activities, which call for the safe and sustainable use of space.Should Astroscale's technology prove effective, it could set a precedent for mandatory debris removal policies in the future, potentially influencing international space law and regulation. This could have far-reaching implications for all space-faring nations and companies, mandating the incorporation of debris mitigation technologies into their spacecraft designs and operations, thus altering the landscape of space operations and compliance costs. 02/18/2024 - 12:24 PM Rocket Lab’s Electron rocket successfully deployed the ADRAS-J satellite for Astroscale Japan Inc to conduct an orbital debris inspection demonstration mission. MAHIA, New Zealand--(BUSINESS WIRE)-- Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today launched its 44th Electron rocket, successfully deploying an orbital debris inspection satellite for Astroscale Japan Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240218296478/en/Rocket Lab's Electron launch vehicle lifts-off for the 'On Closer Inspection' mission for Astroscale Japan. (Photo: Business Wire) The mission, named “On Closer Inspection”, launched from Pad B at Rocket Lab’s Launch Complex 1 in New Zealand at 03:52 NZDT February 19th, 2024 (14:52 UTC, February 18th). Electron deployed the Active Debris Removal by Astroscale-Japan (ADRAS-J), a satellite designed to test technologies and operations for approaching and monitoring debris objects in orbit, also known as space junk. The mission is the first phase in assessing the potential for satellites to rendezvous with orbital debris objects in future and assist in de-orbiting them, supporting space sustainability for future generations. Following the successful launch on Electron, the 150-kilogram ADRAS-J satellite will now approach an aged, derelict rocket stage in orbit to observe it closely, understand how it behaves and determine potential methods for its assisted deorbiting in future. The rocket stage it will be observing is the Japanese H-2A upper stage left in low Earth orbit after the launch of the GOSAT Earth observation satellite in 2009. ADRAS-J will fly around the stage, 11 meters long and four meters in diameter, inspecting it with cameras and sensors. Astroscale’s full mission will take between three and six months to complete. “Congratulations to the Astroscale team on this historic mission that paves the way for new and innovative ways to reduce orbital debris and ensure space remains safely accessible,” said Rocket Lab founder and CEO Peter Beck. “It’s a real honor to provide a dedicated launch service and enable the kind of precise orbital maneuvers required for an advanced mission like this.” To enable the ADRAS-J satellite to rendezvous with the derelict H-2A upper stage in orbit, Rocket Lab had to design a mission with strict launch timing and precision orbital deployment parameters. Rocket Lab only received the final perigee, apogee, and inclination from Astroscale 20 days before launch, parameters that are typically determined many months in advance of a launch. Only then could argument of perigee targets for different days within the launch window be selected, essentially determining the timing of Electron Kick Stage burns to facilitate the unique elliptical orbit required depending on the launch date. The mission demanded highly accurate orbital insertion with tighter margins than required on most standard missions. The exact T-0 was only able to be defined the day prior to launch and the required LTAN accuracy only allows for +/- 15 seconds, demonstrating Rocket Lab’s capability to deliver rapid and responsive advanced guidance, navigation and control analysis. “Today’s successful launch of ADRAS-J marks another milestone toward our efforts to grow the on-orbit servicing sector while creating a sustainable space environment,” said Astroscale founder & CEO Nobu Okada. “We are grateful for the collaboration with Rocket Lab, whose expertise in dedicated launch services has been instrumental to the start of this ground breaking mission.” Images and video from the launch of ‘On Closer Inspection’ are available for download here: https://flic.kr/s/aHBqjBdtqX ‘On Closer Inspection’ was Rocket Lab’s second launch of 2024 and the Company’s 44th Electron launch overall. + About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, the Photon satellite platform, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 177 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. To learn more, visit www.rocketlabusa.com. + About Astroscale Founded in 2013, Astroscale is developing innovative and scalable solutions across the spectrum of on-orbit servicing missions, including life extension, in-situ space situational awareness, end-of-life services, and active debris removal, to create sustainable space systems and mitigate the growing and hazardous buildup of debris in space. Astroscale is also defining business cases and working with government and commercial stakeholders to develop norms, regulations, and incentives for the responsible use of space. Headquartered in Japan, Astroscale has an international presence with subsidiaries in the United Kingdom, the United States, France, and Israel. Astroscale is a rapidly expanding venture company, working to advance safe and sustainable growth in space and solve a growing environmental concern. Find out more about Astroscale at www.astroscale.com. + Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at www.rocketlabusa.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. View source version on businesswire.com: https://www.businesswire.com/news/home/20240218296478/en/ + Rocket Lab Media Contact Morgan Bailey media@rocketlabusa.com Source: Rocket Lab USA, Inc. What is the name of the satellite deployed by Rocket Lab for Astroscale Japan Inc? Rocket Lab deployed the ADRAS-J satellite for Astroscale Japan Inc. What is the mission of the ADRAS-J satellite launched by Rocket Lab? The mission aims to test technologies for approaching and monitoring space junk, supporting space sustainability. What will the ADRAS-J satellite observe in orbit? The ADRAS-J satellite will observe a derelict Japanese H-2A upper stage left in orbit after the launch of the GOSAT Earth observation satellite in 2009. Who congratulated the Astroscale team on the successful mission? Rocket Lab founder and CEO Peter Beck congratulated the Astroscale team on the successful mission. How many launches has Rocket Lab completed in 2024? Rocket Lab completed its second launch of 2024 with 'On Closer Inspection' being the 44th Electron launch overall."
Aeries Technology Announces Earnings Release and Conference Call Date for Fiscal Third Quarter 2024,2024-02-17T05:58:00.000Z,Low,Very Positive,"Aeries Technology (AERT) will host a conference call to discuss financial results on February 22, 2024. The call will be accessible via phone or webcast, with replay options available. Investors can tune in for updates on the company's performance.","Aeries Technology Announces Earnings Release and Conference Call Date for Fiscal Third Quarter 2024 Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags earnings Rhea-AI Summary Aeries Technology (AERT) will host a conference call to discuss financial results on February 22, 2024. The call will be accessible via phone or webcast, with replay options available. Investors can tune in for updates on the company's performance. Positive None. Negative None. 02/17/2024 - 12:58 AM NEW YORK, Feb. 17, 2024 (GLOBE NEWSWIRE) -- Aeries Technology (Nasdaq: AERT), a global professional services and consulting partner, today announced that the company will host a conference call to discuss their financial results on Thursday, February 22, 2024 at 8:00 AM ET. The call will be accessible by telephone at 1-877-300-8521 (domestic) or 1-412-317-6026 (international). The call will also be available live via webcast on the company’s investor relations website at https://ir.aeriestechnology.com. A telephone replay of the conference call will be available following its conclusion at 1-844-512-2921 (domestic) or 1-412-317-6671 (international) with access code 10186664 and will be available until 11:59 PM ET, February 29, 2024. An archive of the webcast will also be available on the Company’s investor relations website at https://ir.aeriestechnology.com. About Aeries Technology Aeries Technology (Nasdaq: AERT) is a global professional services and consulting partner for businesses in transformation mode and their stakeholders, including private equity sponsors and their portfolio companies, with customized engagement models that are designed to provide the right mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client’s business operations. Founded in 2012, Aeries Technology now has over 1,600 professionals specializing in Technology Services and Solutions, Business Process Management, and Digital Transformation initiatives, geared towards providing tailored solutions to drive business success. Aeries Technology’s unique approach to staffing and developing its workforce has earned it the Great Place to Work Certification. Contacts Ryan GardellaAeriesIR@icrinc.com When will Aeries Technology host a conference call to discuss financial results? Aeries Technology will host a conference call on February 22, 2024. How can I access the conference call by phone? The conference call can be accessed by phone at 1-877-300-8521 (domestic) or 1-412-317-6026 (international). Where can I find the webcast of the conference call? The webcast can be found on the company's investor relations website at https://ir.aeriestechnology.com. Is there a replay option available for the conference call? Yes, a telephone replay will be available at 1-844-512-2921 (domestic) or 1-412-317-6671 (international) with access code 10186664. Until when will the telephone replay be available? The telephone replay will be available until 11:59 PM ET, February 29, 2024. Where can I find an archive of the webcast? An archive of the webcast will be available on the company's investor relations website at https://ir.aeriestechnology.com."
"Intchains Group Limited to Report Unaudited Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024",2024-02-18T10:00:00.000Z,Low,Very Positive,"Intchains Group Limited (ICG) will release its unaudited financial results for Q4 and full year of 2023 on February 28, 2024. The earnings conference call will be held at 8:00 P.M. U.S. Eastern Time on the same day.","Intchains Group Limited to Report Unaudited Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024 Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags conferences earnings Rhea-AI Summary Intchains Group Limited (ICG) will release its unaudited financial results for Q4 and full year of 2023 on February 28, 2024. The earnings conference call will be held at 8:00 P.M. U.S. Eastern Time on the same day. Positive None. Negative None. 02/18/2024 - 05:00 AM SHANGHAI, China, Feb. 18, 2024 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“Intchains” or the “Company”), a provider of integrated solutions consisting of high-performance computing ASIC chips and ancillary software and hardware for blockchain applications, today announced that it will release its unaudited financial results for fourth quarter and full year of 2023 after the U.S. market closes on Wednesday, February 28, 2024. The Company will host an earnings conference call to discuss its financial results at 8:00 P.M. U.S. Eastern Time on February 28, 2024 (9:00 A.M. Beijing Time on February 29, 2024). Details for the conference call are as follows: Event Title:Intchains Group Limited Fourth Quarter and Full Year 2023 Earnings Conference CallDate:February 28, 2024Time:8:00 P.M. U.S. Eastern TimeRegistration Link:https://register.vevent.com/register/BI57545434a6a24bcd8e534e49cf5b4c7d All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of dial-in numbers and a personal access PIN, which will be used to join the conference call. Additionally, a live and archived webcast of the conference call will also be available at the Company’s website at https://intchains.com. About Intchains Group Limited Intchains Group Limited is a provider of integrated solutions consisting of high-performance computing ASIC chips and ancillary software and hardware for blockchain applications. The Company utilizes a fabless business model and specializes in the front-end and back-end of IC design, which are the major components of the IC product development chain. The Company has established strong supply chain management with a leading foundry, which helps to ensure its product quality and stable production output. The Company’s products consist of high-performance computing ASIC chips that have high computing power and superior power efficiency as well as ancillary software and hardware, which cater to the evolving needs of the blockchain industry. The Company has built a proprietary technology platform named “Xihe” Platform, which allows the Company to develop a wide range of ASIC chips with high efficiency and scalability. For more information, please visit the Company’s website at: https://intchains.com. For investor and media inquiries, please contact: Intchains Group Limited Investor relationsEmail: ir@intchains.com Piacente Financial Communications In China: Helen WuTel: +86-10-6508-0677Email: intchains@tpg-ir.com In the United States: Brandi PiacenteTel: +1-212-481-2050Email: intchains@tpg-ir.com When will Intchains Group Limited release its unaudited financial results for Q4 and full year of 2023? Intchains Group Limited will release its unaudited financial results on February 28, 2024. What time will the earnings conference call be held on February 28, 2024? The earnings conference call will be held at 8:00 P.M. U.S. Eastern Time on February 28, 2024. Where can participants register for the conference call? Participants can register for the conference call using the following link: https://register.vevent.com/register/BI57545434a6a24bcd8e534e49cf5b4c7d Will there be a webcast of the conference call available? Yes, a live and archived webcast of the conference call will be available at the Company's website at https://intchains.com."
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer,2024-02-17T03:00:00.000Z,Low,Neutral,"AstraZeneca's TAGRISSO with chemotherapy has been approved in the US for EGFRm NSCLC treatment based on FLAURA2 results, showing significant PFS improvement. The addition of chemotherapy reduced the risk of disease progression by 38% compared to monotherapy.","TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary AstraZeneca's TAGRISSO with chemotherapy has been approved in the US for EGFRm NSCLC treatment based on FLAURA2 results, showing significant PFS improvement. The addition of chemotherapy reduced the risk of disease progression by 38% compared to monotherapy. Positive None. Negative None. Oncology Doctor The approval of TAGRISSO in combination with chemotherapy represents a significant advancement in the treatment of EGFR-mutated non-small cell lung cancer. The extension of median progression-free survival by nearly 9 months is a substantial improvement, considering the aggressive nature of metastatic NSCLC. This combination therapy could enhance the quality of life for patients by delaying the progression of the disease, which is a critical factor in oncology where treatment options that prolong life are highly valued.From a medical perspective, the hazard ratio of 0.62 indicates a 38% reduction in the risk of disease progression or death, which is clinically meaningful. This data suggests that the combination therapy could become a new standard of care, potentially replacing TAGRISSO monotherapy in certain patient populations. The integration of this treatment into clinical practice will require oncologists to balance the increased efficacy with the potential for added side effects from chemotherapy. Market Research Analyst The approval of TAGRISSO plus chemotherapy could lead to a significant market share increase for AstraZeneca in the NSCLC treatment space. Given that the majority of lung cancer cases are NSCLC and a significant portion of these are EGFR-mutated, the addressable market for this therapy is considerable. With over 200,000 annual diagnoses in the US alone, the potential patient base is substantial.Furthermore, the improved progression-free survival rates are likely to resonate well with healthcare providers, payers and patients, potentially driving higher adoption rates. AstraZeneca's strategic positioning could be strengthened by this FDA approval, especially if long-term survival benefits are observed, which would further differentiate TAGRISSO from competitors. Market analysts will closely monitor the uptake of this combination therapy and its impact on AstraZeneca's revenue and market valuation. Financial Analyst The FDA's Priority Review and subsequent approval of TAGRISSO in combination with chemotherapy is a positive catalyst for AstraZeneca's financial outlook. The improvement in median progression-free survival is a strong selling point that can lead to increased sales volume. It's important to assess how this approval might affect AstraZeneca's revenue streams, particularly in the oncology segment.Analysts should evaluate the potential market penetration rate and pricing strategy for the combination therapy, as well as the impact on AstraZeneca's overall market share in cancer treatments. Investors will be interested in the short-term revenue boost and the long-term implications for growth, especially considering the high incidence of NSCLC. It's also vital to consider the competitive landscape and how rivals may respond to this new treatment option. 02/16/2024 - 10:00 PM Approval based on FLAURA2 results which showed TAGRISSO plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority Review by the Food and Drug Administration (FDA) was based on the results from the FLAURA2 Phase III trial published in The New England Journal of Medicine. TAGRISSO with the addition of chemotherapy reduced the risk of disease progression or death by 38% compared to TAGRISSO monotherapy which is the 1st-line global standard of care (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.49-0.79; p<0.0001). Median progression-free survival (PFS) by investigator assessment was 25.5 months for patients treated with TAGRISSO plus chemotherapy, an 8.8-month improvement versus TAGRISSO monotherapy (16.7 months). PFS results from blinded independent central review (BICR) were consistent with the results by investigator assessment, showing 29.4 months median PFS with TAGRISSO plus chemotherapy, a 9.5-month improvement over TAGRISSO monotherapy (19.9 months) (HR 0.62; 95% CI 0.48-0.80; p=0.0002). Each year in the US, there are over 200,000 people diagnosed with lung cancer, and 80-85% of these patients are diagnosed with NSCLC, the most common form of lung cancer.1-3 Approximately 70% of people are diagnosed with advanced NSCLC.4 Additionally, about 15% of NSCLC patients in the US have an EGFR mutation.5 Pasi A. Jänne, MD, PhD, medical oncologist at Dana-Farber Cancer Institute and principal investigator for the trial, said: “This approval based on the unprecedented data from FLAURA2 brings a critical new treatment option to patients with advanced EGFR-mutated non-small cell lung cancer. Now, with the choice of two highly effective osimertinib-based options, physicians can better tailor treatment to an individual’s needs and help ensure the best possible outcome for each patient.” Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “This important new treatment option can delay disease progression by nearly nine additional months, establishing a new benchmark with the longest reported progression-free survival benefit in the 1st-line advanced setting. This approval reinforces TAGRISSO as the backbone of EGFR-mutated lung cancer treatment either as monotherapy or in combination with chemotherapy. This news is especially important for those with a poorer prognosis, including patients whose cancer has spread to the brain and those with L858R mutations.” Laurie Ambrose, President and CEO, GO2 for Lung Cancer, said: “We are so excited to see this continued progress advancing more personalized treatment options for our community. The more we can target the right treatments for the right people at the right time, the better outcomes will be for our community – a goal we all collectively share.” Results from a prespecified exploratory analysis of patients in the FLAURA2 trial with brain metastases at baseline showed TAGRISSO plus chemotherapy reduced the risk of central nervous system (CNS) disease progression or death by 42% compared to TAGRISSO alone (HR 0.58; 95% CI 0.33-1.01) as assessed by BICR. With two years of follow up, 74% of patients treated with TAGRISSO plus chemotherapy had not experienced CNS disease progression or death versus 54% of patients treated with TAGRISSO monotherapy. While the overall survival (OS) results remained immature at the second interim analysis (41% maturity), no trend towards a detriment was observed (HR 0.75; 95% CI 0.57-0.97). The trial continues to assess OS as a key secondary endpoint. The safety profile of TAGRISSO with the addition of chemotherapy was generally manageable and consistent with the established profiles of the individual medicines. Adverse event (AE) rates were higher in the TAGRISSO plus chemotherapy arm, driven by well-characterized chemotherapy-related AEs. Discontinuation rates for TAGRISSO due to AEs were low in both arms of the trial (11% for TAGRISSO plus chemotherapy and 6% for monotherapy). In December 2023, TAGRISSO with the addition of chemotherapy was added to the NCCN Clinical Practical Guidelines in Oncology (NCCN Guidelines®) as a NCCN Category 1 Other Recommended regimen for patients with NSCLC whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations based on the data from FLAURA2.6 The US regulatory submission was reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. As part of Project Orbis, TAGRISSO in combination with chemotherapy is also under review by regulatory authorities in Australia, Canada, and Switzerland. Regulatory applications are also under review in several other countries based on the FLAURA2 results. TAGRISSO is approved as monotherapy in more than 100 countries including in the US, EU, China and Japan. Approved indications include for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, and adjuvant treatment of early-stage EGFRm NSCLC. Regulatory applications are under review in several countries based on the FLAURA2 results. As part of AstraZeneca’s ongoing commitment to treating patients as early as possible in lung cancer, TAGRISSO is also being investigated in the neoadjuvant setting in the NeoADAURA Phase III trial with results expected later this year, and in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial. IMPORTANT SAFETY INFORMATION There are no contraindications for TAGRISSO Interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 TAGRISSO-treated patients; 0.4% of cases were fatal. In the FLAURA2 study, ILD/pneumonitis occurred in 3.3% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed Heart rate-corrected QT (QTc) interval prolongation occurs in TAGRISSO-treated patients. Of the 1813 TAGRISSO monotherapy-treated patients in clinical trials, 1.1% were found to have a QTc >500 msec, and 4.3% of patients had an increase from baseline QTc >60 msec. Of the 276 patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy in the FLAURA2 study, 1.8% were found to have a QTc >500 msec, and 10.5% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia Cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. In the FLAURA2 study, cardiomyopathy occurred in 9% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 1.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 4.2% of 1557 patients who had baseline and at least one follow-up LVEF assessment. In the ADAURA study, 1.5% (5/325) of TAGRISSO-treated patients experienced LVEF decreases ≥10% from baseline and a drop to <50%. In the FLAURA2 study, 8% (21/262) of patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, who had baseline and at least one follow-up LVEF assessment, experienced LVEF decreases ≥10% and a drop to less than 50%. For patients receiving TAGRISSO monotherapy, conduct cardiac monitoring in patients with cardiac risk factors, including assessment of LVEF at baseline and during treatment. For patients receiving TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, conduct cardiac monitoring in all patients, including assessment of LVEF at baseline and during treatment. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO Keratitis was reported in 0.6% of 1813 patients treated with TAGRISSO monotherapy in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist Postmarketing cases consistent with erythema multiforme major (EMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if EMM, SJS, or TEN is suspected and permanently discontinue if confirmed Postmarketing cases of cutaneous vasculitis including leukocytoclastic vasculitis, urticarial vasculitis, and IgA vasculitis have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if cutaneous vasculitis is suspected, evaluate for systemic involvement, and consider dermatology consultation. If no other etiology can be identified, consider permanent discontinuation of TAGRISSO based on severity Aplastic anemia has been reported in patients treated with TAGRISSO in clinical trials (0.06% of 1813) and postmarketing. Some cases had a fatal outcome. Inform patients of the signs and symptoms of aplastic anemia including but not limited to, new or persistent fevers, bruising, bleeding, and pallor. If aplastic anemia is suspected, withhold TAGRISSO and obtain a hematology consultation. If aplastic anemia is confirmed, permanently discontinue TAGRISSO. Perform complete blood count with differential before starting TAGRISSO, periodically throughout treatment, and more frequently if indicated Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose Because of the potential for serious adverse reactions in breastfed infants from TAGRISSO, women should not breastfeed during treatment with TAGRISSO and for 2 weeks after the final dose. Most common (≥20%) adverse reactions, including laboratory abnormalities, were: TAGRISSO monotherapy: leukopenia, lymphopenia, thrombocytopenia, anemia, diarrhea, rash, musculoskeletal pain, neutropenia, nail toxicity, dry skin, stomatitis, and fatigue TAGRISSO in combination with pemetrexed and platinum-based chemotherapy: leukopenia, thrombocytopenia, neutropenia, lymphopenia, rash, diarrhea, stomatitis, nail toxicity, dry skin, and increased blood creatinine INDICATIONS [TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test] [TAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test] [TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test] [TAGRISSO is indicated for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy] Please see complete Prescription Information, including Patient Information for TAGRISSO. You may report side effects related to AstraZeneca products by clicking here Notes Lung cancer Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths.7 Lung cancer is broadly split into NSCLC and small cell lung cancer.2 The majority of all NSCLC patients are diagnosed with advanced disease.4 Patients with EGFRm NSCLC are particularly sensitive to treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) which blocks the cell-signaling pathways that drive the growth of tumor cells.8 FLAURA2 FLAURA2 is a randomized, open-label, multi-center, global Phase III trial in the 1st-line treatment of patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC. Patients were treated with TAGRISSO 80mg once daily oral tablets with the addition of chemotherapy (pemetrexed (500mg/m2) plus cisplatin (75mg/m2) or carboplatin (AUC5)) every three weeks for four cycles, followed by TAGRISSO with pemetrexed maintenance every three weeks. The trial enrolled 557 patients in more than 150 centers across more than 20 countries, including in the US, Europe, South America and Asia. The primary endpoint is PFS. The trial is ongoing and will continue to assess the secondary endpoint of OS. TAGRISSO® TAGRISSO® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases. TAGRISSO (40mg and 80mg once-daily oral tablets) has been used to treat more than 800,000 patients across its indications worldwide and AstraZeneca continues to explore TAGRISSO as a treatment for patients across multiple stages of EGFRm NSCLC. There is an extensive body of evidence supporting the use of TAGRISSO in EGFRm NSCLC. TAGRISSO is the only targeted therapy to improve patient outcomes in both early-stage disease in the ADAURA Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2 Phase III trial. The Company is also researching ways to address tumor mechanisms of resistance through the SAVANNAH and ORCHARD Phase II trials, and the SAFFRON Phase III trial, which test TAGRISSO plus savolitinib, an oral, potent and highly selective MET TKI, as well as other potential new medicines. AstraZeneca in lung cancer AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most. The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including TAGRISSO and IRESSA (gefitinib); IMFINZI (durvalumab) and IMJUDO (tremelimumab-aclt); ENHERTU (fam-trastuzumab deruxtecan-nxki) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ORPATHYS (savolitinib) in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action. AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment. AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca. References ASCO. Lung Cancer - Non-Small Cell: Introduction. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/types-treatment. Accessed February 2024. LUNGevity Foundation. Types of Lung Cancer. Available at: https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer. Accessed February 2024. American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/lung-cancer/about/what-is.html#:~:text=About%2080%25%20to%2085%25%20of,(outlook)%20are%20often%20similar. Accessed February 2024. Cagle PT, et al. Lung Cancer Biomarkers: Present Status and Future Developments. Archives Pathology Lab Med. 2013;137:1191-1198. Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27. NCCN, National Comprehensive Cancer Network® (NCCN®). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer Version 1.2024.© National Comprehensive Cancer Network, Inc. [2024]. All rights reserved. Accessed [February 14, 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. World Health Organisation. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed February 2024. Cross DA, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov. 2014;4(9):1046-1061. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216171764/en/ Media Inquiries Brendan McEvoy, +1 302 885 2677 Chelsea Tressler, +1 302 885 2677 US Media Mailbox: usmediateam@astrazeneca.com Source: AstraZeneca What is the latest approval for AstraZeneca related to TAGRISSO? AstraZeneca's TAGRISSO with chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFRm NSCLC. What was the basis for the approval of TAGRISSO with chemotherapy? The approval was based on the results from the FLAURA2 Phase III trial published in The New England Journal of Medicine. How much did the addition of chemotherapy extend the median PFS compared to standard care? The addition of chemotherapy extended median PFS by nearly 9 months compared to standard care. What was the risk reduction percentage in disease progression with TAGRISSO plus chemotherapy? The risk of disease progression or death was reduced by 38% with TAGRISSO plus chemotherapy compared to TAGRISSO monotherapy. What is the median PFS with TAGRISSO plus chemotherapy according to investigator assessment? The median PFS was 25.5 months with TAGRISSO plus chemotherapy, an 8.8-month improvement over TAGRISSO monotherapy. How many people are diagnosed with lung cancer in the US each year? Each year in the US, there are over 200,000 people diagnosed with lung cancer. What percentage of lung cancer patients are diagnosed with NSCLC? 80-85% of lung cancer patients are diagnosed with NSCLC, the most common form of lung cancer. What percentage of people are diagnosed with advanced NSCLC? Approximately 70% of people are diagnosed with advanced NSCLC."
SSR Mining Provides an Update on Incident at Çöpler,2024-02-17T02:58:00.000Z,Neutral,Neutral,"SSR Mining Inc. provides an update on ongoing rescue efforts at the Çöpler Mine in Türkiye. Nine workers are missing following an incident on February 13, 2024, with operations suspended. The Company is actively involved in search and rescue operations, supporting emergency crews and first responders. SSR Mining is cooperating with authorities and will provide further updates during the full-year 2023 financial results release on February 21, 2024.","SSR Mining Provides an Update on Incident at Çöpler Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary SSR Mining Inc. provides an update on ongoing rescue efforts at the Çöpler Mine in Türkiye. Nine workers are missing following an incident on February 13, 2024, with operations suspended. The Company is actively involved in search and rescue operations, supporting emergency crews and first responders. SSR Mining is cooperating with authorities and will provide further updates during the full-year 2023 financial results release on February 21, 2024. Positive None. Negative None. Mining Safety Expert The incident at SSR Mining's Çöpler Mine has significant implications for the mining industry, particularly in terms of safety standards and emergency response protocols. Mining operations inherently carry risks, including cave-ins, explosions and equipment failures. The ongoing rescue efforts highlight the critical need for robust safety measures and the swift mobilization of emergency services. The use of advanced search techniques and aerial drones represents an industry shift towards integrating technology for rescue operations. However, the detainment of employees suggests potential safety oversights or procedural breaches, which may lead to a reevaluation of current safety practices within the industry. Stakeholders should anticipate stricter regulations and possible operational halts as investigations proceed. Financial Analyst The suspension of operations at the Çöpler Mine has direct financial implications for SSR Mining. With the halt in production, there will be an inevitable impact on the company's revenue and profitability in the short term. Investors should monitor the duration of the suspension, as prolonged stoppages could lead to downward revisions in production forecasts and financial performance. The incident may also result in increased regulatory scrutiny and potential fines, which could further strain financial resources. It is crucial for investors to assess the company's contingency plans and insurance coverage to mitigate the financial impact of such incidents. The forthcoming full-year 2023 financial results will be pivotal in understanding the full scope of the incident's financial repercussions. Legal Expert The legal ramifications of the Çöpler Mine incident are multifaceted, involving potential liability issues and regulatory compliance. The detention of employees indicates an investigation into possible negligence or violations of mining regulations. This could lead to legal proceedings and sanctions against the company. Furthermore, the forward-looking statements caution investors about placing undue reliance on them, as they are based on current expectations and subject to risks and uncertainties. It is essential to consider the legal context of such statements, as they may affect investor perceptions and the company's obligations to provide accurate and timely information. Stakeholders should be aware of the legal developments as they may influence the company's operational and financial future. 02/16/2024 - 09:58 PM DENVER--(BUSINESS WIRE)-- SSR Mining Inc. (Nasdaq/TSX: SSRM; ASX: SSR) (“SSR Mining” or the “Company”) today provides an update on ongoing rescue efforts at the Çöpler Mine in Türkiye. Search and rescue operations to locate nine missing workers following the February 13, 2024 incident at the Çöpler Mine continue and all operations remain suspended. All available resources have been deployed to assist in the operation, with emergency crews and first responders working around-the-clock, utilizing advanced search techniques supported by aerial drones. Our thoughts continue to be with the families of the missing workers and the Çöpler community during this incredibly difficult time. We will continue to support the authorities on the ground in Türkiye in their search and rescue efforts. Eight Çöpler Mine employees have been detained while the local authorities conduct their investigation. SSR Mining is providing its full cooperation to the regulators on site and providing support to the individuals and their families. SSR Mining will provide a further update on the incident as it becomes aware of more information or during the Company’s full-year 2023 financial results, currently scheduled for Wednesday, February 21, 2024. Cautionary Note Regarding Forward-Looking Information and Statements Certain statements contained in this news release constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information may be contained in this document and our other public filings. Forward-looking information relates to statements concerning our outlook and anticipated events or results and, in some cases, can be identified by terminology such as “may”, “will”, “could”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “projects”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Forward-looking information and statements in this news release are based on certain key expectations and assumptions made by us. Although we believe that the expectations and assumptions on which such forward-looking information and statements are based are reasonable, undue reliance should not be placed on the forward-looking information and statements because we can give no assurance that they will prove to be correct. Forward-looking information and statements are subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. You should not place undue reliance on forward-looking information. Forward-looking information are only predictions based on our current expectations and our projections about future events. Actual results may vary from such forward-looking information for a variety of reasons including, but not limited to, risks and uncertainties disclosed in our filings on our website at www.ssrmining.com, on SEDAR at www.sedarplus.ca, on EDGAR at www.sec.gov and on the ASX at www.asx.com.au and other unforeseen events or circumstances. Other than as required by law, we do not intend, and undertake no obligation to update any forward-looking information to reflect, among other things, new information or future events. About SSR Mining SSR Mining Inc. is a leading, free cash flow focused gold company with four producing operations located in the USA, Türkiye, Canada, and Argentina, combined with a global pipeline of high-quality development and exploration assets. Over the last three years, the four operating assets combined have produced on average more than 700,000 gold-equivalent ounces annually. SSR Mining is listed under the ticker symbol SSRM on the Nasdaq and the TSX, and SSR on the ASX. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216502653/en/ SSR Mining Contacts: SSR Mining Inc. E-Mail: invest@ssrmining.com Phone: +1 (888) 338-0046 To receive SSR Mining’s news releases by e-mail, please register using the SSR Mining website at www.ssrmining.com. Source: SSR Mining Inc. What is the latest update on the ongoing rescue efforts at the Çöpler Mine involving SSR Mining Inc.? SSR Mining Inc. provides an update on the ongoing rescue efforts at the Çöpler Mine in Türkiye, where nine workers are missing following an incident on February 13, 2024. When did the incident at the Çöpler Mine occur? The incident at the Çöpler Mine occurred on February 13, 2024. How many workers are missing after the incident at the Çöpler Mine? Nine workers are missing after the incident at the Çöpler Mine. When will SSR Mining Inc. provide further updates on the incident? SSR Mining Inc. will provide further updates on the incident during the Company’s full-year 2023 financial results release scheduled for February 21, 2024. What is SSR Mining Inc.'s current involvement in the search and rescue operations at the Çöpler Mine? SSR Mining Inc. is actively involved in search and rescue operations at the Çöpler Mine, supporting emergency crews and first responders."
"/C O R R E C T I O N -- YS Biopharma Co., Ltd./",2024-02-17T01:20:00.000Z,No impact,Neutral,"YS Biopharma recently disclosed the outcomes of its Extraordinary General Meeting and addressed misleading claims. Shareholders approved key resolutions, including the election of new board members. The company refuted inaccurate statements and emphasized its commitment to transparency and shareholder value.","/C O R R E C T I O N -- YS Biopharma Co., Ltd./ Rhea-AI Impact (No impact) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary YS Biopharma recently disclosed the outcomes of its Extraordinary General Meeting and addressed misleading claims. Shareholders approved key resolutions, including the election of new board members. The company refuted inaccurate statements and emphasized its commitment to transparency and shareholder value. Positive None. Negative None. 02/16/2024 - 08:20 PM In the news release, YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting, issued 16-Feb-2024 by YS Biopharma Co., Ltd. over PR Newswire, we are advised by the company that there are updates to the content. The complete, corrected release follows: YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting GAITHERSBURG, Md., Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) (""YS Biopharma"" or the ""Company""), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the ""EGM"") held on February 16, 2024 in Seattle, United States. The Company's shareholders voted against each of the following resolutions: The following Directors be removed from office with immediate effect: (i) Mr Hui Shao; (ii) Mr Bo Tan; (iii) Dr Ajit Shetty; (iv) Dr Viren Mehta; (v) Mr Shaojing Tong and (vi) Ms Rachel Yu.The following persons be elected as Directors with immediate effect: (i) Ms Nan Zhang; (ii) Ms Yun (Monica) Zhang; (iii) Mr Lui Chi Keung (Peter); (iv) Mr Jing Xian Li.As of the close of business on the EGM's record date of February 8, 2024, the Company had 188,327,959 ordinary shares issued and outstanding. Members holding 97,272,542 ordinary shares cast their votes at the EGM. The results of the vote on each of the resolutions submitted for shareholder approval at the EGM were zero vote in favor and 97,272,542 votes against. The Company also cautions investors not to rely on the false, unsubstantiated and misleading statements made by Mr. Yi Zhang and his associates regarding the EGM and the Company contained in the document available here: https://www.prnewswire.com/news-releases/shareholders-led-by-yi-zhang-announce-successful-results-of-removal-of-directors-and-election-of-new-directors-of-ys-biopharma-co-ltd-302064477.html. Pursuant to Article 63 of the Company's Articles of Association (the ""Articles""), the Chairperson of the Board of Directors of the Company (the ""Board"") shall preside as Chairperson at the EGM. Further, Article 88 of the Articles permits a director to attend and be heard on any motion for his removal. Dr. Ajit Shetty, chairperson of the Board, and Dr. Hui Shao, a director of the Company, were denied rightful entry to the offices of DLA Piper LLP (US), 701 5th Avenue #6900, Seattle, WA 98104, United States where the EGM was originally to be held. On February 16, 2024, the Company obtained an injunction order from the Grand Court of the Cayman Islands which restrains Mr. Yi Zhang, Ms. Nan Zhang, Ms. Yun (Monica) Zhang, Mr. Lui Chi Keung, Mr. Jing Xian Li, Dr. Yuan Liu and Mr. Jimin Wang from: (1) holding themselves out to be directors of the Company and from taking any steps to exercise any powers as though they were directors; (2) issuing any press release or filing any document with the United States Securities and Exchange Commission or any other government body either in the Cayman Islands or elsewhere which asserts that (i) they are directors of the Company and/or (ii) that they have been appointed pursuant to a validly constituted EGM; and (3) taking any steps authority for which is purportedly derived from any director resolution or other decision taken by them purportedly acting in the capacity of a director or holding out that any such resolution has been properly passed or any decision has been validly taken. A copy of the injunction order has been posted on the Company's ""Investor Relations"" website at https://investor.ysbiopharm.com/static-files/1c2b506b-557c-42bd-8045-c654e9bf6344. About YS Biopharma YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit investor.ysbiopharm.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains ""forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of the Company, the development progress of all product candidates, the progress and results of all clinical trials, the Company's ability to source and retain talent, and the cash position of the Company following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as ""estimate,"" ""plan,"" ""project,"" ""forecast,"" ""intend,"" ""will,"" ""expect,"" ""anticipate,"" ""believe,"" ""seek,"" ""target"" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma's management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the documents filed by YS Biopharma from time to time with the U.S. Securities and Exchange Commission (""SEC""). These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma, and other risks and uncertainties, including those included under the heading ""Risk Factors"" in the post-effective amendment No. 2 to Form F-1 filed with the SEC on January 23, 2024 which became effective on January 25, 2024, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements. Investor Relations Contact Robin YangPartner, ICR, LLCTel: +1 (212) 537-4035Email: YSBiopharma.IR@icrinc.com View original content:https://www.prnewswire.com/news-releases/ys-biopharma-announces-results-of-extraordinary-general-meeting-and-responds-to-false-statements-about-the-meeting-302064516.html SOURCE YS Biopharma Co., Ltd. What was the focus of YS Biopharma's Extraordinary General Meeting? YS Biopharma's Extraordinary General Meeting centered on crucial resolutions and the appointment of new board members. What were the results of the meeting? Shareholders approved key resolutions and elected new board members during the Extraordinary General Meeting. How did YS Biopharma respond to false statements? YS Biopharma addressed inaccurate claims and reaffirmed its dedication to transparency and shareholder value. What is the impact of the meeting outcomes on YS stock? The outcomes of the Extraordinary General Meeting may influence YS stock performance, reflecting shareholder decisions and company direction."
CardioComm Solutions Appoints New Board Member and Provides Corporate Update,2024-02-17T01:38:00.000Z,Low,Neutral,"CardioComm Solutions, Inc. appoints Dr. Robin Black to its board of directors and provides an update on its financial audit. Dr. Black brings vast experience in medical device technologies. The company has undergone system changes to enhance financial reporting and operations.","CardioComm Solutions Appoints New Board Member and Provides Corporate Update Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags management Rhea-AI Summary CardioComm Solutions, Inc. appoints Dr. Robin Black to its board of directors and provides an update on its financial audit. Dr. Black brings vast experience in medical device technologies. The company has undergone system changes to enhance financial reporting and operations. Positive None. Negative None. 02/16/2024 - 08:38 PM Toronto, Ontario--(Newsfile Corp. - February 16, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) (""CardioComm"" or the ""Company""), a global medical provider of consumer heart monitoring and medical electrocardiogram (""ECG"") software solutions, is pleased to announce that Dr. Robin Black has been added to the Company's board of directors. In addition, the Company would like to provide an update on its audit of its financial statements for the year ended December 31, 2023.The Company confirms that Dr. Robin Black has joined as the fourth member of its Board of Directors. Dr. Black brings a wealth of experience in the development and support of early-stage medical device company technologies. During his time with the National Research Council (NRC), Dr. Black co-founded the NRC Space Life Science program with a special focus on the application of Canada's expertise in tele-medicine to the design of the health care facility on the International Space Station. He subsequently served as an Industrial Technology Advisor with NRC's Industrial Research Assistance Program working under a mandate to support the development of medical device companies nationally. Throughout his career he has been active in supporting the engineering profession through the executive of affiliate organizations of the Engineering Institute of Canada and presently serves on the executive of the Vancouver Island Engineering Society. Dr. Black received a B.Sc. in Biology from McMaster University, a B.A.Sc. in Mechanical Engineering from Queens University and a Ph.D. in Biomedical Engineering from the University of Strathclyde and holds a Certified Clinical Engineer (CCE) designation.In January of 2024, CardioComm undertook a comprehensive review of its financial reporting and accounting infrastructure and proactively implemented system changes which included engaging a professional advisory firm to oversee audit functions and financial operations. These changes will ensure the Company will continue to meet its reporting timelines, starting with the Company's 2023 year-end financial statements and associated disclosures, due April 29, 2024, in addition to improving the quality of the information disseminated to the Company's valued shareholders. The advisor will also provide the Company with access to a range of consulting, accounting and advisory services. The contracted firm has extensive experience with ASPE, IFRS and U.S. GAAP and a variety of securities filings such as prospectuses, registration statements, business acquisition reports and other public filings in the U.S. and Canada, and has assisted companies in going public transactions through CPCs and reverse takeovers as well as assisting with buy-side and sell-side due diligence. To learn more about CardioComm's products and for further updates please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. About CardioComm SolutionsCardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).FOR FURTHER INFORMATION PLEASE CONTACT:Etienne Grima, Chief Executive Officer1-877-977-9425 x227investor.relations@cardiocommsolutions.comForward-looking statementsThis release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198365 Who has been added to CardioComm Solutions, Inc.'s board of directors? Dr. Robin Black has been added to CardioComm Solutions, Inc.'s board of directors. What is Dr. Robin Black's background and experience? Dr. Robin Black has a B.Sc. in Biology, a B.A.Sc. in Mechanical Engineering, and a Ph.D. in Biomedical Engineering. He holds a Certified Clinical Engineer (CCE) designation. When did CardioComm Solutions, Inc. review its financial reporting and accounting infrastructure? CardioComm Solutions, Inc. undertook a comprehensive review of its financial reporting and accounting infrastructure in January 2024. What changes were implemented by CardioComm Solutions, Inc. after the review? CardioComm Solutions, Inc. proactively implemented system changes and engaged a professional advisory firm to oversee audit functions and financial operations. What are the benefits of the system changes made by CardioComm Solutions, Inc.? The changes will ensure the company meets reporting timelines, improves the quality of information for shareholders, and provides access to consulting, accounting, and advisory services."
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting,2024-02-17T01:20:00.000Z,Low,Neutral,"YS Biopharma Co., Ltd. announces results of extraordinary general meeting, with shareholders voting against removal of directors and election of new ones. The company warns against false statements by Mr. Yi Zhang and associates. Legal actions taken to restrain unauthorized actions by certain individuals.","YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary YS Biopharma Co., Ltd. announces results of extraordinary general meeting, with shareholders voting against removal of directors and election of new ones. The company warns against false statements by Mr. Yi Zhang and associates. Legal actions taken to restrain unauthorized actions by certain individuals. Positive None. Negative None. Legal Expert The events described surrounding YS Biopharma's EGM reflect significant governance challenges and legal disputes within the company. The rejection of director nominations and subsequent legal actions, such as the injunction order from the Grand Court of the Cayman Islands, indicate a contentious internal environment that may impact investor confidence. The legal ramifications of such disputes can often lead to delays in implementation of company strategies and potential costs associated with litigation. Furthermore, the company's public dispute with Mr. Yi Zhang and the contested EGM results suggest a potential for ongoing instability in leadership, which can affect strategic decisions and the company's direction.From a governance perspective, the denial of entry to the EGM for certain directors also raises questions about adherence to the company's Articles of Association and general corporate governance principles. This situation could lead to scrutiny from regulatory bodies and might necessitate further legal clarification. Investors will need to monitor the situation closely, as the final outcome of these disputes could have a material effect on the company's operations and its stock performance. Financial Analyst The upheaval in YS Biopharma's boardroom is likely to influence market perception and could have a tangible effect on the company's stock price. The uncertainty generated by such a significant shift in governance, especially when combined with the issuance of injunctions against the newly elected directors, may lead to volatility in the company's shares. Investors typically prefer stability and clear direction, which seems to be at risk here.Moreover, the company's focus on the development of vaccines and therapeutic biologics for infectious diseases and cancer is an area that requires consistent and focused investment in research and development. Any diversion of resources towards resolving internal disputes could potentially slow down product development pipelines, affecting future revenue streams. The market will be observing how these governance issues are resolved and what implications they may have for the company's long-term growth prospects. Market Research Analyst In the biopharmaceutical industry, company leadership and the strategic decisions they make are critical to the success of ongoing research and the commercialization of new therapies. The dispute at YS Biopharma could signal a shift in company strategy or a disruption in its operational execution. Stakeholders will be interested in understanding the implications for the company's product pipeline, particularly in light of the competitive landscape.Investors often look at management stability as a key indicator of a company's ability to execute on its business plan. The current situation at YS Biopharma may raise concerns about the company's future direction, especially if the leadership conflict results in a change in the company's strategic priorities. Given the high costs and long timelines associated with bringing biopharmaceutical products to market, any perceived instability at the executive level can have a disproportionate impact on the company's valuation and market position. 02/16/2024 - 08:20 PM GAITHERSBURG, Md., Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) (""YS Biopharma"" or the ""Company""), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the ""EGM"") held on February 16, 2024 in Seattle, United States. The Company's shareholders voted against each of the following resolutions: The following Directors be removed from office with immediate effect: (i) Mr Hui Shao; (ii) Mr Bo Tan; (iii) Dr Ajit Shetty; (iv) Dr Viren Mehta; (v) Mr Shaojing Tong and (vi) Ms Rachel Yu.The following persons be elected as Directors with immediate effect: (i) Ms Nan Zhang; (ii) Ms Yun (Monica) Zhang; (iii) Mr Lui Chi Keung (Peter); (iv) Mr Jing Xian Li.As of the close of business on the EGM's record date of February 8, 2024, the Company had 188,327,959 ordinary shares issued and outstanding. Members holding 97,272,542 ordinary shares cast their votes at the EGM. The results of the vote on each of the resolutions submitted for shareholder approval at the EGM were zero vote in favor and 97,272,542 votes against. The Company also cautions investors not to rely on the false, unsubstantiated and misleading statements made by Mr. Yi Zhang and his associates regarding the EGM and the Company contained in the document available here: https://www.prnewswire.com/news-releases/shareholders-led-by-yi-zhang-announce-successful-results-of-removal-of-directors-and-election-of-new-directors-of-ys-biopharma-co-ltd-302064477.html. Pursuant to Article 63 of the Company's Articles of Association (the ""Articles""), the Chairperson of the Board of Directors of the Company (the ""Board"") shall preside as Chairperson at the EGM. Further, Article 88 of the Articles permits a director to attend and be heard on any motion for his removal. Dr. Ajit Shetty, chairperson of the Board, and Dr. Hui Shao, a director of the Company, were denied rightful entry to the offices of DLA Piper LLP (US), 701 5th Avenue #6900, Seattle, WA 98104, United States where the EGM was originally to be held. On February 16, 2024, the Company obtained an injunction order from the Grand Court of the Cayman Islands which restrain Mr. Yi Zhang, Ms. Nan Zhang, Ms. Yun (Monica) Zhang, Mr. Lui Chi Keung and Mr. Jing Xian Li from: (1) holding themselves out to be directors of the Company and from taking any steps to exercise any powers as though they were directors; (2) issuing any press release or filing any document with the United States Securities and Exchange Commission or any other government body either in the Cayman Islands or elsewhere which asserts that (i) they are directors of the Company and/or (ii) that they have been appointed pursuant to a validly constituted EGM; and (3) taking any steps authority for which is purportedly derived from any director resolution or other decision taken by them purportedly acting in the capacity of a director or holding out that any such resolution has been properly passed or any decision has been validly taken. A copy of the injunction order has been posted on the Company's ""Investor Relations"" website at https://investor.ysbiopharm.com/static-files/1c2b506b-557c-42bd-8045-c654e9bf6344. About YS Biopharma YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit investor.ysbiopharm.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains ""forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of the Company, the development progress of all product candidates, the progress and results of all clinical trials, the Company's ability to source and retain talent, and the cash position of the Company following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as ""estimate,"" ""plan,"" ""project,"" ""forecast,"" ""intend,"" ""will,"" ""expect,"" ""anticipate,"" ""believe,"" ""seek,"" ""target"" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma's management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the documents filed by YS Biopharma from time to time with the U.S. Securities and Exchange Commission (""SEC""). These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma, and other risks and uncertainties, including those included under the heading ""Risk Factors"" in the post-effective amendment No. 2 to Form F-1 filed with the SEC on January 23, 2024 which became effective on January 25, 2024, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements. Investor Relations Contact Robin YangPartner, ICR, LLCTel: +1 (212) 537-4035Email: YSBiopharma.IR@icrinc.com View original content:https://www.prnewswire.com/news-releases/ys-biopharma-announces-results-of-extraordinary-general-meeting-and-responds-to-false-statements-about-the-meeting-302064516.html SOURCE YS Biopharma Co., Ltd. What were the results of YS Biopharma's extraordinary general meeting? The shareholders voted against removing directors and electing new ones. Who were the directors proposed for removal and election? Directors proposed for removal: Mr. Hui Shao, Mr. Bo Tan, Dr. Ajit Shetty, Dr. Viren Mehta, Mr. Shaojing Tong, and Ms. Rachel Yu. Directors proposed for election: Ms. Nan Zhang, Ms. Yun (Monica) Zhang, Mr. Lui Chi Keung (Peter), Mr. Jing Xian Li. How many ordinary shares were issued and outstanding during the meeting? The company had 188,327,959 ordinary shares issued and outstanding during the meeting. What actions were taken against Mr. Yi Zhang and others? Legal actions were taken to restrain them from acting as directors, issuing press releases, or making filings asserting directorship. Where can the injunction order be found? The injunction order can be found on the Company's 'Investor Relations' website at the provided link."
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call,2024-02-16T21:00:00.000Z,Low,Neutral,"Quanterix Corporation (NASDAQ: QTRX) will host a conference call on February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will feature Masoud Toloue, President and CEO, and Vandana Sriram, CFO. The press release will be available on the company's website.","Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary Quanterix Corporation (NASDAQ: QTRX) will host a conference call on February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will feature Masoud Toloue, President and CEO, and Vandana Sriram, CFO. The press release will be available on the company's website. Positive None. Negative None. 02/16/2024 - 04:00 PM BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company’s President and Chief Executive Officer, and Vandana Sriram, the Company’s Chief Financial Officer. Quanterix will issue a press release regarding the fourth quarter 2023 earnings and full year 2023 financial results prior to the conference call. The press release will be posted on the Quanterix website at https://www.quanterix.com/. Click here to pre-register for the conference call and obtain your dial-in number and passcode. You can also visit this link to listen to the call via live webcast. You may also access the live webcast by visiting the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. The webcast will be available on the Company’s website for one year following completion of the call. About Quanterix From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216642212/en/ Media: PAN Communications Maya Nimnicht 510-334-6273 quanterix@pancomm.com Investor Relations: Amy Achorn (978) 488-1854 ir@quanterix.com Source: Quanterix Corporation When will Quanterix Corporation host a conference call to discuss its financial results? Quanterix Corporation will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. Who will host the conference call for Quanterix Corporation? The conference call will be hosted by Masoud Toloue, the President and CEO, and Vandana Sriram, the CFO of Quanterix Corporation. Where can I find the press release for Quanterix Corporation's financial results? The press release regarding the fourth quarter 2023 earnings and full year 2023 financial results will be posted on the Quanterix website at https://www.quanterix.com/. How can I pre-register for the conference call hosted by Quanterix Corporation? You can pre-register for the conference call and obtain your dial-in number and passcode by clicking on the provided link in the press release. How long will the webcast of the conference call be available on Quanterix Corporation's website? The webcast will be available on the Company’s website for one year following the completion of the call."
"Unusual Machines Announces Closing of $5,000,000 Initial Public Offering",2024-02-16T21:01:00.000Z,Low,Neutral,"Unusual Machines, Inc. closes IPO, offering 1,250,000 shares of common stock at $4.00 per share, trading on NYSE American under the ticker symbol 'UMAC'. The company expects $5.0 million in gross proceeds. Underwriters granted a 45-day option for additional shares. Legal counsel and registration details provided for the Offering.","Unusual Machines Announces Closing of $5,000,000 Initial Public Offering Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags IPO offering Rhea-AI Summary Unusual Machines, Inc. closes IPO, offering 1,250,000 shares of common stock at $4.00 per share, trading on NYSE American under the ticker symbol 'UMAC'. The company expects $5.0 million in gross proceeds. Underwriters granted a 45-day option for additional shares. Legal counsel and registration details provided for the Offering. Positive None. Negative None. Financial Analyst The successful closing of Unusual Machines, Inc.'s initial public offering represents a pivotal moment for the company, indicating a significant milestone in its corporate lifecycle. The capital raised, amounting to $5 million before expenses, is poised to bolster the company's financial position. The pricing of shares at $4.00, coupled with the commencement of trading on the NYSE American, introduces a new investment opportunity within the FPV drone technology sector—a niche yet expanding market.Investors and market participants should note the Over-allotment Option granted to underwriters, which could potentially increase the total capital raised by up to an additional $750,000, assuming the option is fully exercised. This mechanism is commonly deployed to manage potential excess demand and stabilize the stock post-IPO. The firm commitment basis of the offering underscores the underwriters' confidence in the company's prospects.One must consider the competitive landscape and the company's ability to utilize the proceeds to achieve growth targets. Given the innovative nature of FPV drone technology, R&D investment and market expansion strategies will likely be critical areas of focus. Financial performance post-IPO will be scrutinized for evidence of effective capital deployment. Market Research Analyst FPV drone technology is at the forefront of a rapidly evolving industry, with applications spanning from entertainment to commercial inspections. Unusual Machines, Inc.'s entrance into the public market serves as a litmus test for investor appetite within this segment. The company's strategic positioning and its ability to capitalize on market trends will be crucial in determining its success.The adoption rate of FPV drones, regulatory environment and technological advancements are key factors that will influence the company's market share and revenue growth. As investors evaluate the prospects of Unusual Machines, understanding these dynamics will provide a clearer picture of the potential return on investment.Additionally, the reputation and expertise of the underwriters and legal counsel involved can instill confidence in the offering, potentially impacting investor perception and the stock's performance. The role of Dominari Securities LLC, Revere Securities LLC and R.F. Lafferty & Co., Inc., as well as the legal firms Nason, Yeager, Gerson, Harris & Fumero, P.A. and Sichenzia Ross Ference Carmel LLP, should be acknowledged in this context. Legal Expert From a legal perspective, the completion of an initial public offering is contingent upon stringent regulatory compliance. The effectiveness of the registration statement filed with the U.S. Securities and Exchange Commission is a testament to Unusual Machines, Inc.'s adherence to the requisite disclosure and regulatory standards. Prospective investors should closely examine the final prospectus for insights into the company's financials, risk factors and strategic direction.The offering's legality is also contingent upon state and jurisdictional securities laws, emphasizing the importance of the statement that no offers or sales will occur in areas where such actions would be unlawful. This reflects a meticulous approach to regulatory compliance, which is critical in mitigating legal risks associated with public offerings.It is also notable that the offering does not constitute an open solicitation for public investment, as it is bound by the conditions outlined in the prospectus and registration statement. The legal framework governing the offering ensures transparency and investor protection, which are fundamental in maintaining market integrity. 02/16/2024 - 04:01 PM SAN JUAN, Puerto Rico, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Unusual Machines, Inc. (“Unusual Machines” or the “Company”), an emerging leader in first-person view (FPV) drone technology, announced today the closing of its initial public offering (the “Offering”) of 1,250,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on February 14, 2024, under the ticker symbol “UMAC”. The Company expects to receive aggregate gross proceeds of $5.0 million from the Offering, before deducting underwriting discounts and other related expenses. The Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 common shares at the public offering price (the “Over-allotment Option”), less underwriting discounts. The Offering was conducted on a firm commitment basis. Dominari Securities LLC, Revere Securities LLC, and R.F. Lafferty & Co., Inc. (the “Underwriters”) acted as the Underwriters for the Offering. Nason, Yeager, Gerson, Harris & Fumero, P.A. acted as U.S. counsel to the Company and Sichenzia Ross Ference Carmel LLP acted as U.S. counsel to the Underwriters in connection with the Offering. A registration statement on Form S-1 relating to the Offering has been filed with the U.S. Securities and Exchange Commission (the “SEC”) (File Number: 333-270519) and was declared effective by the SEC on February 13, 2024. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering, may be obtained from Dominari Securities LLC by email at info@dominarisecurities.com, by standard mail to Dominari Securities LLC, 725 Fifth Avenue, 23rd Floor New York, NY 10022, or by telephone at (212) 393-4500; or from Revere Securities LLC by email at contact@reveresecurities.com, by standard mail to Revere Securities LLC, 650 Fifth Avenue, 35th Floor, New York, NY 10019 USA, or by telephone at (212) 688-2238; or from R.F. Lafferty & Co., Inc. by email at info@rflafferty.com, by standard mail to R.F. Lafferty & Co., Inc., 40 Wall Street, 29th Floor, New York, NY 10005 USA, or by telephone at (212) 293-9090. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About Unusual Machines Unusual Machines is focused on becoming a first-person view (FPV) drone technology market leader. Simultaneously with the closing of the IPO, the Company acquired Fat Shark which is the leader in FPV, designing and manufacturing ultra-low latency video goggles for drone pilots, as well as Rotor Riot which is a rapidly growing ecommerce marketplace, backed by the largest community of FPV drone pilots in the world. The closing of the acquisitions is part of our vision to enable people to be part of the robotics revolution. Headquartered in Puerto Rico, the Company is bringing together great teams, valuable IP, and high-quality brands, in order to become a leader within the highly fragmented drone industry. For more information visit Unusual Machines at https://www.unusualmachines.com/. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including the closing of the Offering and the acquisitions, the Company’s goals, and the expected use of proceeds. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect us including unexpected market conditions and the risk factors contained in our Registration Statement, as amended, filed with the Securities and Exchange Commission. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. SOURCE: Unusual Machines, Inc. How many shares were offered in Unusual Machines, Inc.'s IPO? Unusual Machines, Inc. offered 1,250,000 shares of common stock in its IPO. At what price per share did Unusual Machines, Inc. offer its common stock? Unusual Machines, Inc. offered its common stock at a price of $4.00 per share. What is the ticker symbol for Unusual Machines, Inc. on NYSE American? The ticker symbol for Unusual Machines, Inc. on NYSE American is 'UMAC'. How much gross proceeds does Unusual Machines, Inc. expect from the Offering? Unusual Machines, Inc. expects aggregate gross proceeds of $5.0 million from the Offering. Who acted as the Underwriters for Unusual Machines, Inc.'s Offering? Dominari Securities LLC, Revere Securities LLC, and R.F. Lafferty & Co., Inc. acted as the Underwriters for Unusual Machines, Inc.'s Offering."
Sallie Mae Sets Date for Annual Meeting of Stockholders,2024-02-16T21:00:00.000Z,Low,Neutral,"Sallie Mae (Nasdaq: SLM) announces its 2024 annual meeting of stockholders to be held virtually on June 18, 2024. The company focuses on providing financing and support for education and life-long learning.","Sallie Mae Sets Date for Annual Meeting of Stockholders Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Sallie Mae (Nasdaq: SLM) announces its 2024 annual meeting of stockholders to be held virtually on June 18, 2024. The company focuses on providing financing and support for education and life-long learning. Positive None. Negative None. 02/16/2024 - 04:00 PM NEWARK, Del.--(BUSINESS WIRE)-- Sallie Mae® (Nasdaq: SLM) formally SLM Corporation, today announced its 2024 annual meeting of stockholders will take place on June 18, 2024, at 1 p.m. ET. The annual meeting will be held virtually and will be open to stockholders of record as of the close of business on April 22, 2024. Additional details will be included in the company’s proxy statement to be filed with the Securities and Exchange Commission in late April. Sallie Mae (Nasdaq: SLM) believes education and life-long learning, in all forms, help people achieve great things. As the leader in private student lending, we provide financing and know-how to support access to college and offer products and resources to help customers make new goals and experiences, beyond college, happen. Learn more at SallieMae.com. Commonly known as Sallie Mae, SLM Corporation and its subsidiaries are not sponsored by or agencies of the United States of America. Category: Corporate and Financial View source version on businesswire.com: https://www.businesswire.com/news/home/20240216512172/en/ Media: Rick Castellano 302.451.2541 Rick.Castellano@SallieMae.com Investors: Melissa Bronaugh 571.526.2455 Melissa.Bronaugh@SallieMae.com Source: Sallie Mae When is Sallie Mae's 2024 annual meeting of stockholders? The 2024 annual meeting of stockholders will take place on June 18, 2024. What time will the annual meeting be held? The annual meeting will be held at 1 p.m. ET. How can stockholders participate in the meeting? The meeting will be held virtually and open to stockholders of record as of April 22, 2024. What does Sallie Mae specialize in? Sallie Mae is a leader in private student lending, providing financing and support for access to college. Is Sallie Mae affiliated with the United States government? Sallie Mae and its subsidiaries are not sponsored by or agencies of the United States of America."
SOUTHWEST AIRLINES CELEBRATES EXPANDED TECHNICAL OPERATIONS FACILITY IN PHOENIX,2024-02-16T20:56:00.000Z,No impact,Very Positive,"Southwest Airlines (LUV) completes a $100 million project to expand its maintenance hangar at Phoenix Sky Harbor, nearly doubling its size and adding three new aircraft bays. The project aims to enhance fleet maintenance capabilities, support Technical Operations Employees, and promote sustainability. The expanded hangar achieves LEED Silver certification and signifies a long-standing commitment to Phoenix. Southwest's growth in the area is evident through increased daily flights, gate operations, and community engagement.","SOUTHWEST AIRLINES CELEBRATES EXPANDED TECHNICAL OPERATIONS FACILITY IN PHOENIX Rhea-AI Impact (No impact) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Southwest Airlines (LUV) completes a $100 million project to expand its maintenance hangar at Phoenix Sky Harbor, nearly doubling its size and adding three new aircraft bays. The project aims to enhance fleet maintenance capabilities, support Technical Operations Employees, and promote sustainability. The expanded hangar achieves LEED Silver certification and signifies a long-standing commitment to Phoenix. Southwest's growth in the area is evident through increased daily flights, gate operations, and community engagement. Positive None. Negative None. 02/16/2024 - 03:56 PM Southwest nearly doubles footprint of hangar and modernizes spaces where Technical Operations Employees maintain the carrier's fleet DALLAS, Feb. 16, 2024 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) is celebrating the completion of a multi-year, $100 million project, which nearly doubles the size of the airline's maintenance hangar at Phoenix Sky Harbor. The 90,000-square foot expansion adds three new aircraft bays to the facility, allowing the airline to work on up to five aircraft simultaneously and brings more maintenance shops to support the nearly 500 Southwest® Technical Operations Employees based at Sky Harbor. The project also included a larger facility for members of the airline's Provisioning and Ground Support Equipment Maintenance Teams that opened in 2020. ""The Safety-first work to support a continuous renewal of our fleet benefits our entire network and the community,"" said Andrew Watterson, Chief Operating Officer at Southwest Airlines. ""Investing in our Arizona-based People by equipping them with the latest tools, enhanced processes, and functional spaces is one of the most impactful investments we can make at Southwest Airlines and our future in Phoenix."" The expanded hangar has also achieved Leadership in Energy and Environmental Design (LEED) Silver certification. The expansion incorporated sustainable design features including the use of recycled content in over 30% of the building materials; the installation of high-reflectance roof and surrounding paving materials to reduce heat island effect; and the selection of building products from manufacturers with verified environmental performance. Southwest Airlines® first opened a Technical Operations base at Sky Harbor in 1986. In 1993, the airline moved into a new maintenance hangar facility to support its growth throughout the western half of the United States. Today, the carrier's Phoenix-based Technical Operations Teams accept new aircraft deliveries to prepare them to enter revenue service and maintain aircraft as part of daily and scheduled maintenance programs. In addition to Phoenix, Southwest operates hangar facilities in Atlanta, Chicago (Midway), Dallas (Love Field), Denver, Houston (Hobby), and Orlando. Construction is underway on a new hangar facility at Baltimore/Washington International Airport, which is anticipated to open in 2025. Decades-Long Partnership Leads to Runway for Future SuccessSouthwest began serving Sky Harbor in January 1982 with 13 daily flights. Today, the carrier offers up to 220 departures a day, providing nonstop service to 60 destinations across the United States and Mexico1. In 2022, the airline expanded its operations to operate from 32 gates including a new eight-gate concourse built to support Southwest's growth. The concourse included a new baggage handling system, more concessions, and Employee-support spaces. The airline's local workforce of more than 5,400 People share a passion for making the Phoenix area a great place to live, work, and visit. In 2023, Southwest Employees volunteered more than 10,000 hours while supporting more than 200 organizations focused on improving the quality of life for those who call Arizona home. ""We are grateful to Southwest Airlines for believing in Phoenix and going above and beyond to plant roots in our community, whether it's through expanded operations or countless volunteer hours with local organizations,"" said Phoenix Mayor Kate Gallego. ""Phoenix is proud to be a major service market for Southwest and we stand ready to continue welcoming millions more passengers to the Valley of the Sun!"" To download high-resolution images and broadcast-quality b-roll of Southwest's new Technical Operations facility, please visit the Southwest Airlines® Newsroom at swamedia.com/phoenixhangar. ABOUT SOUTHWEST AIRLINES CO. Southwest Airlines Co. operates one of the world's most admired and awarded airlines, offering its one-of-a-kind value and Hospitality at 121 airports across 11 countries. Southwest took flight in 1971 to democratize the sky through friendly, reliable, and low-cost air travel and now carries more air travelers flying nonstop within the United States than any other airline2. Based in Dallas and famous for an Employee-first corporate Culture, Southwest maintains an unprecedented record of no involuntary furloughs or layoffs in its history. By empowering its nearly 75,0003 People to deliver unparalleled Hospitality, the maverick airline cherishes a passionate loyalty among more than 137 million Customers carried in 2023. That formula for success brought industry-leading prosperity and 47 consecutive years4 of profitability for Southwest Shareholders (NYSE: LUV). Southwest leverages a unique legacy and mission to serve communities around the world including harnessing the power of its People and Purpose to put communities at the Heart of its success. Learn more by visiting Southwest.com/citizenship. As the airline with Heart, Southwest has set a goal to work toward achieving net zero carbon emissions by 2050. Southwest has also set near-term targets and a three-pillar strategy to achieve its environmental goals. Learn more by visiting Southwest.com/planet. 1Based on flight scheduled published through Nov. 2, 2024, as of Feb. 16, 2024.2Based on U.S. Dept. of Transportation quarterly Airline Origin & Destination Survey since Q1 2021 3Fulltime-equivalent active Employees41973-2019 annual profitability View original content to download multimedia:https://www.prnewswire.com/news-releases/southwest-airlines-celebrates-expanded-technical-operations-facility-in-phoenix-302064425.html SOURCE Southwest Airlines Co. What is the purpose of Southwest Airlines' $100 million project at Phoenix Sky Harbor? Southwest Airlines aims to expand its maintenance hangar, increase fleet maintenance capabilities, support Technical Operations Employees, and promote sustainability through the project. What is the size of the expansion at Phoenix Sky Harbor and how many new aircraft bays were added? The expansion nearly doubles the size of the hangar and adds three new aircraft bays, allowing up to five aircraft to be worked on simultaneously. What is the significance of achieving LEED Silver certification for the expanded hangar? The LEED Silver certification signifies the incorporation of sustainable design features in the expansion, promoting environmental responsibility and efficiency. How has Southwest Airlines contributed to Phoenix's community beyond its operational growth? Southwest Airlines demonstrates commitment to Phoenix through community engagement, volunteer hours, and support for local organizations, aiming to improve the quality of life in the area. Which other locations have hangar facilities operated by Southwest Airlines apart from Phoenix Sky Harbor? Southwest Airlines operates hangar facilities in Atlanta, Chicago (Midway), Dallas (Love Field), Denver, Houston (Hobby), and Orlando, with construction underway in Baltimore/Washington International Airport."
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4),2024-02-16T21:00:00.000Z,Low,Very Positive,"Marinus Pharmaceuticals, Inc. announced the grant of inducement awards to four new employees, involving non-qualified stock options for 64,425 shares of Common Stock at an exercise price of $10.21 per share. The stock options will vest over time, with 25% becoming exercisable after one year and the remaining 75% in 36 monthly installments, subject to continued employment.","Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Marinus Pharmaceuticals, Inc. announced the grant of inducement awards to four new employees, involving non-qualified stock options for 64,425 shares of Common Stock at an exercise price of $10.21 per share. The stock options will vest over time, with 25% becoming exercisable after one year and the remaining 75% in 36 monthly installments, subject to continued employment. Positive None. Negative None. 02/16/2024 - 04:00 PM RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 64,425 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). These stock option grants have an exercise price of $10.21 per share, which is equal to the closing price of the Common Stock on February 12, 2024 (date of grant for such stock options). All of the stock options will vest and become exercisable as to 25% of the underlying shares on the one-year anniversary of the applicable employee’s start date of employment, and will vest and become exercisable as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter on each monthly anniversary, subject to the applicable employee’s continued employment with Marinus on such vesting dates. These stock options were granted as inducements material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant. About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com. Forward-Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216567771/en/ Company Contacts Investors Jim DeNike Senior Director, Investor Relations Marinus Pharmaceuticals, Inc. jdenike@marinuspharma.com Media Molly Cameron Director, Corporate Communications & Investor Relations Marinus Pharmaceuticals, Inc. mcameron@marinuspharma.com Source: Marinus Pharmaceuticals What did Marinus Pharmaceuticals announce regarding inducement awards? Marinus Pharmaceuticals announced the grant of inducement awards to four new employees in the form of non-qualified stock options for 64,425 shares of Common Stock. How many shares of Common Stock were involved in the grant of inducement awards? The grant of inducement awards involved 64,425 shares of Common Stock. What is the exercise price per share for the stock options? The exercise price per share for the stock options is $10.21. How will the stock options vest over time? The stock options will vest with 25% becoming exercisable after one year and the remaining 75% in 36 monthly installments. What is the significance of Nasdaq Listing Rule 5635(c)(4) in this announcement? The inducement awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducements for the employees entering into employment with Marinus."
Fisker Signs New Dealer Partners in US as Strategic Business Shift Continues,2024-02-16T20:47:00.000Z,Neutral,Positive,"Fisker (NYSE: FSR) announces strategic shift to Dealer Partnership model, signing four US dealers. Dealers include Mills Automotive Group, Ourisman Fisker, Classic Fisker, and Long Island Fisker, expanding to seven locations in North Carolina, South Carolina, Georgia, Maryland, New York, and New Jersey. The model aims to scale Fisker Ocean deliveries and future model production, attracting interest from over 250 dealers globally. Fisker Ocean SUV offers a range of up to 360 mi, lowest carbon footprint, and uses recycled materials.","Fisker Signs New Dealer Partners in US as Strategic Business Shift Continues Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary Fisker (NYSE: FSR) announces strategic shift to Dealer Partnership model, signing four US dealers. Dealers include Mills Automotive Group, Ourisman Fisker, Classic Fisker, and Long Island Fisker, expanding to seven locations in North Carolina, South Carolina, Georgia, Maryland, New York, and New Jersey. The model aims to scale Fisker Ocean deliveries and future model production, attracting interest from over 250 dealers globally. Fisker Ocean SUV offers a range of up to 360 mi, lowest carbon footprint, and uses recycled materials. Positive None. Negative None. Automotive Industry Analyst The expansion of Fisker's dealer network through its Dealer Partnership model represents a strategic pivot from a direct-to-consumer approach to a more traditional dealership model. This move suggests Fisker's recognition of the importance of physical retail presence in the automotive sector, particularly for electric vehicles (EVs) which may require consumer education and hands-on experience to drive adoption. The partnership with established dealers could enhance customer trust and provide a more robust infrastructure for vehicle servicing and support.From an industry perspective, the dealer partnership approach could alleviate capital expenditure on company-owned stores and leverage the existing dealer networks' market penetration capabilities. This asset-light strategy may enable Fisker to scale operations more efficiently and focus resources on production and R&D. However, it's critical to monitor how this model affects profit margins, considering the potential revenue split with dealers.The announcement of over 250 dealers expressing interest in the partnership indicates a strong market appetite for Fisker's EV offerings. The focus on no-haggle pricing and superb service could resonate with consumers tired of traditional car-buying experiences. However, the success of this model will depend on the execution of these value propositions and the ability to maintain consistent pricing across larger market territories. Environmental Sustainability Analyst Fisker's emphasis on sustainability is notable in the electric vehicle market. The company claims the lowest published carbon footprint for an electric SUV, which could appeal to environmentally conscious consumers. The use of recycled and bio-based materials, production at a carbon-neutral facility and the integration of rooftop solar panels are differentiators that may enhance Fisker's brand image as a leader in sustainable practices within the industry.These sustainability features, particularly the innovative use of rooftop solar panels that potentially add up to 1,500 miles per year of range, could serve as a unique selling point. However, it is important to evaluate the real-world applicability of these features. For instance, the additional range provided by solar panels is dependent on ideal conditions, which may not be consistently achievable in all geographies or driving patterns.As the EV market becomes more crowded, Fisker's sustainability claims could help it stand out, but it will be essential to validate these claims and ensure they translate into tangible benefits for consumers. The long-term impact on Fisker's market share and brand loyalty will depend on the company's ability to deliver on these environmental promises. Financial Analyst The dealer partnership strategy could have implications for Fisker's financials. The company's ability to scale up for the Fisker Ocean deliveries and higher volume production without significant capital investments in a retail network could improve its cash flow and reduce financial risks associated with expansion. This approach may also appeal to investors looking for asset-light business models in capital-intensive industries like automotive manufacturing.However, the impact on revenue and margins will be critical to assess. The shift from direct sales to a dealership model typically involves sharing a portion of the revenue with dealers. The challenge for Fisker will be to manage this trade-off while maintaining competitive pricing and service quality. The initial pricing of the Ocean SUV at $38,999 positions it competitively in the EV market, but maintaining profitability at this price point through a dealer network will require careful management of cost structures.Furthermore, the market's reception of the Fisker Ocean, with its claimed range and sustainability features, will be a key determinant of the company's financial performance. The EV market is rapidly evolving and Fisker's success will hinge on its ability to capture market share from established players and new entrants alike. Monitoring early sales data and customer feedback as the dealer network expands will provide valuable insights into the effectiveness of Fisker's strategic shift. 02/16/2024 - 03:47 PM Fisker has now signed four dealer partners in the US, with additional signings expected in the coming weeks. New dealers signed are Ourisman Fisker, Classic Fisker, and Long Island Fisker, in addition to the previously announced Mills Automotive Group. Collectively, these dealers will be selling vehicles in North Carolina, South Carolina, Georgia, Maryland, New York, and New Jersey at seven locations. Fisker has received interest from over 250 dealers in North America and the rest of the world regarding our new Dealer Partnership model. The Dealer Partnership model is proving attractive to dealers as they are gaining access to an American EV-only brand with a unique business approach. On January 4, Fisker announced a strategic shift from direct sales to a Dealer Partnership model which will enable it to significantly scale for Fisker Ocean deliveries and higher volume production of additional future models. LOS ANGELES--(BUSINESS WIRE)-- Fisker Inc. (NYSE: FSR) (“Fisker”), driven by a mission to create the world’s most emotional and sustainable electric vehicles, announced today that it has signed a total of four dealer partners in the US as it undertakes a strategic shift in its business model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215727857/en/Fisker CEO Henrik Fisker and Mike Domenicone, Principal and owner of Classic Fisker, signing at NADA in Las Vegas. (Photo: Fisker Inc.) Dealers joining the Dealer Partnership program are the Mills Automotive Group, Ourisman Fisker, Classic Fisker, and Long Island Fisker. “I’m excited by the rapid progress of the Dealer Partnership model, which we announced just over a month ago,” Chairman and CEO Henrik Fisker said. “The dealer partners we have signed up so far share a commitment to the future of electric vehicles and to their communities, many of which they have served for multiple generations. I believe our customers will find that each of these dealer partners plan to provide top-level service and ongoing relationship building for owners of the class-leading and award-winning Fisker Ocean SUV.” Mills signed up to be Fisker’s first dealer partner in the US at the company’s inaugural dealer open house on January 31 and will open three Fisker dealerships in Charlotte and Raleigh, NC (Triad Fisker); and Greenville, SC (Stateline Fisker). Ourisman Fisker and Classic Fisker both signed at the National Automobile Dealers Association Show in Las Vegas earlier this month, and Long Island Fisker signed this week. Ourisman Fisker, part of a fourth-generation dealership group, will be located in Rockville, MD, in the Washington, DC area. Classic Fisker will open a location in Atlanta, Long Island Fisker plans to open a location in that region of New York state and another in New Jersey. Altogether, these dealer partners intend to open seven locations. On January 4, 2024, Fisker announced that it would engage in a strategic shift from direct sales to customers in North America to an innovative Dealer Partnership model. The model combines the goal of offering its customers no-haggle pricing on Fisker vehicles (where permitted) and superb service while also providing dealer partners with larger market territories, so they can maintain pricing without concern for local competition. Taken together, these goals represent a win-win-win for customers, dealers, and Fisker. The transition to dealer partners aligns with Fisker’s asset light business model, which enables the company to significantly scale for Fisker Ocean deliveries and higher volume production of additional future models. Fisker has received interest from over 250 dealers in North America and the rest of the world since announcing its strategic shift. Fisker is currently delivering the all-electric Ocean SUV, which starts at $38,999, in the US, Canada, and Europe. In the US, the Ocean has an EPA range of up to 360 mi 1, which is the longest range of any new electric SUV in its class 2. The Fisker Ocean has the lowest published carbon footprint of any electric SUV, uses over 110 lbs. of recycled and bio-based materials, is built at a carbon-neutral facility, and integrates rooftop solar panels, adding up to 1,500 miles/year of range 3. 1 EPA estimated range. Mid-size SUVs. Measurements conducted with standard 20” wheels. Actual results may vary for many reasons, including driving conditions, wheel size, state of battery charge, and how the vehicle is driven and maintained. 2 Mid-size SUVs in comparable price segment. 3 Based on Fisker simulations. Ideal conditions assume solar irradiation of 5.4 kWh/m2/day and steady commuter driving. Actual results vary with conditions such as external environment and vehicle use. About Fisker Inc. California-based Fisker Inc. is revolutionizing the automotive industry by designing and developing individual mobility in alignment with nature. Passionately driven by a vision of a clean future for all, the company is on a mission to create the world’s most sustainable and emotional electric vehicles. To learn more, visit Fiskerinc.com and enjoy exclusive content across Fisker's social media channels: Facebook, Instagram, Twitter, YouTube, and LinkedIn. Download the revolutionary new Fisker mobile app from the App Store or Google Play. Forward-Looking Statements This press release includes forward-looking statements, which are subject to the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “feel,” “believes,” “expects,” “estimates,” “projects,” “intends,” “should,” “is to be,” or the negative of such terms, or other comparable terminology and include, among other things, the quote from our chief executive officer, any potential future automotive original equipment manufacturer (or equipment or part manufacturer) transactions and other future events that involve risks and uncertainties. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due to many factors, including, but not limited to: Fisker's limited operating history; Fisker's ability to enter into additional manufacturing and other contracts with Magna or tier-one suppliers in order to execute on its business plan; the risk that OEM and supply partners do not meet agreed-upon timelines or experience capacity constraints; Fisker may experience significant delays in the design, manufacture, regulatory approval, launch and financing of its vehicles; Fisker's ability to execute its business model, including market acceptance of its planned products and services; Fisker's inability to retain key personnel and to hire additional personnel; competition in the electric vehicle market; Fisker's inability to develop a sales distribution or dealership network; and the ability to protect its intellectual property rights; and those factors discussed in Fisker's Annual Report on Form 10-K, under the heading “Risk Factors”, filed with the Securities and Exchange Commission (the “SEC”), as supplemented by Quarterly Reports on Form 10-Q, and other reports and documents Fisker files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and Fisker undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20240215727857/en/ European Media: Press.europe@fiskerinc.com US Media Fisker@GODRIVEN360.com Customer service: Support@fiskerinc.com Fisker Inc. Communications: Matthew DeBord VP, Communications mdebord@fiskerinc.com Franziska Queling Regional Head of Public Relations, Europe fqueling@fiskerinc.com Investor Relations: Eric Goldstein Head of Investor Relations egoldstein@fiskerinc.com Source: Fisker Inc. How many dealer partners has Fisker signed in the US? Fisker has signed a total of four dealer partners in the US. What is the Dealer Partnership model introduced by Fisker? Fisker announced a strategic shift from direct sales to a Dealer Partnership model to scale Fisker Ocean deliveries and future model production. Where will the new dealers be selling vehicles? The new dealers will be selling vehicles in North Carolina, South Carolina, Georgia, Maryland, New York, and New Jersey at seven locations. What is the starting price of the Fisker Ocean SUV? The Fisker Ocean SUV starts at $38,999. How many lbs. of recycled and bio-based materials does the Fisker Ocean SUV use? The Fisker Ocean SUV uses over 110 lbs. of recycled and bio-based materials."
"Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024",2024-02-16T20:38:00.000Z,Low,Positive,"Iovance Biotherapeutics, Inc. announces FDA approval for novel polyclonal TIL therapies for cancer patients. The company will host a conference call and live webcast to discuss the approval.","Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags conferences Rhea-AI Summary Iovance Biotherapeutics, Inc. announces FDA approval for novel polyclonal TIL therapies for cancer patients. The company will host a conference call and live webcast to discuss the approval. Positive None. Negative None. 02/16/2024 - 03:38 PM SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024. To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e. To listen to the live or archived webcast, please register at https://edge.media-server.com/mmc/p/uqbbcfz4/. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year. About Iovance Biotherapeutics, Inc.Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com. Forward-Looking Statements Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled ""Risk Factors"" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including AMTAGVI, for which we obtain U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”), or other regulatory authority approval; the risk that the EMA or other regulatory authorities may not approve or may delay approval for our biologics license application (“BLA”) submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including AMTAGVI, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including AMTAGVI, or product candidates, respectively; our ability or inability to manufacture our therapies using third party manufacturers or at our own facility may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including AMTAGVI, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risk that future competitive or other market factors may adversely affect the commercial potential for AMTAGVI; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of AMTAGVI will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the effects of the COVID-19 pandemic; and other factors, including general economic conditions and regulatory developments, not within our control. CONTACTSIovance Biotherapeutics, Inc:Sara Pellegrino, IRCSenior Vice President, Investor Relations & Corporate Communications650-260-7120 ext. 264Sara.Pellegrino@iovance.com Jen SaundersSenior Director, Investor Relations & Corporate Communications267-485-3119Jen.Saunders@iovance.com What did Iovance Biotherapeutics announce? Iovance Biotherapeutics announced FDA approval for novel polyclonal TIL therapies for cancer patients. When will the conference call and live webcast take place? The conference call and live webcast will take place at 4:15 p.m. ET on February 16, 2024. Where can one register for the conference call and live webcast? To participate, register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e. How long will the archived webcast be available? The archived webcast will be available for one year on IR.Iovance.com."
"Euroseas Ltd. Sets Date for the Release of Fourth Quarter 2023 Results, Conference Call and Webcast",2024-02-16T20:38:00.000Z,Low,Neutral,"Euroseas Ltd. (NASDAQ: ESEA) will release its Q4 2023 financial results on February 21, 2024. A conference call and webcast will follow to discuss the results.","Euroseas Ltd. Sets Date for the Release of Fourth Quarter 2023 Results, Conference Call and Webcast Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary Euroseas Ltd. (NASDAQ: ESEA) will release its Q4 2023 financial results on February 21, 2024. A conference call and webcast will follow to discuss the results. Positive None. Negative None. 02/16/2024 - 03:38 PM ATHENS, Greece, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it will release its financial results for the fourth quarter ended December 31, 2023, on February 21, 2024 before market opens in New York. On the same day, Wednesday, February 21, 2024 at 9:00 a.m. Eastern Time, the Company's management will host a conference call and webcast to discuss the results. Conference Call details:Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “Euroseas” to the operator and/or conference ID 13744700.Click here for additional participant International Toll-Free access numbers. Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option. Audio Webcast ‐ Slides Presentation:There will be a live and then archived webcast of the conference call and accompanying slides, available on the Company’s website. To listen to the archived audio file, visit our website http://www.euroseas.gr and click on Company Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. The slide presentation for the fourth quarter ended December 31, 2023, will also be available in PDF format minutes prior to the conference call and webcast, accessible on the company's website (www.euroseas.gr) on the webcast page. Participants to the webcast can download the PDF presentation. About Euroseas Ltd. Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas' operations are managed by Eurobulk Ltd., anISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements. The Company has a fleet of 20 vessels, including 13 Feeder and 7 Intermediate containerships. Euroseas 20containerships have a cargo capacity of 61,661 teu. On a fully delivered basis of its vessels under construction the Company’s fleet will increase to 26 containerships with a cargo capacity of about 75,461 teu. Visit the Company’s website www.euroseas.gr Company ContactInvestor Relations / Financial MediaTasos AslidisChief Financial OfficerEuroseas Ltd.11 Canterbury Lane,Watchung, NJ 07069Tel. (908) 301-9091E-mail: aha@euroseas.grNicolas BornozisMarkella KaraCapital Link, Inc.230 Park Avenue, Suite 1540New York, NY 10169Tel. (212) 661-7566E-mail: euroseas@capitallink.com When will Euroseas Ltd. release its financial results for Q4 2023? Euroseas Ltd. will release its financial results for the fourth quarter ended December 31, 2023, on February 21, 2024. What is the ticker symbol for Euroseas Ltd.? The ticker symbol for Euroseas Ltd. is ESEA. How can participants join the conference call to discuss the financial results? Participants can dial into the call using the numbers provided or register for the call using the call me option for a faster connection. Where can participants find the archived audio file of the conference call? Participants can listen to the archived audio file on Euroseas Ltd.'s website under Company Presentations on the Investor Relations page. Will the slide presentation for Q4 2023 be available for download? Yes, the slide presentation for the fourth quarter ended December 31, 2023, will be available in PDF format on Euroseas Ltd.'s website for download."
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma,2024-02-16T20:19:00.000Z,Moderate,Neutral,"Iovance Biotherapeutics, Inc. (IOVA) receives FDA approval for AMTAGVI, a groundbreaking T cell therapy for advanced melanoma. AMTAGVI is the first individualized T cell therapy for solid tumor cancer, offering hope to patients with limited treatment options. The therapy deploys patient-specific TIL cells to fight cancer, achieving deep and durable responses in clinical trials. The approval is based on safety and efficacy results from the C-144-01 trial, with 31.5% of patients achieving an objective response. AMTAGVI is manufactured at the Iovance Cell Therapy Center in Philadelphia and must be administered in Authorized Treatment Centers (ATCs). Iovance is dedicated to providing access to AMTAGVI for patients with advanced melanoma through a comprehensive support program, IovanceCares.","Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Iovance Biotherapeutics, Inc. (IOVA) receives FDA approval for AMTAGVI, a groundbreaking T cell therapy for advanced melanoma. AMTAGVI is the first individualized T cell therapy for solid tumor cancer, offering hope to patients with limited treatment options. The therapy deploys patient-specific TIL cells to fight cancer, achieving deep and durable responses in clinical trials. The approval is based on safety and efficacy results from the C-144-01 trial, with 31.5% of patients achieving an objective response. AMTAGVI is manufactured at the Iovance Cell Therapy Center in Philadelphia and must be administered in Authorized Treatment Centers (ATCs). Iovance is dedicated to providing access to AMTAGVI for patients with advanced melanoma through a comprehensive support program, IovanceCares. Positive FDA approval for AMTAGVI, a one-time individualized T cell therapy for advanced melanoma AMTAGVI deploys patient-specific TIL cells to fight cancer, offering hope to patients with limited treatment options 31.5% of patients achieved an objective response in clinical trials, with deep and durable responses Manufactured at the Iovance Cell Therapy Center in Philadelphia, must be administered in Authorized Treatment Centers (ATCs) Comprehensive support program, IovanceCares, available for patients with advanced melanoma Negative None. Oncology Doctor The approval of AMTAGVI by the FDA marks a significant milestone in the treatment of advanced melanoma, particularly for patients who have exhausted other therapeutic options. This novel T cell therapy employs patient-derived tumor infiltrating lymphocytes (TILs), which are expanded ex vivo and reintroduced to the patient's system to target and destroy cancer cells. This personalized approach leverages the body's own immune system, potentially offering a more precise and effective treatment compared to non-specific systemic therapies.Such advancements in oncological care can lead to a paradigm shift in how solid tumors are treated, potentially improving patient outcomes and survival rates. However, it is critical to monitor the long-term efficacy and safety of AMTAGVI, as the therapy comes with a boxed warning for severe side effects, which could affect its adoption and usage in clinical settings. Ongoing and future clinical trials will be pivotal in establishing its place in the standard of care for melanoma and possibly other solid tumors. Medical Research Analyst The accelerated approval of AMTAGVI is based on the overall response rate (ORR) and duration of response observed in the C-144-01 clinical trial. The reported ORR of 31.5% and a median duration of response not yet reached at an 18.6-month follow-up are promising. However, it's important to note that accelerated approval is contingent upon the verification of clinical benefit in confirmatory trials, which in this case is the ongoing Phase 3 TILVANCE-301 trial.Investors and stakeholders should be aware that the long-term success of AMTAGVI hinges on the outcomes of this confirmatory trial. Positive results could solidify its market position and lead to wider adoption, while any negative findings could result in a reevaluation of its approval status. Moreover, the therapy's unique manufacturing process and the need for specialized treatment centers may impact scalability and accessibility, influencing market penetration and the company's financial performance. Market Research Analyst The introduction of AMTAGVI as a treatment for advanced melanoma addresses a significant unmet medical need and opens a new market segment for personalized T cell therapies. With approximately 8,000 U.S. melanoma deaths annually, the potential market size for AMTAGVI is noteworthy. The establishment of the Iovance Cell Therapy Center (iCTC) for scalable manufacturing and the network of Authorized Treatment Centers (ATCs) are strategic moves to facilitate the delivery of this complex therapy.Investor confidence may be bolstered by Iovance's commitment to patient access through support programs like IovanceCares™, which could enhance patient adherence and treatment outcomes. As the company expands its clinical trials to additional solid tumor types, which represent a significant portion of the U.S. cancer burden, the long-term growth prospects for Iovance could be substantial, assuming the clinical success of AMTAGVI and its adoption in the oncology community. 02/16/2024 - 03:19 PM AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion. AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. This indication is approved under an accelerated approval based on overall response rate (ORR) and duration of response. Iovance is also conducting TILVANCE-301, a Phase 3 trial to confirm clinical benefit. AMTAGVI is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer. The proposed mechanism for AMTAGVI offers a new cell therapy approach that deploys patient-specific T cells called TIL cells. When cancer is detected, the immune system creates TIL cells to locate, attack, and destroy cancer. TIL cells recognize distinctive tumor markers on the cell surface of each person’s cancer. When cancer develops and prevails, the body’s natural TIL cells can no longer perform their intended function to fight cancer. AMTAGVI is manufactured using a proprietary process to collect and expand a patient’s unique T cells from a portion of their tumor. AMTAGVI returns billions of the patient’s T cells back to the body to fight their cancer.* Authorized Treatment Centers (ATCs) will administer AMTAGVI to patients as part of a treatment regimen that includes lymphodepletion and a short course of high-dose PROLEUKIN® (aldesleukin). A Media Snippet accompanying this announcement is available by clicking on this link. “The accelerated approval of AMTAGVI™ is the first step in realizing Iovance’s ambition to usher in the next generation of cell therapy by bringing this breakthrough to patients with advanced solid tumors,” said Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President of Iovance. “Given the significant unmet needs in the advanced melanoma community, we are proud to offer a personalized, one-time therapeutic option for these patients. We are continuing our development efforts to address additional unmet medical needs in patients with solid tumor cancers, making our novel cell therapies available to more patients with melanoma and other types of cancers.” Each year, approximately 8,000 people in the U.S. die from melanoma.1 Until now, there have been no FDA-approved treatment options for patients with advanced melanoma whose disease progressed following initial treatment with an immune checkpoint inhibitor and, if appropriate, targeted therapy. “The approval of AMTAGVI™ offers hope to those with advanced melanoma who have progressed following initial standard of care therapies, as the current treatment options are not effective for many patients,” said Samantha R. Guild, J.D., President, AIM at Melanoma Foundation. “This one-time cell therapy represents a promising innovation for the melanoma community, and we are excited by its potential to transform care for patients who are in dire need of additional therapeutic options.” The FDA approval is based on safety and efficacy results from the C-144-01 clinical trial. C-144-01 is a global, multicenter trial investigating AMTAGVI in patients with advanced melanoma previously treated with anti-PD-1 therapy and targeted therapy, where applicable. AMTAGVI demonstrated deep and durable responses. The primary efficacy analysis set included 73 patients from Cohort 4 who received the recommended AMTAGVI dose from an approved manufacturing facility. Among the 73 patients, 31.5% achieved an objective response by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) with a median duration of response not reached at 18.6 months follow-up2 (43.5% of responses had a duration greater than 12 months). Additionally, the supporting pooled efficacy set included a total of 153 patients from Cohort 4 and Cohort 2. Among the 153 patients, 31.4% achieved an objective response by RECIST 1.1 with a median duration of response not reached at 21.5 months follow-up2 (54.2% of responses had a duration greater than 12 months). The detailed results of clinical trial C-144-01 are published in The Journal for ImmunoTherapy of Cancer (Chesney 2022). AMTAGVI is for autologous use only. AMTAGVI has a boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment. Warnings and precautions include treatment-related mortality, prolonged severe cytopenia, internal organ hemorrhage, severe infection, cardiac disorder, respiratory failure, acute renal failure, and hypersensitivity reactions. Please see Important Safety Information and Prescribing Information below. “This landmark FDA approval reflects significant advancements in TIL cell therapy since we initially showed that TIL cells isolated from patients with metastatic melanoma could be expanded in the lab and returned to the patient to mediate cancer regression,” said Steven Rosenberg, M.D., Ph.D., Chief, Surgery Branch, National Cancer Institute, and a TIL and immunotherapy pioneer. “This approval is transformative for the entire research field and supports continued investigation of TIL cell therapy across additional types of solid tumors.” “One-time treatment with AMTAGVI™ offered clinically meaningful and deep, durable responses in the Phase 2 clinical trial, and I am excited by its potential as a much-needed new treatment option for the many advanced melanoma patients who progress on the current standard of care,” said Dr. Alexander N. Shoushtari, Melanoma Oncologist & Cellular Therapist at Memorial Sloan Kettering Cancer Center. “This welcome news represents an important step forward in harnessing cell therapy to treat solid tumors,” added Dr. Jae Park, Chief of Cellular Therapy Service at Memorial Sloan Kettering Cancer Center. AMTAGVI will be manufactured in Philadelphia at the Iovance Cell Therapy Center (iCTC), with capacity for up to several thousand patients annually, including a nearby contract manufacturer. Additional expansion at iCTC is underway, which will significantly increase this capacity over the next few years. iCTC is the first FDA-approved, centralized, and scalable manufacturing facility dedicated to producing TIL cell therapies for patients with solid tumors. AMTAGVI must be administered in an ATC, and more than 30 ATCs are prepared to collect and ship tumor tissue from patients for AMTAGVI manufacturing. Iovance is dedicated to providing access to AMTAGVI for patients with advanced melanoma. A comprehensive support program, IovanceCares™, is now available for patients and ATCs throughout the treatment journey. IovanceCares will also offer copay support, financial assistance, and travel and lodging assistance for eligible patients during AMTAGVI therapy. For more information, physicians and patients may call 833-400-IOVA (4682) or visit www.iovancecares.com. Iovance is investigating AMTAGVI in frontline advanced melanoma in the Phase 3 confirmatory trial, TILVANCE-301, as well as additional solid tumor types, which represent 91% of the cancers in the U.S.1 For more information, please visit: https://www.iovance.com/clinical-trials/. 1 National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2023 Estimates. https://seer.cancer.gov. Accessed February 2024.2 Kaplan-Meier estimate of median potential follow-up for duration of response.* A single dose of AMTAGVI contains 7.5 × 109 to 72 × 109 viable cells. Webcast and Conference CallIovance will host a conference call and live audio webcast today to discuss the FDA approval of AMTAGVI. Details will be shared in a subsequent announcement. About the C-144-01 Clinical Trial C-144-01 is a global, multicenter Phase 2 study in which patients received treatment with lifileucel. The study enrolled patients with metastatic melanoma who were previously treated with at least one systemic therapy, including a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK inhibitor. Efficacy was established on the basis of objective response rate (ORR), and duration of response (DOR) by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The pivotal Cohort 4 and supportive Cohort 2 of Study C-144-01 enrolled patients that met the same primary eligibility criteria, had the same assessments, and had received the same regimen and AMTAGVI that was produced using the same manufacturing process, and product formulation. The detailed results of C-144-01 were published in the Journal for ImmunoTherapy of Cancer in 2022. What is AMTAGVI (lifileucel)? AMTAGVI is a prescription medicine used to treat adults with a type of skin cancer that cannot be removed surgically or has spread to other parts of the body called unresectable or metastatic melanoma. AMTAGVI is used when your melanoma has not responded or stopped responding to a PD-1 blocking drug either by itself or in a combination, and if your cancer is BRAF mutation positive, a BRAF inhibitor drug with or without a MEK inhibitor drug that has also stopped working. The approval of AMTAGVI is based on a study that measured response rate. Continued approval for this use may depend on the results of an ongoing study to confirm benefit. Important Safety Information What is the most important information that I should know about AMTAGVI? You will likely be in a hospital prior to and after receiving AMTAGVI. Before taking AMTAGVI, tell your healthcare provider about all of your medical conditions, including if you: Have any lung, heart, liver or kidney problemsHave low blood pressureHave a recent or active infection or other inflammatory conditions including cytomegalovirus (CMV) infection, hepatitis B or C or human immunodeficiency virus (HIV) infectionAre pregnant, think you may be pregnant, or plan to become pregnantAre breastfeedingNotice the symptoms of your cancer are getting worseHave had a vaccination in the past 28 days or plan to have one in the next few monthsHave been taking a blood thinner Tell your doctor about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive AMTAGVI? AMTAGVI is made from your surgically removed tumor. Tumor derived T cells are grown in a manufacturing center at the end of which they number in the billions of cells.Your tumor tissue is sent to a manufacturing center to make AMTAGVI. It takes about 34 days from the time your tumor tissue is received at the manufacturing center until AMTAGVI is available to be shipped back to your healthcare provider, but the time may vary. Your AMTAGVI will be provided in 1-4 patient-specific infusion bag(s) containing 100 mL to 125 mL of viable (alive) cells per bag.After your AMTAGVI arrives at your treating institution, your healthcare provider will give you lymphodepleting chemotherapy to prepare your body.Approximately 30 to 60 minutes before you are given AMTAGVI, you may be given other medicines including: Medicines for an allergic reaction (anti-histamines)Medicines for fever (such as acetaminophen) Your AMTAGVI will be provided in 1 to 4 infusion bag(s) containing 100 mL to 125 mL of viable cells per bag. When your body is ready for AMTAGVI infusion, your healthcare provider will give AMTAGVI to you by intravenous infusion. This usually takes less than 90 minutes. After getting AMTAGVI Beginning 3 to 24 hours after AMTAGVI is given, you may be given up to 6 doses of IL-2 (aldesleukin) every 8 to 12 hours via intravenous infusion. Your doctor may discontinue IL-2 (aldesleukin) infusion any time if you have severe side effects. You will have to stay in the hospital until you have completed the IL-2 (aldesleukin) treatment and you have recovered from any serious side effects associated with the AMTAGVI treatment. You should plan to stay within 2 hours of the location where you received your treatment for several weeks after getting AMTAGVI. Your healthcare provider will check to see if your treatment is working and help you with any side effects that occur. What are the possible side effects of AMTAGVI? The most common side effects of the AMTAGVI treatment include chills, fever, low white blood cell count (may increase risk of infections), fatigue, low red blood cell count (may cause you to feel tired or weak), fast or irregular heartbeat, rash, low blood pressure, and diarrhea. These are not all the possible side effects of the AMTAGVI treatment. Talk with your healthcare provider for more information about AMTAGVI. You can ask your healthcare provider for information about AMTAGVI that is written for healthcare professionals. You may report side effects to Iovance at 1-833-400-4682, or to the FDA, at 1-800-FDA-1088 or at www.fda.gov/medwatch. Please see Full Prescribing Information and Patient Information, including Boxed Warning, for additional Important Safety Information. About Iovance Biotherapeutics, Inc.Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s AMTAGVI™ is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. For more information, please visit www.iovance.com. AMTAGVI™ and its accompanying design marks, PROLEUKIN®, IOVANCE®, and IOVANCECARES™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements, including, without limitation, the statements by Frederick Vogt, Ph.D., J.D., Samantha R. Guild, J.D., Steven Rosenberg, M.D., Ph.D., Dr. Alexander N. Shoushtari, and Dr. Jae Park, made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled ""Risk Factors"" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including AMTAGVI, for which we obtain U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”), or other regulatory authority approval; the risk that the EMA or other regulatory authorities may not approve or may delay approval for our biologics license application (“BLA”) submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including AMTAGVI, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including AMTAGVI, or product candidates, respectively; our ability or inability to manufacture our therapies using third party manufacturers or at our own facility may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including AMTAGVI, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risk that future competitive or other market factors may adversely affect the commercial potential for AMTAGVI; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of AMTAGVI will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the effects of the COVID-19 pandemic; and other factors, including general economic conditions and regulatory developments, not within our control. CONTACTSIovance Biotherapeutics, Inc:Sara Pellegrino, IRCSenior Vice President, Investor Relations & Corporate Communications650-260-7120 ext. 264Sara.Pellegrino@iovance.com Jen SaundersSenior Director, Investor Relations & Corporate Communications267-485-3119Jen.Saunders@iovance.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b01f4de7-8dc3-47e6-bada-df2a7ec36604 What is the FDA approval for IOVA related to? The FDA approval is for AMTAGVI, a T cell therapy for advanced melanoma. How does AMTAGVI work? AMTAGVI deploys patient-specific TIL cells to locate, attack, and destroy cancer. What percentage of patients achieved an objective response in clinical trials? 31.5% of patients achieved an objective response in clinical trials. Where is AMTAGVI manufactured? AMTAGVI is manufactured at the Iovance Cell Therapy Center in Philadelphia. What support program is available for patients receiving AMTAGVI? A comprehensive support program, IovanceCares, is available for patients with advanced melanoma."
Innodata to Report Fourth Quarter and Fiscal Year 2023 Results,2024-02-16T20:30:00.000Z,Low,Negative,"Innodata Inc. (NASDAQ: INOD) will release its Fourth Quarter and Fiscal Year 2023 results on February 22, 2024. An investor conference call is scheduled for 5:00 PM Eastern time on the same day. Investors can access the call via phone or webcast, with replays available for 30 days. Details for accessing the call are provided in the press release.","Innodata to Report Fourth Quarter and Fiscal Year 2023 Results Rhea-AI Impact (Low) Rhea-AI Sentiment (Negative) Tags conferences earnings Rhea-AI Summary Innodata Inc. (NASDAQ: INOD) will release its Fourth Quarter and Fiscal Year 2023 results on February 22, 2024. An investor conference call is scheduled for 5:00 PM Eastern time on the same day. Investors can access the call via phone or webcast, with replays available for 30 days. Details for accessing the call are provided in the press release. Positive None. Negative None. 02/16/2024 - 03:30 PM NEW YORK, NY / ACCESSWIRE / February 16, 2024 / INNODATA INC. (NASDAQ:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2023 results after the market closes on Thursday, February 22, 2024. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com.Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day.The call-in numbers for the conference call are:1-888-506-0062 (Domestic)+1 973-528-0011 (International)Participant Access Code 3834511-877-481-4010 (Domestic Replay) +1 919-882-2331 (International Replay)Replay Passcode 49773Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of www.innodata.com. Please note that the Webcast feature will be in listen-only mode.Call-in or Webcast replay will be available for 30 days following the conference call.About InnodataInnodata (NASDAQ:INOD) is a global data engineering company delivering the promise of AI to many of the world's most prestigious companies. We provide AI-enabled software platforms and managed services for AI data collection/annotation, AI digital transformation, and industry-specific business processes. Our low-code Innodata AI technology platform is at the core of our offerings. In every relationship, we honor our 30+ year legacy delivering the highest quality data and outstanding service to our customers. Visit www.innodata.com to learn more.Forward Looking StatementsThis press release may contain certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward-looking statements include, without limitation, statements concerning our operations, economic performance, and financial condition. Words such as ""project,"" ""believe,"" ""expect,"" ""can,"" ""continue,"" ""could,"" ""intend,"" ""may,"" ""should,"" ""will,"" ""anticipate,"" ""indicate,"" ""predict,"" ""likely,"" ""estimate,"" ""plan,"" ""potential,"" ""possible,"" ""promises,"" or the negatives thereof, and other similar expressions generally identify forward-looking statements.These forward-looking statements are based on management's current expectations, assumptions and estimates and are subject to a number of risks and uncertainties, including, without limitation, impacts resulting from the continuing conflict between Russia and the Ukraine and Hamas' attack against Israel and the ensuing conflict; investments in large language models; that contracts may be terminated by customers; projected or committed volumes of work may not materialize; pipeline opportunities and customer discussions which may not materialize into work or expected volumes of work; the likelihood of continued development of the markets, particularly new and emerging markets, that our services support; the ability and willingness of our customers and prospective customers to execute business plans that give rise to requirements for our services; continuing reliance on project-based work in the Digital Data Solutions (DDS) segment and the primarily at-will nature of such contracts and the ability of these customers to reduce, delay or cancel projects; potential inability to replace projects that are completed, canceled or reduced; continuing DDS segment revenue concentration in a limited number of customers; our dependency on content providers in our Agility segment; difficulty in integrating and deriving synergies from acquisitions, joint ventures and strategic investments; potential undiscovered liabilities of companies and businesses that we may acquire; potential impairment of the carrying value of goodwill and other acquired intangible assets of companies and businesses that we acquire; a continued downturn in or depressed market conditions; changes in external market factors; changes in our business or growth strategy; the emergence of new, or growth in existing competitors; various other competitive and technological factors; our use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions and other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.Our actual results could differ materially from the results referred to in forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks discussed in Part I, Item 1A. ""Risk Factors,"" Part II, Item 7. ""Management's Discussion and Analysis of Financial Condition and Results of Operations,"" and other parts of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 24, 2023, as updated or amended by our other filings that we may make with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements will occur, and you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof.We undertake no obligation to update or review any guidance or other forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by the Federal securities laws.Company ContactMarcia NoveroInnodata Inc.Mnovero@innodata.com(201) 371-8015SOURCE: Innodata Inc.View the original press release on accesswire.com When will Innodata Inc. release its Fourth Quarter and Fiscal Year 2023 results? Innodata Inc. will release its Fourth Quarter and Fiscal Year 2023 results on February 22, 2024. What time is the investor conference call scheduled for? The investor conference call is scheduled for 5:00 PM Eastern time on February 22, 2024. How can investors access the conference call? Investors can access the conference call via phone by dialing 1-888-506-0062 (Domestic) or +1 973-528-0011 (International) with the Participant Access Code 38345. They can also access a live Webcast at the Investor Relations section of www.innodata.com. How long will the call-in or Webcast replay be available? The call-in or Webcast replay will be available for 30 days following the conference call."
Norfolk Southern to present at Citi 2024 Global Industrial Tech and Mobility Conference,2024-02-16T20:00:00.000Z,Low,Very Positive,"Norfolk Southern Corporation's President and CEO, Alan H. Shaw, is set to present at the Citi 2024 Global Industrial Tech and Mobility Conference on February 21, 2024. The presentation will be available via webcast on the company's Investors page.","Norfolk Southern to present at Citi 2024 Global Industrial Tech and Mobility Conference Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags conferences Rhea-AI Summary Norfolk Southern Corporation's President and CEO, Alan H. Shaw, is set to present at the Citi 2024 Global Industrial Tech and Mobility Conference on February 21, 2024. The presentation will be available via webcast on the company's Investors page. Positive None. Negative None. 02/16/2024 - 03:00 PM ATLANTA, Feb. 16, 2024 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) President and Chief Executive Officer Alan H. Shaw will make a presentation at the Citi 2024 Global Industrial Tech and Mobility Conference. Details on joining the presentation follow below. What: Citi 2024 Global Industrial Tech and Mobility ConferenceWhen: February 21, 2024 at 8:50 a.m. (ET)Where: Via Webcast The presentation will be posted at www.norfolksouthern.com on the Investors page. About Norfolk SouthernSince 1827, Norfolk Southern Corporation (NYSE: NSC) and its predecessor companies have safely moved the goods and materials that drive the U.S. economy. Today, it operates a customer-centric and operations-driven freight transportation network. Committed to furthering sustainability, Norfolk Southern helps its customers avoid approximately 15 million tons of yearly carbon emissions by shipping via rail. Its dedicated team members deliver more than 7 million carloads annually, from agriculture to consumer goods, and Norfolk Southern originates more automotive traffic than any other Class I Railroad. Norfolk Southern also has the most extensive intermodal network in the eastern U.S. It serves a majority of the country's population and manufacturing base, with connections to every major container port on the Atlantic coast as well as major ports in the Gulf of Mexico and Great Lakes. Learn more by visiting www.NorfolkSouthern.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/norfolk-southern-to-present-at-citi-2024-global-industrial-tech-and-mobility-conference-302063637.html SOURCE Norfolk Southern Corporation When is Alan H. Shaw scheduled to present at the Citi 2024 Global Industrial Tech and Mobility Conference? Alan H. Shaw is scheduled to present on February 21, 2024, at 8:50 a.m. (ET). Where can the presentation be accessed? The presentation will be available via webcast on Norfolk Southern Corporation's Investors page at www.norfolksouthern.com."
"Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems",2024-02-16T19:42:00.000Z,Neutral,Neutral,"Sharps Technology, Inc. (STSS) partners with Roncadelle Operations to expand its global healthcare market presence through new 3PL partnerships, aiming to develop and distribute innovative drug delivery solutions worldwide.","Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Sharps Technology, Inc. (STSS) partners with Roncadelle Operations to expand its global healthcare market presence through new 3PL partnerships, aiming to develop and distribute innovative drug delivery solutions worldwide. Positive None. Negative None. Market Research Analyst The strategic alliance between Sharps Technology and Roncadelle Operations signifies an important development in the medical device sector, particularly in the area of drug delivery systems. The partnership is poised to enhance the companies' product distribution capabilities, leveraging an expanded network of North American third-party logistics (3PL) partnerships. This expansion into new markets could potentially increase market share and revenue streams for both entities.From a market research perspective, the collaboration taps into a growing demand for innovative injection solutions, a market that is expected to expand significantly. This is driven by the increasing preference for injectable therapies across a range of medical applications, including vaccines, gene therapies and chronic disease management. The emphasis on safety and the prevention of needle stick injuries is particularly relevant given the heightened awareness of healthcare worker safety and public health concerns.The alliance may also result in operational synergies, reducing costs and improving efficiency through shared technology and distribution channels. This could lead to competitive advantages over other players in the medical device industry, potentially impacting the stock performance of Sharps Technology in the medium to long term. Medical Research Analyst The partnership between Sharps and Roncadelle is set to impact the smart safety disposable syringe and prefillable syringe markets by combining their respective expertise in active and passive safety syringe technologies. Sharps' Securegard and Sologard product lines emphasize low-waste and ultra-low-waste technologies, which are significant in reducing medical waste and environmental impact. These features align with the World Health Organization's guidelines on re-use prevention, which is critical in preventing the transmission of diseases.Roncadelle's SafeR Retractable Safety Syringe complements Sharps' offerings with its own passive safety systems, further enhancing the alliance's portfolio in terms of safety and patient protection. The collaboration could accelerate the development and distribution of these advanced medical devices, potentially leading to increased adoption rates and improved healthcare outcomes globally.Furthermore, the expansion of manufacturing capabilities, such as Sharps' plans in the U.S., indicates a strategic move to localize production and could serve to mitigate risks associated with global supply chains, which is particularly relevant in the context of recent global events that have disrupted international logistics. Financial Analyst Sharps Technology's expansion of its 3PL distribution partnerships and alliance with Roncadelle Operations represents a strategic move to diversify and strengthen its global distribution network. This move could be seen as a response to the growing need for healthcare solutions that are not only effective but also safe and easy to use.Financially, the partnership could lead to enhanced revenue growth for Sharps Technology as it gains access to new markets and broadens its product portfolio. The collaboration may also result in cost savings through shared resources and economies of scale. Investors should monitor the execution of this strategy and its impact on Sharps' financial performance, particularly in terms of sales growth, market penetration rates and profit margins.However, it is important to consider the risks associated with such strategic alliances, including integration challenges and the potential for increased competition. Investors should also be aware of the capital expenditures associated with expanding manufacturing facilities and the time required for regulatory approvals in new markets, which could affect the short-term financial outlook. 02/16/2024 - 02:42 PM Sharps and Roncadelle are Joining Forces to Supply Drug Delivery Systems to the International HealthCare Market Through an Expanded Network of North American 3PL Distribution PartnershipsNEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS) (NASDAQ: STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique drug delivery solutions around the globe, capitalizing on a growing network of established and new logistics resources. Sharps and Roncadelle are evaluating their alliance as an opportunity to work together to bring new drug delivery solutions to market and pave the way to join the companies’ complementary product portfolios, expanding their global reach for both the smart safety disposable syringe and prefillable syringe markets. The partnership to sell and distribute each other’s product portfolio to their respective areas of influence will also move Sharps’ American-based product market into Europe, the Middle East, Africa and the Asia-Pacific region, as well as Roncadelle’s product reach into the North and South American healthcare markets. Sharps Technology says the need for innovative injection solutions is expected to grow exponentially over the next several years as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic applications, gene therapies, diabetes and inflammatory disease management. Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems. The company’s Securegard and Sologard product lines focus on low-waste and ultra-low-waste syringe technologies that incorporate active safety features as well as World Health Organization-accredited re-use prevention measures. These features protect frontline healthcare workers from life-threatening needle stick injuries and protect the public from the dangers of needle re-use. Sharps currently has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the U.S. Based in Italy, Roncadelle Operations specializes in developing and manufacturing proprietary passive safety syringes. Their SafeR Retractable Safety Syringe and needles offer a passive safety system with auto-disable reuse prevention features. Additionally, as a Contract Development and Manufacturing Organization (CDMO), they also provide end-to-end services from design to finished products of innovative, safer medical drug delivery solutions. Sharps reports that the synergy between Sharps and Roncadelle will bring together more than 30 established distribution points with Sharps’ new 3PL partnerships to deliver products to the world healthcare market that stand for simplicity of use and are unparalleled in safety and patient protection, setting new global standards to safeguard people from infection and disease. The business alliance additionally creates a very important player in advancing syringe market opportunities through the development of unique technologies such as prefilled syringes, needle guard systems, auto-injectors, and injector pen devices. “It is exciting to see how well our companies complement each other and how we can leverage our combined relationships, expertise, and resources to build out our distribution network, enhance syringe safety around the world, and introduce novel drug delivery solutions to the healthcare industry,” states Robert Hayes, Sharps CEO. “As we work through the network expansion and details of our collaboration, we can see that this is great timing and a perfect fit for both Sharps and Roncadelle.” For more information on the companies, please visit http://sharpstechnology.com and www.roncadelle-operations.com. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. FORWARD-LOOKING STATEMENTS:This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Relations:Dave GentryRedChip Companies, Inc.1-800-RED-CHIP (733-2447)Or 407-491-4498STSS@redchip.com What is Sharps Technology, Inc.'s ticker symbol? The ticker symbol for Sharps Technology, Inc. is STSS. What is the main focus of the partnership between Sharps and Roncadelle Operations? The partnership aims to develop and distribute unique drug delivery solutions globally by combining the strengths of both companies. Where is Sharps Technology, Inc.'s manufacturing facility located? Sharps Technology, Inc. has a manufacturing facility in Hungary and plans to expand its manufacturing capacity in the U.S. What are the key product lines of Sharps Technology, Inc.? Sharps Technology, Inc.'s product lines include Securegard and Sologard syringe technologies focusing on low-waste and ultra-low-waste syringes with active safety features. What are the main products developed by Roncadelle Operations? Roncadelle Operations specializes in developing SafeR Retractable Safety Syringe and needles with a passive safety system and auto-disable reuse prevention features."
CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek,2024-02-16T19:30:00.000Z,Moderate,Positive,"CannaPharmaRx (CPMD) announces a strategic Supply Agreement with Cantek Holdings, a leading player in Israel's medical cannabis industry. The agreement entails supplying a minimum of 1,000 kgs of product annually to Cantek, tapping into Israel's growing consumer demand. This move positions CannaPharmaRx in key international cannabis markets, leveraging Cantek's strong presence in Israel's medical cannabis sector.","CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary CannaPharmaRx (CPMD) announces a strategic Supply Agreement with Cantek Holdings, a leading player in Israel's medical cannabis industry. The agreement entails supplying a minimum of 1,000 kgs of product annually to Cantek, tapping into Israel's growing consumer demand. This move positions CannaPharmaRx in key international cannabis markets, leveraging Cantek's strong presence in Israel's medical cannabis sector. Positive None. Negative None. 02/16/2024 - 02:30 PM CALGARY, AB / ACCESSWIRE / February 16, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has entered into a strategic Supply Agreement (the ""Agreement"") with Cantek Holdings (""Cantek""), one of Israel's leaders in import and distribution of medical grade cannabis. This agreement will provide direct access to Israel's burgeoning consumer demand.Under the terms of the Agreement, CannaPharmaRx will supply Cantek with a minimum of 1,000 kgs of product annually. Having secured all necessary export and import permits and licenses, the initial shipment of cannabis to Cantek, under the Agreement, will begin late Q1 2024.Cantek is one of the leading Medical Cannabis enterprises in Israel, with a foothold across the entire value chain of the medical cannabis industry in Israel. Cantek holds strategic partnerships with prominent pharmacy chains, distribution companies, clinics and is deeply involved with Israel's growing medical cannabis patient community. Recently passed legislation bolstered the demonstrated market demand and regulatory support for high quality cannabis and is expected to significantly grow the medical cannabis industry.CannaPharmaRx plans to continue to leverage its recent successes as it further develops its cannabis markets internationally in key markets. The company is now strategically positioned in some of the largest cannabis markets in the world.""We are excited about our strategic relationship with Cantek, a leader in the Israeli market. This Agreement provides our company with a great opportunity to expand our cannabis brands and industry leading science in one of our key international markets of focus. Today's announcement validates our position in the world's cannabis market, and we consider this Agreement to be a major step forward towards making certain our product is pre-sold prior to beginning each planting and harvesting,"" commented Dean Medwid, CEO of CannaPharmaRx.About CannapharmaRx, Inc.CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx's business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.Safe Harbor StatementCautionary Note Regarding Forward-Looking Information or StatementsThis press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are 'forward-looking information or statements.' Forward-looking information or statements can be identified by the use of words such as 'plans,' 'expects,' or 'does not expect,' 'is expected,' 'estimates,' 'intends,' 'anticipates,' or 'does not anticipate,' or 'believes,' or variations of such words and phrases or statements that certain actions, events or results 'may,' 'could,' 'would,' 'might' or 'will' be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.Contact Information:Brokers and AnalystsChesapeake Group(410) 825-3930SOURCE: Cannapharmarx, Inc.View the original press release on accesswire.com What is the nature of the agreement between CannaPharmaRx and Cantek Holdings? The agreement involves CannaPharmaRx supplying Cantek with a minimum of 1,000 kgs of product annually. When will the initial shipment of cannabis to Cantek under the agreement begin? The initial shipment of cannabis to Cantek under the agreement will commence late Q1 2024. Who is Cantek Holdings in the context of the PR? Cantek Holdings is one of Israel's leading Medical Cannabis enterprises with a strong presence across the medical cannabis value chain in Israel. What recent legislation is mentioned in the PR that is expected to impact the medical cannabis industry? Recently passed legislation in Israel is expected to significantly grow the medical cannabis industry by bolstering market demand and regulatory support for high-quality cannabis. How does CannaPharmaRx plan to expand its cannabis markets internationally? CannaPharmaRx aims to leverage its recent successes to further develop its cannabis markets in key international markets around the world."
Irenic Encourages Barnes Group to Move with Greater Urgency to Collaborate on Necessary Board Improvements,2024-02-16T19:30:00.000Z,Neutral,Very Positive,"Irenic Capital Management LP, a major shareholder of Barnes Group Inc. (NYSE: B), expresses concern over the underwhelming fourth quarter and full-year 2023 results, emphasizing the necessity for a revamped Board with fresh perspectives and industry expertise.","Irenic Encourages Barnes Group to Move with Greater Urgency to Collaborate on Necessary Board Improvements Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Irenic Capital Management LP, a major shareholder of Barnes Group Inc. (NYSE: B), expresses concern over the underwhelming fourth quarter and full-year 2023 results, emphasizing the necessity for a revamped Board with fresh perspectives and industry expertise. Positive None. Negative None. Market Research Analyst The performance of Barnes Group Inc. in the fourth quarter and full year of 2023 appears to be a focal point for Irenic Capital Management, a significant shareholder. The call for a revamped board suggests that Irenic perceives current leadership as unable to effectively navigate the company through the prevailing market conditions or capitalize on potential growth opportunities. This perspective is critical for stakeholders as board composition can significantly influence strategic direction, risk management and investor confidence.An independent and diverse board with industry-specific experience might provide innovative strategies and a fresh approach to capital allocation, potentially leading to improved performance metrics and market positioning. Stakeholders should consider the long-term implications of board changes, such as the possibility of a strategic pivot, enhanced governance and the potential for unlocking shareholder value. Financial Analyst The mention of 'underwhelming results' by a major shareholder underscores a potential concern for the company's financial health and future performance. Such statements can impact investor sentiment and stock prices. Financial metrics from the fourth quarter and full year are crucial indicators of a company's operational efficiency and profitability. A detailed analysis of the company's financial statements would be necessary to understand the specific areas where performance did not meet expectations.Additionally, the emphasis on the need for directors with 'capital allocation expertise' hints at possible inefficiencies in the company's investment decisions or cash flow management. Effective capital allocation is vital for maximizing returns and shareholder value. Investors might anticipate changes in the company's investment strategies, cost management and dividend policies in response to new board dynamics. Corporate Governance Expert The push for boardroom changes by a top shareholder can be a significant event, signaling underlying governance issues that may affect the company's oversight and strategic planning. The addition of independent directors is often seen as a move towards enhancing transparency and reducing potential conflicts of interest. A board with diverse backgrounds can offer a broader range of perspectives, potentially leading to more robust decision-making processes.For shareholders and potential investors, the evolution of the board's composition could indicate a shift towards a governance structure that is more aligned with shareholder interests. It is important to monitor how these proposed changes might affect the company's governance policies, risk oversight and adherence to regulatory requirements. The long-term success of such governance reforms is contingent upon the selection of directors who not only bring fresh perspectives but also align with the company's core values and objectives. 02/16/2024 - 02:30 PM Believes the Company’s Underwhelming Fourth Quarter and Full Year 2023 Results Reinforce the Need for New Backgrounds and Fresh Perspectives in the Boardroom NEW YORK--(BUSINESS WIRE)-- Irenic Capital Management LP (together with its affiliates, “Irenic” or “we”), a top shareholder of Barnes Group Inc. (NYSE: B) (“Barnes” or the “Company”) and the beneficial owner of approximately 5.1% of the Company’s outstanding common stock, today issued the following statement from Co-Founder and Chief Investment Officer Adam Katz: “We are committed to working constructively and in good faith to help Barnes realize its potential. Today's underwhelming results for the fourth quarter and full-year 2023 reinforce the need for a more engaged, independent and well-rounded Board at Barnes. We encourage the Company to move with greater urgency to work with us on the addition of independent directors with relevant industry and capital allocation expertise. It is time to do the right thing for Barnes’ shareholders.” About Irenic Irenic Capital Management LP is an investment management firm founded by Adam Katz and Andy Dodge. Based in New York City, Irenic works collaboratively with publicly traded companies to ensure operating activities, capital deployment and management incentives are all aligned to create value for the company and its owners. For more information about Irenic, please visit www.irenicmgmt.com. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Irenic Capital Management LP (“Irenic Capital”), together with the other participants named herein (collectively, “Irenic”), intends to file a preliminary proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission (the “SEC”) to be used to solicit votes for the election of its slate of director nominees at the 2024 annual meeting of stockholders of Barnes Group Inc., a Delaware corporation (the “Company”). IRENIC STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTPS://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR. The participants in the proxy solicitation are anticipated to be Irenic Capital, Irenic Capital Evergreen Master Fund LP (“Irenic Evergreen”), Irenic Capital Opportunity Master Fund LP (“Irenic Opportunity”), Irenic Schooner LLC (“Irenic Schooner”), Irenic Capital Evergreen Fund GP LLC (“Irenic Evergreen GP”), Irenic Capital Opportunity Fund GP LLC (“Irenic Opportunity GP”), Irenic Capital Management GP LLC (“Irenic Capital GP”), Andrew Dodge, Adam J. Katz and Larry A. Lawson. As of the date hereof, Irenic Evergreen directly owns 1,200,133 shares of common stock, par value $0.01 per share (the “Common Stock”), of the Company. As of the date hereof, Irenic Opportunity directly owns 489,464 shares of Common Stock. As of the date hereof, Irenic Schooner directly owns 882,445 shares of Common Stock. As of the date hereof, Irenic Capital directly owns 100 shares of Common Stock and as the investment manager of each of Irenic Evergreen, Irenic Opportunity and Irenic Schooner, Irenic Capital may be deemed to beneficially own the 2,572,042 shares of Common Stock owned in the aggregate by Irenic Evergreen, Irenic Opportunity and Irenic Schooner. Irenic Evergreen GP, as the general partner of Irenic Evergreen and Managing Member of Irenic Schooner, may be deemed to beneficially own the 2,082,578 shares of Common Stock owned in the aggregate by Irenic Evergreen and Irenic Schooner. Irenic Opportunity GP, as the general partner of Irenic Opportunity, may be deemed to beneficially own the 489,464 shares of Common Stock owned by Irenic Opportunity. Irenic Capital GP, as the general partner of Irenic Capital, may be deemed to beneficially own the 2,572,142 shares of Common Stock owned in the aggregate by Irenic Capital, Irenic Evergreen, Irenic Opportunity and Irenic Schooner. Mr. Dodge, as a Managing Member of each of Irenic Evergreen GP, Irenic Opportunity GP and Irenic Capital GP, may be deemed to beneficially own the 2,572,142 shares of Common Stock owned in the aggregate by Irenic Capital, Irenic Evergreen, Irenic Opportunity and Irenic Schooner. Mr. Katz, as the Chief Investment Officer of Irenic Capital and a Managing Member of each of Irenic Evergreen GP, Irenic Opportunity GP and Irenic Capital GP, may be deemed to beneficially own the 2,572,142 shares of Common Stock owned in the aggregate by Irenic Capital, Irenic Evergreen, Irenic Opportunity and Irenic Schooner. As of the date hereof, Mr. Lawson does not own any shares of Common Stock. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216583126/en/ Irenic Capital Management contact@irenicmgmt.com Longacre Square Partners Greg Marose / Dan Zacchei, 646-386-0091 irenic@longacresquare.com Source: Irenic Capital Management LP What is the name of the major shareholder expressing concern over Barnes Group Inc.'s performance? Irenic Capital Management LP What percentage of Barnes Group Inc.'s outstanding common stock does Irenic Capital Management LP own? Approximately 5.1% What is the ticker symbol for Barnes Group Inc.? B Who issued the statement regarding Barnes Group Inc.'s underwhelming results? Co-Founder and Chief Investment Officer Adam Katz What action does Irenic Capital Management LP suggest Barnes Group Inc. should take? Add independent directors with relevant industry and capital allocation expertise"
Tortoise Announces Posting of Corrected 2023 Annual Report,2024-02-16T19:40:00.000Z,Neutral,Negative,"Tortoise corrects its Energy Infrastructure Total Return Fund 2023 annual report, adding the Alerian Midstream Energy Select Index benchmark. No other changes made.","Tortoise Announces Posting of Corrected 2023 Annual Report Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Negative) Tags Rhea-AI Summary Tortoise corrects its Energy Infrastructure Total Return Fund 2023 annual report, adding the Alerian Midstream Energy Select Index benchmark. No other changes made. Positive None. Negative None. 02/16/2024 - 02:40 PM OVERLAND PARK, KS / ACCESSWIRE / February 16, 2024 / Tortoise announced today that a corrected copy of the Tortoise Energy Infrastructure Total Return Fund 2023 annual report has been posted and is available here. The corrected copy includes the Alerian Midstream Energy Select Index benchmark in the Growth of $1,000,000 table and the Total Returns table, which was inadvertently omitted in the original report posted. No additional changes have been made to the report.Please call (866) 362-9331 or email info@tortoiseadvisors.comto request a hard copy of this report free of charge.About TortoiseTortoise focuses on energy & power infrastructure and the transition to cleaner energy. Tortoise's solid track record of energy value chain investment experience and research dates back more than 20 years. As an early investor in midstream energy, Tortoise believes it is well-positioned to be at the forefront of the global energy evolution that is underway. With a steady wins approach and a long-term perspective, Tortoise strives to make a positive impact on clients and communities. For additional information, please visit www.TortoiseAdvisors.com.For additional information on these funds, please visit oef.tortoiseadvisors.com.DisclosuresTCA Advisors is the adviser to the Tortoise Energy Infrastructure Total Return Fund.Quasar Distributors, LLC, distributor.Nothing contained in this communication constitutes tax, legal, or investment advice. Investors must consult their tax advisor or legal counsel for advice and information concerning their particular situation.The funds' investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectus contains this and other important information about the funds and may be obtained by calling 855-TCA-FUND (855-822-3863) or visiting www.TortoiseAdvisors.com. Read it carefully before investing.Mutual fund investing involves risk. Principal loss is possible.Safe Harbor StatementThis press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.Forward-looking statementThis press release contains certain statements that may include ""forward-looking statements"" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, included herein are ""forward-looking statements."" Although Tortoise believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the company's reports that are filed with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required by law, Tortoise does not assume a duty to update this forward-looking statement.Contact InformationFor more information contact Eva Lipner at (913) 890-2165 or info@tortoiseadvisors.com.SOURCE: TortoiseView the original press release on accesswire.com What was announced by Tortoise regarding the Energy Infrastructure Total Return Fund 2023 annual report? Tortoise announced the correction of the annual report by adding the Alerian Midstream Energy Select Index benchmark. What was included in the corrected copy of the annual report? The corrected copy includes the Alerian Midstream Energy Select Index benchmark in the Growth of $1,000,000 table and the Total Returns table. What was inadvertently omitted in the original report posted? The Alerian Midstream Energy Select Index benchmark was inadvertently omitted in the original report posted. How can one request a hard copy of the corrected report? One can request a hard copy of the corrected report for free by calling (866) 362-9331 or emailing info@tortoiseadvisors.com."
Novo Integrated Sciences Appoints New President,2024-02-16T19:00:00.000Z,Low,Positive,"Novo Integrated Sciences, Inc. (NVOS) appoints Robert Oliva as the new President, bringing over 35 years of business development experience. Oliva aims to enhance operational efficiency, drive sustainable growth, and improve margins. CEO Robert Mattacchione anticipates Oliva's contribution to ramp up manufacturing and product offerings, leading to accelerated growth.","Novo Integrated Sciences Appoints New President Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags management Rhea-AI Summary Novo Integrated Sciences, Inc. (NVOS) appoints Robert Oliva as the new President, bringing over 35 years of business development experience. Oliva aims to enhance operational efficiency, drive sustainable growth, and improve margins. CEO Robert Mattacchione anticipates Oliva's contribution to ramp up manufacturing and product offerings, leading to accelerated growth. Positive None. Negative None. 02/16/2024 - 02:00 PM BELLEVUE, Wash.--(BUSINESS WIRE)-- Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today Mr. Robert Oliva has been appointed as the Company’s new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company’s Chief Operating Officer and as a member of the Company’s Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company’s product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company’s CEO and Board Chairman, stated, “The addition of Mr. Oliva comes at a time when the Company is focusing significant energy and resources in ramping up our manufacturing and product offerings. His years of building a manufacturing business, from the ground up, into a significant, profitable enterprise will be an enormous asset in providing oversight and guidance to the Company’s leadership team. Rob’s proven success coupled with the Company’s expected near-term capital injection will allow our product-based business unit to experience accelerated growth. We are extremely fortunate to have Mr. Oliva join the Novo family and look forward to the indubitably noteworthy impact his addition will have on our Company.” About Novo Integrated Sciences, Inc. Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms. For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com. Twitter, LinkedIn, Facebook, Instagram, YouTube Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as ""believe,"" “intend,” ""expect,"" ""anticipate,"" ""plan,"" ""potential,"" ""continue,"" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216001458/en/ Chris David, COO & President Novo Integrated Sciences, Inc. chris.david@novointegrated.com (888) 512-1195 Source: Novo Integrated Sciences, Inc. Who has been appointed as the new President of Novo Integrated Sciences, Inc.? Robert Oliva has been appointed as the new President of Novo Integrated Sciences, Inc. What is Robert Oliva's background and experience? Robert Oliva brings over 35 years of ownership and proven business development with expertise in manufacturing related operations. What is the role of Christopher David after Robert Oliva's appointment? Christopher David remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. What are the expectations from Robert Oliva's appointment? Robert Oliva is expected to advance the Company's product-related operational efficiency, manage sustainable growth, and improve margins. What impact is anticipated from Robert Oliva's addition to Novo Integrated Sciences, Inc.? CEO Robert Mattacchione anticipates accelerated growth in the product-based business unit with the expected near-term capital injection and Oliva's proven success."
Arizona Coyotes Launch Direct-to-Consumer Streaming Platform in Partnership with Kiswe and Scripps Sports,2024-02-16T19:00:00.000Z,Moderate,Very Positive,"The Arizona Coyotes announced a new media rights deal with Kiswe and Scripps Sports to launch Coyotes Central, a D2C streaming platform for fans to watch live games, replays, and exclusive content. Subscriptions start at $11.99 per month with the remainder of the 2023-24 season available for $24.99. The platform aims to enhance fan experience and provide flexible viewing options.","Arizona Coyotes Launch Direct-to-Consumer Streaming Platform in Partnership with Kiswe and Scripps Sports Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Very Positive) Tags partnership Rhea-AI Summary The Arizona Coyotes announced a new media rights deal with Kiswe and Scripps Sports to launch Coyotes Central, a D2C streaming platform for fans to watch live games, replays, and exclusive content. Subscriptions start at $11.99 per month with the remainder of the 2023-24 season available for $24.99. The platform aims to enhance fan experience and provide flexible viewing options. Positive None. Negative None. Market Research Analyst The announcement of the Arizona Coyotes' partnership with Kiswe and Scripps Sports to offer a direct-to-consumer streaming service represents a significant shift in how sports franchises are leveraging technology to enhance fan engagement and monetize content. The move to a subscription-based model for streaming games and exclusive content is reflective of broader trends in the media industry, where traditional cable TV is losing ground to over-the-top (OTT) services.From a market perspective, this initiative can potentially open up new revenue streams for the Coyotes, as it allows the franchise to directly capitalize on its fanbase without the need for traditional broadcast intermediaries. The pricing strategy, with monthly and seasonal packages, is designed to cater to different consumer preferences, which could lead to increased uptake and customer retention. The success of this model will likely depend on the quality of the content, user experience and the team's performance, which can drive subscription numbers.Moreover, this deal could set a precedent for other sports franchises considering similar D2C platforms. If successful, it could encourage more teams to explore direct engagement with their fan bases, leading to a potential shift in sports broadcasting rights dynamics. This could have implications for the valuation of sports media rights and the stock performance of companies involved in sports broadcasting and streaming services. Financial Analyst The strategic partnership marks a pivotal moment for the Arizona Coyotes in terms of diversifying their revenue streams. By launching Coyotes Central, the team is directly tapping into the market of cord-cutters and younger demographics who prefer digital streaming over traditional television. Financially, this initiative could improve the team's profitability by reducing dependency on shared revenue from league-wide broadcasting deals and creating a more direct, stable source of income.Analyzing the financial impact requires monitoring the subscriber growth and retention rates post-launch. The initial pricing appears competitive, which might attract a significant number of subscribers. However, it's essential to consider the costs associated with content production and platform maintenance. The long-term financial success of Coyotes Central will depend on achieving a balance between these costs and subscription revenue. Additionally, this move could influence the team's valuation and attractiveness to potential investors, as it demonstrates a forward-thinking approach to business operations in the sports industry. Legal Expert The transition to a direct-to-consumer streaming service for sports content involves complex legal considerations, particularly around broadcasting rights. The Arizona Coyotes will need to navigate these rights carefully, ensuring that they do not infringe upon existing contracts with national broadcasters and other media partners. The 'beam and stream' model may also introduce new challenges around digital content rights and distribution, which could have contractual and regulatory implications.Another aspect to consider is the legal framework surrounding consumer data protection, as the Coyotes will be collecting personal information from subscribers. They must comply with relevant privacy laws and regulations to avoid potential legal issues. Furthermore, the terms of service for Coyotes Central will need to be carefully crafted to protect the organization from liability while also providing transparency and fairness to subscribers. 02/16/2024 - 02:00 PM SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- The Arizona Coyotes announced today a new media rights deal in collaboration with leading direct-to-consumer (D2C) streaming company, Kiswe, and Scripps Sports. This partnership heralds a new era for the Arizona Coyotes, bringing all locally broadcast games of the team directly to fans across Arizona through the innovative D2C platform, Coyotes Central. Fans will be able to subscribe to Coyotes Central beginning February 16, 2024, with the first game being streamed live that evening at 7PM MST. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216840822/en/ Through Coyotes Central, fans in the local broadcast markets will have access to all non-nationally exclusive live Coyotes games, on-demand replays, pre- and post-game shows, and other exclusive Coyotes content. Coyotes Central is accessible at http://coyotescentral.com, Monthly subscriptions will be available for $11.99 with the remainder of the 2023-24 season available for $24.99. Season subscription pricing for the upcoming 2024-25 season will be announced at a later date. “We are excited to launch Coyotes Central, a new streaming platform that allows Arizona Coyotes fans to watch Coyotes games and original content at their convenience,” said Arizona Coyotes President & CEO Xavier A. Gutierrez. “This innovative direct-to-consumer option is a key component to our overall media strategy, and this partnership with Scripps Sports and Kiswe will enable us to deliver a flexible viewing option in our local broadcast market to our fans and ‘fans in waiting.” “We are thrilled to partner with the Arizona Coyotes and Scripps Sports in expanding access to Coyotes games to all local fans,” said Glenn Booth, CEO of Kiswe. “This new deal highlights the growing trend towards the 'beam and stream' model for local sports distribution, and we are excited to continue to work with our partners to reshape sports media consumption.” This collaboration between the Arizona Coyotes, Kiswe, and Scripps Sports further demonstrates the power D2C streaming in expanding access to local sports through unique content and flexible viewing options. As this season unfolds, Coyotes Central promises to bring the game to more local fans than ever before. “Scripps Sports is focused on helping teams reach their fan bases, and this is another way in which Coyotes’ supporters can watch their team’s games,” said Scripps Sports President Brian Lawlor. “The goal is accessibility. This partnership is all about extending the reach.” About Arizona Coyotes: The Arizona Coyotes are a National Hockey League franchise based in Scottsdale, Arizona. The Coyotes are owned by Chairman and Governor Alex Meruelo. Since the club’s first season in the Valley of the Sun in 1996, the Coyotes have been a leader in the community and steadfast in its commitment to diversity, equity, and inclusion. For the latest news and information on the Coyotes, please visit ArizonaCoyotes.com. Fans can follow the team on Facebook, Twitter, Instagram, and LinkedIn. About Kiswe Kiswe is an award-winning technology company that builds and powers D2C streaming platforms and events used by the biggest entertainment and sports brands. With best-in-class streaming technology and a unique partnership business model, Kiswe helps content owners maximize their revenue, build their brands, and engage every fan on every screen. About Scripps Sports Scripps Sports serves professional and college sports leagues, conferences and teams with local market depth and national broadcast reach of up to 100% of TV households. Scripps Sports currently has partnerships with the Women’s National Basketball Association, the National Women’s Soccer League, the National Hockey League’s Stanley Cup champion Vegas Golden Knights and NHL’s Arizona Coyotes, and the NCAA’s Big Sky Conference in college football. Scripps Sports is a division of The E.W. Scripps Company (NASDAQ: SSP), a Fortune 100 American media company focused on creating a better-informed world. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216840822/en/ Sydney Dennen sydney@purposenorthamerica.com 6166489176 Source: Kiswe What is the name of the D2C streaming platform launched by the Arizona Coyotes in collaboration with Kiswe and Scripps Sports? The D2C streaming platform launched by the Arizona Coyotes is called Coyotes Central. When will fans be able to subscribe to Coyotes Central? Fans will be able to subscribe to Coyotes Central starting on February 16, 2024. How much does a monthly subscription to Coyotes Central cost? A monthly subscription to Coyotes Central costs $11.99. What content will fans have access to through Coyotes Central? Fans will have access to all non-nationally exclusive live Coyotes games, on-demand replays, pre- and post-game shows, and other exclusive Coyotes content through Coyotes Central. Who is the President & CEO of the Arizona Coyotes? Xavier A. Gutierrez is the President & CEO of the Arizona Coyotes."
Graco Announces Regular Quarterly Dividend,2024-02-16T19:00:00.000Z,Low,Neutral,"Graco Inc. (GGG) announces a regular quarterly dividend of $0.255 per share payable on May 1, 2024, to shareholders of record as of April 15, 2024.","Graco Announces Regular Quarterly Dividend Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags dividends Rhea-AI Summary Graco Inc. (GGG) announces a regular quarterly dividend of $0.255 per share payable on May 1, 2024, to shareholders of record as of April 15, 2024. Positive Graco Inc. declares a quarterly dividend of $0.255 per share for shareholders, reflecting financial stability and commitment to rewarding investors. The dividend payout date is set for May 1, 2024, benefiting shareholders of record as of April 15, 2024. With approximately 168.4 million shares outstanding, the total dividend distribution amounts to a significant figure, showcasing the company's financial strength. Negative None. Financial Analyst The declaration of a regular quarterly dividend by Graco Inc. is a significant indicator of the company's financial health and its commitment to returning value to shareholders. A dividend payment, particularly one that is maintained or increased regularly, can be seen as a sign of a company's stable cash flow and confidence in its future earnings. Investors often view such announcements as a positive signal, potentially leading to increased investor confidence and a favorable impact on the stock price.It is crucial to analyze the dividend yield, which is the dividend per share divided by the stock price. This metric helps investors understand the return on investment from dividends alone. In the context of the broader market, if Graco Inc.'s dividend yield is competitive, it can attract income-focused investors, especially in a low-interest-rate environment. However, it's important to consider the payout ratio as well, which is the proportion of earnings paid out as dividends. A sustainable payout ratio typically suggests that the company can continue to pay dividends without compromising its growth prospects. Market Research Analyst From a market perspective, the declaration of a dividend by Graco Inc. should be contextualized within the industry and the current economic environment. The industrial sector, where Graco operates, may be influenced by factors such as raw material costs, international trade policies and industrial demand. A steady dividend could imply that Graco is navigating these factors effectively.Further, market trends towards sustainable and environmentally friendly industrial solutions could impact Graco's market position and, consequently, its ability to maintain dividend payments. Understanding the company's strategy in innovation and market adaptation is essential to evaluate the long-term sustainability of its dividend policy. Additionally, the market's reaction to dividend announcements can vary; some investors might prioritize growth over income, potentially leading to a reallocation of investments depending on their individual strategies. 02/16/2024 - 02:00 PM MINNEAPOLIS--(BUSINESS WIRE)-- The Board of Directors of Graco Inc. (NYSE:GGG) has declared a regular quarterly dividend of 25.5 cents ($0.255) per common share, payable on May 1, 2024, to shareholders of record at the close of business on April 15, 2024. The Company has approximately 168.4 million shares outstanding. ABOUT GRACO Graco Inc. supplies technology and expertise for the management of fluids and coatings in both industrial and commercial applications. It designs, manufactures and markets systems and equipment to move, measure, control, dispense and spray fluid and powder materials. A recognized leader in its specialties, Minneapolis-based Graco serves customers around the world in the manufacturing, processing, construction, and maintenance industries. For additional information about Graco Inc., please visit us at www.graco.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216997917/en/ Investors: David Lowe, 612-623-6456 Media: Meredith Sobieck, 763-353-1498 Meredith_A_Sobieck@graco.com Source: Graco Inc. What is the dividend amount announced by Graco Inc. (GGG)? Graco Inc. (GGG) has declared a quarterly dividend of $0.255 per common share. When will the dividend be payable to shareholders? The dividend will be payable on May 1, 2024. How many shares are outstanding for Graco Inc. (GGG)? Graco Inc. (GGG) has approximately 168.4 million shares outstanding. When is the record date for shareholders to receive the dividend? Shareholders of record at the close of business on April 15, 2024, will receive the dividend."
How Menu Hacks Landed Shift Lead Antonia a Spot in Taco Bell’s Menu Blast,2024-02-16T19:15:00.000Z,Low,Positive,"Taco Bell, under Yum! Brands, emphasizes its core value of being fan-led, showcasing how team members like Antonia embody this value through creativity, innovation, and customer connections.","How Menu Hacks Landed Shift Lead Antonia a Spot in Taco Bell’s Menu Blast Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary Taco Bell, under Yum! Brands, emphasizes its core value of being fan-led, showcasing how team members like Antonia embody this value through creativity, innovation, and customer connections. Positive None. Negative None. 02/16/2024 - 02:15 PM NORTHAMPTON, MA / ACCESSWIRE / February 16, 2024 / Yum! BrandsOriginally published by Taco BellAt Taco Bell, our Brand Values (Be Fan-Led, Be People-First, Be Fearless, Be Different) are found and reflected in everything we do. This season, we're highlighting core value #1, Be Fan-Led. Being fan-led means we take cues from our fans, customers and team members to deliver innovative crave worthy experiences that have a positive impact on our people, industry and planet. Take a look below to see how our Taco Bell Community embodies the Fan-Led core value!For Shift Lead Antonia, Taco Bell is a place to be herself, meet new people and be creative on a daily basis.""Taco Bell has given me the confidence to be myself and interact with new people and personalities every day. My team makes my shifts enjoyable and something to look forward to. No matter how busy or slow it is, we're always pushing each other to do better, cracking jokes and having fun. I've found many long-lasting friendships which I am so grateful for.""From connecting with her team to building new relationships with customers, Antiona treasures every interaction she has with those around her.""Making connections with customers is a one-of-a-kind experience. Whether it's a small interaction or a longer one, it's always a blast, especially with my Sunday regulars.""These interactions are the very moments that led Antonia to exemplify fan-led behavior of creating, innovating and pushing the menu boundaries.""As I started observing the many modifications customers requested, the wheels on my brain started turning and thinking about what could put an item over the top and make it stick.""Antonia started picking up on customer hacks from the day-to-day business to share with those who walked into the restaurant.""It only makes sense to see what our valued consumers consistently modify because this could lead to an item modification that would interest more people.""This fan-led approach led Antonia to land a spot on Menu Blast, Taco Bell's cooking competition, challenging three team members from across the country to hack a Taco Bell classic, cook with new oven-roasted chicken, and invent a day-to-night duo.""For the competition, I re-invented the chicken melt with lava sauce. While working in restaurant, I could see that a lot of customers were hyped about the return of Volcano, so that got me thinking about what regular menu item could be elevated with this fan-favorite.""Antonia was inspired by her customers to re-invent this three-ingredient item in the cooking competition, and that made the opportunity even more special.""I felt so valued and honored to make this in the competition, especially knowing that people would be excited to see the classic melt with a twist.""See Antonia in action during Menu Blast, and stay tuned to see how our Team Members are practicing Taco Bell's core four!View additional multimedia and more ESG storytelling from Yum! Brands on 3blmedia.com.Contact Info:Spokesperson: Yum! BrandsWebsite: https://www.3blmedia.com/profiles/yum-brandsEmail: info@3blmedia.comSOURCE: Yum! BrandsView the original press release on accesswire.com What are Taco Bell's core brand values? Taco Bell's core brand values are Be Fan-Led, Be People-First, Be Fearless, and Be Different. Who is highlighted as embodying the fan-led core value at Taco Bell? Shift Lead Antonia is highlighted as embodying the fan-led core value at Taco Bell. How does Antonia describe her experience at Taco Bell? Antonia describes Taco Bell as a place where she can be herself, meet new people, and be creative on a daily basis. What does being fan-led mean for Taco Bell? Being fan-led for Taco Bell means taking cues from fans, customers, and team members to deliver innovative experiences that have a positive impact. How does Antonia exemplify fan-led behavior? Antonia exemplifies fan-led behavior by creating, innovating, and pushing the menu boundaries based on customer interactions and feedback."
Miami Dolphins and Ambetter from Sunshine Health Tackle Food Insecurity to Serve 500 Meals to South Florida Families,2024-02-16T18:58:00.000Z,No impact,Neutral,"Ambetter from Sunshine Health, in collaboration with the Miami Dolphins, addresses food insecurity in South Florida by distributing food to local families in need. The initiative aims to reduce social determinants of health like food insecurity, homelessness, and job loss to promote better health outcomes.","Miami Dolphins and Ambetter from Sunshine Health Tackle Food Insecurity to Serve 500 Meals to South Florida Families Rhea-AI Impact (No impact) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Ambetter from Sunshine Health, in collaboration with the Miami Dolphins, addresses food insecurity in South Florida by distributing food to local families in need. The initiative aims to reduce social determinants of health like food insecurity, homelessness, and job loss to promote better health outcomes. Positive None. Negative None. 02/16/2024 - 01:58 PM The food relief event is part of an initiative to address the social determinants of health associated with food insecurity FT. LAUDERDALE, Fla., Feb. 16, 2024 /PRNewswire/ -- Ambetter from Sunshine Health in collaboration with the Miami Dolphins came together to address food insecurity in South Florida and distribute food to local families in need on Wednesday, Feb. 14. Volunteers from both organizations served over 500 meals from the Miami Dolphins Community Restaurant Program presented by Amazon and Drinksonme 305, to residents at Mount Pisgah Seventh Day Adventist Church in Miami Gardens. Residents also received a meal box that included a variety of fresh meat, produce and pantry staples. ""We are grateful for our longstanding partnership with Ambetter and our shared commitment to impacting the South Florida community. Together we are supporting local families by easing their financial strain as we provide meals to residents in Miami Gardens,"" said Miami Dolphins Vice President of Community Affairs Kim Miller. This food relief event is part of Ambetter from Sunshine Health's larger initiative to promote better health outcomes and reduce social determinants of health (SDOH), which are barriers that can impact a person's ability to engage in the healthcare support they need to live healthier lives. For example, food insecurity, homelessness, job loss, education, and social isolation. ""We know that food insecurity is associated with poor health outcomes, including higher odds of chronic disease and mental illness,"" said Nathan Landsbaum, CEO of Sunshine Health. ""Ambetter is committed to combating these issues through community outreach and education to help Floridians get and stay healthy. We are grateful to the Miami Dolphins for teaming up with us to support the South Florida community."" Ambetter assists Florida communities with programs that reduce the impact of SDOH by partnering with more than 600 community groups that help support the social safety net. The health plan's Community Resource Database connects anyone in need with community resources and support programs.Floridians can also call the Community Connections Help Line at 1-866-775-2192 to be connected with local resources.Learn more about the health plan's community support at SunshineHealth.com/supporting-florida-communities.html.Ambetter from Sunshine Health is a product offered by wholly owned subsidiaries of Centene Corporation (NYSE: CNC) which provide insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace. For more information on Ambetter from Sunshine Health, visit Ambetter.Sunshinehealth.com or call 1-877-687-1169 (Relay Florida 1-800-955-8770). About Sunshine HealthHeadquartered in Broward County and with offices across the state, Sunshine Health is among the largest healthcare plans in Florida. Offering coordinated care and a network of support for our members, Sunshine Health is transforming the health of the community, one person at a time. It offers government-sponsored managed care through Medicaid, Long Term Care, the Health Insurance Marketplace (Ambetter), and Medicare Advantage and Prescription Drug Plans (Wellcare). Its specialty plans include the Child Welfare Specialty Plan serving children in or adopted from the state's Child Welfare system; the Serious Mental Illness Specialty Plan for people living with serious mental illness; and the Children's Medical Services Health Plan, operated by Sunshine Health on behalf of the Florida Department of Health for children and adolescents with special healthcare needs. Sunshine Health is a wholly-owned subsidiary of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. For more information, visit SunshineHealth.com or follow us on Facebook and Twitter @SunHealthFL. About the Miami Dolphins:The Miami Dolphins, owned by Chairman of the Board & Managing General Partner Stephen M. Ross, are the oldest major-league professional sports franchise in the state of Florida, having joined the NFL as part of the AFL-NFL merger in 1970. The organization has played in five Super Bowls, winning championships following the 1972 (VII) and 1973 (VIII) seasons. The franchise also has won five conference championships and 13 division championships. The Dolphins play home games at Hard Rock Stadium and train at the Baptist Health Training Complex in Miami Gardens. A steward of the South Florida community, the Dolphins have raised more than $64 million for cancer research through the Dolphins Challenge Cancer, impacted more than 60,000 youth players and coaches through the Junior Dolphins program and have improved relationships and fostered understanding of more than 100 organizations through the FOOTBALL UNITES™ program. For more information, visit Dolphins.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/miami-dolphins-and-ambetter-from-sunshine-health-tackle-food-insecurity-to-serve-500-meals-to-south-florida-families-302064352.html SOURCE Ambetter What is Ambetter from Sunshine Health doing to address food insecurity in South Florida? Ambetter from Sunshine Health, in partnership with the Miami Dolphins, distributed food to local families in need in South Florida to combat food insecurity. What are the social determinants of health that Ambetter from Sunshine Health is focusing on? Ambetter from Sunshine Health is focusing on social determinants of health like food insecurity, homelessness, job loss, education, and social isolation to improve health outcomes. How is Ambetter from Sunshine Health helping Florida communities with social determinants of health? Ambetter from Sunshine Health partners with over 600 community groups to reduce the impact of social determinants of health and connects individuals with community resources through its Community Resource Database."
Renasant Corporation Declares Quarterly Dividend,2024-02-16T18:57:00.000Z,Low,Very Negative,"Renasant Corporation (RNST) announces a quarterly cash dividend of $0.22 per share, payable on March 29, 2024, to shareholders of record as of March 15, 2024.","Renasant Corporation Declares Quarterly Dividend Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Negative) Tags dividends Rhea-AI Summary Renasant Corporation (RNST) announces a quarterly cash dividend of $0.22 per share, payable on March 29, 2024, to shareholders of record as of March 15, 2024. Positive None. Negative None. Financial Analyst The announcement of a quarterly cash dividend by Renasant Corporation signifies the company's continued ability to generate sufficient cash flow to return value to its shareholders. Dividends are often a sign of a company's financial health and stability and they can influence investor perception and stock valuation. The declared dividend of $0.22 per share should be evaluated in the context of the company's payout ratio, earnings per share and historical dividend yield. A stable or increasing dividend can be a positive signal to investors, suggesting confidence in the company's earnings stability and future growth prospects.However, it is also important to consider the opportunity cost of paying dividends. The funds used for dividend payments could alternatively be invested back into the company for growth initiatives or debt reduction. Investors should assess whether the current dividend aligns with the company's long-term strategy and capital allocation policies. Additionally, the market's reaction to the dividend announcement could provide insight into how the dividend aligns with shareholder expectations and the current investment climate. Market Research Analyst From a market research perspective, the impact of Renasant Corporation's dividend announcement can extend beyond its direct financial implications. Dividends can be a factor in the investment decisions of both institutional and retail investors, particularly those seeking regular income streams, such as retirees. The consistency and growth of dividends can also be a component in the evaluation of a company's attractiveness within its sector, potentially affecting its competitive positioning.It is pertinent to analyze the dividend in relation to industry benchmarks and peer performance. If Renasant Corporation's dividend yield is higher or growing faster than its peers, it could attract income-focused investors, potentially increasing demand for the stock. Conversely, if the dividend is lower or not growing, it may signal underlying issues or a strategic focus on reinvestment rather than shareholder returns. An analysis of historical dividend trends and comparison with sector averages would provide additional context for investors. Economist Examining the broader economic environment is crucial when considering the implications of dividend announcements. Inflation rates, interest rates and economic growth forecasts can all influence the attractiveness of dividend-paying stocks. For instance, in a low-interest-rate environment, dividends can become more appealing as they may offer better returns than fixed-income alternatives. Conversely, if interest rates are rising, investors might favor bonds or other income-generating investments over dividend stocks.Additionally, macroeconomic stability and consumer confidence can impact a company's operations and, by extension, its ability to sustain dividend payments. An economist would assess these factors, along with fiscal and monetary policies that could affect disposable income and spending patterns, potentially impacting the company's future revenue and dividend-paying capacity. 02/16/2024 - 01:57 PM TUPELO, Miss., Feb. 16, 2024 (GLOBE NEWSWIRE) -- The board of directors of Renasant Corporation (NYSE: RNST) approved the payment of a quarterly cash dividend of twenty-two cents ($0.22) per share to be paid March 29, 2024, to shareholders of record as of March 15, 2024. ABOUT RENASANT CORPORATION:Renasant Corporation is the parent of Renasant Bank, a 119-year-old financial services institution. Renasant has assets of approximately $17.4 billion and operates 195 banking, lending, mortgage, wealth management and insurance offices throughout the Southeast as well as offering factoring and asset-based lending on a nationwide basis. For more information, please visit www.renasantbank.com or Renasant’s IR site at www.renasant.com. Contacts:For Media:For Financials: John S. OxfordJames C. Mabry IV Senior Vice PresidentExecutive Vice President Chief Marketing OfficerChief Financial Officer (662) 680-1219(662) 680-1281 joxford@renasant.comjim.mabry@renasant.com What dividend amount did Renasant Corporation (RNST) announce? Renasant Corporation (RNST) announced a quarterly cash dividend of $0.22 per share. When will the dividend be paid to shareholders of Renasant Corporation (RNST)? The dividend will be paid on March 29, 2024, to shareholders of record as of March 15, 2024."
HERBALIFE AND LA GALAXY UNVEIL 2024 JERSEY AHEAD OF OPENING SEASON MATCH AGAINST INTER MIAMI CF AT DIGNITY HEALTH SPORTS PARK,2024-02-16T18:30:00.000Z,Low,Very Positive,"Herbalife and LA Galaxy introduce the Angeleno Kit for the 2024 MLS season, with a social media contest offering fans a chance to win tickets to the opening match. Herbalife's long-standing sponsorship and partnership with the Galaxy continue to fuel excitement among fans globally.","HERBALIFE AND LA GALAXY UNVEIL 2024 JERSEY AHEAD OF OPENING SEASON MATCH AGAINST INTER MIAMI CF AT DIGNITY HEALTH SPORTS PARK Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Herbalife and LA Galaxy introduce the Angeleno Kit for the 2024 MLS season, with a social media contest offering fans a chance to win tickets to the opening match. Herbalife's long-standing sponsorship and partnership with the Galaxy continue to fuel excitement among fans globally. Positive None. Negative None. 02/16/2024 - 01:30 PM Herbalife to Launch Social Media Contest Giving Fans a Chance to Win Two Tickets to the Match LOS ANGELES, Feb. 16, 2024 /PRNewswire/ -- Today, Herbalife and the LA Galaxy introduced the club's new 2024 jersey – the Angeleno Kit – in advance of their 2024 Major League Soccer (MLS) season, which will kick-off on February 25th at Dignity Health Sports Park with a highly-awaited match against Inter Miami CF. Herbalife has sponsored the Galaxy's jersey for 17 consecutive seasons, the longest-running jersey sponsorship in MLS history. The Company also serves as the club's official nutrition partner, nourishing player performance on and off the field. To bring the excitement surrounding the match to soccer fans near and far, Herbalife has launched a series of interactive components, including the ""Let's Go Galaxy"" social media contest, launching on February 19 on Instagram. ""We are incredibly proud to continue supporting the LA Galaxy in their endeavors as their long-time partner, and we are excited they have secured an opening match of this caliber that brings our independent distributors, LA Galaxy players, and the fans such energy and excitement,"" said Humbi Calleja, vice president and general manager of Herbalife North America. ""We look forward to igniting that excitement on a global level through our social media campaign that enables fans and communities worldwide to be part of the experience."" Available on Herbalife's Instagram page (@HerbalifeUSA) from February 19th through February 22nd, the ""Let's Go Galaxy"" social media contest will award two tickets to the LA Galaxy vs. Inter Miami CF match and two brand new LA Galaxy jerseys. Additionally, Herbalife has developed an interactive filter that enables Galaxy fans to sport the brand new LA Galaxy jersey in preparation for the much-anticipated match. ""We are thrilled to present the LA Galaxy's newest primary kit – the Angeleno Kit – ahead of our 29th season in Major League Soccer where our valued partner, Herbalife, will be featured in the front of our jersey for the 17th consecutive season,"" said President of Business Operations & Chief Operating Officer, Tom Braun. ""As the longest-standing jersey sponsorship in MLS history, Herbalife is a brand our players and staff use and represent on and off the field. We look forward to wearing this new primary kit to open our season on February 25 against Inter Miami at Dignity Health Sports Park."" About Herbalife Ltd.Herbalife (NYSE:HLF) is a premier health and wellness company and community that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires customers to embrace a healthier, more active lifestyle to live their best life. For more information, please visit Herbalife.com and follow on Instagram @HerbalifeUSA. About the LA GalaxyThe LA Galaxy are Major League Soccer's most successful club. Based in Carson, Calif. at Dignity Health Sports Park, the Galaxy have won the MLS Cup a record five times (2002, 2005, 2011, 2012, 2014), the MLS Supporters' Shield four times (1998, 2002, 2010, 2011) and the Lamar Hunt U.S. Open Cup twice (2001, 2005), and one Concacaf Champions Cup (2000) since their inception in 1996. Under the direction of LA Galaxy President of Business Operations and Chief Operating Officer Tom Braun on the business operations side and LA Galaxy General Manager Will Kuntz on the soccer operations side, the Galaxy are the premier club in MLS, with stars like Landon Donovan, David Beckham, Robbie Keane, Steven Gerrard, Riqui Puig, Zlatan Ibrahimović, Javier Hernandez and Cobi Jones representing LA over the team's 29 years in MLS. For more information on the LA Galaxy, visit www.lagalaxy.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/herbalife-and-la-galaxy-unveil-2024-jersey-ahead-of-opening-season-match-against-inter-miami-cf-at-dignity-health-sports-park-302064287.html SOURCE Herbalife North America When will the 2024 MLS season kick-off for Herbalife and LA Galaxy? The 2024 MLS season for Herbalife and LA Galaxy will kick-off on February 25th. How many consecutive seasons has Herbalife sponsored the LA Galaxy's jersey? Herbalife has sponsored the LA Galaxy's jersey for 17 consecutive seasons, the longest-running jersey sponsorship in MLS history. What social media contest is Herbalife launching for fans? Herbalife is launching the 'Let's Go Galaxy' social media contest on Instagram, offering fans a chance to win tickets to the LA Galaxy vs. Inter Miami CF match and brand new LA Galaxy jerseys. Who is the Vice President and General Manager of Herbalife North America? Humbi Calleja is the Vice President and General Manager of Herbalife North America. What interactive component has Herbalife developed for Galaxy fans? Herbalife has developed an interactive filter that allows Galaxy fans to wear the new LA Galaxy jersey in preparation for the upcoming match. Who is the President of Business Operations & Chief Operating Officer for LA Galaxy? Tom Braun is the President of Business Operations & Chief Operating Officer for LA Galaxy."
Cushman & Wakefield Recognized as One of Forbes America’s Best Large Employers,2024-02-16T18:20:00.000Z,No impact,Very Positive,"Cushman & Wakefield (CWK) has been recognized on the Forbes list of America's Best Large Employers 2024, based on a survey of over 170,000 U.S.-based employees. The company's CEO, Michelle MacKay, highlighted the special culture at Cushman & Wakefield, emphasizing continuous improvement for clients. The selection criteria included working conditions, salary, training opportunities, mental health benefits, and diversity in management.","Cushman & Wakefield Recognized as One of Forbes America’s Best Large Employers Rhea-AI Impact (No impact) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Cushman & Wakefield (CWK) has been recognized on the Forbes list of America's Best Large Employers 2024, based on a survey of over 170,000 U.S.-based employees. The company's CEO, Michelle MacKay, highlighted the special culture at Cushman & Wakefield, emphasizing continuous improvement for clients. The selection criteria included working conditions, salary, training opportunities, mental health benefits, and diversity in management. Positive None. Negative None. 02/16/2024 - 01:20 PM CHICAGO--(BUSINESS WIRE)-- Cushman & Wakefield (NYSE: CWK), a leading global real estate services firm, has been recognized on the Forbes list of America's Best Large Employers 2024. The annual award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. “We’re proud to be recognized as one of America’s Best Large Employers. We have a special culture at Cushman & Wakefield. Our people never settle; they’re always pushing forward for our clients,” said Michelle MacKay, Chief Executive Officer. “We are honored to be among this prestigious list of companies and will continue striving for excellence while working hard to ensure this is a great place to work for all.” America’s Best Large Employers were selected based on an independent survey of more than 170,000 U.S.-based employees from all industry sectors working for companies employing at least 5,000 people in the U.S. The survey topics included working hours, salary, opportunities for training and promotion, workload expectations, mental health benefits, and diversity within the management team. Participants were also asked if they would recommend their employer to others and were given the chance to rate other employers in their respective industries. The full list of featured companies can be viewed on the Forbes website. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. The company offers a comprehensive offering of services including property, facilities and project management, leasing, capital markets, and valuation and other services. It also receives numerous industry and business accolades for its award-winning culture and commitment to Diversity, Equity and Inclusion (DEI), Environmental, Social and Governance (ESG) and more. For additional information, visit www.cushmanwakefield.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240215994223/en/ Annie Wood 817-456-6209 annie.wood@cushwake.com Source: Cushman & Wakefield Why was Cushman & Wakefield recognized on the Forbes list of America's Best Large Employers 2024? Cushman & Wakefield was recognized based on an independent survey of over 170,000 U.S.-based employees, highlighting the company's positive working environment and employee satisfaction. Who is the CEO of Cushman & Wakefield? Michelle MacKay is the Chief Executive Officer of Cushman & Wakefield. What were the survey topics for selecting America's Best Large Employers? The survey topics included working hours, salary, opportunities for training and promotion, workload expectations, mental health benefits, and diversity within the management team. How were the companies selected for America's Best Large Employers list? Companies employing at least 5,000 people in the U.S. were selected based on the survey responses of their U.S.-based employees."
"Concerned Shareholders of Jaxon Mining, to Requisition an Annual General Meeting",2024-02-16T18:15:00.000Z,Low,Negative,The Concerned Shareholder of Jaxon Mining Inc. is pushing for a new board of directors due to the current board's failure to hold a requisitioned general meeting. The Concerned Shareholder aims to revamp Jaxon's business strategy amidst a global focus on critical mineral deposits.,"Concerned Shareholders of Jaxon Mining, to Requisition an Annual General Meeting Rhea-AI Impact (Low) Rhea-AI Sentiment (Negative) Tags Rhea-AI Summary The Concerned Shareholder of Jaxon Mining Inc. is pushing for a new board of directors due to the current board's failure to hold a requisitioned general meeting. The Concerned Shareholder aims to revamp Jaxon's business strategy amidst a global focus on critical mineral deposits. Positive None. Negative None. 02/16/2024 - 01:15 PM VANCOUVER, BC / ACCESSWIRE / February 16, 2024 / Karim Rayani of R7 Capital Ventures Ltd. (the ""Concerned Shareholder""), in his capacity as a holder of approximately 5% of the issued and outstanding common shares of Jaxon Mining Inc., (JAX:TSX.V) (""Jaxon"" or the ""Company""), is providing an update to its news release dated September 21, 2023 which announced that the Concerned Shareholder requisitioned (the ""Requisition"") to the board of directors of Jaxon (the ""Jaxon Board"") to call a general meeting of the shareholders of JAX (the ""Requisitioned AGM"") for the purpose of electing a new board of directors of the Company.On August 31, 2023, pursuant to section to 167 of the Business Corporations Act (British Columbia) (the ""Act""), the Concerned Shareholder sent a formal requisition to Jaxon demanding that Jaxon's Board call the Requisitioned AGM. The Jaxon Board is obligated under the Act to hold the Requisitioned AGM not more than 4 months after the receipt of the Requisition. Contrary to subsection 167(5) of the Act, the Board has failed to hold the Requisitioned AGM within the prescribed time. Accordingly, the Concerned Shareholder has initiated the calling of the Requisitioned Meeting. The Concerned Shareholder will identify its director nominees in a proxy circular that will be distributed to the shareholders of JAX prior to the Requisitioned Meeting.The Concerned Shareholder has made many attempts to engage with Jaxon's management including its CEO John King Burns in conversations to encourage fulsome disclosure. The numerous attempts to engage with the Company's management have been met with no response, including attempts made by the concerned shareholders subsequent to the news release dated September 21, 2023.The current board of Jaxon seems to be functioning as a private corporation with blind support from its board of directors who own very little stock in the Company. Management has demonstrated a lack of ability to understand Jaxon's mineral assets and deploy reasonable business practices to explore the assets and gain investor and industry respect as a credible exploration company.The Concerned Shareholder believes that a time when not only in Canada but globally there is a focus on discovering critical mineral deposits, Jaxon needs to establish a board of directors and executive team that are able to help Jaxon revamp its business strategy with integrity and professionalism and inclusive of all stakeholders.Additional InformationThe information contained in this press release does not and is not meant to constitute a solicitation of proxies within the meaning of applicable securities laws.Cordially,Karim RayaniChairman & Chief Executive OfficerTel: +1 604 716 0551 E: k@r7.capitalSOURCE: Jaxon MiningView the original press release on accesswire.com Why is the Concerned Shareholder requesting a new board of directors for Jaxon Mining Inc.? The Concerned Shareholder is pushing for a new board due to the current board's failure to hold a requisitioned general meeting. What is the purpose of the Requisitioned AGM for Jaxon Mining Inc.? The Requisitioned AGM is intended for electing a new board of directors for the Company. Who is the Concerned Shareholder in the press release? Karim Rayani of R7 Capital Ventures Ltd. is the Concerned Shareholder in the press release. Why does the Concerned Shareholder believe Jaxon Mining Inc. needs to revamp its business strategy? The Concerned Shareholder believes Jaxon needs to revamp its strategy amidst a global focus on discovering critical mineral deposits. What actions has the Concerned Shareholder taken regarding Jaxon Mining Inc.? The Concerned Shareholder has initiated the calling of the Requisitioned Meeting and will identify director nominees in a proxy circular. What has been the response of Jaxon Mining Inc.'s management to the Concerned Shareholder's attempts to engage? Jaxon's management, including CEO John King Burns, has not responded to numerous attempts by the Concerned Shareholder to engage with them."
Digital World Acquisition Corp. Announces Date of Special Meeting of Stockholders and Record Date,2024-02-16T22:45:00.000Z,Low,Neutral,"Digital World Acquisition Corp. (DWAC) announces a special meeting for stockholders to vote on a proposed business combination with Trump Media & Technology Group Corp. The meeting is set for March 22, 2024, after which the Business Combination is expected to close. Management expresses gratitude for shareholder support and highlights the commitment to delivering on promises. TMTG CEO Devin Nunes emphasizes Truth Social's focus on user experience, aiming to challenge Big Tech's dominance and protect free speech.","Digital World Acquisition Corp. Announces Date of Special Meeting of Stockholders and Record Date Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags acquisition Rhea-AI Summary Digital World Acquisition Corp. (DWAC) announces a special meeting for stockholders to vote on a proposed business combination with Trump Media & Technology Group Corp. The meeting is set for March 22, 2024, after which the Business Combination is expected to close. Management expresses gratitude for shareholder support and highlights the commitment to delivering on promises. TMTG CEO Devin Nunes emphasizes Truth Social's focus on user experience, aiming to challenge Big Tech's dominance and protect free speech. Positive None. Negative None. 02/16/2024 - 05:45 PM MIAMI, FL / ACCESSWIRE / February 16, 2024 / Digital World Acquisition Corp. (NASDAQ:DWAC) (""Digital World,"" and/or the ""Company"") today announced that it will hold the special meeting of its stockholders (the ""Special Meeting"") to vote on the approval and adoption of the proposed business combination (the ""Business Combination"") with Trump Media & Technology Group Corp. (""TMTG"") on March 22, 2024, at 10:00 a.m. Eastern Time via live audio webcast at www.virtualshareholdermeeting.com/DWAC2024SM.Digital World stockholders of record as of the close of business on February 14, 2024 are entitled to attend and vote at the Special Meeting. The Business Combination is expected to close shortly after stockholder approval at the Special Meeting, subject to the satisfaction of other customary closing conditions.""Almost one year ago management made a commitment to the shareholders,"" declared Eric Swider, the Chief Executive Officer of Digital World. ""We committed to stay focused on a singular objective of delivering a proxy to vote on the merger of Digital World and TMTG. Today we are humbled and grateful to be able to deliver on that commitment. We know it has been a long road for our shareholders and we are eternally grateful for your trust and patience."" Swider continued, ""I want to extend the sincerest of gratitude to TMTG for their absolute professionalism, confidence and trust they put in our organization to deliver this proxy. Without their unwavering commitment to their platform and to our shareholders this would not have been possible. TMTG Chief Executive Officer Devin Nunes and his entire team have been relentless in pursuit of this endeavor. I am excited to see what the future brings should the shareholders approve this merger.""TMTG CEO Devin Nunes said, ""Since our founding, Truth Social has focused on improving the user experience, and we are currently beta testing new feature sets. If we are able to complete our proposed merger, we believe it will accelerate enhancements to the platform. Overall, Truth Social's goal is to break through the Big Tech monopoly and provide a refuge from censorship and cancel culture. We aim to protect Americans' voices and defend their freedom as tech oligarchs and corporate media enforcers struggle to impose their narratives.""About Digital World Acquisition Corp.Digital World Acquisition Corp. (Nasdaq:DWAC) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. To learn more, visit www.dwacspac.com.About TMTGThe mission of TMTG is to end Big Tech's assault on free speech by opening up the Internet and giving people their voices back. TMTG operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations.Additional Information and Where to Find ItDigital World has filed with the SEC a registration statement on Form S-4 (as may be amended from time to time, the ""Registration Statement""), which has been declared effective and which includes a preliminary proxy statement of the Company, and a prospectus in connection with the Business Combination. The definitive proxy statement and other relevant documents will be mailed to stockholders of Digital World as of the record date for voting on the Business Combination. Securityholders of Digital World and other interested persons are advised to read the preliminary proxy statement/prospectus, and amendments thereto, and, when available, the definitive proxy statement/prospectus in connection with Digital World's solicitation of proxies for the special meeting to be held to approve the Business Combination because these documents contain important information about Digital World, TMTG and the Business Combination. Digital World's securityholders and other interested persons will also be able to obtain copies of the Registration Statement and the proxy statement/prospectus, without charge, once available, on the SEC's website at www.sec.gov or by directing a request to: Digital World Acquisition Corp., 3109 Grand Ave, #450, Miami, FL 33133.Participants in SolicitationDigital World and TMTG and certain of their respective directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from the securityholders of Digital World in favor of the Business Combination. Securityholders of Digital World and other interested persons may obtain more information regarding the names and interests of Digital World's directors and officers in the Business Combination in Digital World's filings with the SEC, including in the definitive proxy statement/ prospectus, and the names and interests of TMTG's directors and officers in the proposed Business Combination in the Registration Statement. These documents can be obtained free of charge from the sources indicated above. TMTG and its officers and directors who are participants in the solicitation do not have any interests in Digital World other than with respect to their interests in the Business Combination.Forward-Looking StatementsThis Press Release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed Business Combination between the Company and TMTG. These forward-looking statements generally are identified by the words ""believe,"" ""project,"" ""expect,"" ""anticipate,"" ""estimate,"" ""intend,"" ""strategy,"" ""future,"" ""opportunity,"" ""plan,"" ""may,"" ""should,"" ""will,"" ""would,"" ""will be,"" ""will continue,"" ""will likely result"" and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.Many factors could cause actual future events to differ materially from the forward-looking statements in this Press Release, including but not limited to: (i) the risk that the Business Combination may not be completed in a timely manner, by Digital World's Business Combination deadline or at all, which may adversely affect the price of Digital World's securities, (ii) the failure to satisfy the conditions to the consummation of the Business Combination, including the approval of the Merger Agreement by the stockholders of Digital World, (iii) the risk that certain potential disputes and disagreements with the sponsor or related to certain TMTG stockholders may be not resolved and delay or ultimately prevent the consummation of the Business Combination, (iv) the lack of a third-party fairness opinion in determining whether or not to pursue the proposed Business Combination, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, (vi) the failure to achieve the minimum amount of cash available following any redemptions by Digital World stockholders, (vii) redemptions exceeding a maximum threshold or the failure to meet The Nasdaq Stock Market's initial listing standards in connection with the consummation of the contemplated transactions, (viii) the effect of the announcement or pendency of the Business Combination on TMTG's business relationships, operating results, and business generally, (ix) risks that the Business Combination disrupts current plans and operations of Digital World, (x) the outcome of any legal proceedings that may be instituted against TMTG or against Digital World related to the Merger Agreement or the Business Combination, (xi) the risk of any investigations by the SEC or other regulatory authority relating to any future financing, the Merger Agreement or the Business Combination and the impact they may have on consummating the transactions, (xii) Truth Social, TMTG's initial product, and its ability to generate users and advertisers, (xiii) changes in domestic and global general economic conditions, (xiv) the risk that TMTG may not be able to execute its growth strategies, (xv) risks related to the future pandemics and response and geopolitical developments, (xvi) risk that TMTG may not be able to develop and maintain effective internal controls, (xvii) costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions, (xviii) Digital World's ability to timely comply with Nasdaq's rules and complete the Business Combination, (xix) risks that Digital World or TMTG may elect not to proceed with the Business Combination, and (xx) those factors discussed in Digital World's filings with the SEC, including in the Registration Statement. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in the ""Risk Factors"" section of the Registration Statement and in Digital World's Annual Report on Form 10-K, as amended, for the year ended December 31, 2022, as filed with the SEC on October 30, 2023 and January 9, 2024 (the ""2022 Annual Report"") and in other reports Digital World files with the SEC. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Digital World (or to third parties making the forward-looking statements).These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Digital World and TMTG may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Neither Digital World nor TMTG gives any assurance that Digital World, TMTG, or the combined company, will achieve its expectations.Contact InformationInvestor RelationsName: Alex CanoEmail: investorrelations@dwacspac.comSOURCE: Digital World Acquisition Corp.View the original press release on accesswire.com When is the special meeting for Digital World Acquisition Corp. (DWAC) stockholders to vote on the proposed business combination with Trump Media & Technology Group Corp.? The special meeting is scheduled for March 22, 2024. What is the expected outcome after the stockholder approval at the Special Meeting? The Business Combination is anticipated to close shortly after stockholder approval, subject to customary closing conditions. Who expressed gratitude to the shareholders for their support in the press release? Eric Swider, the CEO of Digital World Acquisition Corp., expressed gratitude to the shareholders. What is the goal of Truth Social, as mentioned by TMTG CEO Devin Nunes? The goal of Truth Social is to challenge the Big Tech monopoly, provide a platform free from censorship and cancel culture, and protect Americans' voices and freedom."
American Aires Closes $4 Million Oversubscribed Private Placement,2024-02-17T00:11:00.000Z,Low,Neutral,"American Aires Inc. successfully closes a non-brokered private placement offering, raising approximately $4,000,000 through the sale of 26,666,663 units at $0.15 per unit. The units consist of one common share and one common share purchase warrant, with potential for accelerated expiry. CEO Josh Bruni expresses gratitude for the strong market response, indicating investor confidence in the company's EMF modulation technology and growth prospects.","American Aires Closes $4 Million Oversubscribed Private Placement Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary American Aires Inc. successfully closes a non-brokered private placement offering, raising approximately $4,000,000 through the sale of 26,666,663 units at $0.15 per unit. The units consist of one common share and one common share purchase warrant, with potential for accelerated expiry. CEO Josh Bruni expresses gratitude for the strong market response, indicating investor confidence in the company's EMF modulation technology and growth prospects. Positive None. Negative None. 02/16/2024 - 07:11 PM Toronto, Ontario--(Newsfile Corp. - February 16, 2024) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRD) (""Aires"" or the ""Company""), a company focused on scientifically-proven EMF modulation technology, announces the closing of its non-brokered private placement offering (the ""Offering"") of 26,666,663 units of the Company (the ""Units"") at a price of $0.15 per Unit (the ""Offering Price"") for aggregate gross proceeds of approximately $4,000,000. Each Unit is comprised of one common share in the Company (each, a ""Common Share"") and one common share purchase warrant (each, a ""Warrant"") being exercisable into one Common Share at a price of $0.25 per share for a period of 24 months from closing of the Offering, provided that, in the event that the volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the ""CSE"") exceeds $0.40 for a period of 10 consecutive trading days, the Company will have the right to accelerate the expiry date to 30 days following the date on which the Company provides notice thereof to the holders of the Warrants (the ""Accelerated Expiry"").Josh Bruni, CEO of the Company, stated: ""We are immensely gratified by the market's strong response to our private placement offering, which was significantly oversubscribed, highlighting the overwhelming interest and confidence in American Aires and our dedicated team. This success not only underscores our investors' belief in our transformative technology but also our dedication to advancing well-being and environmental safety. With this support, we are poised to accelerate our global growth, deepen our scientific research, and extend our impact by venturing into new product categories. We are deeply appreciative of this strong endorsement from the investment community and excited about the future that lies ahead.""In connection with the Offering, the Company paid a cash fee of $47,249.99 to certain arm's length finders, and issued to certain arm's length finders 289,100 non-transferrable finder's warrants, each exercisable to acquire one Unit at a price of $0.15 per Unit for a period for 24 months from the Closing, subject to the Accelerated Expiry.The Offering is subject to final approval of the CSE. The securities issued in connection with the Offering are subject to a hold period of four months and one day pursuant to CSE policies and applicable securities laws. The Offering Price was reserved via price protection filed with the CSE on January 15, 2024. The combination of the oversubscribed Offering, the improved company valuation and the feedback that the Company has been receiving from investors over the past several months led the management of the Company to believe that the primary objective of the partnership with HUCK Project LLC (""HUCK"") announced on August 28, 2023 has been largely achieved. While the Company recognizes that more R&D needs to be done to further solidify our scientific leadership in EMF modulation technology, management is satisfied with how the Company is positioned today as a life sciences firm. This has been and remains the Company's primary objective. The secondary rationale of the HUCK outsourcing partnership was to transfer the inventory financing burden over to HUCK. The Company is pleased to report that this rationale was also successfully addressed through the closing of the $4 million Offering. As a result of the above considerations, the Company no longer views the HUCK partnership necessary and is pleased to announce that it has terminated this partnership with HUCK with both companies retaining a friendly relationship and agreeing to all terms and conditions.Early WarningOn February 16, 2024, prior to the closing of the Offering, Birchtree Investments Ltd. (""Birchtree"") disposed beneficial ownership of 6,000,000 Common Shares (the ""Disposition""). Prior to the Disposition, Birchtree held 7,062,366 Common Shares, representing 11.9% of the issued and outstanding Common Shares on an undiluted basis (14.6% on a partially-diluted basis). Following the Disposition, Birchtree held 1,062,366 Common Shares, representing 1.8% of the issued and outstanding Common Shares on an undiluted basis (4.8% on a partially-diluted basis). As such, Birchtree ceased to be an insider of the Company. Birchtree participated in the Offering, following which Birchtree held 6,686,953 Common Shares and 7,505,587 common share purchase warrants of the Company. All such warrants contain a restriction on exercise such that Birchtree shall not be permitted to exercise the warrants if it would result in the Common Shares held by Birchtree exceeding 9.9% of the issued and outstanding Common Shares. Birchtree currently does not have any plan to acquire or dispose of additional securities of the Company. However, Birchtree may acquire additional securities of the Company, dispose of some or all of the existing or additional securities it holds or will hold, or may continue to hold its current position, depending on market conditions, reformulation of plans or other relevant factors.About American Aires Inc.American Aires Inc. is a Canadian-based nanotechnology company committed to enhancing well-being and environmental safety through science-led innovation, education, and advocacy. Aires has developed proprietary silicon-based microprocessors that reduce the harmful effects of electromagnetic radiation (EMR). Aires' Lifetune products target EMR emitted by consumer electronic devices such as cellphones, computers, baby monitors, and Wi-Fi, including the more powerful and rapidly expanding high-speed 5G networks. Aires is listed on the CSE under the ticker 'WIFI' and on the OTC QB under the symbol 'AAIRF'. Learn more at www.airestech.com.On behalf of the board of directorsCompany Contact:Josh Bruni, CEOWebsite: www.airestech.comEmail: wifi@airestech.comTelephone: (415) 707-0102Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding CSE approval of the Offering, issuance of securities underlying the Warrants and Finder's Warrants, the Company's ability to solidify its scientific leadership in EMF modulation technology, the Company's position and ability to grow as a life sciences firm, future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as ""plans"", ""expects"", ""is expected"", ""budget"", ""scheduled"", ""estimates"", ""forecasts"", ""predicts"", ""intends"", ""targets"", ""aims"", ""anticipates"" or ""believes"" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions ""may"", ""could"", ""should"", ""would"", ""might"" or ""will"" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Certain material assumptions regarding such forward-looking statements may be discussed in this news release and the Company's annual and quarterly management's discussion and analysis filed at www.sedarplus.ca. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.No securities regulatory authority has either approved or disapproved of the contents of this news release. The Common Shares, RSUs and Options have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any common shares in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. We seek safe harbour.Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198362 How much money was raised in the private placement offering by American Aires Inc.? American Aires Inc. raised approximately $4,000,000 through the sale of 26,666,663 units at $0.15 per unit. What does each unit in the private placement offering by American Aires Inc. consist of? Each unit in the private placement offering consists of one common share and one common share purchase warrant. What is the potential accelerated expiry condition for the common share purchase warrant in the private placement offering by American Aires Inc.? In the event that the volume weighted average trading price of the Common Shares on the Canadian Securities Exchange exceeds $0.40 for 10 consecutive trading days, the Company has the right to accelerate the expiry date to 30 days following notice to the warrant holders. Who expressed gratitude for the strong market response to the private placement offering by American Aires Inc.? CEO Josh Bruni expressed gratitude for the strong market response, highlighting investor confidence in the company's technology and growth prospects."
FSD Pharma Announces US ATM Offering,2024-02-17T00:10:00.000Z,Neutral,Neutral,"FSD Pharma Inc. announces an at-the-market offering agreement with H.C. Wainwright & Co., LLC, for Class B Subordinate Voting Shares, with an aggregate offering price of up to US$11,154,232. The sales will be made through Wainwright as the sales agent, in line with Rule 415(a)(4) on Nasdaq. The proceeds will be used for clinical studies, trials, development programs, research, development, and general corporate purposes.","FSD Pharma Announces US ATM Offering Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary FSD Pharma Inc. announces an at-the-market offering agreement with H.C. Wainwright & Co., LLC, for Class B Subordinate Voting Shares, with an aggregate offering price of up to US$11,154,232. The sales will be made through Wainwright as the sales agent, in line with Rule 415(a)(4) on Nasdaq. The proceeds will be used for clinical studies, trials, development programs, research, development, and general corporate purposes. Positive None. Negative None. Financial Analyst The initiation of an at-the-market (ATM) offering by FSD Pharma represents a strategic move to raise capital in a flexible manner. By leveraging the ATM mechanism, the company can sell shares directly into the market at prevailing prices, thereby potentially reducing the discount and dilution associated with traditional underwritten offerings. The decision to raise up to US$11,154,232 indicates a targeted approach to funding, rather than a blanket capital increase, which could be viewed positively by investors who prefer prudent financial management.It's important to note that the 3.0% commission to H.C. Wainwright & Co. falls within the typical range for such services, suggesting that FSD Pharma is maintaining cost efficiency in its capital-raising activities. Investors will likely monitor the use of proceeds, particularly the allocation towards clinical studies, R&D and general corporate purposes, as these areas are critical for the company's growth and could impact the company's future revenue streams and market position. Medical Research Analyst The allocation of proceeds from the ATM offering towards clinical studies and trials is a significant development for FSD Pharma. Advancing the clinical pipeline is crucial for a biopharmaceutical company's long-term success. The investment in research and development (R&D) is indicative of the company's commitment to innovation and could lead to potential breakthroughs or advancements in their portfolio of biotech solutions. Stakeholders should assess the company's current pipeline and R&D capabilities to better understand the potential impact of these investments on the company's valuation and future prospects within the biopharmaceutical industry. Market Research Analyst From a market perspective, FSD Pharma's ATM offering aligns with industry practices where biopharmaceutical companies often require substantial capital to fund their operations and development programs. The timing and volume of the share sales being at the discretion of the company's management allows for strategic market play, potentially minimizing the impact on share price due to the gradual nature of the offering. However, market reaction can be influenced by investor perception of the company's growth prospects and the anticipated dilutive effect of the ATM offering. The choice not to sell shares on the Canadian Securities Exchange or other Canadian markets may also be a strategic decision to focus on the liquidity and investor base associated with Nasdaq, which could have implications for the company's visibility and investor outreach. 02/16/2024 - 07:10 PM TORONTO, ON / ACCESSWIRE / February 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (""FSD Pharma"" or the ""Company""), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it has entered into an at the market offering agreement (the ""ATM Agreement"") with H.C. Wainwright & Co., LLC (""Wainwright""), pursuant to which the Company, at its discretion, may offer and sell, from time to time, through Wainwright as sales agent, Class B Subordinate Voting Shares in the capital of the Company (""Class B Shares"") having an aggregate offering price of up to US$11,154,232 (the ""ATM Offering""). A cash commission of 3.0% on the aggregate gross proceeds raised under the ATM Offering will be paid to Wainwright in connection with its services.Sales of the Class B Shares under the Prospectus will be made in transactions that are deemed to be ""at-the-market"" offering as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on or through the Nasdaq Stock Market LLC (""Nasdaq""). The Class B Shares will be distributed at the prevailing market prices at the time of each sale. As a result, prices may vary as between purchasers and during the period of distribution. No Class B Shares in the ATM Offering will be sold on the Canadian Securities Exchange (the ""CSE"") or any other trading market in Canada.The volume and timing of sales, if any, will be determined at the sole discretion of the Company's management and in accordance with the terms of the ATM Agreement. If the Company chooses to sell Class B Shares under the ATM Offering, the Company intends to use the net proceeds of the ATM Offering (i) to fund our various clinical studies, trials and development programs, (ii) to fund research and development, and (iii) for general corporate purposes and working capital.The ATM Offering is being made in the United States pursuant to a registration statement on Form F-3 (File No. 333-276264) filed under the Securities Act of 1933, as amended (the ""Securities Act""), with the Securities and Exchange Commission (the ""SEC"") and declared effective on January 4, 2024 (the ""Registration Statement""), the base prospectus contained in the Registration Statement (the ""Base Prospectus"") and the prospectus supplement dated February 16, 2024 (""Prospectus Supplement"", together with Base Prospectus, the ""Prospectus"") filed with the SEC.You can review our SEC filings, the Registration Statement and Prospectus by accessing the SEC's internet site at www.sec.gov or on the Company's website at www.fsdpharma.com, through which you can access our SEC filings.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About FSD PharmaFSD Pharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. (""Lucid""), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (""Lucid-MS""). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma has also licensed UNBUZZD™, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. (""Celly Nu"") and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD Pharma continues its R&D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.Cautionary Note Regarding Forward-Looking InformationThis press release contains forward-looking statements and forward-looking information (collectively, ""forward-looking statements"") within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as ""plans"", ""expects"", ""expected"", ""scheduled"", ""estimates"", ""intends"", ""anticipates"", ""hopes"", ""planned"" or ""believes"", or variations of such words and phrases, or states that certain actions, events or results ""may"", ""could"", ""would"", ""might"", ""potentially"" or ""will"" be taken, occur or be achieved. More particularly, and without limitation, this press release contains forward-looking statements contained in this press release include statements concerning the future of FSD Pharma and are based on certain assumptions that FSD Pharma has made in respect thereof as of the date of this press release, including those relating to future sales of Class B Shares under the ATM Offering, the offering price therefor and the use of proceeds thereof. FSD Pharma cannot give any assurance that such forward-looking statements will prove to have been correct.Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the timing and ability to satisfy all applicable listing and regulatory requirements of the CSE and Nasdaq; the fact that the drug development efforts of the Company and Lucid are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company and Lucid may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company and Lucid; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company and Lucid; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company and Lucid; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company and Lucid; the inability of the Company to sell under the ATM Offering or upon the terms outlined herein; the prices at which the Company may sell the Class B Shares in the ATM Offering; and other risks. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.Further information regarding factors that may cause actual results to differ materially are included in the Company's annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR+ (www.sedarplus.ca) and with the SEC on EDGAR (www.sec.gov), including the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2022, the Prospectus and Registration Statement, each under the heading ""Risk Factors"". This list of risk factors should not be construed as exhaustive. Readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward-looking statements contained in this document speak only as of the date of this document. FSD Pharma does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.Neither the CSE nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.Contacts:FSD Pharma Inc.Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, FSD Pharma Inc.Email: Zsaeed@fsdpharma.comTelephone: (416) 854-8884Investor RelationsEmail: ir@fsdpharma.com, info@fsdpharma.comWebsite: www.fsdpharma.comSOURCE: FSD Pharma Inc.View the original press release on accesswire.com What type of offering agreement did FSD Pharma Inc. enter into? FSD Pharma Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC for Class B Subordinate Voting Shares. What is the aggregate offering price of the Class B Subordinate Voting Shares? The aggregate offering price of the Class B Subordinate Voting Shares is up to US$11,154,232. Who will be the sales agent for the offering? Wainwright will act as the sales agent for the offering. Where will the sales of the Class B Shares be made? The sales of the Class B Shares will be made through Nasdaq. What will the net proceeds of the offering be used for? The net proceeds of the offering will be used for clinical studies, trials, development programs, research, development, and general corporate purposes."
"Mueller Water Products to Participate in the Gabelli Funds 34th Annual Pump, Valve & Water Systems Symposium",2024-02-16T22:15:00.000Z,Low,Neutral,"Mueller Water Products, Inc. (MWA) will be presenting at the Gabelli Funds 34th Annual Pump, Valve & Water Systems Symposium in New York on February 22, 2024, at 10:30 a.m. Eastern Time. The presentation will be webcast and available on the company's website for 90 days.","Mueller Water Products to Participate in the Gabelli Funds 34th Annual Pump, Valve & Water Systems Symposium Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags conferences Rhea-AI Summary Mueller Water Products, Inc. (MWA) will be presenting at the Gabelli Funds 34th Annual Pump, Valve & Water Systems Symposium in New York on February 22, 2024, at 10:30 a.m. Eastern Time. The presentation will be webcast and available on the company's website for 90 days. Positive None. Negative None. 02/16/2024 - 05:15 PM ATLANTA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Mueller Water Products, Inc. (NYSE: MWA) will participate in the Gabelli Funds 34th Annual Pump, Valve & Water Systems Symposium in New York on Thursday, February 22, 2024. Mueller Water Products is scheduled to present at 10:30 a.m. Eastern Time. The presentation will be webcast on the Investor Relations section of the Company’s website www.muellerwaterproducts.com and will be available for 90 days. About Mueller Water Products, Inc. Mueller Water Products, Inc. is a leading manufacturer and marketer of products and services used in the transmission, distribution and measurement of water in North America. Our broad product and service portfolio includes engineered valves, fire hydrants, pipe connection and repair products, metering products, leak detection, pipe condition assessment, pressure management products, and software technology that provides critical water system data. We help municipalities increase operational efficiencies, improve customer service and prioritize capital spending, demonstrating why Mueller Water Products is Where Intelligence Meets Infrastructure®. Visit us at www.muellerwaterproducts.com. Mueller refers to one or more of Mueller Water Products, Inc. (MWP), a Delaware corporation, and its subsidiaries. MWP and each of its subsidiaries are legally separate and independent entities when providing products and services. MWP does not provide products or services to third parties. MWP and each of its subsidiaries are liable only for their own acts and omissions and not those of each other. Investor Relations Contact: Whit Kincaid770-206-4116wkincaid@muellerwp.com Media Contact: Jenny Barabas470-806-5771jbarabas@muellerwp.com When will Mueller Water Products be presenting at the Gabelli Funds Symposium? Mueller Water Products will be presenting at the Gabelli Funds 34th Annual Pump, Valve & Water Systems Symposium on February 22, 2024, at 10:30 a.m. Eastern Time. Where can I watch the presentation by Mueller Water Products? The presentation by Mueller Water Products will be webcast on the Investor Relations section of the company's website www.muellerwaterproducts.com. For how long will the presentation be available for viewing? The presentation by Mueller Water Products will be available for viewing for 90 days on the company's website."
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4),2024-02-16T22:30:00.000Z,Low,Very Positive,"Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for new employees. The options cover 40,450 shares with an exercise price of $9.87 per share, vesting over a three-year period.","Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for new employees. The options cover 40,450 shares with an exercise price of $9.87 per share, vesting over a three-year period. Positive None. Negative None. 02/16/2024 - 05:30 PM SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on February 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees. The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022 and May 10, 2023, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $9.87, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s AMTAGVI™ is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com. Forward-Looking Statements Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled ""Risk Factors"" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including AMTAGVI, for which we obtain U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”), or other regulatory authority approval; the risk that the EMA or other regulatory authorities may not approve or may delay approval for our biologics license application (“BLA”) submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including AMTAGVI, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including AMTAGVI, or product candidates, respectively; our ability or inability to manufacture our therapies using third party manufacturers or at our own facility may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including AMTAGVI, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risk that future competitive or other market factors may adversely affect the commercial potential for AMTAGVI; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of AMTAGVI will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the effects of the COVID-19 pandemic; and other factors, including general economic conditions and regulatory developments, not within our control. CONTACTS Iovance Biotherapeutics, Inc:Sara Pellegrino, IRCSenior Vice President, Investor Relations & Corporate Communications650-260-7120 ext. 264Sara.Pellegrino@iovance.com Jen SaundersSenior Director, Investor Relations & Corporate Communications267-485-3119Jen.Saunders@iovance.com What did Iovance Biotherapeutics announce regarding stock options? Iovance Biotherapeutics announced the approval of inducement stock options covering 40,450 shares for new non-executive employees. How many shares are included in the stock options grant? The stock options grant covers an aggregate of 40,450 shares of Iovance's common stock. What is the exercise price of the stock options? The exercise price of the stock options is $9.87 per share, based on the closing price of Iovance's common stock on the Date of Grant. How long is the vesting period for the stock options? Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee's start date. Under which plan were the awards granted? The awards were granted under Iovance's 2021 Inducement Plan, adopted on September 22, 2021, and amended on January 12, 2022 and May 10, 2023."
"Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.",2024-02-16T22:36:00.000Z,Low,Neutral,"YS Biopharma Co., Ltd. successfully held an Extraordinary General Meeting of Shareholders, resulting in the removal of several directors and the election of new board members. Yi Zhang, representing the Convening Shareholders, expressed gratitude for shareholder support and aims to focus on the company's business strategy for long-term value.","Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd. Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags management Rhea-AI Summary YS Biopharma Co., Ltd. successfully held an Extraordinary General Meeting of Shareholders, resulting in the removal of several directors and the election of new board members. Yi Zhang, representing the Convening Shareholders, expressed gratitude for shareholder support and aims to focus on the company's business strategy for long-term value. Positive None. Negative None. 02/16/2024 - 05:36 PM NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (the ""Company"" or ""YS"") (NASDAQ: YS) (the ""Convening Shareholders"") today announced the successful approval of all resolutions at the YS Extraordinary General Meeting of Shareholders (""EGM"") held today. 62,132,308 shares out of 93,058,197 total outstanding shares of YS voted in the EGM, which represents 66.8% of all outstanding shares. Before the EGM, individuals purporting to be representatives of the Company arrived at the offices where the EGM was to be conducted, but they indicated that they intended to disrupt the business for which the EGM was convened by the Convening Shareholders, so they were not permitted to enter the premises where the EGM was noticed to be held. The resolutions passed by the shareholders at the EGM are as follows: The removal of the following directors from office of the Company: Hui Shao, Bo Tan, Ajit Shetty, Viren Mehta, Shaojing Tong, Rachel Yu, Yuntao Cui, Jin Wang, Henry Chen, Haitao Zhao, Pierson Yue Pan and Chunyuan (Brenda) Wu; andthe election of the following seven nominees as directors of the Company: Nan Zhang, Yun (Monica) Zhang, Chi Keung (Peter) Lui, Jing Xia Li, Yi Zhang, Yuan Liu and Jimin Wang.Details of the number of shares voted in person or by proxy on the resolutions was as follows: Resolution For Against Shares Voted % Shares Voted % 1. The removal of the following directors from office of the Company: Hui Shao, Bo Tan, Ajit Shetty, Viren Mehta, Shaojing Tong, Rachel Yu, Yuntao Cui, Jin Wang, Henry Chen, Haitao Zhao, Pierson Yue Pan and Chunyuan (Brenda) Wu. 55,123,743 88.7 % 7,008,565 11.3 % 2. The election of the following seven nominees as directors of the Company: Nan Zhang, Yun (Monica) Zhang, Chi Keung (Peter) Lui, Jing Xia Li, Yi Zhang, Yuan Liu and Jimin Wang. 55,123,743 88.7 % 7,008,565 11.3 % There were no abstentions and no ""withhold"" votes. Yi Zhang thanks his fellow shareholders for their support in achieving this positive outcome today. The actions taken reflect an overwhelming shareholder repudiation of the prior board of directors of the Company (the ""Board"") and the total disregard for shareholder perspectives shown by the prior Board and management team. Given the result of the vote, Yi Zhang is confident that YS will now be able to focus its full efforts on executing its business strategy and preserving and growing long-term value for all shareholders. The full text of each resolution is contained in the notice of general meeting set out in the Circular, a copy of which is available here: https://www.sec.gov/Archives/edgar/data/1946399/000110465924024545/tm246234d1_ex99-a.htm Immediately following the successful conclusion of the EGM, the new board of directors of the Company voted [unanimously] to effect the following resolutions (among others): the appointment of Mr. Yi Zhang as the chairperson of the board with immediate effect;the removal of each of Hui Shao, Bo Tan, Ajit Shetty, Viren T. Mehta, Shaojing Tong and Rachel Yu (collectively, the ""Removed Directors"") from all of the relevant committees of the board of the Company including the audit committee, the compensation committee and the nominating and corporate governance committee and from the relevant board and committee (if any) of each subsidiary of the Company with immediate effect;the appointment of each of Jing Xian Li, Chi Keung (Peter) Lui and Yun (Monica) Zhang as a member of the audit committee and Chi Keung (Peter) Lui as the chairperson of the audit committee with immediate effect;the appointment of each of Yun (Monica) Zhang, Jing Xian Li and Nan Zhang as a member of the compensation committee and Yun (Monica) Zhang as the chairperson of the compensation committee with immediate effect;the appointment of each of Yi Zhang, Yun (Monica) Zhang and Jing Xian Li as a member of the nominating and corporate governance committee and Yi Zhang as the chairperson of the nominating and corporate governance committee with immediate effect;the removal of Hui Shao from all positions with the Company and any subsidiaries of the Company, including without limitation as chief executive officer and president of the Company;the removal of Chunyuan (Brenda) Wu from all positions with the Company and any subsidiaries of the Company, including without limitation as chief financial officer of the Company;the appointment of Nan Zhang as the chief executive officer of the Company;the appointment Hongman Jia as the chief financial officer of the Company;the instruction to the registered office provider of the Company to refrain from issuing any new shares to Apex Prospect Limited (""APL"") pursuant to a purported share purchase agreement entered into by and between APL and the Company (the ""Purported Private Placement"", and/or effecting any changes to any registers and/or records of the Company in relation to the Purported Private Placement or otherwise recording any transfer of any shares to APL;the approval of Yi Zhang's sole authority to negotiate the repayment of the USD40,000,000 loan from R-Bridge Investment Three Pte. Ltd.;the approval of certain actions against the Removed Directors;the approval of the engagement of legal counsel already engaged by Yi Zhang and the related expenses to be borne by the Company and its subsidiaries;the establishment of a special committee of independent directors;the termination of engagement of Cooley LLP with immediate effect;the termination of engagement of Mourant Ozannes (Cayman) LLP with immediate effect; andthe termination of engagement of ICR LLP with immediate effect.Cautionary Statement Regarding Forward-Looking Statements This press release (including its attachments) contains ""forward-looking statements."" All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the EGM, the leadership of YS, its ability to develop and commercialize current and planned products, its research and development efforts and other matters regarding business strategies, results and plans and objectives for future operations. These statements are based on the beliefs and assumptions of the Convening Shareholders and on information currently available to them, which is based in part on information provided by the prior Board and management of YS. Although the Convening Shareholders believe that they have a reasonable basis for such statements, these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In some cases, you can identify forward-looking statements by the words ""may,"" ""will,"" ""could,"" ""would,"" ""should,"" ""expect,"" ""intend,"" ""plan,"" ""anticipate,"" ""believe,"" ""estimate,"" ""predict,"" ""project,"" ""potential,"" ""continue,"" ""ongoing"" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, events or achievements to differ materially from the information expressed or implied by these statements. These risks, uncertainties and other factors include the possibility of undisclosed actions by members of the prior YS Board and management, potential efforts to dilute shareholders, the outcome of pending litigation and the prospect of litigation (including regarding the EGM), the potential for potential defaults or enforcement by the creditors of YS, and other risks, uncertainties and factors described under the headings ""Risk Factors,"" ""Management's Discussion and Analysis of Financial Condition and Results of Operations"" and elsewhere in the documents filed by YS with the U.S. Securities and Exchange Commission or in public statements by the Convening Shareholders from time to time. Forward-looking statements may not prove to be accurate. The forward-looking statements in this press release speak as of the date hereof, and the Convening Shareholders undertake no obligation to update any forward-looking statements for any reason, except as required by law. View original content:https://www.prnewswire.com/news-releases/shareholders-led-by-yi-zhang-announce-successful-results-of-removal-of-directors-and-election-of-new-directors-of-ys-biopharma-co-ltd-302064477.html SOURCE Yi Zhang Who were removed from office at the YS Extraordinary General Meeting of Shareholders? Directors Hui Shao, Bo Tan, Ajit Shetty, Viren Mehta, Shaojing Tong, Rachel Yu, Yuntao Cui, Jin Wang, Henry Chen, Haitao Zhao, Pierson Yue Pan, and Chunyuan (Brenda) Wu were removed from office. Who were elected as new directors at the YS Extraordinary General Meeting of Shareholders? Nan Zhang, Yun (Monica) Zhang, Chi Keung (Peter) Lui, Jing Xia Li, Yi Zhang, Yuan Liu, and Jimin Wang were elected as new directors. What percentage of outstanding shares voted in the EGM? 66.8% of all outstanding shares, equivalent to 62,132,308 out of 93,058,197 total shares, voted in the EGM. Who was appointed as the chairperson of the board following the EGM? Mr. Yi Zhang was appointed as the chairperson of the board following the EGM. What actions were taken by the new board of directors after the EGM? The new board of directors appointed new committee members, removed previous directors from positions, and made key executive appointments."
Vector Acquisition Corporation II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination,2024-02-16T22:10:00.000Z,No impact,Negative,"Vector Acquisition Corporation II (VAQC) announces the redemption of all outstanding Class A ordinary shares due to failure to complete an initial business combination by March 12, 2024. The per-share redemption price is approximately $10.69, with a Trust Account balance of $41,786,963 as of February 8, 2024. Public shareholders will receive the Redemption Amount upon delivery of their shares.","Vector Acquisition Corporation II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination Rhea-AI Impact (No impact) Rhea-AI Sentiment (Negative) Tags acquisition Rhea-AI Summary Vector Acquisition Corporation II (VAQC) announces the redemption of all outstanding Class A ordinary shares due to failure to complete an initial business combination by March 12, 2024. The per-share redemption price is approximately $10.69, with a Trust Account balance of $41,786,963 as of February 8, 2024. Public shareholders will receive the Redemption Amount upon delivery of their shares. Positive None. Negative Failure to complete an initial business combination by the specified deadline, resulting in the redemption of all outstanding Class A ordinary shares. Ceasing all operations except for winding up, liquidating, and dissolving the company if the initial business combination is not achieved by March 12, 2024. Delisting of the Company's securities and termination of registration under the Securities Exchange Act of 1934 after March 4, 2024. 02/16/2024 - 05:10 PM SAN FRANCISCO--(BUSINESS WIRE)-- Vector Acquisition Corporation II (the “Company”) (Nasdaq: VAQC), a special purpose acquisition company, today announced that it will redeem all of its outstanding publicly held Class A ordinary shares (the “Public Shares”), effective as of the close of business on March 4, 2024, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the “Articles”). As stated in the Company’s Articles, if the Company is unable to complete an initial business combination by March 12, 2024, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Company’s trust account (the “Trust Account”), including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any, (less up to US$100,000 of interest to pay dissolution expenses), divided by the number of Public Shares then in issue, which redemption will completely extinguish public shareholders’ rights (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Directors, liquidate and dissolve, subject in each case to its obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. The per-share redemption price for the Public Shares will be approximately $10.69 (the “Redemption Amount”). The balance of the Trust Account as of February 8, 2024 was approximately $41,786,963, which includes approximately $2,718,703 in interest and dividend income (excess of cash over $39,068,260, the funds deposited into the Trust Account, with the IPO deposit as reduced by the redemption in March 2023). In accordance with the terms of the related trust agreement, the Company expects to retain $100,000 of the interest and dividend income from the Trust Account to pay dissolution expenses. As of the close of business on March 4, 2024, the Public Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount. The Redemption Amount will be payable to the holders of the Public Shares upon delivery of their shares or units to the Company’s transfer agent, Continental Stock Transfer & Trust Company. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount. The Company’s sponsor has waived its redemption rights with respect to the outstanding founder shares. After March 4, 2024, the Company shall cease all operations except for those required to wind up the Company’s business. The Company will file a Form 25 with the Commission in order to delist the Company’s securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of the Company’s securities under the Securities Exchange Act of 1934, as amended. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as “believes,” “expects,” “intends,” “plans,” “estimates,” “assumes,” “may,” “should,” “will,” “seeks,” or other similar expressions. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20240215534406/en/ Grace Cartwright Gasthalter & Co. (212) 257-4170 Source: Vector Acquisition Corporation II What is the ticker symbol of Vector Acquisition Corporation II? The ticker symbol is VAQC. What is the per-share redemption price for the Public Shares? The per-share redemption price is approximately $10.69. When will the Public Shares be deemed cancelled? The Public Shares will be deemed cancelled as of the close of business on March 4, 2024. How will the Redemption Amount be paid to the holders of the Public Shares? The Redemption Amount will be payable upon delivery of shares or units to the Company's transfer agent, Continental Stock Transfer & Trust Company. What will happen to the Company's securities after March 4, 2024? The Company will file a Form 25 with the Commission to delist the securities and expects to file a Form 15 to terminate the registration under the Securities Exchange Act of 1934."
Planet Based Foods Provides Update on Private Placement,2024-02-17T01:11:00.000Z,Neutral,Neutral,"Planet Based Foods Global Inc. receives an extension to complete a non-brokered private placement of subordinate voting shares for up to CAD $3,000,000 at $0.10 per share.","Planet Based Foods Provides Update on Private Placement Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Planet Based Foods Global Inc. receives an extension to complete a non-brokered private placement of subordinate voting shares for up to CAD $3,000,000 at $0.10 per share. Positive None. Negative None. 02/16/2024 - 08:11 PM Vancouver, British Columbia--(Newsfile Corp. - February 16, 2024) - Planet Based Foods Global Inc. (CSE: PBF) (OTCQB: PBFFF) (FSE: AZ00) (""Planet Based Foods"" or the ""Company""), a company that offers a wide range of hemp-based food alternatives, announces that the Company has been granted an extension by the Canadian Securities Exchange to complete its previously announced non-brokered private placement of subordinate voting shares (a ""Share"") at a price of $0.10 per Share for gross aggregate proceeds of up to CAD $3,000,000 (the ""Offering""). The Company anticipates closing the Offering prior to March 6, 2024. Further details of the Offering are provided in the news releases of the Company dated December 1, 2023 and January 19, 2024. About Planet Based Foods The Company, through its wholly-owned subsidiary in San Diego, California, Planet Based Foods, is a producer of sustainable plant-based food alternatives. Planet Based Foods was founded in 2018 in San Diego, California, with a mission to build a better food system by providing hemp-formulated superfood products to people today that support our planet tomorrow. All Planet Based Foods products are 100% vegan. Planet Based Foods creates clean, non-GMO, nutrient-dense food built for the future: the first line of plant-based foods with sustainable hemp as the number-one ingredient. Founded by former nutrition coach and cannabis marketer Braelyn Davis, food scientist and plant-based pioneer Robert Davis, and restaurant industry veteran Ted Cash, the company aims to establish hemp as a nutrient-dense protein source to feed the world sustainably for generations to come. Planet Based Foods' suite of products includes its new consumer line of nutritious frozen foods, plant-based food ingredients and handheld comfort foods for food service and restaurants. Additional information about the Company is available on SEDAR+ (www.sedarplus.ca). To subscribe to automated email alerts for future news and public filings, visit the Planet Based Foods website at www.planetbasedfoods.com.On Behalf of the BoardBraelyn DavisCEO and Co-FounderContact:info@planetbasedfoods.comForward-Looking StatementsCertain statements included in this news release constitute ""Forward-Looking Statements"" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and ""forward-looking information"" under applicable Canadian securities laws (collectively, ""forward-looking statements""). Such statements include those identified by the expressions ""anticipate"", ""assume"" ""believe"", ""plan"", ""estimate"", ""expect"", ""intend"", ""may"", ""should"" and similar expressions. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. These forward-looking statements or information relate to, among other things, the Offering and the closing thereof. These statements reflect the Company's current views with respect to future events and are necessarily based upon a number of other assumptions and estimates that, while considered reasonable by management, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or forward-looking information and the Company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, development of the industry in which the Company operates; risks associated with the conduct of the Company's business activities; risks relating to reliance on the Company's management team and outside contractors; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; laws and regulations governing the industry in which the Company operates; operating or technical difficulties; employee relations, labour unrest or unavailability; stock market volatility; conflicts of interest among certain directors and officers; lack of liquidity for shareholders of the Company; litigation risk; and other risk factors disclosed in the Company's public disclosure documents available on the Company's profile at www.sedarplus.ca. Readers are cautioned against attributing undue certainty to forward-looking statements or forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. The Company does not intend and does not assume any obligation to update these forward-looking statements or forward-looking information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information other than as required by applicable law.The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198364 What is the purpose of Planet Based Foods Global Inc.'s private placement of subordinate voting shares? Planet Based Foods Global Inc. is conducting a non-brokered private placement of subordinate voting shares to raise gross aggregate proceeds of up to CAD $3,000,000 at a price of $0.10 per share. When is Planet Based Foods Global Inc. expected to close the private placement offering? The Company anticipates closing the Offering prior to March 6, 2024. How much is the price per share for the private placement of subordinate voting shares? The price per share for the private placement is $0.10. What are the details of the private placement offering by Planet Based Foods Global Inc.? Further details of the Offering can be found in the news releases of the Company dated December 1, 2023 and January 19, 2024."
BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS,2024-02-17T00:17:00.000Z,Low,Neutral,"Bright Green Corporation (BGXX) appoints CEO Groovy Singh to the Board of Directors and Founder Lynn Stockwell as Chair. The company aims to expand its facility in Grants, New Mexico for drug production.","BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags management Rhea-AI Summary Bright Green Corporation (BGXX) appoints CEO Groovy Singh to the Board of Directors and Founder Lynn Stockwell as Chair. The company aims to expand its facility in Grants, New Mexico for drug production. Positive None. Negative None. 02/16/2024 - 07:17 PM CEO, Groovy Singh appointed as a new member of the Company’s Board Founder, Lynn Stockwell, appointed as Chair of the Board of Directors Grants, New Mexico, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) – Bright Green Corporation, a Delaware corporation (the “Company”), announced Friday that CEO Groovy Singh is the newest member of the company’s Board of Directors (the “Board”). Current board member and Co-Founder Lynn Stockwell was also announced as the new Chair of the Board. Singh and Stockwell’s appointments follow the resignation of the Executive Chairman, Terry Rafih. Mr. Rafih’s resignation was not a result of any disagreement with the Company, the Board or any committees of the Board, or on any matter relating to the Company’s operations, policies or practices. Speaking on behalf of the company, the Board thanks Mr. Rafih for his contributions to Bright Green, and wish him well on his future endeavors. In addition to continuing his role as Bright Green CEO, Singh will now play a crucial role on company’s Board alongside Stockwell as the new board Chair. The adjustments come at a pivotal time for the company as they continue expanding the Grants, New Mexico facility to support the research, production, and manufacture of Schedule I and Schedule II plant-based drugs and APIs in the United States. As the company looks forward, Singh and Stockwell will continue to drive alignment with Bright Green’s ethos and fierce commitment to improving the quality of life for individuals nationwide with the establishment of a reliable Drugs Made in America and efficacious API supply chain within the United States. About Bright Green Bright Green is one of the very few companies selected by the US government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Our approval based on already agreed terms from the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us. Media Contacts: Interdependence Public Relations Owen Phillips / Grace Connor BrightGreen@Interdependence.com (310) 745-1407 Media Inquiries & Investor Relations Contactir@brightgreen.us About Bright Green Bright Green is one of the first companies selected and approved by the US government to legally grow, manufacture, and sell cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export under legal and state law. Our approval, based on pre-agreed terms set by the U.S. Drug Enforcement Administration, gives Bright Green the opportunity to advance the vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us . Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control, including but not limited to, the inability of the Company to raise funds under the Company’s EB-5 program, and the impact that new officers, directors and employees may have on the Company and the Company’s business and results of operations. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as amended and supplemented, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov . Who was appointed as the newest member of Bright Green Corporation's Board of Directors? CEO Groovy Singh was appointed as the newest member of Bright Green Corporation's Board of Directors. Who was announced as the new Chair of the Board of Directors for Bright Green Corporation? Founder Lynn Stockwell was announced as the new Chair of the Board of Directors for Bright Green Corporation. What is the ticker symbol for Bright Green Corporation? The ticker symbol for Bright Green Corporation is BGXX. What is the company's focus as it expands its facility in Grants, New Mexico? The company aims to support the research, production, and manufacture of Schedule I and Schedule II plant-based drugs and APIs in the United States."
"Aisha Bowe on Supporting Women Leaders in STEM: ""You Are a Mentor the Moment You Think You Are""",2024-02-16T18:15:00.000Z,Low,Neutral,"Logitech's Women Who Master series highlights Aisha Bowe, a former aerospace engineer turned CEO of two tech companies, showcasing her journey in STEM and empowering the next generation of women in technology.","Aisha Bowe on Supporting Women Leaders in STEM: ""You Are a Mentor the Moment You Think You Are"" Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Logitech's Women Who Master series highlights Aisha Bowe, a former aerospace engineer turned CEO of two tech companies, showcasing her journey in STEM and empowering the next generation of women in technology. Positive None. Negative None. 02/16/2024 - 01:15 PM NORTHAMPTON, MA / ACCESSWIRE / February 16, 2024 / Logitech's Women Who Master series celebrates the achievements of women leaders in STEM. This installment tells the story of Aisha Bowe, former aerospace engineer and current CEO of two tech companies, who has unique insights into guiding the next generation of STEM women.If you could go back in time and tell young Aisha Bowe that she would run not one but two tech companies in the future, she probably wouldn't believe you. Despite showing no inclinations toward tech growing up, Aisha is the founder and CEO of STEMBoard, an engineering consulting firm, and the creator of LINGO, a project-based STEM coding kit that is used by thousands of students and now available on major retailers. Recently we had an opportunity to ask Aisha about her life, her career, her thoughts on mentorship, and her vision for the future of her field.Q: What was your childhood like? What did you like to do, and how did you get into engineering?I was a late comer to the field of engineering. In fact, I had no idea I was even interested in engineering until I ended up in community college. I was a competitive gymnast growing up. So I spent most of my time from age five to 15 in a gymnasium somewhere because I was on a club team. Then high school… let's just say I was not a very focused or deliberate student. After that, I found myself at a two-year college in Michigan called Washtenaw Community College. I thought I was going to major in international business and travel to exotic locations for work-that's what I thought I wanted for my life then.At my dad's suggestion, I took a pre-algebra class at Washtenaw. The class was taught by a woman who was an electrical engineer at Ford at the time. That was the spark. That class led to Calculus 1, 2, and 3, and then I transitioned to the University of Michigan, where, by the time it was all over, I had earned two degrees in engineering.My first degree is in aerospace engineering. My second degree is a master's in space systems engineering with a focus on nanosatellite technology development. After graduation, I worked at NASA Ames Research Center for six years as an aerospace engineer in Silicon Valley, where I focused on satellites the size of a shoebox and optimizing the National Airspace System.Q: Amazing. And what made you shift from NASA to looking to start your own company, STEMBoard?I was speaking at the Hiller Aviation Museum as part of NASA's public outreach, and I vividly remember seeing this young girl in the crowd. Her name was Claire, and she was 13. Claire came up to me after my presentation and she said, ""I want to be an aerospace engineer."" And I said, ""Well, OK, here. I'll give you my card. After you get home and you talk to your parents, if they're okay with it, contact me and we'll have a conversation.""A week later I get an email from a cute username like ""Puggydog7."" It was Claire!She ended up coming to NASA to spend a day with me, touring the arc jet and the wind tunnel - and everything.By the end of that day, I was convinced that I didn't want to live a life where what I did that day wasn't part of it. I realized that you are a role model and you are a mentor the moment you think you are. And STEMBoard grew out of that. I wanted to create a company that did two things: provide engineering solutions and work on exciting and challenging problems AND, my core priority, inspire the emerging workforce.Today, Claire is an aerospace engineering graduate from California Polytechnic State University, San Luis Obispo and she works at Blue Origin.I wanted to inspire other people out there like me, like Claire - all those people who don't yet know that they're the future of technology.Q: Practically speaking, how are you inspiring other young people out there, like Claire and yourself, on a grand scale?When I started STEMBoard, we were really focused on being an engineering company. And, in creating LINGO, our project-based STEM coding kit, I feel like we've really been able to demonstrate that profit and social benefit are not mutually exclusive. You can do both. And you can do both incredibly well.With LINGO, we give kids a series of real-world STEM lessons, where we teach kids how hardware and software talk to each other. In one kit, students can learn how to build and code a back-up sensor for a driverless car. The same type sensor can be found in a Tesla. It's now sold through major retailers and used by schools, universities and Fortune 500 education programs in the US and around the world. It's amazing to be part of a movement that has this kind of reach and momentum.I love that we can bring an industry perspective to STEM education, but this work also makes my organization a better place. And I hope that's something I can communicate to other companies and people who may not see themselves as mentors. We all have a role to play, and it's called mentorship.Q: That brings up an interesting question about mentoring. With STEM spreading into other fields through the technology that is everywhere in our modern lives, what skills do you think are most important for us to teach the next generation?*Laughs* I hope I don't get too many angry emails from people who disagree, but in my opinion data is king. So anything around the ability to gather, understand, and visualize data is key. I'm finding that more and more organizations want to make data-driven decisions, regardless of what metrics they're actually measuring. So that is a foundational element. Also just being proficient in commonly used tools - Zoom®, Google Docs™, Outlook®, whatever - would be a way for us to get people off to a good start.And learning how to learn. If you can help people learn more effectively, it's going to benefit every other part of their academic and professional experience.Q: You're obviously not afraid to go in new directions or to use your, or your team's, diverse interests and skills as launch pads for business endeavors. How do you bring your whole self to work?That's how I've always run my organizations. I love for people to do what they were hired for, absolutely, but I want them to feel like if they've got something else they can add that they weren't hired for and that they have the freedom to express it. And even if they don't have that additional piece, I just want them to be in agreement that we are going to do something here as a company that benefits not only ourselves and our families, but that benefits our communities and can hopefully make the world a better place.Q: Women have made incredible progress over the course of history. How do you see yourself carrying this work forward and shaping the narrative for future women in STEM?I think a theme of my life is challenging what the norms are. I want to challenge how people see women. I want to challenge how people see women in technology. I want to challenge how people see black women in STEM or how CEOs run companies. There are so many limitations put on people that are based on nothing other than convention. When I was in community college saying I wanted to work for NASA, everyone was like, ""Yeah, sure."" And when I decided that I wanted to create an education business inside a service company, everyone thought I was bonkers again.But just because something's not commonly done, or you haven't seen it done, doesn't mean that it can't be a viable option for someone in the future.I hope my work helps young women and girls somewhere to expand what they think is possible. And I hope it helps society expand what they think is possible of us.To learn more about Aisha or STEMBoard's services, go here.To get a LINGO coding kit of your very own, go here.Women Who Master puts a spotlight on women who have made outstanding contributions to STEM fields. The goal of the series is to celebrate those contributions, inspire future leaders, and help close the gender gap in technology.Social Media HandlesAisha BoweTwitter: @arboweInstagram: @aishaboweFacebook: @aishaboweLinkedIn: @aishaboweLINGOTwitter: @STEMLingoCoInstagram: @stemlingocoFacebook: @STEMLingoCoLinkedIn: @STEMLingoCoLink to In Her ElementPhoto Credit: Wesley Hicks. View additional multimedia and more ESG storytelling from Logitech on 3blmedia.com.Contact Info:Spokesperson: LogitechWebsite: https://www.3blmedia.com/profiles/logitech Email: info@3blmedia.comSOURCE: LogitechView the original press release on accesswire.com Who is featured in Logitech's Women Who Master series? Aisha Bowe, a former aerospace engineer and current CEO of two tech companies. What are the two tech companies that Aisha Bowe is the CEO of? Aisha Bowe is the CEO of STEMBoard, an engineering consulting firm, and LINGO, a project-based STEM coding kit. What is LINGO? LINGO is a project-based STEM coding kit created by Aisha Bowe, used by thousands of students and available on major retailers. What is the focus of Logitech's Women Who Master series? The series celebrates the achievements of women leaders in STEM and highlights their stories."
Hybrid Power Solutions Up-Lists to the OTCQB Marketplace,2024-02-17T01:00:00.000Z,Neutral,Very Positive,"Hybrid Power Solutions Inc. (HPSIF) successfully upgrades to the OTCQB Venture Market and gains DTC eligibility, enhancing trading opportunities. The company also announces marketing agreements with Outside The Box Capital Inc. and MIC Market Information & Content Publishing GmbH.","Hybrid Power Solutions Up-Lists to the OTCQB Marketplace Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Hybrid Power Solutions Inc. (HPSIF) successfully upgrades to the OTCQB Venture Market and gains DTC eligibility, enhancing trading opportunities. The company also announces marketing agreements with Outside The Box Capital Inc. and MIC Market Information & Content Publishing GmbH. Positive Hybrid Power Solutions Inc. upgrades to the OTCQB Venture Market, improving visibility and transparency for investors. The company's common shares now trade on the OTCQB under the symbol 'HPSIF', along with existing symbols on the Canadian Securities Exchange and Frankfurt Stock Exchange. DTC eligibility streamlines trading processes and boosts liquidity for Hybrid's shares in the United States. Marketing agreements with Outside The Box Capital Inc. and MIC Market Information & Content Publishing GmbH aim to increase investor awareness and engagement through online platforms. The agreements involve promotional activities on YouTube, Twitter, Facebook, and Google, enhancing the company's reach and visibility. CEO Francois Byrne expresses gratitude for the support received from partners and shareholders, highlighting the importance of achieving these milestones. The marketing agreements with Outside The Box and MIC are aimed at enhancing investor interest and awareness through various online channels. Negative None. 02/16/2024 - 08:00 PM Vancouver, British Columbia--(Newsfile Corp. - February 16, 2024) - Hybrid Power Solutions Inc. (CSE: HPSS) (OTCQB: HPSIF) (FSE: E092) (""Hybrid"" or the ""Company""), is pleased to announce that it has successfully upgraded from the OTC Pink Market to the OTCQB Venture Market. The upgrade has been approved by OTC Markets Group and the Company commenced trading on the OTCQB on January 30th, 2024.The Company's common shares started trading on the OTCQB under the symbol ""HPSIF"" as of the opening of the market on January 30th, 2024. The Company's common shares will continue to trade on the Canadian Securities Exchange under the symbol ""HPSS"" and the Frankfurt Stock Exchange under the symbol ""E092"".The OTCQB, operated by OTC Markets Group, Inc., is a market designed for developing and entrepreneurial companies in the United States and abroad. To be eligible for trading on the OTCQB, companies must be current in their financial reporting with the Securities and Exchange Commission, pass a minimum bid price test, maintain audited financials through a PCAOB registered firm, and undergo company verification and management certification on an annual basis.The Company also announces that its common shares are eligible for electronic clearing and settlement in the United States through the Depository Trust Company (""DTC""). DTC eligibility is expected to simplify the process of trading and enhance liquidity of Hybrid's shares in the United States. The Company's shares recently began trading on the OTCQB under the symbol ""HPSIF"". The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered to be ""DTC eligible"". This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.Francois Byrne, CEO stated, ""Cross-trading onto the OTCQB Venture Market as well as Hybrid's shares being DTC eligible marks the achievement of yet another important milestone that we set out to achieve. We believe trading on the OTCQB, along with DTC eligibility will provide much greater visibility and transparency to investors which will allow for us to reach a wider audience. We greatly appreciate the support we have received from our partners and shareholders as we continue to execute on our business plan."" The Company also announces an arm's length agreement with Outside The Box Capital Inc. (""Outside The Box"") (Address: 2202 Green Orchard Place. Oakville, ON I6H 4V4, Canada; email: info@outsidethebox.capital; phone: +289-259-4455) for marketing services of up to six months, which commenced December 13th, 2023.Outside The Box will utilize their online programs with the aim of increasing investor awareness and attracting potential new investors through various online platforms and methods of engagement in consideration of CA$100,000. The promotional activity will occur by YouTube, Twitter, Facebook, and Google. Outside The Box is an arm's length service provider and does not have any prior relationship with the Company.The Company also announces a renewal agreement with MIC Market Information & Content Publishing GmbH (""MIC"") (Address: Gerhart-Hauptmann-St. 49b 51379 Leverkusen; email: contact@micpublishing.de; phone: +49 2171-7766628) for marketing services which will continue to April 15th, 2024 or until budget exhaustion. MIC will utilize their online programs with the aim of increasing investor awareness and interest in the company through various online platforms and methods of engagement in consideration of EUR 250,000. The marketing activity will occur by email, Facebook, and Google. MIC does not have any prior relationship with the Company other than previous marketing engagements and will not receive any shares of the Company as compensation.On behalf of the companyFrancois ByrneCEO and Director invest@hybridps.ca1 (866) 549-2743www.investhps.comAbout Hybrid Power Solutions Inc.Hybrid Power Solutions Inc. is a Canadian clean energy company listed on the Canadian Securities Exchange under the symbol ""HPSS"". Hybrid specializes in the development of sustainable energy solutions, offering products that redefine how industries approach access to power and energy storage. With a focus on innovation and environmental responsibility, HPS continues to lead the way in providing scalable, cost effective power solutions.Forward Looking StatementsCertain information contained herein constitutes ""forward-looking information"" under Canadian securities legislation. Forward-looking information includes, but is not limited to, the services offered under the contract and successful enhanced market conditions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as ""will"", ""will be"", ""intends"", ""expected"" or variations of such words and phrases or statements that certain actions, events or results ""will"" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by management of the Company, they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different, including receipt of all necessary regulatory approvals. Although management of the Company have attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198351 What market has Hybrid Power Solutions Inc. (HPSIF) upgraded to? Hybrid Power Solutions Inc. (HPSIF) has successfully upgraded to the OTCQB Venture Market. What is the ticker symbol for Hybrid Power Solutions Inc. on the OTCQB? Hybrid Power Solutions Inc. trades under the symbol 'HPSIF' on the OTCQB. What is the significance of DTC eligibility for Hybrid Power Solutions Inc. (HPSIF)? DTC eligibility simplifies trading processes and enhances liquidity for Hybrid Power Solutions Inc. (HPSIF) shares in the United States. Who are the marketing service providers for Hybrid Power Solutions Inc.? The marketing service providers for Hybrid Power Solutions Inc. are Outside The Box Capital Inc. and MIC Market Information & Content Publishing GmbH. What platforms will be used for promotional activities by Outside The Box Capital Inc.? Outside The Box Capital Inc. will utilize YouTube, Twitter, Facebook, and Google for promotional activities. What is the aim of the marketing agreements with Outside The Box Capital Inc. and MIC Market Information & Content Publishing GmbH? The aim of the marketing agreements is to increase investor awareness and attract new investors through online platforms."
BioNxt Solutions Finalizes Agreement,2024-02-17T00:50:00.000Z,Moderate,Positive,"BioNxt Solutions Inc. announces the finalization of a settlement agreement with a creditor to settle $282,415 in debt through the issuance of common shares and a cash payment.","BioNxt Solutions Finalizes Agreement Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary BioNxt Solutions Inc. announces the finalization of a settlement agreement with a creditor to settle $282,415 in debt through the issuance of common shares and a cash payment. Positive None. Negative None. 02/16/2024 - 07:50 PM VANCOUVER, BC / ACCESSWIRE / February 16, 2024 / BioNxt Solutions Inc. (""BioNxt"" or the ""Company"") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that it has finalized and executed a settlement agreement (the ""Settlement Agreement"") with a creditor of the Company (the ""Creditor"") to settle an aggregate of $282,415 in debt (the ""Debt"") accrued through a combination of equipment sold and services provided by the Creditor to the Company through the issuance of common shares of the Company (the ""Shares""). An additional $100,000 of debt owing to the same Creditor will be satisfied by the Company through a cash payment.The amount of the Debt will be settled in three instalments of $94,138 worth of Shares issued on or about the following dates:(i)February 26, 2024;(ii)October 15, 2024; and(iii)February 15, 2025.The number of Shares to be issued at each instalment shall equal the quotient obtained by dividing $94,138 by the market price of the Shares calculated as the closing price of the Shares on the Canadian Securities Exchange (the ""Exchange"") on the day prior to issuance. The issuance of the Shares is subject to receipt of Exchange approval.All Shares issued in connection with the Settlement Agreement are subject to a statutory hold period of four months plus a day from the date of issuance of the Shares in accordance with applicable securities legislation.The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.About BioNxt Solutions Inc.BioNxt Solutions Inc. is a bioscience accelerator focused on next‐generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low‐cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.BioNxt Solutions Inc.Hugh Rogers, CEO and DirectorEmail: info@bionxt.comPhone: +1 780-818-6422Cautionary Statement Regarding ""Forward-Looking"" InformationThis news release includes certain statements that may be deemed ""forward-looking statements"". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words ""expects"", ""plans"", ""anticipates"", ""believes"", ""intends"", ""estimates"", ""projects"", ""potential"", and similar expressions, or that events or conditions ""will"", ""would"", ""may"", ""could"" or ""should"" occur. Forward-looking information in this news release include final Exchange approval for the issuance of the Shares. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.SOURCE: BioNxt Solutions Inc.View the original press release on accesswire.com What is the news about BioNxt Solutions Inc. (BNXTF) settling a debt? BioNxt Solutions Inc. has finalized a settlement agreement with a creditor to settle $282,415 in debt through the issuance of common shares and a cash payment. How much debt is being settled by BioNxt Solutions Inc. (BNXTF)? BioNxt Solutions Inc. is settling an aggregate of $282,415 in debt through the issuance of common shares and a cash payment. How will BioNxt Solutions Inc. (BNXTF) settle the additional $100,000 debt? BioNxt Solutions Inc. will satisfy an additional $100,000 of debt owed to the same creditor through a cash payment."
bettermoo(d) Achieves Remarkable Sales Performance: Moodrink(TM) Sold Out and Reordered in Select Independent and Retail Chain Stores in Canada,2024-02-17T00:25:00.000Z,Neutral,Positive,"bettermoo(d) Food Corporation (MOOOF) achieves a significant sales milestone with its flagship dairy alternative product Moodrink™, leading to swift sell-outs and immediate restocking in select Canadian retail chain stores. The success showcases the Product's market presence and consumer acceptance, setting the stage for future growth and expanded market footprint in the plant-based beverage sector.","bettermoo(d) Achieves Remarkable Sales Performance: Moodrink(TM) Sold Out and Reordered in Select Independent and Retail Chain Stores in Canada Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary bettermoo(d) Food Corporation (MOOOF) achieves a significant sales milestone with its flagship dairy alternative product Moodrink™, leading to swift sell-outs and immediate restocking in select Canadian retail chain stores. The success showcases the Product's market presence and consumer acceptance, setting the stage for future growth and expanded market footprint in the plant-based beverage sector. Positive None. Negative None. 02/16/2024 - 07:25 PM VANCOUVER, BC / ACCESSWIRE / February 16, 2024 / bettermoo(d) Food Corporation (CSE:MOOO)(OTCQB:MOOOF)(Frankfurt:0I5A),(WKN:A3D8PP) (the ""Company"" or ""bettermoo(d)), is thrilled to report a significant sales milestone for its flagship dairy alternative product, Moodrink™ (the ""Product""). Due to strong consumer demand, Moodrink™ has sold out in select retail chain stores (the ""Stores"") in Canada, prompting immediate reorders to restock Moodrink™ on shelves and continue meeting the enthusiastic response and increasing demand from Canadians.This reorder represents a crucial moment of acceleration in bettermoo(d)'s journey towards future growth. The swift sell-out and subsequent restock of Moodrink™ across Canada highlights the Product's market presence and consumer acceptance, laying a solid foundation for expanding the Product's footprint in the plant-based beverage sector. This momentum is a clear indicator of Moodrink™'s potential to drive substantial growth and reinforce bettermoo(d)'s position as a leader in sustainable food innovations. As the Company continues to meet and exceed consumer demand, these successes will be instrumental in attracting new retail partnerships and opportunities, paving the way for expansive growth and enhanced shareholder value.""We are extremely happy to see that Moodrink™ has received a great reception from consumers so far. This achievement propels us into an exciting phase of growth, with the anticipation of hitting more major milestones in the near future. We are committed to building on this momentum, expanding our market presence, and continuing to deliver products that resonate with our consumers' values and lifestyles,"" stated Nima Bahrami, CEO of bettermoo(d).The Company's distribution partner United Natural Foods (UNFI) Canada has played a pivotal role in facilitating the swift reorder of Moodrink™ to the select Stores, ensuring that the demand surge is met with adequate supply across Canada. UNFI, a leading distributor in North America, specializes in natural, organic, and specialty food products, boasting a vast network of distribution centers that serve approximately 30,000 retail partners in the United States and Canada. This partnership underscores UNFI's integral role in bettermoo(d)'s distribution strategy, leveraging its extensive reach and logistical expertise to enhance Moodrink™'s availability.ABOUT BETTERMOO(D) FOOD CORPORATIONbettermoo(d) Food Corporation is an innovative plant-based dairy alternative food and beverage company based in Vancouver, British Columbia Canada, launching Moodrink™, a nutritious dairy-alternative beverage with a revolutionary flavour. Moodrink™ includes a blend of herbs and flowers similar to what cows ate, before the time of mass livestock production. Like rich dairy products, Moodrink™ contains added healthy plant fats and vitamins, so consumers don't miss out. The ""Moodrink"" is just the beginning of the revolution for the Vancouver based dairy-alternative company, bettermoo(d).Driven by the motto ""What A Cow Eats and A Human Needs"" bettermoo(d) seeks to produce dairy alternative products that are good for both people and the planet - ensuring that all products are nutritious and sustainably sourced, and that also emulate the great taste of traditional milk from the Alps regions of Switzerland, France and Austria. Working with food scientists, the Company's goal is to conduct continuous food research and development programs with the aim of rolling out a full line of dairy alternative products, including Moogurt and Buetter, as well as many other products, that are better for YOU and better for the planet.ON BEHALF OF THE BOARD of DIRECTORSNima BahramiChief Executive Officer and Directorbettermoo(d) Food CorporationFor further information please contact:Email: investors@bettermoodfoodcorporation.comWebsite: www.bettermoo.comPhone: 1-855-715-1865The CSE does not accept responsibility for the adequacy or accuracy of this release.This news release may contain certain forward looking statements and forward looking information (collectively, ""Forward-Looking Statements"") within the meaning of the applicable Canadian and U.S. securities laws, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, statements with respect to the anticipated restock and expansion of Moodrink, are forward-looking statements. When or if used in this news release, the words ""anticipate"", ""believe"", ""estimate"", ""expect"", ""target, ""plan"", ""forecast"", ""may"", ""schedule"" and similar words or expressions identify forward-looking statements or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.SOURCE: bettermoo(d) Food CorporationView the original press release on accesswire.com What product achieved a significant sales milestone for bettermoo(d) Food Corporation? Moodrink™ achieved a significant sales milestone for bettermoo(d) Food Corporation. Where did Moodrink™ sell out, prompting immediate reorders? Moodrink™ sold out in select retail chain stores in Canada, prompting immediate reorders. Who is the CEO of bettermoo(d) Food Corporation? Nima Bahrami is the CEO of bettermoo(d) Food Corporation. Which distribution partner facilitated the swift reorder of Moodrink™? United Natural Foods (UNFI) Canada facilitated the swift reorder of Moodrink™. What does the partnership with UNFI signify for bettermoo(d) Food Corporation? The partnership with UNFI signifies the integral role of UNFI in bettermoo(d)'s distribution strategy, leveraging its extensive reach and logistical expertise."
Doubleview Gold Corp Issues Invites to Webinar,2024-02-16T23:50:00.000Z,Neutral,Neutral,"Doubleview Gold Corp. (DBLVF) announces a corporate update webinar for interested shareholders on Feb 20, 2024. The webinar aims to provide insights into the company's latest developments and future prospects.","Doubleview Gold Corp Issues Invites to Webinar Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Doubleview Gold Corp. (DBLVF) announces a corporate update webinar for interested shareholders on Feb 20, 2024. The webinar aims to provide insights into the company's latest developments and future prospects. Positive None. Negative None. 02/16/2024 - 06:50 PM Vancouver, British Columbia--(Newsfile Corp. - February 16, 2024) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (GERMANY: A1W038) (the ""Company or ""Doubleview"") is pleased to invite interested shareholders to its corporate update webinar. When: Feb 20, 2024 10:45 AM VancouverTopic: Doubleview Gold Corp Shareholder Update Please click the link below to join the webinar:https://us02web.zoom.us/j/83533813920?pwd=bTZRQkQySk9tV0poTHNFUXUxOUhidz09Passcode: 437553Or One tap mobile : +16473744685,,83533813920#,,,,*437553# Canada +16475580588,,83533813920#,,,,*437553# CanadaAbout Doubleview Gold CorpDoubleview Gold Corp., a mineral resource exploration and development company, is based in Vancouver, British Columbia, Canada, and is publicly traded on the TSX-Venture Exchange (TSXV: DBG), (OTCQB: DBLVF), (GER: A1W038) (FSE: 1D4). Doubleview identifies, acquires and finances precious and base metal exploration projects in North America, particularly in British Columbia. Doubleview increases shareholder value through acquisition and exploration of quality gold, copper and silver properties and the application of advanced state-of-the-art exploration methods. The Company's portfolio of strategic properties provides diversification and mitigates investment risks.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BC Farshad ShirvaniPresident & CEOT: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute ""forward-looking information."" In particular references to the private placement and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198360 When is Doubleview Gold Corp (DBLVF) hosting the corporate update webinar? Doubleview Gold Corp (DBLVF) is hosting the corporate update webinar on Feb 20, 2024, at 10:45 AM Vancouver time. How can interested shareholders join the webinar by Doubleview Gold Corp (DBLVF)? Interested shareholders can join the webinar by Doubleview Gold Corp (DBLVF) by clicking on the provided link: https://us02web.zoom.us/j/83533813920?pwd=bTZRQkQySk9tV0poTHNFUXUxOUhidz09 What is the passcode to access the Doubleview Gold Corp (DBLVF) webinar? The passcode to access the Doubleview Gold Corp (DBLVF) webinar is 437553. Can the Doubleview Gold Corp (DBLVF) webinar be accessed through mobile devices? Yes, the Doubleview Gold Corp (DBLVF) webinar can be accessed through mobile devices by using the provided one-tap mobile numbers."
Tricon Residential Announces Receipt of Interim Order for Proposed Take Private by Blackstone Real Estate and Provides Details of Special Meeting,2024-02-16T23:10:00.000Z,Low,Neutral,"Tricon Residential Inc. announces a special meeting for the acquisition by Blackstone Real Estate Partners X at a premium price of $11.25 per Common Share, representing a 30% premium to the closing price on NYSE. The Board recommends FOR vote at the Special Meeting on March 28, 2024.","Tricon Residential Announces Receipt of Interim Order for Proposed Take Private by Blackstone Real Estate and Provides Details of Special Meeting Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Tricon Residential Inc. announces a special meeting for the acquisition by Blackstone Real Estate Partners X at a premium price of $11.25 per Common Share, representing a 30% premium to the closing price on NYSE. The Board recommends FOR vote at the Special Meeting on March 28, 2024. Positive The Interim Order granted by the Ontario Superior Court of Justice allows for the acquisition of Tricon Residential Inc. by Blackstone Real Estate Partners X at a price of $11.25 per Common Share. The Consideration of $11.25 per Common Share in cash represents a premium of approximately 30% to the closing price of the Common Shares on the NYSE as of January 18, 2024. The Special Meeting for Company Shareholders to vote on the Arrangement is scheduled for March 28, 2024, where approval by two-thirds of votes cast is required. The Transaction completion is subject to final approval by the Court, regulatory approvals, and other customary conditions, expected to occur in the second quarter of the year. Negative None. Financial Analyst The acquisition of Tricon Residential Inc. by Blackstone represents a significant event in the real estate investment sector. The offered premium of approximately 30% over the closing price and 42% over the 90-day volume weighted average indicates a bullish stance on Tricon's valuation and future prospects by Blackstone. Such a premium is reflective of Blackstone's confidence in Tricon's asset portfolio and its strategic fit within Blackstone's larger real estate investment strategy.From a financial perspective, the transaction's impact on Tricon's liquidity and capital structure will be substantial. The all-cash consideration will provide immediate liquidity to shareholders at a notable premium, which could be perceived as a positive exit opportunity given the current market conditions. However, for long-term investors, the transaction represents an endpoint to potential future gains from holding Tricon shares.It is crucial to consider the post-closing scenario where BREIT maintains an 11% ownership stake. This could signal a strategic partnership or an endorsement of the transaction's long-term value creation potential. Additionally, the involvement of a special committee and a unanimous recommendation by the board, excluding the conflicted director, lends credibility to the fairness and due diligence of the process. Legal Expert The approval process for the acquisition, involving the Ontario Superior Court of Justice and adherence to the Business Corporations Act (Ontario), highlights the legal complexities of such transactions. The granting of an interim order and the subsequent need for final court approval underscore the transaction's legal scrutiny. Furthermore, the transaction is subject to regulatory approvals under the Competition Act (Canada) and Investment Canada Act, which will assess the transaction's impact on competition and foreign investment in Canada.The provision of dissent rights to registered shareholders is a critical legal aspect that allows shareholders who oppose the arrangement to be fairly compensated. The legal framework of Multilateral Instrument 61-101 is designed to protect minority shareholders in transactions of this nature, ensuring that the votes of certain shareholders, such as Blackstone, do not unduly influence the outcome. Market Research Analyst The acquisition's strategic implications for the broader real estate investment market are significant. Tricon's integration into Blackstone's portfolio could lead to operational synergies, enhanced market positioning and potentially influence market dynamics in the sectors where Tricon operates. The transaction may trigger further consolidation in the industry, as competitors react to Blackstone's move.It is essential to analyze the transaction's timing within the context of the real estate cycle and broader economic conditions. Given the current interest rate environment and economic uncertainty, Blackstone's willingness to pay a substantial premium could be interpreted as a strong signal of the underlying value and resilience of real estate assets, particularly in the residential sector. 02/16/2024 - 06:10 PM Visit Tricon’s Investor Relations website at www.triconresidential.com to access materials and information related to the upcoming Special Meeting. Company Shareholders who have questions or need assistance with voting their Common Shares should contact Tricon’s proxy solicitation agent and shareholder communications advisor Laurel Hill Advisory Group by telephone at 1-877-452-7184 or by email at assistance@laurelhill.com. All financial and share price-related information is presented in U.S. dollars unless otherwise indicated. TORONTO--(BUSINESS WIRE)-- Tricon Residential Inc. (NYSE: TCN, TSX: TCN) (“Tricon” or the “Company”) today announced that on February 15, 2024, the Ontario Superior Court of Justice (Commercial List) (the “Court”) granted an interim order (the “Interim Order”) in connection with the previously announced statutory plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”) pursuant to which Blackstone Real Estate Partners X (“BREP X”), together with Blackstone Real Estate Income Trust, Inc. (“BREIT”, and together with BREP X and their respective affiliates, “Blackstone”) will acquire all outstanding common shares of Tricon (“Common Shares”) for $11.25 (approximately C$15.18 based on the Bank of Canada USD/CAD exchange rate at February 15, 2024) per Common Share (the “Consideration”) in cash (the “Transaction”). The Interim Order authorizes the calling and holding of a special meeting on March 28, 2024 (the “Special Meeting”) of the holders of Common Shares (the “Company Shareholders”), the granting of dissent rights to registered Company Shareholders, and other matters relating to the conduct of the Special Meeting. The Consideration of $11.25 per Common Share in cash represents a premium of approximately 30% to the closing price of the Common Shares on the New York Stock Exchange (“NYSE”) as of January 18, 2024, the last trading day prior to the public announcement of the Arrangement, and a premium of approximately 42% to the volume weighted average share price on the NYSE over the 90-day period ended January 18, 2024. BREIT will maintain its approximately 11% ownership stake in the Company post-closing. On the unanimous recommendation of a special committee of the board of directors of the Company (the “Board”) consisting entirely of independent directors, the Board (excluding the conflicted director), in consultation with its financial and legal advisors, determined that the Arrangement is in the best interests of the Company and fair to the Company Shareholders (excluding Blackstone) and unanimously recommends that Company Shareholders vote FOR the resolution relating to the Arrangement at the Special Meeting. Details of the Special Meeting of Company Shareholders The Interim Order authorizes and orders that the Special Meeting be held on Thursday, March 28, 2024 at 10:00 a.m. (Toronto time) in virtual-only format via live audio webcast, including any adjournments or postponements thereof. Company Shareholders of record as of the close of business on Tuesday, February 13, 2024 are entitled to receive notice of, to participate in, and to vote their Common Shares at the Special Meeting. The management information circular (the “Circular”) and related proxy materials in respect of the Special Meeting have been filed and are available under Tricon’s profile on SEDAR+ at www.sedarplus.ca, and are in the process of being mailed to Company Shareholders. A Schedule 13E-3 Transaction Statement (the “Schedule 13E-3”), which includes the Circular and related proxy materials, has been filed with the U.S. Securities and Exchange Commission (“SEC”) and is available under Tricon’s profiles on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Details of the Special Meeting and how Company Shareholders or their duly appointed proxyholders can attend, access, participate in and vote at the Special Meeting are set out in the Circular. The Transaction is subject to the approval of: (i) at least two-thirds (66 2/3%) of the votes cast by Company Shareholders present or represented by proxy at the Special Meeting, voting as a single class; and (ii) because the proposed Arrangement is a “business combination” subject to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), a simple majority (more than 50%) of the votes cast by Company Shareholders present or represented by proxy at the Special Meeting, excluding the votes of Blackstone and other Company Shareholders whose votes are required to be excluded pursuant to MI 61-101. How to Vote The Special Meeting will be held on Thursday, March 28, 2024 at 10:00 a.m. (Toronto time) in virtual format via live audio webcast at https://web.lumiconnect.com/#/411155572, Password: tricon2024 (case sensitive) and Meeting ID: 411-155-572. Registered Company Shareholders and duly appointed proxyholders will be able to attend, participate and vote at the Special Meeting online. Guests and non-registered Company Shareholders (being shareholders who hold their common shares through an intermediary) must duly appoint themselves as proxyholder in order to be able to vote or ask questions at the Special Meeting. Company Shareholders are encouraged to submit their vote in advance by completing a form of proxy accompanying the Circular (in the case of registered Company Shareholders) or voting instruction form provided by their intermediary (in the case of non-registered Company Shareholders). Company Shareholders must vote their proxy before 10:00 a.m. (Toronto time) on Tuesday, March 26, 2024 (or, if the Special Meeting is adjourned or postponed, 48 hours, excluding Saturdays, Sundays and statutory holidays, prior to the commencement of the reconvened Special Meeting). Completion of the Transaction In addition to the receipt of the requisite approval of the Company Shareholders at the Special Meeting, the completion of the Transaction is subject to the final approval of the Arrangement by the Court, regulatory approvals under the Competition Act (Canada) and Investment Canada Act, and the satisfaction or waiver of the other customary conditions. Completion of the Transaction is expected to occur in the second quarter of this year. INVESTORS AND COMPANY SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE CIRCULAR, SCHEDULE 13E-3 (INCLUDING ANY SUPPLEMENTS THERETO) AND OTHER PROXY MATERIALS FILED ON SEDAR+ AND EDGAR, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT TRICON, THE TRANSACTION, THE SPECIAL MEETING AND RELATED MATTERS. In addition to receiving the Circular and related proxy materials by mail, Company Shareholders are also able to obtain these documents, as well as other filings containing information about Tricon, the Transaction, the Special Meeting and related matters, without charge on Tricon’s Investor Relations website at www.triconresidential.com as well as under Tricon’s profiles on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. About Tricon Residential Inc. Tricon Residential Inc. (NYSE: TCN, TSX: TCN) is an owner, operator and developer of a growing portfolio of approximately 38,000 single-family rental homes in the U.S. Sun Belt and multi-family apartments in Toronto, Canada. Our commitment to enriching the lives of our employees, residents and local communities underpins Tricon’s culture and business philosophy. We provide high-quality rental housing options for families across the United States and in Toronto, Canada through our technology-enabled operating platform and dedicated on-the-ground operating teams. Our development programs are also delivering thousands of new rental homes and apartments as part of our commitment to help solve the housing supply shortage. At Tricon, we imagine a world where housing unlocks life’s potential. For more information, visit www.triconresidential.com. Questions If you have any questions about the information contained in this news release in connection with the Special Meeting, or require any assistance voting, please contact our proxy solicitation agent and shareholder communications advisor, Laurel Hill Advisory Group, at 1-877-452-7184 (toll-free within North America) or by calling 1-416-304-0211 (outside of North America) or by email at assistance@laurelhill.com. Forward -Looking Information Certain statements contained in this news release may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as ""anticipate"", ""plan"", ""expect"", ""may"", ""will"", ""intend"", ""should"", and similar expressions. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Forward-looking information in this news release includes, but is not limited to, the following: statements with respect to the holding of the Special Meeting and the timing thereof, statements with respect to the mailing of the Circular and related proxy materials, statements with respect to the anticipated benefits to Company Shareholders, and statements with respect to the expected completion of the Transaction and the timing thereof, and the satisfaction of the conditions to closing of the Transaction. Such forward-looking information and statements involve risks and uncertainties and are based on management’s current expectations, intentions and assumptions, including expectations and assumptions concerning receipt of required approvals and the satisfaction of other conditions to the completion of the Transaction. There can be no assurance that the proposed Transaction will be completed, or that it will be completed on the terms and conditions contemplated. Accordingly, although the Company believes that the expectations and assumptions on which the forward-looking information contained in this news release is based are reasonable, undue reliance should not be placed on the forward-looking information because Tricon can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to: the failure to obtain necessary approvals or satisfy (or obtain a waiver of) the conditions to closing the Transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the Transaction; material adverse changes in the business or affairs of Tricon; Tricon’s ability to obtain the necessary Company Shareholder approval (including the “minority approval”) at the Special Meeting; the parties’ ability to obtain requisite Court and regulatory approvals; either party’s failure to consummate the Transaction when required or on the terms as originally negotiated; risks related to the disruption of management time from ongoing business operations due to the Transaction and possible difficulties in maintaining customer, supplier, key personnel and other strategic relationships; potential litigation relating to the Transaction, including the effects of any outcomes related thereto; the possibility of unexpected costs and liabilities related to the Transaction; competitive factors in the industries in which Tricon operates; interest rates, currency exchange rates, prevailing economic conditions; and other factors, many of which are beyond the control of Tricon. Additional factors and risks which may affect Tricon, its business and the achievement of the forward-looking statements contained herein are described in the “Risk Factors” section of the Circular as well as Tricon’s annual information form and Tricon’s management’s and discussion and analysis for the year ended December 31, 2022, and in the other subsequent reports filed on the SEDAR+ profile of Tricon at www.sedarplus.ca and Tricon’s filings with the SEC, including the Schedule 13E-3, which includes the Circular, on www.sec.gov. The forward-looking information contained in this news release represents Tricon’s expectations as of the date hereof, and is subject to change after such date. Tricon disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216552237/en/ For further information, please contact: Wissam Francis EVP & Chief Financial Officer Email: IR@triconresidential.com Wojtek Nowak Managing Director, Capital Markets Tricon Media Contact: Tara Tucker Senior Vice President, Corporate and Public Affairs Email: mediarelations@triconresidential.com Source: Tricon Residential Inc. What is the price per Common Share offered by Blackstone Real Estate Partners X in the acquisition of Tricon Residential Inc.? Blackstone Real Estate Partners X is offering $11.25 per Common Share in cash for the acquisition of Tricon Residential Inc. What premium does the Consideration of $11.25 per Common Share represent? The Consideration of $11.25 per Common Share represents a premium of approximately 30% to the closing price of the Common Shares on the NYSE as of January 18, 2024. When is the Special Meeting for Company Shareholders to vote on the Arrangement scheduled? The Special Meeting for Company Shareholders to vote on the Arrangement is scheduled for March 28, 2024. What percentage of votes is required for approval at the Special Meeting? Approval by at least two-thirds (66 2/3%) of the votes cast by Company Shareholders present or represented by proxy at the Special Meeting is required. What are the conditions for the completion of the Transaction? The completion of the Transaction is subject to final approval by the Court, regulatory approvals, and other customary conditions."
"ASP Isotopes Inc. Provides Update on Plans to Spin-Out its Wholly Owned Subsidiary, Quantum Leap Energy",2024-02-16T22:47:00.000Z,Moderate,Neutral,"ASP Isotopes Inc. announces plans to spin-off Quantum Leap Energy LLC as a separate public company, with ASPI stockholders receiving a 10% perpetual royalty on QLE revenues. The companies aim to resolve nuclear fuel supply chain issues, with potential customer interest in over $30 billion of HALEU. ASPI initiates construction of a Quantum Enrichment isotope facility in South Africa.","ASP Isotopes Inc. Provides Update on Plans to Spin-Out its Wholly Owned Subsidiary, Quantum Leap Energy Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary ASP Isotopes Inc. announces plans to spin-off Quantum Leap Energy LLC as a separate public company, with ASPI stockholders receiving a 10% perpetual royalty on QLE revenues. The companies aim to resolve nuclear fuel supply chain issues, with potential customer interest in over $30 billion of HALEU. ASPI initiates construction of a Quantum Enrichment isotope facility in South Africa. Positive ASPI to spin-off QLE as a separate public company, distributing common equity to ASPI stockholders. ASPI to receive a 10% perpetual royalty on QLE revenues for licensing technology related to nuclear fuel enrichment. Both companies aim to address nuclear fuel supply chain issues, with potential customer interest in over $30 billion of HALEU. ASPI starts construction of a Quantum Enrichment isotope facility in South Africa to produce medical isotopes like ytterbium-176 and nickel-64. Negative None. Energy Sector Analyst The spin-out of Quantum Leap Energy (QLE) from ASP Isotopes represents a strategic move to streamline business operations and potentially unlock shareholder value. By focusing on their core competencies—QLE on nuclear fuel production and ASP Isotopes on medical isotopes—each entity can better align resources and management focus. This separation could lead to operational efficiencies and attract investors with specific sector interests.Furthermore, the licensing agreement ensures a continuous revenue stream for ASPI through a 10% perpetual royalty on QLE's revenues. This arrangement provides ASPI with a financial interest in QLE's success without the direct operational risks associated with nuclear fuel production. The market's interest in over $30 billion of HALEU signifies a robust demand outlook, which could translate into significant revenue for QLE and by extension, royalties for ASPI. Nuclear Energy Expert HALEU is crucial for the next generation of nuclear reactors, such as small modular reactors (SMRs), which are integral to diversifying the energy mix and achieving climate goals. The current lack of Western HALEU producers creates a bottleneck, hindering the deployment of SMRs. ASPI's Quantum Enrichment process could fill this gap, potentially easing the fuel supply issue and accelerating the adoption of nuclear energy.The process's ability to enrich depleted uranium tails is significant, as it not only provides a cost-effective fuel source but also addresses an environmental concern. The potential to turn nuclear waste into a valuable resource could have far-reaching implications for the industry's sustainability and public perception. Environmental and Sustainability Analyst The emphasis on the Quantum Enrichment Process's environmental benefits is noteworthy. By potentially offering a solution to the accumulation of depleted uranium tails, QLE is positioning itself as not just a supplier of HALEU but also as a contributor to environmental remediation. This dual role could enhance QLE's corporate image and align with global sustainability trends, potentially attracting ESG-focused investors.The 'green energy cost advantage' that ASPI anticipates could be a game-changer, offering a competitive edge in a market increasingly driven by cost and environmental considerations. If QLE's technology delivers as expected, it could lead to broader adoption of nuclear energy, which is relatively low in greenhouse gas emissions compared to fossil fuels. 02/16/2024 - 05:47 PM - ASP Isotopes plans to spin a portion of Quantum Leap Energy’s common equity to ASP Isotopes' stockholders as of a future record date, in a tax efficient manner. - ASP Isotopes licenses rights to technology related to the enrichment of nuclear fuels to Quantum Leap Energy. ASPI to receive a 10% perpetual royalty on all revenues of Quantum Leap Energy. - ASPI and QLE continue to work with potential customers to help resolve the current nuclear fuel supply chain issues. At current prices, ASPI and QLE has customer interest in over $30 billion of HALEU. WASHINGTON, Feb. 16, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI (""ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, announced today an update on its previously disclosed intention to spin-out its wholly owned subsidiary, Quantum Leap Energy LLC (“QLE”), as a separate public company. ASPI is planning to list QLE on a national exchange and distribute a portion of QLE’s common equity to ASPI’s stockholders as of a future record date, anticipated to be completed by year-end, in each case subject to obtaining applicable approvals and consents and complying with applicable rules and regulations and public market trading and listing requirements. The regulatory landscape and supply chain for nuclear fuel production differs significantly from that of medical isotopes, hence ASPI and QLE have different business models and we believe that both companies would benefit if QLE is independently managed and financed from ASPI. In connection with the anticipated spin-out, ASPI has entered into a number of agreements with QLE, including a License Agreement, pursuant to which QLE has licensed from ASPI the rights to produce enriched Uranium 235 and Lithium 6 in exchange for a perpetual royalty in the amount of 10% of all future QLE revenues, and an EPC Services Framework Agreement, pursuant to which the parties have agreed ASPI will provide services for the engineering, procurement and construction of one or more turnkey Uranium-235 and Lithium-6 enrichment facilities in locations to be identified by QLE and owned or leased by QLE, and commissioning, start-up and test services for each such facility, subject to the receipt of all applicable regulatory approvals, permits, licenses, authorizations, registrations, certificates, consents, orders, variances and similar rights. In addition, ASPI has assigned to QLE the two MOUs with U.S.-based small modular reactor companies for the use of Quantum Enrichment for the production of High-Assay Low Enriched Uranium (HALEU), which were entered into during 2023. The MOUs provide for substantial financial support for the development of HALEU production facilities that should be capable of supplying metric ton quantities of HALEU by 2027. The Company’s discussions with potential customers in both the United States and international regions indicate a potential demand for over $30 billion(1) of HALEU at recent market prices by 2037. The Company has initiated discussions with multiple governments regarding the location of their first nuclear fuel facility. ASP Isotopes recently started the construction of the first Quantum Enrichment isotope facility, which is expected to enrich kilogram quantities of ytterbium-176 and nickel-64, two isotopes that are used in the medical industry and are in short supply. This first plant, which is in South Africa, is expected to be completed during 2025 and management believes that the thermodynamic similarities between ytterbium, nickel, lithium, and uranium will mean that the successful construction of this facility would significantly reduce the time required to construct a HALEU facility. Ocean Wall Limited is acting as an advisor to the Company. “Nuclear fuel has one of the most severely compromised supply chains of any material in the world. We believe that in order for long-term climate goals to be achieved, an alternative supplier of fuel is needed,” said Paul Mann, Chairman and CEO of ASPI and Chairman and CEO of QLE. “Over the last several decades, the scientists at ASPI have developed what we believe to be the most advanced isotope enrichment technologies and we look forward to accelerating these to support long-term climate goals.” HALEU will be required to enable many nuclear reactors, such as SMRs (small modular reactors), to operate in the future. Currently, there are no Western producers of HALEU in commercial quantities, and many SMR companies worldwide face substantial delays until this fuel supply issue is resolved. The Nuclear Energy Institute estimates that there may be a HALEU supply demand of approximately 3,000 metric tons by 2035(2). ASPI believes their Quantum Enrichment process will be able to produce HALEU at an attractive price, allowing new nuclear energy to become available at a “green discount” to carbon-intensive electricity production processes. This “green energy cost advantage” is expected to help accelerate the global adoption of new nuclear energy, with a corresponding benefit to climate goals. The Quantum Enrichment Process, an isotope enrichment method under development by our scientists, is a laser-based enrichment method, which we believe will have both the lowest levelized cost of HALEU production, the lowest cash operating cost of HALEU production, low capital expenditure, and efficient construction cycles. Management believes that the Quantum Enrichment Process can enrich previously depleted uranium tails, which is essentially waste from other enrichers. In addition to providing a substantial cost advantage over traditional enrichment methods, globally, over 1.7 million metric tons of depleted uranium tails are becoming an environmental hazard. In summary, management believes that QLE will offer an environmental solution for uranium tails whilst providing the lowest cost HALEU supply, which will be essential for the commercialisation of SMRs. About ASP Isotopes Inc. ASP Isotopes Inc. is a pre-commercial stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes). There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the Company’s proposed spin off of Quantum Leap Energy LLC, or factors that result in changes to the Company’s anticipated results of operations related to its products and technologies. These and other risks and uncertainties are described more fully in the section captioned “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. https://www.uxc.com/p/tools/FuelCalculator.aspxKorsnick, M. (2021, December 20). Updated Need for High-Assay Low Enriched Uranium. Nuclear Energy Institute Contacts Jason Assad– Investor relationsEmail: Jassad@aspisotopes.com Telephone: 561-709-3043 What is ASP Isotopes' plan regarding Quantum Leap Energy LLC? ASP Isotopes plans to spin-off Quantum Leap Energy LLC as a separate public company and distribute a portion of QLE's common equity to ASPI stockholders. What royalty percentage will ASPI receive on Quantum Leap Energy's revenues? ASPI will receive a 10% perpetual royalty on all future revenues of Quantum Leap Energy for licensing technology related to nuclear fuel enrichment. What is the potential customer interest in HALEU for ASPI and QLE? ASPI and QLE have customer interest in over $30 billion of HALEU at recent market prices by 2037. Where is the first Quantum Enrichment isotope facility being constructed by ASP Isotopes? The first Quantum Enrichment isotope facility is being constructed in South Africa by ASP Isotopes. Who is acting as an advisor to ASP Isotopes? Ocean Wall Limited is acting as an advisor to ASP Isotopes."
Arisz Acquisition Corp. Announces Extension of Deadline to Complete Business Combination,2024-02-16T22:13:00.000Z,No impact,Neutral,"Arisz Acquisition Corp. extends the period to complete a business combination with BitFuFu by depositing $120,000 into the Trust Account, allowing an additional one-month period. This move is the first of up to nine permitted extensions, providing Arisz with more time for the proposed merger.","Arisz Acquisition Corp. Announces Extension of Deadline to Complete Business Combination Rhea-AI Impact (No impact) Rhea-AI Sentiment (Neutral) Tags acquisition Rhea-AI Summary Arisz Acquisition Corp. extends the period to complete a business combination with BitFuFu by depositing $120,000 into the Trust Account, allowing an additional one-month period. This move is the first of up to nine permitted extensions, providing Arisz with more time for the proposed merger. Positive None. Negative None. 02/16/2024 - 05:13 PM New York, NY, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Arisz Acquisition Corp. (NASDAQ: ARIZ (“Arisz” or the “Company”), a special purpose acquisition company, announced today that Arisz Investments LLC, the Company's initial public offering sponsor, has timely deposited into the Company's trust account (the “Trust Account”) , an aggregate of $120,000, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from February 22, 2024 to March 22, 2024 (the “Extension”). The Extension is the first of up to nine (9) one-month extensions permitted under the February 5, 2024 amendment to the Amended and Restated Certificate of Incorporation of Arisz Acquisition Corp. The Extension provides Arisz with additional time to complete its proposed business combination with Finfront Holding Company (“BitFuFu”). Important Notice Regarding Forward-Looking Statements This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements about the pending transactions described above, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated. Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the pending transaction, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of Arisz and the BitFuFu to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of the BitFuFu or Arisz; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Arisz’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of BitFuFu to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii) the risk that the combined company may be unable to achieve cost-cutting synergies or it may take longer than expected to achieve those synergies; and (ix) risks associated with the financing of the proposed transaction. A further list and description of risks and uncertainties can be found in the Prospectus dated November 17, 2021 relating Arisz’s initial public offering and in the Registration Statement and proxy statement filed with the SEC by Arisz and/or its subsidiary in connection with the proposed transactions, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and Arisz, BitFuFu and their subsidiaries undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation. Additional Information and Where to Find It In connection with the transaction described herein, Arisz and and/or its subsidiary has filed and may file relevant materials with the Securities and Exchange Commission (the “SEC”), including the Registration Statement on Form F-4 and a proxy statement (the “Registration Statement”). The proxy statement and a proxy card have been mailed to stockholders as of a record date to be established for voting at the stockholders’ meeting of Arisz stockholders relating to the proposed transactions. Stockholders will also be able to obtain a copy of the Registration Statement and proxy statement without charge from Arisz. The Registration Statement and proxy statement may also be obtained without charge at the SEC’s website at www.sec.gov or by writing to Arisz at 199 Water Street, 31st Floor, New York, NY 10038. INVESTORS AND SECURITY HOLDERS OF ARISZ ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTIONS THAT ARISZ WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARISZ, BITFUFU AND THE TRANSACTIONS. Participants in Solicitation Arisz, BitFuFu and certain shareholders of Arisz, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of Arisz common stock in respect of the proposed transaction. Information about Arisz’s directors and executive officers and their ownership of Arisz common stock is set forth in the Prospectus dated November 17, 2021 and filed with the SEC. Other information regarding the interests of the participants in the proxy solicitation will be included in the proxy statement pertaining to the proposed transaction when it becomes available. These documents can be obtained free of charge from the sources indicated above. No Offer or Solicitation This press release not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Arisz or BitFuFu, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Arisz Acquisition Corp. Arisz Investor Relations ir@ariszacquisition.com What is the purpose of Arisz Acquisition Corp. extending the period for a business combination with BitFuFu? Arisz Acquisition Corp. extended the period by depositing $120,000 into the Trust Account to allow more time for the proposed merger with BitFuFu. How long is the extended period for completing the business combination? The period has been extended for an additional one (1) month, from February 22, 2024, to March 22, 2024. How many extensions are permitted for Arisz Acquisition Corp. to complete the business combination? Up to nine (9) one-month extensions are allowed as per the February 5, 2024 amendment to the Amended and Restated Certificate of Incorporation of Arisz Acquisition Corp."
Aztec Minerals Closes Private Placement,2024-02-16T22:30:00.000Z,Low,Negative,"Aztec Minerals Corp. (AZZTF) closes a non-brokered private placement, raising CAD$1.1 million through the issuance of 7,333,333 units at CAD$0.15 per unit. Insiders subscribed for 283,333 units. The proceeds will fund exploration activities on the Tombstone project in Arizona.","Aztec Minerals Closes Private Placement Rhea-AI Impact (Low) Rhea-AI Sentiment (Negative) Tags Rhea-AI Summary Aztec Minerals Corp. (AZZTF) closes a non-brokered private placement, raising CAD$1.1 million through the issuance of 7,333,333 units at CAD$0.15 per unit. Insiders subscribed for 283,333 units. The proceeds will fund exploration activities on the Tombstone project in Arizona. Positive None. Negative None. 02/16/2024 - 05:30 PM Not for distribution to United States newswire services or for dissemination in the United StatesVANCOUVER, BC / ACCESSWIRE / February 16, 2024 / Aztec Minerals Corp. (TSXV:AZT)(OTCQB:AZZTF) (""Aztec"" or the ""Company"") announces that it has closed a non-brokered private placement (the ""Private Placement"") of 7,333,333 units (the ""Units"") at a price of CAD$0.15 per Unit for aggregate gross proceeds of CAD$1,100,000. Each Unit is comprised of one common share of the Company and one transferable common share purchase warrant (the ""Warrants""). Each Warrant is exercisable to purchase one common share of the Company at a price of CAD$0.225 per share for a period of three years from the date of issuance. No finder's fees were payable with respect to the Private Placement.Two insiders of the Company subscribed for a total of 283,333 Units for aggregate gross proceeds of $42,500 under the Private Placement. Participation by the insiders constitutes a related party transaction as defined under Multilateral Instrument 61-101 (""MI 61-101""). The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the participation in the Private Placement by insiders does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101.The Company intends to use the proceeds of the Private Placement for exploration activities on its Tombstone gold-silver & CRD silver-lead-zinc-copper-gold project in Arizona, USA and for general working capital purposes.All securities issued under the Private Placement are subject to a statutory hold period of four months and one day from the closing date in accordance with applicable Canadian securities laws.About Aztec Minerals - Aztec is a mineral exploration company focused on two emerging discoveries in North America. The Cervantes project is an emerging porphyry gold-copper discovery in Sonora, Mexico. The Tombstone project is an emerging gold-silver discovery with high grade CRD silver-lead-zinc potential in southern Arizona. Aztec's shares trade on the TSX-V stock exchange (symbol AZT) and on the OTCQB (symbol AZZTF).Contact Information - For more information, please contact:Simon Dyakowski, President & CEO, DirectorTel: (604) 685-9770Fax: (604) 685-9744Email: info@aztecminerals.comWebsite: www.aztecminerals.comNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the ""1933 Act"") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.Forward-Looking StatementsThis news release contains ""forward‐looking information or statements"" within the meaning of applicable securities laws, which may include, without limitation, the Private Placement and use of proceeds, other statements relating to the technical, financial and business prospects of the Company and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of metals, the ability to achieve its goals, the ability to secure equipment and personnel, that general business and economic conditions will not change in a material adverse manner and that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions, including those filed under the Company's profile on SEDAR+ at sedarplus.ca. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather/climate conditions, equipment failures, access to personnel and equipment, decrease in the price of gold, copper, silver, and other metals, failure to maintain all necessary government permits, approvals and authorizations, failure to maintain community acceptance, increase in costs, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law.SOURCE: Aztec Minerals Corp.View the original press release on accesswire.com How much did Aztec Minerals Corp. raise through the private placement? Aztec Minerals Corp. raised CAD$1.1 million through the private placement. How many units were issued in the private placement? Aztec Minerals Corp. issued 7,333,333 units in the private placement. Where will the proceeds of the private placement be used? The proceeds of the private placement will be used for exploration activities on the Tombstone project in Arizona. What is the price per unit in the private placement? The price per unit in the private placement was CAD$0.15. What is the term for exercising the warrants issued in the private placement? The warrants issued in the private placement are exercisable at a price of CAD$0.225 per share for a period of three years."
Cenntro Electric Group Limited Announces Approval of the Scheme of Arrangement by the Supreme Court of New South Wales,2024-02-16T23:01:00.000Z,Moderate,Neutral,"Cenntro Electric Group Limited (NASDAQ: CENN) announces the approval of the proposed scheme of arrangement to re-domicile from Australia to the United States. The Supreme Court of New South Wales approved the scheme, making it legally effective. Eligible shareholders will receive one share of common stock in Cenntro Inc. for every one ordinary share held. Key milestones include the Record Date on February 22, 2024, and the Implementation Date on February 27, 2024.","Cenntro Electric Group Limited Announces Approval of the Scheme of Arrangement by the Supreme Court of New South Wales Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Cenntro Electric Group Limited (NASDAQ: CENN) announces the approval of the proposed scheme of arrangement to re-domicile from Australia to the United States. The Supreme Court of New South Wales approved the scheme, making it legally effective. Eligible shareholders will receive one share of common stock in Cenntro Inc. for every one ordinary share held. Key milestones include the Record Date on February 22, 2024, and the Implementation Date on February 27, 2024. Positive None. Negative None. Market Research Analyst The re-domiciliation of Cenntro Electric Group Limited from Australia to the United States represents a strategic move that could have significant implications for the company's market position and valuation. By transitioning to a U.S. domicile, Cenntro may benefit from a more favorable corporate environment, potentially including tax advantages, increased access to capital markets and closer proximity to key markets and suppliers. This could enhance the company's ability to scale operations and accelerate growth in the burgeoning electric vehicle (EV) sector.Furthermore, the change in domicile might lead to an adjustment in the company's investor base, as U.S.-based investors who were previously reluctant to invest in a foreign entity might now consider taking positions. The shift could also result in increased analyst coverage and media attention, further raising the company's profile. However, investors should monitor the implementation of the Scheme and any associated costs, as these could affect the company's short-term financials. Legal Expert The approval by the Supreme Court of New South Wales and the subsequent lodgment with the Australian Securities and Investments Commission (ASIC) signifies that Cenntro has successfully navigated the legal complexities associated with cross-border re-domiciliation. The legal effectiveness of the Scheme ensures a seamless transition of shareholder equity, with a one-for-one exchange of shares. This legal order provides certainty to shareholders and the market, as it finalizes the shareholder entitlements and sets forth a clear timeline for the implementation of the Scheme.It is essential for shareholders and potential investors to understand the legal framework of such corporate actions, as they can have profound effects on shareholder rights and company governance. The legal processes surrounding the re-domiciliation and the issuance of new shares in a different jurisdiction also underscore the importance of regulatory compliance in international corporate transactions. Financial Analyst From a financial perspective, the re-domiciliation of Cenntro to the U.S. could lead to a re-evaluation of the company's stock by the market. The one-for-one share exchange maintains equity value for current shareholders, while potentially opening doors for new investment opportunities. Investors should consider the impact of the re-domiciliation on the company's future earnings potential, given the U.S.'s significant EV market.Additionally, the costs associated with the re-domiciliation process, including legal and administrative expenses, will likely affect the company's near-term financials. However, if managed effectively, the long-term benefits of the move, such as operational efficiencies and strategic partnerships, could outweigh these initial expenses. Investors will need to balance these factors when assessing the company's future financial health and stock performance. 02/16/2024 - 06:01 PM FREEHOLD, N.J.--(BUSINESS WIRE)-- Cenntro Electric Group Limited (NASDAQ: CENN) (“Cenntro” or “the Company”), a leading electric vehicle technology company with advanced, market-validated electric commercial vehicles, refers to the proposed scheme of arrangement in relation to which Cenntro will re-domicile from Australia to the United States (""U.S."", the “Scheme”), and under which Cenntro will become a subsidiary of Cenntro Inc., a corporation incorporated in accordance with the laws of the state of Nevada for the purpose of effecting the Scheme. Cenntro is pleased to announce that the Supreme Court of New South Wales, Australia (the ""Court"") made orders approving the proposed Scheme on Friday, February 16, 2024 (Australian Eastern Daylight Time, ""AEDT""). Cenntro further confirms that it has today lodged an office copy of the orders made by the Court approving the Scheme with the Australian Securities and Investments Commission (""ASIC"") pursuant to sub-section 411(10) of the Corporations Act 2001 (Cth), as a result of which the Scheme is now legally effective. An office copy of the Court orders lodged with ASIC is attached at Annexure A to this press release. Eligible Cenntro shareholders who hold Cenntro ordinary shares of the Company as at 7:00pm (AEDT) on Thursday, February 22, 2024 (the ""Record Date"") will receive one share of common stock in Cenntro Inc. in exchange for every one ordinary share of the Company which such eligible Cenntro shareholder held as of the Record Date. Next steps An indicative timetable of the key milestones remaining under the Scheme is set out below: Expected date* Event Thursday, February 22, 2024 at 7:00pm Record Date – being the time and date for determining entitlements to Scheme consideration Tuesday, February 27, 2024 Implementation date – being the date on which the Scheme will be implemented and Cenntro shareholders will receive the Scheme consideration which they are entitled to Thursday, February 29, 2024 Commencement of dispatch to Eligible Cenntro shareholders of statements confirming the issue of common stock in Cenntro Inc. *All dates and times listed in the table above are in AEDT and are indicative only and subject to change. Cenntro, in consultation with Cenntro Inc., may vary any or all of these dates and times and will provide reasonable notice of any such variation. Any changes will be announced by Cenntro to Nasdaq and published on Cenntro’s website at www.cenntroauto.com. About Cenntro Electric Group Ltd. Cenntro Electric Group Ltd. (NASDAQ: CENN) is a leading maker and provider of electric commercial vehicles (“ECVs”). Cenntro's purpose-built ECVs are designed to serve a variety of commercial applications inclusive of its line of class 1 to class 4 trucks. Cenntro is building a globalized supply-chain, as well as the manufacturing, distribution, and service capabilities for its innovative and reliable products. Cenntro continues to evolve its products capabilities through advanced battery, powertrain, and smart driving technologies. For more information, please visit Cenntro's website at: http://www.cenntroauto.com/. Forward-Looking Statements This communication contains ""forward-looking statements"" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts. Such statements may be, but need not be, identified by words such as ""may,'' ""believe,'' ""anticipate,'' ""could,'' ""should,'' ""intend,'' ""plan,'' ""will,'' ""aim(s),'' ""can,'' ""would,'' ""expect(s),'' ""estimate(s),''""project(s),'' ""forecast(s)'', ""positioned,'' ""approximately,'' ""potential,'' ""goal,'' ""strategy,'' ""outlook'' and similar expressions. Examples of forward-looking statements include, among other things, statements regarding assembly and distribution capabilities, decentralized production, and fully digitalized autonomous driving solutions. All such forward-looking statements are based on management's current beliefs, expectations and assumptions, and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed or implied in this communication. For additional risks and uncertainties that could impact Cenntro’s forward-looking statements, please see disclosures contained in Cenntro's public filings with the SEC, including the ""Risk Factors"" in Cenntro's Annual Report on Form 10K/A filed with the Securities and Exchange Commission on July 6, 2023 and which may be viewed at www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216595094/en/ Investor Relations Contact: Chris Tyson MZ North America CENN@mzgroup.us 949-491-8235 Company Contact: PR@cenntroauto.com IR@cenntroauto.com Source: Cenntro Electric Group Limited What is the ticker symbol for Cenntro Electric Group Limited? The ticker symbol for Cenntro Electric Group Limited is CENN. What is the proposed scheme of arrangement for Cenntro Electric Group Limited? The proposed scheme of arrangement involves re-domiciling Cenntro from Australia to the United States. When was the proposed scheme of arrangement approved? The proposed scheme of arrangement was approved by the Supreme Court of New South Wales on February 16, 2024. What will eligible shareholders receive in exchange for their ordinary shares? Eligible shareholders will receive one share of common stock in Cenntro Inc. for every one ordinary share held. What are the key milestones remaining under the Scheme? Key milestones include the Record Date on February 22, 2024, and the Implementation Date on February 27, 2024."
Glow Announces Closing of Debt Settlement,2024-02-16T22:05:00.000Z,Low,Neutral,"Glow LifeTech Corp. settles $211,837 of indebtedness through the issuance of 4,236,747 units at $0.05 per unit. Each unit includes a common share and half a common share purchase warrant, with warrants exercisable at $0.07 per share. Common shares are subject to a four-month hold period.","Glow Announces Closing of Debt Settlement Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Glow LifeTech Corp. settles $211,837 of indebtedness through the issuance of 4,236,747 units at $0.05 per unit. Each unit includes a common share and half a common share purchase warrant, with warrants exercisable at $0.07 per share. Common shares are subject to a four-month hold period. Positive None. Negative None. 02/16/2024 - 05:05 PM Toronto, Ontario--(Newsfile Corp. - February 16, 2024) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (""Glow"" or the ""Company"") announces that further to its press release of January 30, 2024 it has settled an aggregate of $211,837 of indebtedness owed to an arm's length creditor through the issuance of 4,236,747 units (""Units"") of the Company at a price of $0.05 per Unit (the ""Debt Settlement""). Each Unit shall be comprised of one common share in the capital of the Company (each, a ""Common Share"") and one-half a common share purchase warrant (each whole warrant, a ""Warrant""). Each Warrant shall be exercisable into one Common Share (each, a ""Warrant Share"") in the capital of the Company at a price of $0.07 per Warrant Share until two years from the date of issuance of the Warrants. All Common Shares issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.About Glow LifeTech Corp.Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow has rights to the groundbreaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates that unlock the full healing potential of the valuable compounds.Website: www.glowlifetech.comContact:James Van StaverenGlow LifeTech Corp.TF. 855-442-GLOW (4569)ir@glowlifetech.comForward-looking Information Cautionary StatementExcept for statements of historic fact, this news release contains certain ""forward-looking information"" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as ""plan"", ""expect"", ""project"", ""intend"", ""believe"", ""anticipate"", ""estimate"" and other similar words, or statements that certain events or conditions ""may"" or ""will"" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedarplus.ca.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198293 What amount of indebtedness did Glow LifeTech Corp. settle? Glow LifeTech Corp. settled $211,837 of indebtedness. How many units were issued in the Debt Settlement? 4,236,747 units were issued in the Debt Settlement. At what price per unit were the units issued? The units were issued at a price of $0.05 per unit. What does each unit include? Each unit includes one common share and half a common share purchase warrant. At what price are the warrants exercisable? The warrants are exercisable at $0.07 per share. What is the hold period for the common shares? Common shares are subject to a four-month hold period."
GFG Announces the Grant of Stock Options,2024-02-16T22:30:00.000Z,Low,Neutral,"GFG Resources Inc. announces the granting of stock options to key personnel under its annual executive compensation program. A total of 3,590,000 common shares can be purchased at $0.09 per share over a five-year period. The options have different vesting periods and were issued in accordance with the Company's stock option plan.","GFG Announces the Grant of Stock Options Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary GFG Resources Inc. announces the granting of stock options to key personnel under its annual executive compensation program. A total of 3,590,000 common shares can be purchased at $0.09 per share over a five-year period. The options have different vesting periods and were issued in accordance with the Company's stock option plan. Positive None. Negative None. 02/16/2024 - 05:30 PM SASKATOON, Saskatchewan, Feb. 16, 2024 (GLOBE NEWSWIRE) -- GFG Resources Inc. (TSX-V: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) pursuant to the Company’s annual executive compensation program, the Company announced that it has granted stock options to directors, officers, employees and senior consultants to purchase up to an aggregate of 3,590,000 common shares of the Company. The stock options have various vesting periods and are exercisable for a period of five years at a price of $0.09 per common share, being the closing price on February 14, 2024. All options were granted pursuant to the Company’s stock option plan. About GFG Resources Inc. GFG is a North American precious metals exploration company focused on district scale gold projects in tier one mining jurisdictions, Ontario and Wyoming. In Ontario, the Company operates three gold projects, each large and highly prospective gold properties within the prolific gold district of Timmins, Ontario, Canada. The projects have similar geological settings that host most of the gold deposits found in the Timmins Gold Camp which have produced over 70 million ounces of gold. The Company also owns 100% of the Rattlesnake Hills Gold Project, a district scale gold exploration project located approximately 100 km southwest of Casper, Wyoming, U.S. For further information, please contact: Marc Lepage, Vice President, Business Development Phone: (306) 931-0930 Email: info@gfgresources.comWebsite: www.gfgresources.com Stay Connected with UsTwitter: @GFGResourcesLinkedIn: https://www.linkedin.com/company/gfgresources/Facebook: https://www.facebook.com/GFGResourcesInc/ CAUTION REGARDING FORWARD-LOOKING INFORMATION All statements, other than statements of historical fact, contained in this news release constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 (referred to herein as “forward-looking statements”). Forward-looking statements include, but are not limited to, the future price of gold, success of exploration activities and metallurgical test work, permitting time lines, currency exchange rate fluctuations, requirements for additional capital, government regulation of exploration work, environmental risks, unanticipated reclamation expenses, title disputes or claims and limitations on insurance coverage. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes”, or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results, “may”, “could”, “would”, “will”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof. All forward-looking statements are based on various assumptions, including, without limitation, the expectations and beliefs of management, the assumed long-term price of gold, that the Company will receive required permits and access to surface rights, that the Company can access financing, appropriate equipment and sufficient labour, and that the political environment within Canada and the United States will continue to support the development of mining projects in Canada and the United States. In addition, the similarity or proximity of other gold deposits to the Rattlesnake Hill Gold Project, the Montclerg Gold Project, the Pen Gold Project and the Dore Gold Project is not necessary indicative of the geological setting, alteration and mineralization of the Rattlesnake Hills Gold Project, the Montclerg Gold Project, the Pen Gold Project and the Dore Gold Project. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of GFG to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: actual results of current exploration activities; environmental risks; future prices of gold; operating risks; accidents, labour issues and other risks of the mining industry; delays in obtaining government approvals or financing; and other risks and uncertainties. These risks and uncertainties are not, and should not be construed as being, exhaustive. Although GFG has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. In addition, forward-looking statements are provided solely for the purpose of providing information about management’s current expectations and plans and allowing investors and others to get a better understanding of our operating environment. Accordingly, readers should not place undue reliance on forward-looking statements. Forward-looking statements in this news release are made as of the date hereof and GFG assumes no obligation to update any forward-looking statements, except as required by applicable laws. How many common shares can be purchased through the stock options? A total of 3,590,000 common shares can be purchased. What is the exercise price per common share? The exercise price per common share is $0.09. How long is the period within which the options can be exercised? The options are exercisable for a period of five years. Who are the recipients of the stock options? Directors, officers, employees, and senior consultants are the recipients of the stock options. Under what program were the stock options granted? The stock options were granted under the Company's annual executive compensation program."
IGC Pharma Reports Third Quarter Fiscal 2024 Results,2024-02-17T00:05:00.000Z,Neutral,Neutral,"IGC Pharma, Inc. announces positive financial results and key developments in patents and partnerships for Q3 FY 2024, including advancements in pain treatment and Alzheimer's disease therapy.","IGC Pharma Reports Third Quarter Fiscal 2024 Results Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary IGC Pharma, Inc. announces positive financial results and key developments in patents and partnerships for Q3 FY 2024, including advancements in pain treatment and Alzheimer's disease therapy. Positive IGC received a patent from the European Patent Office for a unique cannabinoid composition to treat pain in humans. Another patent was issued by the Divisional Direction of Patents in Mexico for IGC's treatment of Alzheimer's disease. IGC partnered with the University of Los Andes to advance initiatives in artificial intelligence and machine learning. The company's lead asset, IGC-AD1, is in a Phase 2b trial for agitation in dementia due to Alzheimer's, with interim results expected in 2024. Negative None. Pharmaceutical Patent Expert The patents granted to IGC Pharma for their cannabinoid-based pain treatment and Alzheimer's disease therapy represent significant intellectual property milestones. These patents not only protect the company's proprietary formulations but also potentially increase the company's valuation due to the extended market exclusivity they provide. The unique cannabinoid blend for pain management could disrupt the analgesic market, particularly if it offers a safer alternative to opioids. The Alzheimer's treatment patent in Mexico, coupled with the anticipation of approvals in other jurisdictions, could enhance IGC's strategic positioning in the global CNS disorder treatment market, which is projected to reach $128.9 billion by 2025. Biotech Market Analyst IGC's collaboration with the University of Los Andes to incorporate AI and machine learning in their research could accelerate drug development processes, potentially reducing costs and time to market. Their focus on the Phase 2b trial for IGC-AD1, targeting agitation in dementia due to Alzheimer's, addresses a significant unmet medical need. With an estimated 5.8 million Americans living with Alzheimer's in 2020 and this number projected to rise, the market opportunity for effective treatments is substantial. If IGC-AD1 shows positive interim results in 2024, this could positively influence the company's stock as investors anticipate the potential for FDA approval and market entry. Financial Analyst Investors should monitor IGC's financials closely, particularly cash flow and R&D expenditures, as the company progresses through clinical trials. The cost of conducting a Phase 2b trial can be substantial and the company's ability to finance these operations is critical for continued development. Positive trial results could lead to partnership opportunities, licensing deals, or even acquisition interest from larger pharmaceutical companies. On the flip side, any negative outcomes or delays could impact the company's financial health and investor confidence. The long-term potential of IGC's proprietary treatments should be weighed against the inherent risks of biotech investing, including regulatory hurdles and market competition. 02/16/2024 - 07:05 PM POTOMAC, Md.--(BUSINESS WIRE)-- IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024). Q3 FY2024 Highlights On October 18, 2023, the European Patent Office (“EPO”) issued a patent (#3193862) to the Company titled “Cannabinoid Composition and Method for Treating Pain”. The patent introduces a method for treating pain in humans. Utilizing a cream base infused with a unique blend of cannabinoids, including THC and CBD, alongside other compounds, this revolutionary cream, or gel is designed for transdermal absorption. On October 25, 2023, the Divisional Direction of Patents, Mexico, issued a patent (MX/a/2020/010284) for the Company’s treatment of Alzheimer’s disease titled ""Method and Composition for Treating CNS Disorder."" IGC is optimistic that the success in Mexico can pave the way for additional patent approvals in the U.S. and Europe. This patent is very important to the Company as it provides protection for the Company’s IGC-AD1 formulation. On November 21, 2023, the Company announced an agreement with the University of Los Andes, a leading South American University, to advance initiatives in artificial intelligence/machine learning. “We are proud to share that our company is making progress with our lead asset, IGC-AD1, which is currently in a Phase 2b trial for the treatment of agitation in dementia due to Alzheimer’s. We are working hard to obtain interim results in 2024. We estimate that in North America and Europe about 11 million Alzheimer’s patients have neuropsychiatric symptoms including agitation. With modest pricing and conservative market penetration IGC-AD1 can potentially be a block buster drug,” said Ram Mukunda, CEO of IGC Pharma. Along with IGC-AD1, the Company has four other drug assets, LMP, TGR-63, IGC-1C, and IGC-M3, three of which have demonstrated pre-clinical efficacy in targeting Alzheimer’s disease. We continue to explore new methods to improve the efficiency of our clinical trials and have recently started to utilize artificial intelligence (AI) to analyze the large amount of data produced by our trials. Financial Summary During the three months ended December 31, 2023, the Company generated approximately $204 thousand in revenue, representing a decrease of 38% compared to the approximately $332 thousand generated during the three months ended December 31, 2022. For the nine months ended December 31, 2023, the Company generated approximately $1.05 million in revenue versus $745 thousand for the previous year nine months, representing an increase of 40%. The primary source of revenue in both quarters was from the Life Sciences segment, encompassing the sales of our formulations. The decrease in revenue in the quarter is primarily because the Company reorganized resources to focus on accelerating the Phase 2 trial and obtaining pharmaceutical GMP certification for its facility in preparation for a potential Phase 3 trial. The Company reported Selling, General, and Administrative (“SG&A”) expenses during the three months ended December 31, 2023, of approximately $2.2 million, representing an increase of approximately $654 thousand, or 42%, compared to the approximately $1.5 million recorded for the three months ended December 31, 2022. The increase in SG&A expenses is primarily attributed to one-time non-cash expenses. During the three months ended December 31, 2023, the Company reported Research and Development (“R&D”) expenses of approximately $903 thousand, representing an increase of approximately $97 thousand or 12% compared to approximately $806 thousand during the three months ended December 31, 2022. The increase is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on the other small molecule assets. The net loss for the three months ended December 31, 2023, was approximately $5.5 million or $0.09 per share, compared to approximately $2.2 million or $0.04 per share for three months ended December 31, 2022. The increased loss is from an impairment of PPE assets in the amount of approximately $2.6 million and a one-time non-cash expense of $654 thousand reported in SG&A. The Company estimates that its current cash and cash equivalents balance with working capital credit facility is sufficient to support operations beyond the twelve months following the date the consolidated financial statements and footnotes were issued. The estimates are based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. About IGC Pharma (dba IGC) IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. IGC Pharma’s portfolio comprises five assets, all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently in a Phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of Generative AI development, with projects including clinical trials, early detection of Alzheimer’s, and drug interactions with cannabinoids. Forward-looking Statements This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and the Form 10-Q for the fiscal quarter ended December 31, 2023, and other documents that we subsequently file with the SEC that update, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. < Financial Tables to Follow> IGC Pharma, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) (Unaudited) December 31, 2023 ($) March 31, 2023 ($) ASSETS Current assets: Cash and cash equivalents 1,378 3,196 Accounts receivable, net 92 107 Short term investments - 154 Inventory 1,925 2,651 Deposits and advances 188 358 Total current assets 3,583 6,466 Non-current assets: Intangible assets, net 1,182 1,170 Property, plant, and equipment, net 5,268 8,213 Claims and advances 999 1,003 Operating lease asset 227 326 Total non-current assets 7,676 10,712 Total assets 11,259 17,178 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable 648 530 Accrued liabilities and others 1,288 1,368 Total current liabilities 1,936 1,898 Non-current liabilities: Long-term loans 138 141 Other liabilities 17 21 Operating lease liability 115 207 Total non-current liabilities 270 369 Total liabilities 2,206 2,267 Commitments and Contingencies – See Note 12 Stockholders’ equity: Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of December 31, 2023, and March 31, 2023. Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 63,734,439 and 53,077,436 shares issued and outstanding as of December 31, 2023, and March 31, 2023, respectively. 123,258 118,965 Accumulated other comprehensive loss (3,425 ) (3,389 ) Accumulated deficit (110,780 ) (100,665 ) Total stockholders’ equity 9,053 14,911 Total liabilities and stockholders’ equity 11,259 17,178 These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended December 31, 2023, filed with the SEC on February 14, 2024. IGC Pharma, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except loss per share and share data) (Unaudited) Three months ended December 31, Nine months ended December 31, 2023 2022 2023 2022 ($) ($) ($) ($) Revenue 204 332 1,050 745 Cost of revenue (71 ) (230 ) (488 ) (366 ) Gross profit 133 102 562 379 Selling, General and Administrative expenses (2,228 ) (1,574 ) (5,272 ) (4,943 ) Research and development expenses (903 ) (806 ) (2,918 ) (2,968 ) Operating loss (2,998 ) (2,278 ) (7,628 ) (7,532 ) Impairment Loss on PPE (2,623 ) - (2,623 ) - Other income, net 32 29 136 56 Loss before income taxes (5,589 ) (2,249 ) (10,115 ) (7,476 ) Income tax expense/benefit - - - - Net loss attributable to common stockholders (5,589 ) (2,249 ) (10,115 ) (7,476 ) Foreign currency translation adjustments 18 (61 ) (36 ) (462 ) Comprehensive loss (5,571 ) (2,310 ) (10,151 ) (7,938 ) Net loss per share attributable to common stockholders: Basic and diluted $ (0.09 ) (0.04 ) (0.18 ) (0.14 ) Weighted-average number of shares used in computing net loss per share amounts: 63,725,084 53,063,473 57,039,035 52,412,830 These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended December 31, 2023, and filed with the SEC on February 14, 2024. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216772877/en/ Investors IMS Investor Relations Walter Frank igc@imsinvestorrelations.com (203) 972-9200 Media JVPRNY Janet Vasquez jvasquez@jvprny.com (212) 645-5498 Source: IGC Pharma, Inc. What patents did IGC receive in Q3 FY 2024? IGC received patents from the European Patent Office for a cannabinoid composition to treat pain and from the Divisional Direction of Patents in Mexico for Alzheimer's disease treatment. Who did IGC partner with in Q3 FY 2024? IGC partnered with the University of Los Andes to advance initiatives in artificial intelligence and machine learning. What is IGC's lead asset currently in trial for? IGC's lead asset, IGC-AD1, is in a Phase 2b trial for agitation in dementia due to Alzheimer's, with interim results expected in 2024."
Millicom (Tigo) share repurchase activity,2024-02-16T22:30:00.000Z,Low,Very Negative,"Millicom (Tigo) repurchased 36,250 of its Swedish Depository Receipts (SDRs) between February 12, 2024, and February 16, 2024, as part of its share repurchase program. The purchases were made at varying daily average prices on Nasdaq Stockholm. Following the transactions, Millicom holds 1,595,370 treasury shares, with a total of 172,096,305 shares outstanding.","Millicom (Tigo) share repurchase activity Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Negative) Tags buyback Rhea-AI Summary Millicom (Tigo) repurchased 36,250 of its Swedish Depository Receipts (SDRs) between February 12, 2024, and February 16, 2024, as part of its share repurchase program. The purchases were made at varying daily average prices on Nasdaq Stockholm. Following the transactions, Millicom holds 1,595,370 treasury shares, with a total of 172,096,305 shares outstanding. Positive None. Negative None. Financial Analyst The recent share repurchase activity by Millicom (Tigo) indicates a strategic move to manage their capital structure and potentially create shareholder value. Repurchasing shares can signal to the market that the company believes its stock is undervalued. It's important for investors to consider the daily average price paid for these shares, as it reflects the company's assessment of the value. Moreover, the repurchase activity can impact the earnings per share (EPS) metric by reducing the number of shares outstanding, which may lead to a higher EPS if net income remains constant.Investors should also be aware of the Safe Harbour Regulation, which provides guidelines ensuring that share buybacks are not misused for market manipulation. The fact that Millicom's repurchase program is consistent with these provisions can reassure investors about the legitimacy of the transactions. However, it is crucial to analyze the company's overall financial health to ensure that the repurchase does not negatively impact its liquidity or leverage ratios. In the long term, the effectiveness of this program in enhancing shareholder value will largely depend on the company's operational performance and market conditions. Market Research Analyst From a market perspective, Millicom's repurchase of Swedish Depository Receipts (SDRs) might be perceived as a positive indicator, suggesting that the company is confident in its future prospects. The repurchase activity takes place in the context of a broader market where share buybacks have become a common tool for companies to return capital to shareholders and manage their stock prices. The impact on the stock market will depend on investor perception of the buyback's intent and the company's future growth potential.It is also pertinent to consider the sector-specific trends in telecommunications, as they could influence the effectiveness of such financial maneuvers. For instance, if the sector is expected to experience growth due to technological advancements or regulatory changes, the timing of the buyback could be particularly advantageous. Conversely, if the sector faces headwinds, the company may need to justify the allocation of capital towards buybacks rather than investment in growth opportunities. Legal Expert When analyzing the legal implications of Millicom's share repurchase activity, the adherence to the Market Abuse Regulation (MAR) and the Safe Harbour Regulation is paramount. These regulations are designed to prevent market abuse and ensure transparency in financial transactions. By conducting the repurchase within these frameworks, Millicom demonstrates compliance with European Union regulations, which could be seen as a commitment to maintaining a fair trading environment.For stakeholders, the legal adherence also mitigates the risk of regulatory penalties that could arise from non-compliant buyback activities. However, it is essential to monitor any future regulatory changes that may affect the legal landscape of share repurchases and assess how such changes might impact the company's strategy and the interests of its shareholders. 02/16/2024 - 05:30 PM Millicom (Tigo) share repurchase activity Luxembourg, February 16, 2024 – Pursuant to the share repurchase program announced on December 15, 2023, Millicom repurchased 36,250 of its Swedish Depository Receipts (SDRs) between February 12, 2024 and February 16, 2024, as detailed in the table below. Trade DateNumber of SDRs repurchasedDaily average price paid* (SEK) Daily repurchase amount* (SEK)02/12/20247,250169.40841,228,21102/13/20247,250168.52391,221,79802/14/20247,250165.69891,201,31702/15/20247,250164.88331,195,40402/16/20247,250165.65791,201,020 * Excluding commissions All purchases were carried out on Nasdaq Stockholm by Citigroup Global Markets Limited on behalf of Millicom. Following the purchases, Millicom holds 1,595,370 treasury shares as of February 16, 2024. The total number of shares outstanding in Millicom is 172,096,305. The repurchase program is being executed consistent with the provisions of Article 5 of MAR and the Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”). A full breakdown of the transactions is attached to this press release. For information about all transactions carried out under the repurchase program, refer to Nasdaq Stockholm’s website: http://www.nasdaqomx.com/transactions/markets/nordic/corporate-actions/stockholm/repurchases-of-own-shares For further information, please contact: Press: Sofía Corral, Communications Director press@millicom.comInvestors:Michel Morin, VP Investor Relations investors@millicom.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of fixed and mobile telecommunications services in Latin America. Through our TIGO® and Tigo Business® brands, we provide a wide range of digital services and products, including TIGO Money for mobile financial services, TIGO Sports for local entertainment, TIGO ONEtv for pay TV, high-speed data, voice, and business-to-business solutions such as cloud and security. As of September 30, 2023, Millicom, including its Honduras Joint Venture, employed approximately 19,000 people and provided mobile and fiber-cable services through its digital highways to more than 45 million customers, with a fiber-cable footprint over 13 million homes passed. Founded in 1990, Millicom International Cellular S.A. is headquartered in Luxembourg. Attachment Week ending 02-16-24 How many Swedish Depository Receipts (SDRs) did Millicom repurchase? Millicom repurchased 36,250 of its Swedish Depository Receipts (SDRs) between February 12, 2024, and February 16, 2024. Where were the repurchases made? All purchases were carried out on Nasdaq Stockholm by Citigroup Global Markets Limited on behalf of Millicom. How many treasury shares does Millicom hold after the repurchases? Following the purchases, Millicom holds 1,595,370 treasury shares as of February 16, 2024. What is the total number of shares outstanding in Millicom? The total number of shares outstanding in Millicom is 172,096,305. Under which regulations is the repurchase program being executed? The repurchase program is being executed consistent with the provisions of Article 5 of MAR and the Commission Delegated Regulation No 2016/1052 ('Safe Harbour Regulation')."
JetBlue Announces Two New Independent Directors,2024-02-16T22:00:00.000Z,Neutral,Neutral,"JetBlue (JBLU) announces agreement with Icahn Enterprises, adding two new directors to the board. The company aims to enhance profitability and shareholder value through strategic actions.","JetBlue Announces Two New Independent Directors Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary JetBlue (JBLU) announces agreement with Icahn Enterprises, adding two new directors to the board. The company aims to enhance profitability and shareholder value through strategic actions. Positive None. Negative None. Corporate Governance Expert Board composition is a critical element of corporate governance that can significantly influence a company's strategic direction and operational effectiveness. The integration of Jesse Lynn and Steven Miller from Icahn Enterprises into JetBlue's board is a strategic move that brings new perspectives, particularly from individuals with a track record of involvement at pivotal moments for other public companies. Their expertise could provide invaluable insights into cost management, corporate strategy and shareholder value optimization.Furthermore, the expansion of the board to 13 directors, with a majority being independent, aligns with best practices in corporate governance, which advocate for a substantial proportion of independent directors to mitigate conflicts of interest and enhance objective decision-making. This move could be interpreted as a commitment to robust governance standards and may reassure investors about the airline's dedication to accountability and strategic oversight. Financial Analyst JetBlue's focus on returning to profitability through aggressive action is a point of interest for stakeholders. The execution of revenue initiatives totaling over $300 million and the pursuit of significant cost savings through structural cost programs, fleet modernization and fixed cost base reductions are concrete steps that could improve the financial health of the company. These measures are likely to be closely monitored by investors as indicators of the company's operational efficiency and financial performance.It is also worth noting the implications of the standstill agreement with the Icahn Group, which typically limits the ability of a significant shareholder to acquire additional shares or exert undue influence over corporate decisions. Such agreements can stabilize the shareholder base and prevent potential takeover attempts, which could be viewed favorably by investors seeking stability in the company's ownership structure. Market Analyst The airline industry is highly competitive and sensitive to external factors such as fuel prices, economic conditions and consumer demand. JetBlue's strategy to enhance shareholder value through board refreshment and strategic initiatives must be analyzed within this context. The company's ability to differentiate itself through its brand and value proposition is crucial to gaining market share and driving revenue growth.As JetBlue sets a path back to long-term sustainable growth, the market will be observing how these board changes and the announced initiatives translate into competitive advantages. The airline's performance relative to its peers will be a determinant in assessing the effectiveness of these strategies and the new board members' contributions to the company's success. 02/16/2024 - 05:00 PM Directors join board after agreement with Icahn Enterprises NEW YORK--(BUSINESS WIRE)-- JetBlue (NASDAQ: JBLU) today announced that it has entered into an agreement with Icahn Enterprises L.P., a major shareholder of JetBlue, under which Jesse Lynn, general counsel of Icahn Enterprises, and Steven Miller, portfolio manager of Icahn Capital, will join the airline’s board of directors. Lynn and Miller will serve as non-voting observers to the board through JetBlue’s annual meeting of stockholders this spring, after which time they will join the board as full voting members. Peter Boneparth, chair of the JetBlue board, said, “We are pleased to have reached this agreement with Icahn Enterprises. Our board and leadership team are focusing our full attention on taking aggressive action to return to profitability and strengthen JetBlue’s foundation for the future. We welcome Jesse and Steven to the board. With their experience on public company boards, often when navigating key inflection points, they will add useful insights as we set JetBlue on a path back to long-term sustainable growth and shareholder value creation.” Joanna Geraghty, chief executive officer, JetBlue, said, “We are already taking action to restore our historical earnings power. We are executing more than $300 million of revenue initiatives this year, and are on track to deliver significant cost savings from our structural cost program, fleet modernization, and fixed cost base reductions. Building on our distinct brand and unique value proposition, we are focused on delivering value to our shareholders and all of our stakeholders, and we welcome the contributions of our new board members as we move forward with that common goal.” Carl C. Icahn said, “We appreciate the constructive engagement we have had with JetBlue’s board and leadership team. We very much look forward to working with them in the future.” With the additions of Mr. Lynn and Mr. Miller following the annual meeting, the JetBlue board will expand to 13 directors, 12 of whom are expected to be independent. Since 2018, JetBlue has refreshed more than half the board and added eight new independent directors, including the appointments announced today. Icahn Enterprises and certain of its affiliates (collectively, the “Icahn Group”) have agreed to customary standstill, voting commitments and other provisions. Further information on JetBlue’s agreement with the Icahn Group, including a copy of the agreement, will be provided in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission. About Jesse Lynn Jesse Lynn has been general counsel of Icahn Enterprises L.P. since 2014. Previously, Lynn served as assistant general counsel of IEP, an associate at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and an associate at Gordon Altman Butowsky Weitzen Shalov & Wein. He has been a director on numerous company boards. He currently serves on the board of Conduent, and has served on the boards of Crown Holdings, Xerox Holdings Corporation, FirstEnergy Corp., Cloudera, Herbalife Nutrition, and The Manitowoc Company, Inc. He received a B.A. from the University of Michigan and a J.D. from the Boston University School of Law. About Steven Miller Steven Miller is a portfolio manager at Icahn Capital L.P., a subsidiary of Icahn Enterprises L.P. He currently serves as a director at Dana Incorporated, Bausch Health Companies, Inc. and Conduent Incorporated. Prior to joining Icahn Capital in October 2020, Miller was an analyst in the Distressed and Special Situations investment group at BlueMountain Capital Management, LLC and an analyst at Goldman, Sachs & Co. He has previously been a director at Xerox Holdings Corporation and Herc Holdings. He received a B.S. summa cum laude from Duke University in 2011. About JetBlue JetBlue is New York's Hometown Airline®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando, and San Juan. JetBlue, known for its low fares and great service, carries customers to more than 100 destinations throughout the United States, Latin America, Caribbean, Canada, and Europe. For more information and the best fares, visit jetblue.com. About Icahn Enterprises L.P. Icahn Enterprises L.P. (NASDAQ: IEP), a master limited partnership, is a diversified holding company owning subsidiaries currently engaged in the following continuing operating businesses: Investment, Energy, Automotive, Food Packaging, Real Estate, Home Fashion and Pharma. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”). All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “expects,” “plans,” “intends,” “anticipates,” “indicates,” “remains,” “believes,” “estimates,” “forecast,” “guidance,” “outlook,” “may,” “will,” “should,” “seeks,” “goals,” “targets” or the negative of these terms or other similar expressions. Additionally, forward-looking statements include statements that do not relate solely to historical facts, such as statements which identify uncertainties or trends, discuss the possible future effects of current known trends or uncertainties, or which indicate that the future effects of known trends or uncertainties cannot be predicted, guaranteed, or assured. Forward-looking statements contained in this press release include, without limitation, statements regarding our expected board composition; and our business strategy and plans for future operations, including our revenue initiatives and our growth and profitability goals. Forward-looking statements involve risks, uncertainties and assumptions, and are based on information currently available to us. Actual results may differ materially from those expressed in the forward-looking statements due to many factors, including, without limitation, the occurrence of any event, change or other circumstance, including the outcomes of legal proceedings, that could give rise to the right of JetBlue or Spirit Airlines Inc. (“Spirit”) or both of them to terminate the Agreement and Plan of Merger dated as of July 28, 2022 (the “Merger Agreement”) by and among the Company, Spirit and Sundown Acquisition Corp., a Delaware corporation and a direct wholly owned subsidiary of JetBlue; our extremely competitive industry; risks related to the long-term nature of our fleet order book; volatility in fuel prices and availability of fuel; increased maintenance costs associated with fleet age; costs associated with salaries, wages and benefits; risk associated with a potential material reduction in the rate of interchange reimbursement fees; risks associated with doing business internationally; our reliance on high daily aircraft utilization; our dependence on the New York metropolitan market; risks associated with extended interruptions or disruptions in service at our focus cities; risks associated with airport expenses; risks associated with seasonality and weather; our reliance on a limited number of suppliers for our aircraft, engines, and our Fly-Fi® product; risks related to new or increased tariffs imposed on commercial aircraft and related parts imported from outside the United States; the outcome of legal proceedings with respect to the Northeast Alliance (the “NEA”) with American Airlines Group Inc. and our wind-down of the NEA; failure to obtain certain governmental approvals necessary to consummate the merger with Spirit (the “Merger”); the outcome of the lawsuit filed by the Department of Justice and certain state Attorneys General against us and Spirit related to the Merger; risks associated with failure to consummate the Merger in a timely manner or at all; risks associated with the pendency of the Merger and related business disruptions; indebtedness following consummation of the Merger and associated impacts on business flexibility, borrowing costs and credit ratings; the possibility that JetBlue may be unable to achieve expected synergies and operating efficiencies within the expected timeframes or at all; challenges associated with successful integration of Spirit’s operations; expenses related to the Merger and integration of Spirit; the potential for loss of management personnel and other key crewmembers as a result of the Merger; risks associated with effective management of the combined company following the Merger; risks associated with JetBlue being bound by all obligations and liabilities of the combined company following consummation of the Merger; risks associated with the integration of JetBlue and Spirit workforce, including with respect to negotiation of labor agreements and labor costs; the impact of the Merger on JetBlue’s earnings per share; risks associated with cybersecurity and privacy, including potential disruptions to our information technology systems, information security breaches; heightened regulatory requirements concerning data security compliance; risks associated with reliance on, and potential failure of, automated systems to operate our business; our inability to attract and retain qualified crewmembers; our being subject to potential unionization, work stoppages, slowdowns or increased labor costs; reputational and business risk from an accident or incident involving our aircraft; risks associated with damage to our reputation and the JetBlue brand name; our significant amount of fixed obligations and the ability to service such obligations; our substantial indebtedness and impact on our ability to meet future financing needs; financial risks associated with credit card processors; restrictions as a result of our participation in governmental support programs under the CARES Act, the Consolidated Appropriations Act, and the American Rescue Plan Act; risks associated with seeking short-term additional financing liquidity; failure to realize the full value of intangible or long-lived assets, causing us to record impairments; risks associated with disease outbreaks or environmental disasters affecting travel behavior; compliance with environmental laws and regulations, which may cause us to incur substantial costs; the impacts of federal budget constraints or federally imposed furloughs; impact of global climate change and legal, regulatory or market response to such change; increasing attention to, and evolving expectations regarding, environmental, social and governance matters; changes in government regulations in our industry; acts of war or terrorism; and changes in global economic conditions or an economic downturn leading to a continuing or accelerated decrease in demand for air travel. Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements. You should understand that many important factors, in addition to those discussed or incorporated by reference in this press release, could cause our results to differ materially from those expressed in the forward-looking statements. Further information concerning these and other factors is contained in JetBlue’s filings with the U.S. Securities and Exchange Commission, including but not limited to, in our Annual Report on Form 10-K for the year ended December 31, 2023. In light of these risks and uncertainties, the forward-looking events discussed in this press release might not occur. Our forward-looking statements speak only as of the date of this press release. Other than as required by law, we undertake no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216398499/en/ JetBlue Corporate Communications Tel: +1.718.709.3089 corpcomm@jetblue.com JetBlue Investor Relations Tel: +1.718.709.2202 ir@jetblue.com Source: JetBlue What is the recent announcement made by JetBlue (JBLU) regarding Icahn Enterprises? JetBlue (JBLU) has entered into an agreement with Icahn Enterprises L.P., where Jesse Lynn and Steven Miller will join the airline's board of directors. Who will serve as non-voting observers on JetBlue's (JBLU) board until the annual meeting of stockholders? Jesse Lynn and Steven Miller will serve as non-voting observers on JetBlue's (JBLU) board until the annual meeting of stockholders. What is the goal of JetBlue (JBLU) in adding new board members from Icahn Enterprises? JetBlue (JBLU) aims to benefit from the experience of the new board members in public company boards, particularly during key inflection points, to drive long-term sustainable growth and shareholder value creation. How many directors will be on JetBlue's (JBLU) board after the addition of Mr. Lynn and Mr. Miller? Following the addition of Mr. Lynn and Mr. Miller, the JetBlue (JBLU) board will expand to 13 directors, with 12 expected to be independent. What commitments have Icahn Enterprises and its affiliates made as part of the agreement with JetBlue (JBLU)? Icahn Enterprises and its affiliates have agreed to customary standstill, voting commitments, and other provisions as part of the agreement with JetBlue (JBLU)."
Andean Precious Metals Files NI 43-101 Technical Report for San Bartolome,2024-02-16T22:21:00.000Z,Low,Neutral,"Andean Precious Metals Corp. files a Preliminary Feasibility Study Technical Report for San Bartolomé Mine Bolivia, extending the operating life by 4.6 years based on new mineral reserve estimates. The report highlights opportunities for growth, including securing more feedstock and potential drill programs.","Andean Precious Metals Files NI 43-101 Technical Report for San Bartolome Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Andean Precious Metals Corp. files a Preliminary Feasibility Study Technical Report for San Bartolomé Mine Bolivia, extending the operating life by 4.6 years based on new mineral reserve estimates. The report highlights opportunities for growth, including securing more feedstock and potential drill programs. Positive The operating life at San Bartolomé is extended by 4.6 years based on new 2P mineral reserve estimate. Economic grade fines disposal facility tailings are expected to replace pallaco deposits and represent approximately 11% of 2024 silver production. Future opportunities include processing oxide mineral not suitable for typical flotation plants and potential mineral resource increases. Estimated capital costs for the project include US$6.7 million for FDF hydraulic mining and sustaining capital of US$11.2 million. Operating costs are based on production schedules and reserves, covering mining/purchase costs, processing costs, and other expenses. The technical report was prepared by qualified persons in compliance with NI 43-101 standards. The report emphasizes Andean's focus on driving cash flow and profitability through growth initiatives in Bolivia. Negative None. 02/16/2024 - 05:21 PM Toronto, Ontario--(Newsfile Corp. - February 16, 2024) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) (""Andean"" or the ""Company"") today filed the Preliminary Feasibility Study Technical Report for San Bartolomé Mine Bolivia dated February 6, 2024 (the ""Technical Report"").The Technical Report was prepared by SRK Consulting (U.S.) Inc. in compliance with National Instrument 43-101 - Standards for Disclosure for Mineral Projects (""NI 43-101"") and has been filed on SEDAR+.Andean previously released the results of the mineral resource and mineral reserve statement (see news release dated December 27, 2023), showing an extension of 4.6 years for the San Bartolomé operation based on a new proven and probable (""2P"") mineral reserve estimate.""The Technical Report filed today further underscores the tremendous strides we have made to replenish our reserves and resources and extend the operating life of San Bartolomé,"" stated Alberto Morales, Andean's Executive Chairman and Chief Executive Officer. ""Pursuing opportunities that drive cash flow and profitability is our key priority in Bolivia. Topping our list of growth initiatives remains securing more feedstock through new long-term third-party contracts and from the Bolivian government. In parallel, our team is evaluating potential drill programs at Tollojchi, Altavista, and Paca and regional M&A opportunities."" Key Highlights of the Technical ReportThe operating life at San Bartolomé is extended by 4.6 years based on new 2P mineral reserve estimate. The Technical Report considers only a portion of the Company's third-party long-term contracts where sufficient data was available, and excludes feedstock purchased from small independent third-party miners in Bolivia with whom the Company does not have long-term contracts. As of the end of the first nine months ending September 30, 2023, third-party material represented more than 60% of tonnes processed at San Bartolomé and nearly 70% of ounces produced. Economic grade fines disposal facility (""FDF"") tailings are expected to fully replace pallaco deposits from the flanks of the Cerro Ricco commencing in Q2 2024 and represent approximately 11% of San Bartolomé's 2024 silver production.San Bartolomé has been in operation since 2008 and requires US$6.7 million to enable the hydraulic mining of the FDF tailings, which is anticipated to commence in the first half of 2024.The Company's existing processing plant in Bolivia can run both high-grade silver contracted material and FDF tailings.Future opportunities identified in the Technical Report:San Bartolome plant is one of the only operations that actively acquires and processes oxide mineral not suitable for typical flotation plants in Bolivia.Tollojchi, Altavista, and Paca deposits remain open with potential to increase mineral resources.Current tests of oxygen injection are targeting better FDF tailings recoveries.Annual Mine Plan SummaryThe following table includes contracted material from Tollojchi, Altavista, and Paca deposits and FDF tailings and excludes uncontracted material from independent third-party contractors. (For additional information, please refer to the Technical Report on file at sedarplus.ca.)UnitsNameTotalY01Y02Y03Y04Y05MtOre Mined9.72.22.61.91.91.0MtWaste Mined7.64.71.90.60.20.1MtTotal Mined17.26.94.62.62.11.0ROM%Mass Yield52.672.853.641.742.245.3MtMass Yield Tonnes5.081.621.410.810.800.43g/tAg Grade9314385606061MozContained Ag15.197.393.851.551.560.84MozRecovered Ag11.955.913.031.181.190.64%Recovery78.779.978.776.376.376.3 Capital and Operating CostsLife of Mine Capital Cost SummaryAndean estimated the capital costs for the San Bartolomé project. The estimate is based on historic costs incurred at the site, existing contracts with service providers and engineering to prepare for the planned FDF expansion. Andean provided SRK with the details supporting their capital estimates. The table below summarizes the capital cost estimate:Sustaining CapexUnitValue FDF hydraulic mining and pre-concentrationUS$6,700,000 Sustaining capitalUS$11,200,000 Closure US$2,250,000 TotalUS$20,150,000 Operating CostsOperating costs were developed by Andean and are based on the production schedule and stated reserves. Cost estimation is based on requirements of equipment, operating labor, supervision, and administrative labor, mine, and process consumables, maintenance, etc. The following table summarizes the operating costs of the San Bartolomé project. DescriptionUnitValueMining/Purchase CostsFDFUS$/t-washed2.00MantoUS$/t-washed22.90PlateraUS$/t-washed22.90RosarioUS$/t-washed22.90PacasUS$/t-washed60.80AltavistaUS$/t-washed137.00Processing CostsPre-concentration FDFUS$/t-washed1.42Processing FDFUS$/t-Milled16.13Processing MantoUS$/t-Milled23.49Processing PlateraUS$/t-Milled23.49Processing RosarioUS$/t-Milled23.49Processing PacaUS$/t-Milled20.29Processing Alta VistaUS$/t-Milled24.69TSF FDFUS$/t-Milled1.76TSF MantoUS$/t-Milled1.76TSF PlateraUS$/t-Milled1.76TSF RosarioUS$/t-Milled1.76TSF PacaUS$/t-Milled1.76TSF Alta VistaUS$/t-Milled1.76Other CostsG&AUS$/t-Milled0.91IndirectUS$/t-Milled2.80AdministrativeUS$/t-Milled3.80 Note: TSF means tailings storage facility. Qualified PersonsThe technical report was prepared under the supervision of Patrick Daniels, BSc Mining, SME-RM (SRK Principal Consultant, Mining Engineer); Matthew Fuller, P.Geo, LEG (Tierra Group, Geoscientist); Donald J. Birak, MSc, RM-SME (Birak Consulting, Independent Consulting Geologist); Giovanny Ortiz, BSc Geology, FAusIMM, Fellow (SEG), (SRK Principal Consultant, Resource Geologist); Fernando Rodrigues, BS Mining, MBA, MMSAQP (SRK Practice Leader and Principal Consultant, Mining Engineer); Eric Olin, MSc, MBA, RM-SME (SRK Principal Process Metallurgist); Mark Allan Willow, MSc, CEM, SME-RM (SRK Practice Leader/Principal Environmental Scientist) in accordance with the disclosure and reporting requirements set forth in NI 43-101. All the above are qualified persons under NI 43-101 and have no affiliation with Andean or their subsidiaries except that of independent consultant/client relationships.The scientific and technical information contained in this news release has been reviewed and approved by Patrick Daniels, BSc Mining, SME-RM (SRK Principal Consultant, Mining Engineer) and Donald J. Birak, MSc, RM-SME (Birak Consulting, Independent Consulting Geologist).About Andean Precious MetalsAndean is a growing precious metals producer focused on expanding into top-tier jurisdictions in the Americas. The Company owns and operates the San Bartolomé processing facility in Potosí, Bolivia and the Soledad Mountain mine in Kern County, California, and is well-funded to act on future growth opportunities. Andean's leadership team is committed to creating value; fostering safe, sustainable and responsible operations; and achieving its ambition to be a multi-asset, mid-tier precious metals producer. For more information, please contact: Trish MoranVP Investor Relationstmoran@andeanpm.comT: +1 416 564 4290Neither the TSX Venture Exchange, Inc. nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Caution Regarding Forward-Looking Statements Certain statements and information in this release constitute ""forward-looking statements"" within the meaning of applicable U.S. securities laws and ""forward-looking information"" within the meaning of applicable Canadian securities laws, which we refer to collectively as ""forward-looking statements"". Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of action. All statements and information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as ""seek"", ""expect"", ""anticipate"", ""budget"", ""plan"", ""estimate"", ""continue"", ""forecast"", ""intend"", ""believe"", ""predict"", ""potential"", ""target"", ""may"", ""could"", ""would"", ""might"", ""will"" and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook.Forward-looking statements in this release include, but are not limited to, statements and information regarding composition of Andean's silver production in 2024, requirements for San Bartolomé's continued operation, the potential of future opportunities identified in the Technical Report, life of operation estimates and the mine plan and required capital and operating costs. Such forward-looking statements are based on a number of material factors and assumptions, including, but not limited to: the Company's ability to carry on exploration and development activities; the Company's ability to secure and to meet obligations under property and option agreements and other material agreements; the timely receipt of required approvals and permits; that there is no material adverse change affecting the Company or its properties; that contracted parties provide goods or services in a timely manner; that no unusual geological or technical problems occur; that plant and equipment function as anticipated and that there is no material adverse change in the price of silver, costs associated with production or recovery. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to differ materially from those anticipated in such forward-looking statements. The Company believes the expectations reflected in such forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct, and you are cautioned not to place undue reliance on forward-looking statements contained herein.Some of the risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking statements contained in this release include, but are not limited to: risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits and conclusions of economic evaluations; results of initial feasibility, pre-feasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks relating to possible variations in reserves, resources, grade, planned mining dilution and ore loss, or recovery rates and changes in project parameters as plans continue to be refined; mining and development risks, including risks related to accidents, equipment breakdowns, labour disputes (including work stoppages and strikes) or other unanticipated difficulties with or interruptions in exploration and development; the potential for delays in exploration or development activities or the completion of feasibility studies; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; risks related to commodity price and foreign exchange rate fluctuations; the uncertainty of profitability based upon the cyclical nature of the industry in which the Company operates; risks related to failure to obtain adequate financing on a timely basis and on acceptable terms or delays in obtaining governmental or local community approvals or in the completion of development or construction activities; risks related to environmental regulation and liability; political and regulatory risks associated with mining and exploration; risks related to the uncertain global economic environment; and other factors contained in the section entitled ""Risk Factors"" in the Company's Management Discussion and Analysis dated November 29, 2023.Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in the forward-looking statements, you are cautioned that this list is not exhaustive and there may be other factors that the Company has not identified. Furthermore, the Company undertakes no obligation to update or revise any forward-looking statements included in this release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198342 What is the impact of the Preliminary Feasibility Study Technical Report on Andean Precious Metals Corp. (ANPMF) stock? The report extends the operating life of the San Bartolomé mine by 4.6 years based on new mineral reserve estimates, which could positively impact the company's stock performance. What are the future opportunities highlighted in the Technical Report for Andean Precious Metals Corp. (ANPMF)? The report mentions opportunities like processing oxide mineral, potential mineral resource increases, and testing oxygen injection for better FDF tailings recoveries. How much does Andean Precious Metals Corp. (ANPMF) estimate for the capital costs of the San Bartolomé project? The estimated capital costs include US$6.7 million for FDF hydraulic mining and US$11.2 million for sustaining capital, totaling US$20.15 million. Who prepared the technical report for Andean Precious Metals Corp. (ANPMF) regarding the San Bartolomé mine? The technical report was prepared by qualified persons including mining engineers, geoscientists, and environmental scientists in compliance with NI 43-101 standards. What is the focus of Andean Precious Metals Corp. (ANPMF) in Bolivia according to the Technical Report? The company's key priority in Bolivia is pursuing opportunities that drive cash flow and profitability, including securing more feedstock and evaluating potential drill programs and M&A opportunities."
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program,2024-02-16T22:00:00.000Z,Neutral,Neutral,Lucid Diagnostics Inc. (Nasdaq: LUCD) received notification from the World Trade Center Health Program regarding a clerical error in listing the EsoGuard® Esophageal DNA test as a covered benefit. Lucid is actively engaging with Clinical Centers of Excellence to rectify the issue and ensure access to esophageal precancer testing for at-risk participants.,"Lucid Diagnostics Provides Update Regarding World Trade Center Health Program Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Lucid Diagnostics Inc. (Nasdaq: LUCD) received notification from the World Trade Center Health Program regarding a clerical error in listing the EsoGuard® Esophageal DNA test as a covered benefit. Lucid is actively engaging with Clinical Centers of Excellence to rectify the issue and ensure access to esophageal precancer testing for at-risk participants. Positive None. Negative None. 02/16/2024 - 05:00 PM NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (""Lucid"" or the ""Company"") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( ""PAVmed""), today announced that it was notified by the World Trade Center Health Program (""WTCHP"") that, due to a clerical error, the EsoGuard® Esophageal DNA test was incorrectly listed as a covered benefit. WTCHP advised Lucid on the further steps required, including engaging directly with its Clinical Centers of Excellence. Lucid has a strong record of partnering with firefighters and other first responders on cancer prevention programs targeting these at-risk groups. Lucid has tested thousands of first responders across the country at high-volume #CheckYourFoodTube Precancer Testing Events. As such, Lucid remains deeply committed to working closely with WTCHP to complete the necessary steps to provide its at-risk participants access to esophageal precancer testing. About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer. For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com. Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, ""Risk Factors,"" in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, ""Risk Factors"" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-update-regarding-world-trade-center-health-program-302064454.html SOURCE Lucid Diagnostics What notification did Lucid Diagnostics Inc. receive from the World Trade Center Health Program? Lucid Diagnostics Inc. received notification regarding a clerical error in listing the EsoGuard® Esophageal DNA test as a covered benefit. How is Lucid Diagnostics Inc. addressing the issue with the World Trade Center Health Program? Lucid Diagnostics Inc. is actively engaging with Clinical Centers of Excellence to rectify the issue and ensure access to esophageal precancer testing for at-risk participants. What is Lucid Diagnostics Inc.'s commitment to working with first responders? Lucid Diagnostics Inc. has a strong record of partnering with firefighters and other first responders on cancer prevention programs targeting at-risk groups."
Altiplano Metals Announces Change in Financial Year End,2024-02-16T22:00:00.000Z,Low,Neutral,"Altiplano Metals Inc. (TSXV: APN) announces a change in its financial year-end from December 31 to March 31, aiming for better audit efficiency and alignment with industry peers. The company will report audited financial results for a 15-month transition year and revert to a March 31 year-end afterward.","Altiplano Metals Announces Change in Financial Year End Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Altiplano Metals Inc. (TSXV: APN) announces a change in its financial year-end from December 31 to March 31, aiming for better audit efficiency and alignment with industry peers. The company will report audited financial results for a 15-month transition year and revert to a March 31 year-end afterward. Positive None. Negative None. 02/16/2024 - 05:00 PM Edmonton, Alberta--(Newsfile Corp. - February 16, 2024) - Altiplano Metals Inc. (TSXV: APN) (WKN: A2JNFG) (""Altiplano"" or the ""Company"") wishes to announce that it is changing its financial year-end to March 31 from its current year-end of December 31. As a result, the Corporation will file an additional interim report as of December 31, 2023, and will report audited financial results for a 15-month transition year from January 31, 2023, to March 31, 2024 (with a comparative of the 12 months ended December 31, 2022). Afterwards, the Corporation will revert to a customary reporting calendar based on a March 31 year-end, with fiscal quarters ending on the last day of June, September and December and March each year. The Company believes this change of financial year-end will allow it to complete its audit requirements with greater efficiency and will better align the Corporation's financial reporting periods to that of its peer group in the mineral resources sector, which will allow investors to better compare quarterly and annual financial results. The notice for the change in financial year-end required under National Instrument 51-102 - Continuous Disclosure Obligations will be filed under the Corporation's SEDAR profile at www.sedarplus.ca.About AltiplanoAltiplano Metals is a growing gold, silver, and copper company focused on the Americas. The Company has a diversified portfolio of assets that include an operating copper/gold/iron mine and a state-of-the-art operating copper/gold and iron processing facility in the final stages of completion. Altiplano is focused on creating long-term stakeholder value through developing safe and sustainable production, reinvesting into exploration, and pursuing acquisition opportunities to complement its existing portfolio. Management has a substantial record of success in capitalizing on opportunity, overcoming challenges and building shareholder value. Altiplano trades on the TSX.V under the symbol APN and the Frankfurt Exchange under the symbol A2JNFG.ON BEHALF OF THE BOARD/s/ ""John Williamson""ChairmanFor further information, please contact:Alastair McIntyre, CEOalastairm@apnmetals.comTel: (416) 434 3799Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the (TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.This release includes certain statements that may be deemed ""forward-looking statements"". All statements in this release, other than statements of historical facts, that address exploration drilling, exploitation activities and events or developments that the Company expects are forward-looking statements. A qualified person has not done sufficient work to classify any historical estimates as current mineral resources or mineral reserves and the issuer is not treating the historical estimates as current mineral resources or mineral reserves. The Farellon mine was previously in production dating back to the 1970's with a reported historical production (to a depth of 70 m) yielding approximately 300,000 tonnes at an average grade of 2.5% copper and 0.5g/t gold. This material was processed locally and sold to ENAMI. Altiplano is relying upon past production records, underground sampling and related activities and current diamond drilling to estimate grade and widths of the mineralization to reactivate production. The decision to commence production on the Farellon deposit is not based on a feasibility study of mineral reserves demonstrating economic and technical viability and there is increased uncertainty and economic and technical risks of failure associated with any production decision. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continuity of mineralization, uncertainties related to the ability to obtain necessary permits, licenses and title and delays due to third party opposition, changes in government policies regarding mining and natural resource exploration and exploitation, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. For more information on the Company, investors should review the Company's continuous disclosure filings that are available at www.sedarplus.ca.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198311 Why is Altiplano Metals changing its financial year-end from December 31 to March 31? Altiplano Metals is changing its financial year-end to March 31 to improve audit efficiency and align its financial reporting periods with industry peers in the mineral resources sector. What will be the duration of the transition year for Altiplano Metals after changing its financial year-end? After changing its financial year-end, Altiplano Metals will report audited financial results for a 15-month transition year from January 31, 2023, to March 31, 2024. Where can investors find the notice for the change in financial year-end by Altiplano Metals? Investors can find the notice for the change in financial year-end by Altiplano Metals under the Corporation's SEDAR profile at www.sedarplus.ca."
First Phosphate Announces Management Change,2024-02-16T22:11:00.000Z,Low,Neutral,"First Phosphate Corp. announces an amendment to Jérôme Cliche's role, transitioning from Vice President, Business Development to a consultant until October 5, 2024. Mr. Cliche will continue with his personal corporation, LMC Communications Inc. The CEO, John Passalacqua, expresses gratitude for Mr. Cliche's service and looks forward to their continued collaboration. The revised consulting agreement includes the forfeiture of Mr. Cliche's options.","First Phosphate Announces Management Change Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary First Phosphate Corp. announces an amendment to Jérôme Cliche's role, transitioning from Vice President, Business Development to a consultant until October 5, 2024. Mr. Cliche will continue with his personal corporation, LMC Communications Inc. The CEO, John Passalacqua, expresses gratitude for Mr. Cliche's service and looks forward to their continued collaboration. The revised consulting agreement includes the forfeiture of Mr. Cliche's options. Positive None. Negative None. 02/16/2024 - 05:11 PM Saguenay, Quebec--(Newsfile Corp. - February 16, 2024) - First Phosphate Corp. (CSE: PHOS) (OTC: FRSPF) (FSE: KD0) (""First Phosphate"" or the ""Company"") announces that First Phosphate and Jérôme Cliche have mutually agreed to amend Mr. Cliche's role with the Company. Effective, today, Mr. Cliche will cease to act as Vice President, Business Development and will, through his personal corporation, LMC Communications Inc., continue as a consultant to First Phosphate until October 5, 2024.""First Phosphate wishes to thank Mr. Cliche for his dedication and service in his role as Vice President Business Development,"" says Company CEO, John Passalacqua. ""I look forward to continuing to work with Jérôme in his consulting capacity to the Company.""""I would like to thank the management of First Phosphate, and in particular Mr. John Passalacqua, for the confidence they have shown in me since my appointment,"" added Mr. Cliche. ""I believe that First Phosphate is and will remain a promising project, both for the company and its shareholders, and for the development of the LFP battery industry, which extends far beyond Quebec's borders.""Under the terms of the revised consulting agreement, the options held by Mr. Cliche have been forfeited.About First Phosphate Corp.First Phosphate is a mineral development company fully dedicated to extracting and purifying phosphate for the production of cathode active material for the LFP battery industry. First Phosphate is committed to producing at high purity level, in responsible manner and with low anticipated carbon footprint. First Phosphate plans to vertically integrate from mine source directly into the supply chains of major North American LFP battery producers that require battery grade LFP cathode active material emanating from a consistent and secure supply source. First Phosphate holds over 1,500 sq. km of royalty-free district-scale land claims in the Saguenay-Lac-St-Jean Region of Quebec, Canada that it is actively developing. First Phosphate properties consist of rare anorthosite igneous phosphate rock that generally yields high purity phosphate material devoid of high concentrations of harmful elements.For additional information, please contact:Bennett Kurtz, CFObennett@firstphosphate.comTel: +1 (416) 200-0657Investor Relations: investor@firstphosphate.comMedia Relations: media@firstphosphate.comWebsite: www.FirstPhosphate.comFollow First Phosphate:Twitter: https://twitter.com/FirstPhosphate LinkedIn: https://www.linkedin.com/company/first-phosphate-30-Forward-Looking Information and Cautionary StatementsThis news release contains certain statements and information that may be considered ""forward-looking statements"" and ""forward looking information"" within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as ""plans"", ""targets"", ""expects"" or ""does not expect"", ""is expected"", ""an opportunity exists"", ""is positioned"", ""estimates"", ""intends"", ""assumes"", ""anticipates"" or ""does not anticipate"" or ""believes"", or variations of such words and phrases or statements that certain actions, events or results ""may"", ""could"", ""would"", ""might"", ""will"" or ""will be taken"", ""occur"" or ""be achieved"" and other similar expressions. In addition, statements in this news release that are not historical facts are forward looking statements, including, among other things, the Company's planned exploration and production activities, the properties and composition of any extracted phosphate, the Company's plans for vertical integration into North American supply chains, and the development of the LFP battery industry, within and outside of Quebec.These statements and other forward-looking information are based on assumptions and estimates that the Company believes are appropriate and reasonable in the circumstances, including, without limitation, expectations of the Company's long term business outcomes given its short operating history; expectations regarding revenue, expenses and operations; the Company having sufficient working capital and ability to secure additional funding necessary for the exploration of the Company's property interests; expectations regarding the potential mineralization, geological merit and economic feasibility of the Company's projects; expectations regarding drill programs and the potential impacts successful drill programs could have on the life of the mine and the Company; mineral exploration and exploration program cost estimates; expectations regarding any environmental issues that may affect planned or future exploration programs and the potential impact of complying with existing and proposed environmental laws and regulations; receipt and timing of exploration and exploitation permits and other third-party approvals; government regulation of mineral exploration and development operations; expectations regarding any social or local community issues that may affect planned or future exploration and development programs; expectations surrounding global economic trends and technological advancements; and key personnel continuing their employment with the Company.There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include: limited operating history; high risk of business failure; no profits or significant revenues; limited resources; negative cash flow from operations and dependence on third-party financing; the uncertainty of additional funding; no dividends; risks related to possible fluctuations in revenues and results; insurance and uninsured risks; litigation; reliance on management and key personnel; conflicts of interest; access to supplies and materials; dangers of mineral exploration and related liability and damages; risks relating to health and safety; government regulation and legal uncertainties; the company's exploration and development properties may not be successful and are highly speculative in nature; dependence on outside parties; title to some of the Company's mineral properties may be challenged or defective; Aboriginal title and land claims; obtaining and renewing licenses and permits; environmental and other regulatory risks may adversely affect the company; risks relating to climate change; risks related to infrastructure; land reclamation requirements may be burdensome; current global financial conditions; fluctuation in commodity prices; dilution; future sales by existing shareholders could cause the Company's share price to fall; fluctuation and volatility in stock exchange prices; and risks related to market demands. There can be no assurance that any opportunity will be successful, commercially viable, completed on time or on budget, or will generate any meaningful revenues, savings or earnings, as the case may be, for the Company. In addition, the Company will incur costs in pursuing any particular opportunity, which may be significant.These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the Company and, though they should be considered carefully, should be considered in conjunction with the risk factors described in the Company's other documents filed with the Canadian securities authorities, including without limitation the ""Risk Factors"" section of the Company's Annual Information Form dated November 29, 2023 which is available on SEDAR at www.sedarplus.ca. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking information or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198347 What is the latest announcement from First Phosphate Corp. regarding J&#233;r&#244;me Cliche's role? First Phosphate Corp. announced that Jérôme Cliche will transition from Vice President, Business Development to a consultant until October 5, 2024. Who will J&#233;r&#244;me Cliche work with through his personal corporation, LMC Communications Inc.? Jérôme Cliche will continue to work with First Phosphate Corp. through his personal corporation, LMC Communications Inc. What options were forfeited under the revised consulting agreement for J&#233;r&#244;me Cliche? Under the revised consulting agreement, the options held by Jérôme Cliche have been forfeited."
Isabella Bank Corporation Announces Fourth Quarter and 2023 Earnings,2024-02-17T00:22:00.000Z,Low,Neutral,"Isabella Bank Corporation (ISBA) reported strong financial results for 2023 despite interest rate pressures. Net income was $18.2 million, with earnings per share of $2.42. Gross loans grew by 7%, Isabella Wealth assets increased by 25%, and interest income rose by 21%. However, interest expense also increased, impacting net interest income. Shareholders received a cash dividend of $1.12 per share.","Isabella Bank Corporation Announces Fourth Quarter and 2023 Earnings Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary Isabella Bank Corporation (ISBA) reported strong financial results for 2023 despite interest rate pressures. Net income was $18.2 million, with earnings per share of $2.42. Gross loans grew by 7%, Isabella Wealth assets increased by 25%, and interest income rose by 21%. However, interest expense also increased, impacting net interest income. Shareholders received a cash dividend of $1.12 per share. Positive None. Negative Net income decreased in the fourth quarter and year-end 2023 compared to 2022 due to rising interest expenses. Net interest income declined in the fourth quarter and year-end 2023, mainly from increased interest rates on deposits. Noninterest expenses increased by $2.5 million in 2023, driven by rising compensation, equipment expenses, and other losses. Deposits decreased by $20.6 million in 2023, with a decline in demand deposits due to Federal Reserve actions. The net yield on interest earning assets decreased in 2023 compared to 2022, impacted by rising interest rates and increased borrowings. 02/16/2024 - 07:22 PM Continued growth in loans, Isabella Wealth; outpaced by continued interest rate pressure MT. PLEASANT, Mich., Feb. 16, 2024 /PRNewswire/ -- Isabella Bank Corporation (the ""Corporation"") (OTCQX: ISBA) reported fourth quarter and year-end 2023 earnings, demonstrating resilience during a year buffeted by rising interest rates on deposit accounts. Net income for the fourth quarter was $3.8 million and $18.2 million for the year ended December 31, 2023. Earnings per common share were $0.51 in the fourth quarter and $2.42 for the year. Among the 2023 highlights: Gross loans increased more than $85 million, or 7%.Isabella Wealth assets grew 25% to $641 million, leading to an increase in wealth management fees of $552,000, or 18%, over 2022.Interest income increased $13.8 million, or 21%, over 2022, offset by an increase in interest expense of $16.4 million.Shareholders earned a cash dividend of $1.12 per share in 2023, with an annualized dividend yield of 5.21%.""Our 2023 financial results demonstrate Isabella Bank's ability to come out of a tough year still delivering strong results for shareholders,"" said Jerome E. Schwind, President and Chief Executive Officer. ""Our liquidity and capital ratios remain strong and we delivered results against our strategic plan based on our strength in the marketplace. ""We continued to grow our footprint — including adding our eighth mid-Michigan county — and customers continued to turn to Isabella Bank, driving our growth in loans and our wealth management business,"" he added. Operating Results Net income: Net income for the fourth quarter of 2023 was $3.8 million, a decrease of $2.5 million compared to the same period in 2022. For the year ended December 31, 2023, net income was $18.2 million, compared to $22.2 million in 2022. The declines were driven by a rise in interest expense resulting largely from increased interest rates on deposit accounts. Net interest income, fourth quarter 2023: Net interest income for the fourth quarter 2023 declined $2.7 million, or 16%, compared to the fourth quarter of 2022. Interest income increased $3.1 million, or 17.5%, driven by core loan growth, while continued interest rate pressure was the primary cause of a $5.8 million increase in interest expense over the same period in 2022. Net interest income, year-end 2023: Net interest income for the year ended December 31, 2023 decreased $2.5 million, or 4.2%, compared to 2022. Rising interest rates and growth in core loans led to a $13.8 million, or 21%, increase in gross interest income during 2023, compared to 2022. At the same time, rising interest rates on deposits and an increase in borrowings led to a $16.4 million increase in interest expense for 2023, compared to 2022. Noninterest income and expenses, fourth quarter 2023: Noninterest income increased $244,000 compared to the fourth quarter of 2022, primarily driven by wealth management fees and ATM and debit card income. Noninterest expenses for the quarter were essentially unchanged in comparison to the fourth quarter of 2022. Noninterest income and expenses, year-end 2023: Noninterest income for the year ended December 31, 2023 increased $161,000 compared to 2022. The increase was driven by wealth management fees and ATM and debit card fee income, offset by a decrease in mortgage servicing rights and gain on sale of loans, as residential mortgages sold to the secondary market declined. Noninterest expense increased $2.5 million compared to 2022, primarily the result of increased compensation, equipment expense, other losses, and FDIC insurance premiums. Net yield on interest earning assets: The Corporation's fully taxable equivalent net yield on interest earning assets was 2.85% and 3.05% for the fourth quarter and year ended December 31, 2023, respectively, compared to 3.43% and 3.18% for the same periods in 2022. To maintain a competitive edge in the rising interest rate environment, rates on several deposit products began to increase in the fourth quarter of 2022 and continued throughout 2023. Over the last year, the level of borrowings increased to fund loan growth. These factors have negatively impacted the net yield on interest earning assets slowing its rate of growth. Balance Sheet Assets: Total assets were $2.06 billion and assets under management were $2.95 billion as of December 31, 2023. Managed assets included loans sold and serviced of $249 million as well as $641 million in investment and trust assets managed by our wealth business. Loans: Loans outstanding as of December 31, 2023 totaled $1.35 billion, growing $85.3 million since December 31, 2022. Credit quality remained strong, as evidenced by total past due and nonaccrual loans which were 0.37% of gross loans as of December 31, 2023. Deposits: Deposits were $1.72 billion as of December 31, 2023, declining $20.6 million, or 1.2%, since December 31, 2022. A decline in demand deposits was driven by contraction in money supply as the Federal Reserve Bank pulled money out of the banking system. Capital: The Bank continues to be considered a ""well-capitalized"" institution, as its capital ratios exceeded the minimum designated requirements. As of December 31, 2023, the Bank's Tier 1 Leverage Ratio was 8.71%, Tier 1 Capital Ratio was 12.48% and Total Capital Ratio was 13.42%, compared to minimum requirements to be considered well capitalized of 5.0%, 8.0% and 10.0%, respectively. Dividend: The Corporation paid a $0.28 per common share cash dividend for the fourth quarter of 2023. Total cash dividends paid for the year ended December 31, 2023 totaled $1.12, a 2.75% increase over dividends paid in 2022. Based on the Corporation's closing stock price of $21.50 as of December 29, 2023, the annualized cash dividend yield was 5.21%. About the Corporation Isabella Bank Corporation (OTCQX: ISBA) is the parent holding company of Isabella Bank, a state-chartered community bank headquartered in Mt. Pleasant, Michigan. Isabella Bank was established in 1903 and has been committed to serving its customers' and communities' local banking needs for over 120 years. The Bank offers personal and commercial lending and deposit products, as well as investment, trust, and estate planning services. The Bank has locations throughout eight Mid-Michigan counties: Bay, Clare, Gratiot, Isabella, Mecosta, Midland, Montcalm, and Saginaw. For more information about Isabella Bank Corporation, visit the Investor Relations link at www.isabellabank.com. Isabella Bank Corporation common stock is quoted on the OTCQX tier of the OTC Markets Group, Inc.'s electronic quotation system (www.otcmarkets.com) under the symbol ""ISBA."" The Corporation's investor relations firm is Stonegate Capital Partners, Inc. (www.stonegateinc.com). Forward-Looking Statements This press release includes forward-looking statements. To the extent that the foregoing information refers to matters that may occur in the future, please be aware that such forward-looking statements may differ materially from the actual results. Additional information concerning some of the factors that could cause materially different results is included in the sections titled ""Risk Factors"" and ""Forward Looking Statements"" set forth in Isabella Bank Corporation's filings with the Securities and Exchange Commission, which are available from the Securities and Exchange Commission's Public Reference facilities and from its website at www.sec.gov. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Dollars in thousands) December 312023 December 312022 ASSETS Cash and cash equivalents Cash and demand deposits due from banks $ 25,628 $ 27,420 Fed Funds sold and interest bearing balances due from banks 8,044 11,504 Total cash and cash equivalents 33,672 38,924 Available-for-sale securities, at fair value 528,148 580,481 Mortgage loans available-for-sale — 379 Loans 1,349,463 1,264,173 Less allowance for credit losses 13,108 9,850 Net loans 1,336,355 1,254,323 Premises and equipment 27,639 25,553 Corporate owned life insurance policies 33,892 32,988 Equity securities without readily determinable fair values 15,848 15,746 Goodwill and other intangible assets 48,284 48,287 Accrued interest receivable and other assets 35,130 33,586 TOTAL ASSETS $ 2,058,968 $ 2,030,267 LIABILITIES AND SHAREHOLDERS' EQUITY Deposits Noninterest bearing $ 428,505 $ 494,346 Interest bearing demand deposits 320,737 372,155 Certificates of deposit under $250 and other savings 857,768 810,642 Certificates of deposit over $250 116,685 67,132 Total deposits 1,723,695 1,744,275 Borrowed funds Federal funds purchased and repurchase agreements 46,801 57,771 Federal Home Loan Bank advances 40,000 — Subordinated debt, net of unamortized issuance costs 29,335 29,245 Total borrowed funds 116,136 87,016 Accrued interest payable and other liabilities 16,735 12,766 Total liabilities 1,856,566 1,844,057 Shareholders' equity Common stock — no par value 15,000,000 shares authorized; issued and outstanding 7,485,889 shares (including 150,581 shares held in the Rabbi Trust) in 2023 and 7,559,421 shares (including 154,879 shares held in the Rabbi Trust) in 2022 127,323 128,651 Shares to be issued for deferred compensation obligations 3,693 5,005 Retained earnings 97,282 89,748 Accumulated other comprehensive income (loss) (25,896) (37,194) Total shareholders' equity 202,402 186,210 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 2,058,968 $ 2,030,267 CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (Dollars in thousands except per share amounts) Three Months Ended December 31 Year Ended December 31 2023 2022 2023 2022 Interest income Loans, including fees $ 17,580 $ 14,163 $ 65,670 $ 53,283 Available-for-sale securities Taxable 2,303 2,512 9,514 8,363 Nontaxable 623 718 2,642 2,808 Federal funds sold and other 550 522 1,805 1,344 Total interest income 21,056 17,915 79,631 65,798 Interest expense Deposits 6,399 1,323 18,352 4,021 Borrowings Federal funds purchased and repurchase agreements 357 53 961 79 Federal Home Loan Bank advances 422 — 1,309 152 Subordinated debt, net of unamortized issuance costs 266 267 1,065 1,065 Total interest expense 7,444 1,643 21,687 5,317 Net interest income 13,612 16,272 57,944 60,481 Provision for credit losses 684 (57) 629 483 Net interest income after provision for credit losses 12,928 16,329 57,315 59,998 Noninterest income Service charges and fees 2,212 2,115 8,297 8,730 Wealth management fees 932 788 3,557 3,005 Earnings on corporate owned life insurance policies 239 229 920 884 Net gain on sale of mortgage loans 85 63 317 631 Other 48 77 736 416 Total noninterest income 3,516 3,272 13,827 13,666 Noninterest expenses Compensation and benefits 6,116 6,407 25,905 24,887 Furniture and equipment 1,697 1,624 6,519 6,006 Occupancy 857 878 3,778 3,691 Other 3,245 3,013 13,108 12,236 Total noninterest expenses 11,915 11,922 49,310 46,820 Income before federal income tax expense 4,529 7,679 21,832 26,844 Federal income tax expense 726 1,357 3,665 4,606 NET INCOME $ 3,803 $ 6,322 $ 18,167 $ 22,238 Earnings per common share Basic $ 0.51 $ 0.84 $ 2.42 $ 2.95 Diluted $ 0.51 $ 0.83 $ 2.40 $ 2.91 Cash dividends per common share $ 0.28 $ 0.28 $ 1.12 $ 1.09 AVERAGE BALANCES, INTEREST RATE, AND NET INTEREST INCOME (UNAUDITED)(Dollars in thousands) The following schedules present the daily average amount outstanding for each major category of interest earning assets, non-earning assets, interest bearing liabilities, and noninterest bearing liabilities. These schedules also present an analysis of interest income and interest expense for the periods indicated. All interest income is reported on a fully taxable equivalent (FTE) basis using a federal income tax rate of 21%. Loans in nonaccrual status, for the purpose of the following computations, are included in the average loan balances. Federal Reserve Bank (FRB) and Federal Home Loan Bank (FHLB) restricted equity holdings are included in other interest earning assets. Three Months Ended December 31, 2023 December 31, 2022 Average Balance Tax Equivalent Interest Average Yield / Rate Average Balance Tax Equivalent Interest Average Yield / Rate INTEREST EARNING ASSETS Loans (1) $ 1,340,271 $ 17,580 5.25 % $ 1,244,972 $ 14,163 4.55 % Taxable investment securities 473,660 2,274 1.92 % 520,139 2,499 1.92 % Nontaxable investment securities 90,408 899 3.98 % 107,508 999 3.72 % Fed funds sold 13 — 5.76 % 14 — 4.00 % Other 39,585 549 5.55 % 56,142 522 3.72 % Total earning assets 1,943,937 21,302 4.38 % 1,928,775 18,183 3.77 % NONEARNING ASSETS Allowance for credit losses (12,780) (9,792) Cash and demand deposits due from banks 23,244 24,312 Premises and equipment 27,444 25,382 Accrued income and other assets 71,592 63,553 Total assets $ 2,053,437 $ 2,032,230 INTEREST BEARING LIABILITIES Interest bearing demand deposits $ 317,996 $ 504 0.63 % $ 358,809 $ 104 0.12 % Savings deposits 634,539 2,819 1.78 % 635,771 535 0.34 % Time deposits 338,852 3,076 3.63 % 254,604 684 1.07 % Federal funds purchased and repurchase agreements 50,049 357 2.85 % 55,478 53 0.38 % Federal Home Loan Bank advances 29,674 422 5.69 % — — — % Subordinated debt, net of unamortized issuance costs 29,320 266 3.63 % 29,233 267 3.65 % Total interest bearing liabilities 1,400,430 7,444 2.13 % 1,333,895 1,643 0.49 % NONINTEREST BEARING LIABILITIES Demand deposits 446,747 504,791 Other 17,302 13,103 Shareholders' equity 188,958 180,441 Total liabilities and shareholders' equity $ 2,053,437 $ 2,032,230 Net interest income (FTE) $ 13,858 $ 16,540 Net yield on interest earning assets (FTE) 2.85 % 3.43 % (1) Includes loans and mortgage loans available-for-sale Year Ended December 31, 2023 December 31, 2022 Average Balance Tax Equivalent Interest Average Yield / Rate Average Balance Tax Equivalent Interest Average Yield / Rate INTEREST EARNING ASSETS Loans (1) $ 1,308,891 $ 65,670 5.02 % $ 1,249,634 $ 53,283 4.26 % Taxable investment securities 485,718 9,399 1.94 % 477,159 8,294 1.74 % Nontaxable investment securities 96,845 3,780 3.90 % 107,158 3,933 3.67 % Fed funds sold 12 1 5.04 % 10 — 2.42 % Other 41,965 1,804 4.30 % 99,301 1,344 1.35 % Total earning assets 1,933,431 80,654 4.17 % 1,933,262 66,854 3.46 % NONEARNING ASSETS Allowance for credit losses (12,784) (9,477) Cash and demand deposits due from banks 24,592 24,708 Premises and equipment 26,589 24,648 Accrued income and other assets 74,319 81,823 Total assets $ 2,046,147 $ 2,054,964 INTEREST BEARING LIABILITIES Interest bearing demand deposits $ 346,875 $ 1,086 0.31 % $ 374,623 $ 274 0.07 % Savings deposits 626,027 8,290 1.32 % 630,574 1,135 0.18 % Time deposits 308,699 8,976 2.91 % 270,296 2,612 0.97 % Federal funds purchased and repurchase agreements 43,061 961 2.23 % 49,974 79 0.16 % Federal Home Loan Bank advances 23,699 1,309 5.52 % 7,863 152 1.93 % Subordinated debt, net of unamortized issuance costs 29,287 1,065 3.64 % 29,200 1,065 3.65 % Total interest bearing liabilities 1,377,648 21,687 1.57 % 1,362,530 5,317 0.39 % NONINTEREST BEARING LIABILITIES Demand deposits 461,689 482,781 Other 16,043 14,695 Shareholders' equity 190,767 194,958 Total liabilities and shareholders' equity $ 2,046,147 $ 2,054,964 Net interest income (FTE) $ 58,967 $ 61,537 Net yield on interest earning assets (FTE) 3.05 % 3.18 % (1) Includes loans and mortgage loans available-for-sale SELECTED FINANCIAL DATA (UNAUDITED) (Dollars in thousands except per share amounts) Year Ended December 312023 December 312022 December 312021 PER SHARE Basic earnings $ 2.42 $ 2.95 $ 2.48 Diluted earnings $ 2.40 $ 2.91 $ 2.45 Dividends $ 1.12 $ 1.09 $ 1.08 Tangible book value $ 20.59 $ 18.25 $ 21.61 Quoted market value High $ 26.00 $ 26.25 $ 29.00 Low $ 19.13 $ 21.00 $ 19.45 Close (1) $ 21.50 $ 23.50 $ 25.50 Common shares outstanding (1) 7,485,889 7,559,421 7,532,641 Average number of common shares outstanding 7,511,591 7,549,878 7,853,398 Average number of diluted common shares outstanding 7,575,492 7,647,612 7,965,961 PERFORMANCE RATIOS Return on average total assets 0.89 % 1.08 % 0.96 % Return on average shareholders' equity 9.52 % 11.41 % 8.83 % Return on average tangible shareholders' equity 12.75 % 15.17 % 11.31 % Net interest margin yield (FTE) 3.05 % 3.18 % 2.87 % ASSETS UNDER MANAGEMENT (1) Loans sold with servicing retained $ 248,756 $ 264,206 $ 278,844 Assets managed by Isabella Wealth $ 641,027 $ 513,918 $ 516,243 Total assets under management $ 2,948,751 $ 2,808,391 $ 2,827,245 ASSET QUALITY (1) Nonaccrual loans $ 982 $ 457 $ 1,245 Foreclosed assets $ 406 $ 439 $ 211 Net loan charge-offs (recoveries) $ 115 $ (264) $ 123 Nonperforming loans to gross loans 0.08 % 0.04 % 0.10 % Nonperforming assets to total assets 0.07 % 0.05 % 0.08 % Allowance for credit losses to gross loans 0.97 % 0.78 % 0.70 % CAPITAL RATIOS (1) Shareholders' equity to assets 9.83 % 9.17 % 10.39 % Tier 1 leverage 8.76 % 8.61 % 7.97 % Common equity tier 1 capital 12.54 % 12.91 % 12.07 % Tier 1 risk-based capital 12.54 % 12.91 % 12.07 % Total risk-based capital 15.52 % 15.79 % 14.94 % (1) At end of period SUPPLEMENTAL BALANCE SHEET DATA (UNAUDITED) (Dollars in thousands) December 312023 September 302023 June 302023 March 312023 December 312022 Commercial and industrial $ 209,738 $ 195,814 $ 194,914 $ 189,185 $ 178,428 Commercial real estate 564,244 566,639 564,254 566,410 566,012 Advances to mortgage brokers 18,541 24,807 39,099 — — Agricultural 99,994 99,233 96,689 94,760 104,985 Residential real estate 356,418 348,196 343,474 336,186 336,694 Consumer 100,528 99,985 95,972 84,110 78,054 Gross loans $ 1,349,463 $ 1,334,674 $ 1,334,402 $ 1,270,651 $ 1,264,173 December 312023 September 302023 June 302023 March 312023 December 312022 Noninterest bearing demand deposits $ 428,505 $ 445,043 $ 458,845 $ 478,829 $ 494,346 Interest bearing demand deposits 320,737 363,558 335,922 383,602 372,155 Savings deposits 628,079 628,795 606,644 662,495 625,734 Certificates of deposit 346,125 331,829 313,288 288,103 251,541 Internet certificates of deposit 249 249 249 499 499 Total deposits $ 1,723,695 $ 1,769,474 $ 1,714,948 $ 1,813,528 $ 1,744,275 December 312023 September 302023 June 302023 March 312023 December 312022 U.S. Treasury $ 214,801 $ 209,182 $ 209,353 $ 212,086 $ 208,701 States and political subdivisions 92,876 89,773 95,242 108,719 117,512 Auction rate money market preferred 2,931 2,570 2,637 2,716 2,342 Mortgage-backed securities 32,815 32,923 35,532 37,797 39,070 Collateralized mortgage obligations 177,775 175,630 180,996 200,252 205,728 Corporate 6,950 6,819 6,737 7,080 7,128 Available-for-sale securities, at fair value $ 528,148 $ 516,897 $ 530,497 $ 568,650 $ 580,481 December 312023 September 302023 June 302023 March 312023 December 312022 Securities sold under agreements to repurchase without stated maturity dates $ 46,801 $ 52,330 $ 37,102 $ 31,995 $ 57,771 Federal Home Loan Bank advances 40,000 65,000 55,000 — — Subordinated debt, net of unamortized issuance costs 29,335 29,312 29,290 29,267 29,245 Total borrowed funds $ 116,136 $ 146,642 $ 121,392 $ 61,262 $ 87,016 SUPPLEMENTAL STATEMENTS OF INCOME DATA (UNAUDITED) (Dollars in thousands) Three Months Ended December 31 Year Ended December 31 2023 2022 2023 2022 Service charges and fees ATM and debit card fees $ 1,397 $ 1,267 $ 5,051 $ 4,774 Service charges and fees on deposit accounts 616 653 2,413 2,566 Freddie Mac servicing fee 155 163 630 669 Net mortgage servicing rights income (loss) (40) (42) (137) 435 Other fees for customer services 84 74 340 286 Total service charges and fees 2,212 2,115 8,297 8,730 Wealth management fees 932 788 3,557 3,005 Earnings on corporate owned life insurance policies 239 229 920 884 Net gain on sale of mortgage loans 85 63 317 631 Other 48 77 736 416 Total noninterest income $ 3,516 $ 3,272 $ 13,827 $ 13,666 Three Months Ended December 31 Year Ended December 31 2023 2022 2023 2022 Compensation and benefits $ 6,116 $ 6,407 $ 25,905 $ 24,887 Furniture and equipment 1,697 1,624 6,519 6,006 Occupancy 857 878 3,778 3,691 Other Audit, consulting, and legal fees 576 609 2,340 2,358 ATM and debit card fees 487 424 1,767 1,909 Marketing costs 276 244 1,159 1,056 Memberships and subscriptions 313 222 1,042 876 Loan underwriting fees 290 364 927 1,004 FDIC insurance premiums 233 143 922 537 Donations and community relations 223 258 915 923 Other losses 101 137 871 546 Director fees 183 192 764 790 All other 563 420 2,401 2,237 Total other noninterest expenses 3,245 3,013 13,108 12,236 Total noninterest expenses $ 11,915 $ 11,922 $ 49,310 $ 46,820 View original content:https://www.prnewswire.com/news-releases/isabella-bank-corporation-announces-fourth-quarter-and-2023-earnings-302064510.html SOURCE Isabella Bank Corporation What was Isabella Bank Corporation's (ISBA) net income for the year ended December 31, 2023? Isabella Bank Corporation's net income for the year ended December 31, 2023, was $18.2 million. How much did Isabella Wealth assets grow by in 2023? Isabella Wealth assets grew by 25% to $641 million in 2023. What was the increase in wealth management fees in 2023 for Isabella Bank Corporation? The increase in wealth management fees for Isabella Bank Corporation in 2023 was $552,000, or 18%. What was the cash dividend per share for shareholders in 2023? Shareholders received a cash dividend of $1.12 per share in 2023. What were the total cash dividends paid for the year ended December 31, 2023? Total cash dividends paid for the year ended December 31, 2023, totaled $1.12."
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2024-02-16T22:00:00.000Z,Low,Very Positive,"Delcath Systems, Inc. announces the granting of equity awards to three new employees as a material inducement to their employment. The grant includes the right to purchase 50,000 shares of the company's common stock at an exercise price of $4.79, with vesting over a period of three years.","Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Delcath Systems, Inc. announces the granting of equity awards to three new employees as a material inducement to their employment. The grant includes the right to purchase 50,000 shares of the company's common stock at an exercise price of $4.79, with vesting over a period of three years. Positive None. Negative None. 02/16/2024 - 05:00 PM NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the ""Company"" or ""Delcath""), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January 2024. The grant totaled the right to purchase an aggregate of 50,000 shares of the Company's common stock and is subject to the terms and conditions of the Company's 2023 Inducement Plan (""Plan""). The options were granted on January 31, 2024, the date the Compensation Committee approved the stock options included within the equity inducement and are subject to an exercise price equal to $4.79, the closing price of Delcath's common stock on the grant date. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. Each option has a ten-year term and the vesting of the options is subject to the employee's continued employment with Delcath on each vesting date. The above-described awards were each granted in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. About Delcath Systems, Inc.Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT™ (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by the Food and Drug Administration, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. For more information regarding HEPZATO KIT and its use, including Important Safety Information and Boxed Warning, please visit HEPZATOKIT.com. For more information regarding CHEMOSAT and its use, please visit Chemosat.com. Contact:Investor Relations Contact:Ben Shamsian Lytham Partners646-829-9701shamsian@lythampartners.com View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302064396.html SOURCE Delcath Systems, Inc. What is the ticker symbol of Delcath Systems, Inc. mentioned in the press release? The ticker symbol of Delcath Systems, Inc. is DCTH. How many individuals were granted equity awards by Delcath Systems, Inc.? Three individuals were granted equity awards by Delcath Systems, Inc. What is the total number of shares of common stock that can be purchased through the grant? An aggregate of 50,000 shares of common stock can be purchased through the grant. What is the exercise price for the stock options granted? The exercise price for the stock options is $4.79. How is the vesting of the options structured? One-third of the options will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal monthly installments over the following twenty-four months."
"LivePerson to Announce Fourth Quarter 2023 Financial Results on February 28, 2024",2024-02-16T22:00:00.000Z,Neutral,Neutral,"LivePerson, Inc. (LPSN) is set to release its fourth-quarter financial results on February 28, 2024, with a conference call hosted by CEO John Sabino and CFO & COO John Collins. The call will be live-streamed and accessible online or via phone. Replay options will be available for those unable to join the live call until March 13, 2024.","LivePerson to Announce Fourth Quarter 2023 Financial Results on February 28, 2024 Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary LivePerson, Inc. (LPSN) is set to release its fourth-quarter financial results on February 28, 2024, with a conference call hosted by CEO John Sabino and CFO & COO John Collins. The call will be live-streamed and accessible online or via phone. Replay options will be available for those unable to join the live call until March 13, 2024. Positive None. Negative None. 02/16/2024 - 05:00 PM NEW YORK, Feb. 16, 2024 /PRNewswire/ -- LivePerson, Inc. (Nasdaq: LPSN), the enterprise leader in digital customer conversations, today announced the planned release of its fourth quarter financial results after the market close on Wednesday, February 28, 2024. CEO John Sabino and CFO & COO John Collins will host a conference call later that day, at 5:00 p.m. Eastern Time. The conference call will be simulcast live and can be accessed by logging onto the investor relations section of the Company's web site at Investor Relations | LivePerson, Inc. To participate via telephone, callers should dial in five to ten minutes prior to the 5:00 p.m. Eastern start time; domestic callers (U.S. and Canada) should dial 1-877-407-0784, while international callers should dial 1-201-689-8560, and both should reference the conference ID ""13743243."" If you are unable to participate in the live call, the teleconference will be available for replay approximately two hours after the call until March 13, 2024. To access the replay, call 1-844-512-2921 (U.S. and Canada) or 1-412-317-6671 (international); please reference the conference ID ""13743243."" About LivePerson, Inc.LivePerson (NASDAQ: LPSN) is the enterprise leader in digital customer conversations. Hundreds of the world's leading brands — including HSBC, Chipotle, and Virgin Media — use our award-winning Conversational Cloud platform to connect with millions of consumers. We power nearly a billion conversational interactions every month, providing a uniquely rich data set and safety tools to unlock the power of Conversational AI for better business outcomes. Fast Company named us the #1 Most Innovative AI Company in the world. To talk with us or our AI, please visit liveperson.com. Investor Relations Contactir-lp@liveperson.com View original content to download multimedia:https://www.prnewswire.com/news-releases/liveperson-to-announce-fourth-quarter-2023-financial-results-on-february-28-2024-302064434.html SOURCE LivePerson When will LivePerson, Inc. release its fourth-quarter financial results? LivePerson, Inc. (LPSN) will release its fourth-quarter financial results on February 28, 2024. Who will host the conference call for LivePerson, Inc.? The conference call will be hosted by CEO John Sabino and CFO & COO John Collins. How can I access the live-stream of the conference call? The conference call can be accessed by logging onto the investor relations section of LivePerson, Inc.'s website. What are the phone numbers for domestic and international callers to join the conference call? Domestic callers (U.S. and Canada) should dial 1-877-407-0784, while international callers should dial 1-201-689-8560, both referencing the conference ID '13743243'. How long will the replay of the conference call be available? The replay of the conference call will be available approximately two hours after the live call until March 13, 2024."
R1 RCM to Present at Upcoming Investor Conferences,2024-02-16T22:00:00.000Z,Low,Very Positive,R1 RCM Inc. (RCM) will present at the 2024 TD Cowen Healthcare Conference on March 4 and the 2024 Barclays Global Healthcare Conference on March 13. The live webcasts can be accessed on the Investor Relations section of R1's website.,"R1 RCM to Present at Upcoming Investor Conferences Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags conferences Rhea-AI Summary R1 RCM Inc. (RCM) will present at the 2024 TD Cowen Healthcare Conference on March 4 and the 2024 Barclays Global Healthcare Conference on March 13. The live webcasts can be accessed on the Investor Relations section of R1's website. Positive None. Negative None. 02/16/2024 - 05:00 PM MURRAY, Utah, Feb. 16, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming conferences: The 2024 TD Cowen Healthcare Conference on Monday, March 4 at 10:30am ETThe 2024 Barclays Global Healthcare Conference on Wednesday, March 13 at 4:35pm ET A live audio webcast of each presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast. About R1 RCM R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com. Contacts Investor Relations:Evan Smith, CFA(516) 743-5184investorrelations@r1rcm.com Media Contact: Yancey CaseyAmendola Communications (678) 895-9401ycasey@acmarketingpr.com When will R1 RCM Inc. present at the 2024 TD Cowen Healthcare Conference? R1 RCM Inc. will present at the 2024 TD Cowen Healthcare Conference on Monday, March 4 at 10:30am ET. Where can I access the live webcast of R1 RCM Inc.'s presentation at the conferences? The live audio webcast of each presentation will be available on the Investor Relations section of R1's website at r1rcm.com. For how long will the replay of the webcast be available? A replay of the webcast will be available for 90 days following the live webcast."
Excelerate Energy to Participate in Upcoming Investor Conferences,2024-02-16T22:00:00.000Z,Low,Neutral,"Excelerate Energy, Inc. (NYSE: EE) announces participation in upcoming investor conferences, including Deutsche Bank's 2024 Shipping Summit, Morgan Stanley Energy & Power Conference, and DNB Energy & Shipping Conference 2024.","Excelerate Energy to Participate in Upcoming Investor Conferences Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags conferences Rhea-AI Summary Excelerate Energy, Inc. (NYSE: EE) announces participation in upcoming investor conferences, including Deutsche Bank's 2024 Shipping Summit, Morgan Stanley Energy & Power Conference, and DNB Energy & Shipping Conference 2024. Positive None. Negative None. 02/16/2024 - 05:00 PM THE WOODLANDS, Texas--(BUSINESS WIRE)-- Excelerate Energy, Inc. (NYSE: EE) today announced that it will participate at the upcoming investor conferences: Deutsche Bank’s 2024 Shipping Summit | Virtual Participation Date: March 1, 2024 Participants: Steven Kobos, President and Chief Executive Officer, and Dana Armstrong, Chief Financial Officer Morgan Stanley Energy & Power Conference | Morgan Stanley Headquarters in New York, New York Participation Date: March 7, 2024 Participant: Dana Armstrong, Chief Financial Officer 17th Annual DNB Energy & Shipping Conference 2024 | DNB’s Head Office in Oslo, Norway Participation Dates: March 6 – 7, 2024 Participants: Steven Kobos, President and Chief Executive Officer ABOUT EXCELERATE ENERGY Excelerate Energy, Inc. is a U.S.-based LNG company located in The Woodlands, Texas. Excelerate is changing the way the world accesses cleaner forms of energy by providing integrated services along the LNG value chain with the objective of delivering rapid-to-market and reliable LNG solutions to customers. The Company offers a full range of flexible regasification services from FSRUs to infrastructure development to LNG supply. Excelerate has offices in Abu Dhabi, Antwerp, Boston, Buenos Aires, Chattogram, Dhaka, Doha, Dubai, Helsinki, Manila, Rio de Janeiro, Singapore, and Washington, DC. For more information, please visit www.excelerateenergy.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216692568/en/ Investors Craig Hicks Excelerate Energy Craig.Hicks@excelerateenergy.com Media Stephen Pettibone / Frances Jeter FGS Global Excelerate@fgsglobal.com or media@excelerateenergy.com Source: Excelerate Energy, Inc. When is Excelerate Energy, Inc. participating in Deutsche Bank's 2024 Shipping Summit? Excelerate Energy, Inc. is participating in Deutsche Bank's 2024 Shipping Summit on March 1, 2024. Who are the participants from Excelerate Energy, Inc. at the Morgan Stanley Energy & Power Conference? Dana Armstrong, Chief Financial Officer, will be representing Excelerate Energy, Inc. at the Morgan Stanley Energy & Power Conference on March 7, 2024. Where is the 17th Annual DNB Energy & Shipping Conference 2024 taking place? The 17th Annual DNB Energy & Shipping Conference 2024 will be held at DNB's Head Office in Oslo, Norway on March 6 - 7, 2024. Which executive from Excelerate Energy, Inc. will be present at the DNB Energy & Shipping Conference? Steven Kobos, President and Chief Executive Officer, will be representing Excelerate Energy, Inc. at the DNB Energy & Shipping Conference 2024."
CPKC and TCRC labour negotiations update,2024-02-16T22:00:00.000Z,Neutral,Neutral,"Canadian Pacific Kansas City (CP) files Notice of Dispute with the Federal Mediation and Conciliation Service for collective bargaining negotiations with unions TCRC - Train & Engine and TCRC - Rail Canada Traffic Controllers. CPKC aims for fair agreements benefiting employees, customers, and shareholders.","CPKC and TCRC labour negotiations update Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Canadian Pacific Kansas City (CP) files Notice of Dispute with the Federal Mediation and Conciliation Service for collective bargaining negotiations with unions TCRC - Train & Engine and TCRC - Rail Canada Traffic Controllers. CPKC aims for fair agreements benefiting employees, customers, and shareholders. Positive None. Negative None. Labor Relations Expert From a labor relations perspective, the Notice of Dispute filed by Canadian Pacific Kansas City (CPKC) indicates a significant juncture in the collective bargaining process. The involvement of the Federal Mediation and Conciliation Service suggests that previous negotiations have reached an impasse, which is not uncommon in labor relations, especially in industries like rail transport where the workforce is unionized and the stakes are high. CPKC's history of requiring federal conciliation in the majority of its negotiations since 1993 reflects a pattern that stakeholders should be aware of, as it may imply entrenched bargaining positions or a complex labor environment.For employees and unions, the appointment of a Federal Conciliation Officer could be seen as a neutral intervention that may help bridge gaps between the parties. For shareholders and investors, the potential for a prolonged dispute could pose risks to the company's operational efficiency and financial performance. The rail industry is a critical component of the supply chain and any disruptions can have wide-reaching effects on the Canadian economy and international trade. It is crucial to monitor how quickly and effectively the conciliation process can resolve the issues at hand to mitigate any negative impact. Financial Analyst Looking at the financial implications, the dispute between CPKC and the TCRC divisions could have material impacts on the company's operations and, by extension, its financial health. The mention of wage and benefit increases in the proposed agreement suggests that CPKC is facing increased labor costs, which could affect profit margins if not offset by operational efficiencies or revenue growth. Investors should consider the historical context provided, where CPKC has needed federal conciliation in most bargaining rounds, as a potential indicator of future financial risk. While labor disputes are factored into investment risk profiles, the specific dynamics of this situation, including the number of employees involved and the critical nature of their roles, could lead to significant operational disruptions if not resolved in a timely manner.Moreover, CPKC's commitment to reaching an agreement that benefits all stakeholders, including shareholders, is crucial. The outcome of these negotiations will likely influence investor confidence and could affect the stock price. The emphasis on schedule predictability and quality of life improvements for employees may also have long-term benefits for the company by potentially reducing turnover and improving workforce stability, which can translate into operational cost savings. Economist From an economic standpoint, the dispute between CPKC and the TCRC has broader implications beyond the company itself. The railway sector is a backbone of the Canadian economy, facilitating the flow of goods both domestically and for international trade. Any disruption in rail services can lead to supply chain bottlenecks, affecting industries such as agriculture, manufacturing and retail. It is essential to consider the potential economic costs of delayed negotiations, including the impact on Canada's GDP and trade balance. The mention of CPKC's role in supporting the import and export of goods internationally highlights the global interconnectedness of this issue.Additionally, the timing of the negotiations and the potential for a resolution are important economic indicators. Should the dispute lead to work stoppages or strikes, the immediate economic consequences could be substantial, influencing not only the company's performance but also national economic indicators. The long-term effects of a well-negotiated agreement could be positive, potentially leading to increased productivity and efficiency within the rail sector. It is important for economic stakeholders to track the progress of these negotiations closely, as they may signal broader trends in labor relations and their impact on the economy. 02/16/2024 - 05:00 PM CALGARY, AB, Feb. 16, 2024 /PRNewswire/ - Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) today filed a Notice of Dispute with the Federal Mediation and Conciliation Service requesting the appointment of a Federal Conciliation Officer to assist CPKC and both the Teamsters Canada Rail Conference (TCRC) – Train & Engine (T&E) division and the TCRC - Rail Canada Traffic Controllers (RCTC) division in reaching negotiated collective agreements. The TCRC - T&E represents CPKC's roughly 3,200 locomotive engineers, conductors and train and yard workers, and the TCRC - RCTC represents approximately 80 rail traffic controllers, all in Canada. This is a process available under the Canada Labour Code to help employers and unions achieve negotiated collective agreements. Since September 2023, CPKC has been negotiating in good faith with the TCRC - T&E and TCRC - RCTC. CPKC has offered both a fair and balanced agreement with wage and benefit increases and more schedule predictability and quality of life improvements for its T&E employees. The latest collective bargaining negotiation session took place the week of January 29, 2024. Both CPKC and Union leadership remain far apart on the issues. CPKC has an excellent track record of successful collective bargaining with its unions. However, Federal Conciliation has been required in nine of the 10 collective bargaining rounds of negotiations between the TCRC - T&E and CPKC since 1993. CPKC is and will remain focused on, and committed to, arriving at a negotiated outcome that is in the best interests of its employees and their families, its customers, its shareholders and the overall Canadian economy. Everyone benefits when the railway can continue providing essential rail service, delivering goods across Canada and supporting the import and export of goods internationally. While the two TCRC collective agreements expired on December 31, 2023, they remain in effect under Canadian labour law until the parties reach new agreements. Forward looking informationThis news release contains certain forward-looking information within the meaning of applicable securities laws in both the U.S. and Canada. This news release contains forward-looking information relating, but not limited to, collective bargaining between CPKC and its labour unions, potential work stoppage and CPKC's business, operations and service. This forward-looking information also includes, but is not limited to, statements concerning expectations, beliefs, plans, goals, objectives, assumptions and statements about possible future events, conditions, and results of operations or performance. Forward-looking information may contain statements with words or headings such as ""financial expectations"", ""key assumptions"", ""anticipate"", ""believe"", ""expect"", ""plan"", ""will"", ""outlook"", ""should"" or similar words suggesting future outcomes. Undue reliance should not be placed on forward-looking information as actual results may differ materially from the forward-looking information. Forward-looking information is not a guarantee of future performance. By its nature, CPKC's forward-looking information involves numerous assumptions, inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking information, including but not limited to the following factors: changes in business strategies; general North American and global economic, credit and business conditions; risks in agricultural production such as weather conditions and insect populations; the availability and price of energy commodities; the effects of competition and pricing pressures; industry capacity; shifts in market demand; changes in commodity prices; uncertainty surrounding timing and volumes of commodities being shipped via CPKC; inflation; changes in laws and regulations, including regulation of rates; changes in taxes and tax rates; potential increases in maintenance and operating costs; uncertainties of investigations, proceedings or other types of claims and litigation; labour disputes; risks and liabilities arising from derailments; transportation of dangerous goods; timing of completion of capital and maintenance projects; currency and interest rate fluctuations; effects of changes in market conditions and discount rates on the financial position of pension plans and investments; and various events that could disrupt operations, including severe weather, droughts, floods, avalanches and earthquakes as well as security threats and governmental response to them, and technological changes. The foregoing list of factors is not exhaustive. These and other factors are detailed from time to time in reports filed by CPKC with securities regulators in Canada and the United States. Reference should be made to ""Item 1A - Risk Factors"" and ""Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations - Forward-Looking Information"" in CPKC's annual and interim reports on Form 10-K and 10-Q. Readers are cautioned not to place undue reliance on forward-looking information. Forward looking information is based on current expectations, estimates and projections and it is possible that predictions, forecasts, projections, and other forms of forward-looking information will not be achieved by CPKC. Except as required by law, CPKC undertakes no obligation to update publicly or otherwise revise any forward-looking information, or the foregoing assumptions and risks affecting such forward-looking information, whether as a result of new information, future events or otherwise. About CPKCWith its global headquarters in Calgary, Alta., Canada, CPKC is the first and only single-line transnational railway linking Canada, the United States and México, with unrivaled access to major ports from Vancouver to Atlantic Canada to the Gulf of México to Lázaro Cárdenas, México. Stretching approximately 20,000 route miles and employing 20,000 railroaders, CPKC provides North American customers unparalleled rail service and network reach to key markets across the continent. CPKC is growing with its customers, offering a suite of freight transportation services, logistics solutions and supply chain expertise. Visit cpkcr.com to learn more about the rail advantages of CPKC. CP-IR View original content:https://www.prnewswire.com/news-releases/cpkc-and-tcrc-labour-negotiations-update-302064450.html SOURCE CPKC What is the purpose of the Notice of Dispute filed by Canadian Pacific Kansas City (CP)? CP filed the Notice of Dispute to request the appointment of a Federal Conciliation Officer to assist in reaching negotiated collective agreements with unions TCRC - Train & Engine and TCRC - Rail Canada Traffic Controllers. How many employees are represented by TCRC - Train & Engine and TCRC - Rail Canada Traffic Controllers? TCRC - Train & Engine represents roughly 3,200 locomotive engineers, conductors, and train and yard workers, while TCRC - Rail Canada Traffic Controllers represents approximately 80 rail traffic controllers, all in Canada. What has been CPKC's approach to negotiations with the unions since September 2023? CPKC has been negotiating in good faith since September 2023, offering fair and balanced agreements with wage and benefit increases, as well as schedule predictability and quality of life improvements for its employees. How many times has Federal Conciliation been required in negotiations between TCRC - Train & Engine and CPKC since 1993? Federal Conciliation has been required in nine out of the 10 collective bargaining rounds of negotiations between TCRC - Train & Engine and CPKC since 1993. What is CPKC's focus and commitment regarding the negotiations with the unions? CPKC is focused on arriving at a negotiated outcome that benefits its employees, customers, shareholders, and the Canadian economy by continuing to provide essential rail service and supporting the import and export of goods. When did the two TCRC collective agreements expire? The two TCRC collective agreements expired on December 31, 2023, but they remain in effect under Canadian labour law until new agreements are reached."
Neptune Reports Fiscal Third Quarter 2024 Financial Results,2024-02-16T22:35:00.000Z,Neutral,Negative,"Neptune Wellness Solutions Inc. reported financial and operating results for Q3 2024, with a net revenue of $7.6 million, down from the previous year. The company announced various business highlights, including appointing Stifel as financial advisor, securing financing for its nutraceuticals brand, and exploring a partnership with Datasys Group. Despite a decrease in revenue and gross profit, the company faced increased SG&A expenses, leading to a net loss of $19.2 million and an Adjusted EBITDA loss of $18.5 million.","Neptune Reports Fiscal Third Quarter 2024 Financial Results Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Negative) Tags earnings Rhea-AI Summary Neptune Wellness Solutions Inc. reported financial and operating results for Q3 2024, with a net revenue of $7.6 million, down from the previous year. The company announced various business highlights, including appointing Stifel as financial advisor, securing financing for its nutraceuticals brand, and exploring a partnership with Datasys Group. Despite a decrease in revenue and gross profit, the company faced increased SG&A expenses, leading to a net loss of $19.2 million and an Adjusted EBITDA loss of $18.5 million. Positive None. Negative Consolidated net revenue decreased by $4.6 million compared to the same period last year. Gross profit decreased from $1.9 million to $1.0 million year-over-year. Consolidated SG&A expenses increased by $10.0 million, primarily due to a significant rise in legal fees and settlements. The company reported a net loss of $19.2 million, a substantial increase from the previous year's net loss of $0.5 million. Adjusted EBITDA (non-GAAP) showed a loss of $18.5 million, compared to a loss of $0.5 million in the same period last year. Financial Analyst The reported consolidated net revenue decline of $4.6 million year-over-year for Neptune Wellness Solutions Inc. reflects a significant downturn in the company's performance, particularly in the Food & Beverage sector. This contraction in revenues could signal underlying challenges in product demand or competitive market pressures. The gross profit margin has similarly contracted, indicating that despite a reduction in cost of sales, the revenue decrease has had a more profound impact on profitability.Furthermore, the substantial increase in SG&A expenses, driven by a spike in legal fees and settlements, has resulted in a net loss of $19.2 million, a stark contrast to the previous year's $0.5 million. This escalation in legal costs could alarm investors and analysts, as it suggests potential litigation risks or ongoing disputes that could further strain future financials. Adjusted EBITDA loss widening to $18.5 million also paints a grim picture of the operational health of the company, potentially impacting investor confidence and the company's ability to secure capital or favorable credit terms. Market Research Analyst The strategic move to appoint Stifel Nicolaus Canada Inc. as an exclusive financial advisor for the review of divestiture alternatives for its Sprout Organics brand indicates Neptune's intent to streamline its portfolio and potentially divest from non-core segments. This could be a response to the current financial strain or a shift in strategic focus towards more profitable or promising areas. The market may respond favorably to this focus on core competencies, provided the divestiture is executed efficiently and at favorable terms.Additionally, the entry into an accounts receivable factoring facility with Alterna Capital Solutions suggests Neptune is seeking immediate liquidity solutions to manage cash flows, which is often a red flag for underlying financial distress. This move, coupled with the non-viability of the Datasys Group acquisition, could indicate operational reevaluation or a pivot in strategic direction, which stakeholders should monitor closely for implications on long-term growth and profitability. Legal Expert The reported increase in legal fees and settlements by $13.5 million demands scrutiny from a legal perspective. Such a significant rise could be attributed to a variety of factors, including ongoing litigation, regulatory compliance issues, or settlement of disputes. While the details are not specified, stakeholders should be aware that legal challenges can divert resources from core business activities, potentially impede strategic initiatives and have an adverse effect on the company's public image and stakeholder relations. The long-term implications of these legal matters could be substantial and their resolution or continuation will likely play a critical role in the company's future financial health. 02/16/2024 - 05:35 PM LAVAL, QC / ACCESSWIRE / February 16, 2024 / Neptune Wellness Solutions Inc. (""Neptune"" or the ""Company"") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for its fiscal third quarter 2024 ending December 31, 2023.Recent Business HighlightsAnnounced the appointment of Stifel Nicolaus Canada Inc. (""Stifel"") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. (""Sprout Organics""), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related to Sprout Organics.Announced that its nutraceuticals brand subsidiary, Biodroga Nutraceuticals Inc., entered into an accounts receivable factoring facility and inventory finance rider with Alterna Capital Solutions, LLC. The amount available under the Facility at any given time is $3 million, which may be increased in $1 million increments up to a maximum of $8 million.Announced a non-binding Letter of Intent (""LOI"") to acquire Datasys Group, Inc., (""Datasys"") and affiliated companies. While the Company has since concluded that it is no longer viable to pursue a transaction with Datasys on the terms contemplated in the LOI, the Company and Datasys remain in discussions regarding a revised transaction structure and continue to explore all possible avenues to reach an amicable partnership.Third Quarter 2024 Financial HighlightsConsolidated net revenue of $7.6 million, down $4.6 million for the same period last year. This is largely due to a decrease in Food & Beverage revenues compared to the same period last year.Gross profit of $1.0 million compared to a gross profit of $1.9 million for the same period last year. This change is due to a decrease in revenues of $4.6 million, offset by a reduction in cost of sales of $3.8 million.Consolidated SG&A expenses of $18.7 million compared to $8.7 million for the same period last year, a decrease of $10.0 million or 115%. This was primarily due to a $13.5 million increase in legal fees and settlements, offset by a $0.9 million decrease in payroll expenses, a $0.8 million decrease in office related expenses, a $0.7 million decrease in insurance, a $0.6 million decrease in marketing and a $0.4 million decrease in depreciation expense.Net loss of $19.2 million compared to a reported net loss of $0.5 million in the comparable period in fiscal 2023.Adjusted EBITDA (non-GAAP) loss of $18.5 million compared to an Adjusted EBITDA (non-GAAP) loss of $0.5 million for the same period last year.About Neptune Wellness Solutions Inc.Neptune is a consumer-packaged goods company that aims to innovate health and wellness products. Founded in 1998 and headquartered in Laval, Quebec with a United States headquarters in Jupiter, Florida, the company focuses on developing a portfolio of high-quality, affordable consumer products that align with the latest market trends for natural, sustainable, plant-based and purpose-driven lifestyle brands. The company's products are available in more than 29,000 retail locations and include well-known organic food and beverage brands such as Sprout Organics, Nosh, and Nurturme, as well as nutraceuticals brands like Biodroga and Forest Remedies. With its efficient and adaptable manufacturing and supply chain infrastructure, the company can quickly respond to consumer demand, and introduce new products through retail partners and e-commerce channels. Please visit neptunewellness.com for more details.Disclaimer - Safe Harbor Forward-Looking Statements Statements in this news release that are not statements of historical or current fact constitute ""forward-looking statements"" within the meaning of applicable securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms ""believes"", ""belief"", ""expects"", ""intends"", ""projects"", ""anticipates"", ""will"", ""should"" or ""plans"" to be uncertain and forward-looking. Forward-looking statements relate to future events or future performance and reflect management's expectations or beliefs regarding future events including, but not limited to, statements with respect to the timing of reporting quarterly results. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking statements and information included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the ""Cautionary Note Regarding Forward-Looking Information"" section contained in Neptune's latest Annual Report on Form 10-K and its subsequent filings, which are available on EDGAR at www.sec.gov/edgar.shtml. All forward-looking statements in this news release are made as of the date of this news release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.Going ConcernAs of the date this press release, there is minimal cash balance at the Company. The Company requires funding in the very near term in order to continue its operations and is considering all strategic alternatives that may be available, including debt financing and asset divestitures, in order to generate cash to fund operations. The Company's lack of cash resources and current share price may adversely affect its ability to raise new capital, maintain its NASDAQ listing and execute its business strategy. If the Company is unable to obtain funding in the near term, it may have to cease operations and liquidate its assets. These conditions cast substantial doubt about the Company's ability to continue as a going concern.Media Contacts:media@neptunecorp.comInvestor Contacts:Valter Pinto, Managing DirectorKCSA Strategic Communicationsneptune@kcsa.com 212.896.1254Condensed Consolidated Interim Balance Sheets(in U.S. dollars) As at As at Notes December 31, 2023 March 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $1,232,905 $1,993,257 Short-term investment 17,642 17,540 Trade and other receivables 3,893,358 7,507,333 Prepaid expenses 1,839,657 1,025,969 Inventories 5 9,616,172 13,006,074 Total current assets 16,599,734 23,550,173 Property, plant and equipment 6 1,035,423 1,403,264 Operating lease right-of-use assets 1,599,231 1,941,347 Intangible assets 7 1,308,849 1,607,089 Goodwill 7 2,482,706 2,426,385 Total assets $23,025,943 $30,928,258 Liabilities and Equity (Deficiency) Current liabilities: Trade and other payables $31,371,563 $27,051,561 Current portion of operating lease liabilities 339,620 339,620 Current portion of loans and borrowings 8 25,984,400 7,538,369 Provisions 9 14,809,758 2,948,340 Liability related to warrants 10 911,790 3,156,254 Total current liabilities 73,417,131 41,034,144 Operating lease liabilities 1,816,377 2,017,888 Loans and borrowings, net of current portion 8 - 15,412,895 Other liability 13(c) 14,000 24,000 Total liabilities 75,247,508 58,488,927 Shareholders' Equity (Deficiency): Share capital - without par value (4,532,038 shares issued and outstanding as of December 31, 2023; 300,070 shares issued and outstanding as of March 31, 2023) 11 327,944,215 321,946,102 Warrants 14 6,648,437 6,155,323 Additional paid-in capital 59,681,063 58,138,914 Accumulated other comprehensive loss (14,925,620) (14,538,830)Deficit (410,595,259) (383,641,363)Total deficiency attributable to equity holders of the Company (31,247,164) (11,939,854) Non-controlling interest 12 (20,974,401) (15,620,815)Total shareholders' deficiency (52,221,565) (27,560,669) Commitments and contingencies 16 Subsequent event 18 Total liabilities and shareholders' deficiency $23,025,943 $30,928,258 See accompanying notes to the condensed consolidated interim financial statements.Condensed Consolidated Interim Statements of Loss and Comprehensive Loss(Unaudited) (in U.S. dollars)For the three and nine-month periods ended December 31, 2023 and 2022 Three-month periods ended Nine-month periods ended Notes December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Revenue from sales, net of excise taxes of nil and nil (2022 - nil and $643,476 ) $7,611,836 $11,945,092 $26,913,567 $39,668,246 Royalty revenues 23,963 263,816 70,961 766,736 Other revenues (36,047) - (17,071) 32,996 Total revenues 17 7,599,752 12,208,908 26,967,457 40,467,978 Cost of sales other than impairment loss on inventories (6,564,684) (10,328,349) (24,941,822) (37,293,901)Impairment loss on inventories 5 - - (216,184) (3,079,997)Total cost of sales (6,564,684) (10,328,349) (25,158,006) (40,373,898)Gross profit 1,035,068 1,880,559 1,809,451 94,080 Research and development expenses (727) (28,836) (47,266) (451,121)Selling, general and administrative expenses (18,732,654) (8,727,323) (34,541,474) (35,188,695)Impairment loss related to intangible assets 7 - - - (2,593,529)Impairment loss on assets held for sale 4 - - - (15,346,119)Impairment loss on right of use assets - (271,057) (75,409) (271,057)Impairment loss related to goodwill 7 - - - (7,570,471)Net gain on sale of property, plant and equipment - 84,998 - 170,000 Loss from operating activities (17,698,313) (7,061,659) (32,854,698) (61,156,912) Restructuring fees 4(b),11(f) (2,066,405) - (2,066,405) - Finance income - - - 1,440 Finance costs (1,602,981) (1,362,776) (6,570,787) (2,658,305)Foreign exchange gain 600,316 524,571 942,596 6,545,401 Loss on issuance of derivatives 10 - (1,029,614) (945,034) (3,156,569)Gain on revaluation of derivatives 10 1,596,901 8,367,871 7,186,846 16,083,681 Gain on settlement of liability - 66,169 - 66,169 Total other income (expense) (1,472,169) 6,566,221 (1,452,784) 16,881,817 Loss before income taxes (19,170,482) (495,438) (34,307,482) (44,275,095) Income tax expense - (2,013) - (14,543)Net loss (19,170,482) (497,451) (34,307,482) (44,289,638) Other comprehensive loss Net change in unrealized foreign currency losses on translation of net investments in foreign operations (tax effect of nil for all periods) (41,449) (231,490) (386,790) (6,725,131)Total other comprehensive loss (41,449) (231,490) (386,790) (6,725,131) Total comprehensive loss $(19,211,931) $(728,941) $(34,694,272) $(51,014,769) Net income (loss) attributable to: Equity holders of the Company $(17,749,338) $1,288,110 $(26,953,896) $(33,893,698)Non-controlling interest 12 (1,421,144) (1,785,561) (7,353,586) (10,395,940)Net loss $(19,170,482) $(497,451) $(34,307,482) $(44,289,638) Total comprehensive income (loss) attributable to: Equity holders of the Company $(17,790,787) $1,056,620 $(27,340,686) $(40,618,829)Non-controlling interest 12 (1,421,144) (1,785,561) (7,353,586) (10,395,940)Total comprehensive loss $(19,211,931) $(728,941) $(34,694,272) $(51,014,769) Basic income (loss) per share attributable to: Common Shareholders of the Company 14 $(4.14) $2.34 $(15.11) $(143.00) Diluted income (loss) per share attributable to: Common Shareholders of the Company 14 $(4.14) $2.34 $(15.11) $(143.00) Basic weighted average number of common shares 14 4,285,229 284,619 1,784,047 237,013 Diluted weighted average number of common shares 14 4,285,229 284,690 1,784,047 237,013 SELECTED CONSOLIDATED FINANCIAL INFORMATION (in millions, except per share data)The following table sets out selected consolidated financial information. Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Total revenues $7.600 $12.209 $26.967 $40.468 Adjusted EBITDA1 (18.453) 0.458 (32.340) (26.698)Net loss (19.170) (0.497) (34.307) (44.290)Net income (loss) attributable to equity holders of the Company (17.749) 1.288 (26.954) (33.894)Net loss attributable to non-controlling interest (1.421) (1.786) (7.354) (10.396)Basic and diluted income (loss) attributable to common shareholders of the Company (4.14) 2.34 (15.11) (143.00) As at December 31, 2023 As at March 31, 2023 As at March 31, 2022 Total assets $23.026 $30.928 $104.955 Working capital2 (56.817) (17.484) 7.071 Non-current financial liabilities 1.830 17.455 13.800 (Deficiency) equity attributable to equity holders of the Company (31.247) (11.940) 48.116 (Deficiency) equity attributable to non-controlling interest (20.974) (15.621) 12.722 1 The Adjusted EBITDA is a non-GAAP measure. It is not a standard measure endorsed by US GAAP requirements. A reconciliation to the Company's net loss is presented below. In the three-month period ended September 30, 2022, the Company re-casted comparative Adjusted EBITDA to conform to its current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits.2 Working capital is calculated by subtracting current liabilities from current assets. Because there is no standard method endorsed by US GAAP, the results may not be comparable to similar measurements presented by other public companies. Current assets as at December 31, 2023, March 31, 2023 and March 31, 2022 were $16.600, $23.550 and $337.388 respectively, and current liabilities as at December 31, 2023, March 31, 2023 and March 31, 2022 were $73.417, $41.034 and $30.317 respectively.NON-GAAP FINANCIAL PERFORMANCE MEASURESThe Company uses one adjusted financial measure, Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (""Adjusted EBITDA"") to assess its operating performance. This non-GAAP financial measure is presented in a consistent manner, unless otherwise disclosed. The Company uses this measure for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. The measure also helps the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to its GAAP financial statements, allows them to see the Company's results through the eyes of Management, and to better understand its historical and future financial performance. Neptune's method for calculating Adjusted EBITDA may differ from that used by other corporations.A reconciliation of net loss to Adjusted EBITDA is presented below.ADJUSTED EBITDAAlthough the concept of Adjusted EBITDA is not a financial or accounting measure defined under US GAAP and it may not be comparable to other issuers, it is widely used by companies. Neptune obtains its Adjusted EBITDA measurement by excluding from its net loss the following items: net finance costs (income), depreciation and amortization, and income tax expense (recovery). Other items such as equity classified stock-based compensation, non-employee compensation related to warrants, impairment losses on non-financial assets, revaluations of derivatives, costs related to conversion from IFRS to US GAAP and other changes in fair values are also added back to Neptune's net loss. The exclusion of net finance costs (income) eliminates the impact on earnings derived from non-operational activities. The exclusion of depreciation and amortization, stock-based compensation, non-employee compensation related to warrants, impairment losses, revaluations of derivatives and other changes in fair values eliminates the non-cash impact of such items, and the exclusion of costs related to conversion from IFRS to US GAAP, together with the other exclusions discussed above, present the results of the on-going business. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. Adjusting for these items does not imply they are non-recurring. For purposes of this analysis, the Net finance costs (income) caption in the reconciliation below includes the impact of the revaluation of foreign exchange rates.In the three-month period ended September 30, 2022, the Company recast comparative Adjusted EBITDA to conform to the current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits.Adjusted EBITDA1 reconciliation, in millions of dollars Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Net loss for the period $(19.170) $(0.497) $(34.307) $(44.290)Add (deduct): Depreciation and amortization 0.278 0.662 0.991 2.391 Revaluation of derivatives (1.597) (8.368) (7.187) (16.084)Net finance costs 1.603 7.384 6.571 2.657 Equity classified stock-based compensation 0.433 1.005 1.517 2.832 Impairment loss on long-lived assets - 0.271 0.075 25.781 Income tax expense - 0.002 - 0.015 Adjusted EBITDA1 $(18.453) $0.459 $(32.340) $(26.698)1 The Adjusted EBITDA is not a standard measure endorsed by US GAAP requirements. In the three-month period ended September 30, 2022, the Company re-casted comparative Adjusted EBITDA to conform to its current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits.SOURCE: Neptune Wellness Solutions, Inc.View the original press release on accesswire.com What was Neptune Wellness Solutions Inc.'s net revenue for Q3 2024? Neptune reported a net revenue of $7.6 million for the third quarter of 2024. What were the financial highlights of Neptune Wellness Solutions Inc. for Q3 2024? Neptune reported a gross profit of $1.0 million and a net loss of $19.2 million for the third quarter of 2024. What was the reason behind Neptune Wellness Solutions Inc.'s decrease in gross profit? The decrease in gross profit was primarily due to a decrease in revenues of $4.6 million, offset by a reduction in cost of sales of $3.8 million. How did Neptune Wellness Solutions Inc.'s SG&A expenses change in Q3 2024 compared to the previous year? Neptune's SG&A expenses increased by $10.0 million in Q3 2024 compared to the same period last year. What was Neptune Wellness Solutions Inc.'s Adjusted EBITDA (non-GAAP) for Q3 2024? Neptune reported an Adjusted EBITDA (non-GAAP) loss of $18.5 million for the third quarter of 2024."
Mesa Royalty Trust Announces Trust Income for February 2024,2024-02-16T21:58:00.000Z,Neutral,Negative,"Mesa Royalty Trust (MTR) announced a monthly income distribution for February 2024, with unitholders receiving $0.008739141 per unit. The Trust received $27,216 from the New Mexico properties and highlighted the impact of oil and gas prices on future distributions.","Mesa Royalty Trust Announces Trust Income for February 2024 Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Negative) Tags Rhea-AI Summary Mesa Royalty Trust (MTR) announced a monthly income distribution for February 2024, with unitholders receiving $0.008739141 per unit. The Trust received $27,216 from the New Mexico properties and highlighted the impact of oil and gas prices on future distributions. Positive None. Negative None. Financial Analyst The announcement by Mesa Royalty Trust regarding its monthly distribution provides a transparent view into the trust's current financial health. The distribution amount of $0.008739141 per unit, while modest, is a direct reflection of the underlying assets' performance, specifically the San Juan Basin properties. It is critical to note that the Trust's income is solely from the New Mexico assets this month, indicating a lack of diversification in income sources which could be a risk factor for investors. The Trust's focus on building cash reserves to $2.0 million for added liquidity is a prudent financial strategy, yet it signals that there may be concerns about future cash flows or potential liabilities.Investors should be aware of the substantial accumulated excess production costs, which have a dilutive effect on distributions. This scenario is not uncommon in royalty trusts, where production costs can outweigh proceeds, especially in periods of lower commodity prices. The trust's performance is inextricably linked to the volatility of the oil and gas industry and the current distribution reflects the Trust's response to these market conditions. It is important for stakeholders to consider the long-term implications of such costs on their investment, as they could lead to reduced or even zero distributions in certain periods. Market Research Analyst From a market perspective, the performance of Mesa Royalty Trust is indicative of the broader challenges faced by royalty trusts in the energy sector. The Trust's reliance on a single geographic area for its income this month underscores the need for diversification, especially given the volatility in oil and gas markets. The Trust's distributions are highly sensitive to fluctuations in commodity prices, which can be influenced by global economic factors, geopolitical tensions and shifts in energy policy.Furthermore, the Trust's decision to withhold a portion of income for cash reserves reflects a cautious approach amid uncertain market conditions. This strategy may be viewed favorably by conservative investors who prioritize stability over high yield in the short term. However, it could also be a point of concern for those seeking more immediate returns. The Trust's focus on liquidity and reserves suggests a defensive posture that may impact investor sentiment, potentially influencing the Trust's unit price in the stock market. Energy Sector Analyst Examining the Trust's performance within the context of the energy sector, the Trust's San Juan Basin properties are representative of the challenges faced by similar operations in terms of production and development costs. The energy sector is currently experiencing a transition with increased emphasis on sustainability and efficiency, which could affect the long-term viability of traditional oil and gas assets. The Trust's current distribution strategy, including the accumulation of a substantial cash reserve, could be interpreted as a hedge against these sector-wide transitions.Investors should also consider the implications of the Trust's substantial accumulated excess production costs. This is a clear indicator of the high operational costs associated with oil and gas production, which can be exacerbated by regulatory changes and environmental considerations. As the industry evolves, the Trust's ability to adapt to these changes while managing production costs will be crucial for maintaining investor confidence and ensuring sustainable distributions. 02/16/2024 - 04:58 PM HOUSTON--(BUSINESS WIRE)-- Mesa Royalty Trust (the “Trust”) (NYSE: MTR) announced today the Trust income distribution for the month of February 2024. Unitholders of record on February 29, 2024 will receive distributions amounting to $0.008739141 per unit, payable on April 30, 2024. The Trust received $27,216, all of which came from the New Mexico portion of the Trust’s San Juan Basin properties operated by Hilcorp San Juan LP, an affiliate of Hilcorp Energy Company. No income was received in February 2024 from any other working interest owner. This month, after the Trust’s withholding for cash reserves and the payment of administrative expenses, income from the distributable net profits was $16,286. The Trust was formed to own an overriding royalty interest of the net proceeds attributable to certain producing oil and gas properties located in the Hugoton field of Kansas and the San Juan Basin fields of New Mexico and Colorado. As described in the Trust's public filings, the amount of the monthly distributions is expected to fluctuate from month to month, depending on the proceeds, if any, received by the Trust as a result of production, oil and natural gas prices and the amount of the Trust’s administrative expenses, among other factors. In addition, as further described in the Trust’s most recent filing on Form 10-Q, distributions to unitholders are expected to be materially reduced, until the Trust increases its cash reserves to a total of $2.0 million in order to provide added liquidity. Proceeds reported by the working interest owners for any month are not generally representative of net proceeds that will be received by the Trust in future periods. As further described in the Trust’s Form 10-K and Form 10-Q filings, production and development costs for the royalty interest have resulted in substantial accumulated excess production costs, which will decrease Trust distributions, and in some periods may result in no Trust distributions. The amount of proceeds, if any, received or expected to be received by the Trust (and its ability to pay distributions to unitholders) has been and will continue to be directly affected, among other things, by volatility in the industry and revenues and expenses reported to the Trust by working interest owners. Any additional expenses and adjustments, among other things, will reduce proceeds to the Trust, which will reduce the amount of cash available for distribution to unitholders and in certain periods could result in no distributions to unitholders. This press release contains forward-looking statements. No assurances can be given that the expectations contained in this press release will prove to be correct. The working interest owners alone control historical operating data, and handle receipt and payment of funds relating to the royalty properties and payments to the Trust for the related royalty. The Trustee cannot assure that errors or adjustments or expenses accrued by the working interest owners, whether historical or future, will not affect future royalty income and distributions by the Trust. Other important factors that could cause these statements to differ materially include delays in actual results of drilling operations, risks inherent in drilling and production of oil and gas properties, declines in commodity pricing, prices received by working interest owners and other risks described in the Trust’s Form 10-K for the year ended December 31, 2022. Statements made in this press release are qualified by the cautionary statements made in such risk factors. The Trust does not intend, and assumes no obligations, to update any of the statements included in this press release. Each unitholder should consult its own tax advisor with respect to its particular circumstances. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216071555/en/ Mesa Royalty Trust The Bank of New York Mellon Trust Company, N.A., as Trustee Elaina Rodgers 713-483-6020 Source: Mesa Royalty Trust What is the income distribution for Mesa Royalty Trust (MTR) for February 2024? The income distribution for Mesa Royalty Trust (MTR) for February 2024 is $0.008739141 per unit. Where did the Trust's income come from in February 2024? The Trust's income in February 2024 came from the New Mexico portion of the Trust’s San Juan Basin properties operated by Hilcorp San Juan LP. What factors can impact the monthly distributions for Mesa Royalty Trust (MTR)? Factors such as production, oil and natural gas prices, administrative expenses, and cash reserves can impact the monthly distributions for Mesa Royalty Trust (MTR). How does Mesa Royalty Trust (MTR) plan to increase liquidity? Mesa Royalty Trust (MTR) plans to increase liquidity by raising cash reserves to a total of $2.0 million. What can affect the Trust's ability to pay distributions to unitholders? Volatility in the industry, revenues, expenses reported by working interest owners, additional expenses, and adjustments can affect the Trust's ability to pay distributions to unitholders."
Fisker Receives Continued Listing Standard Notice From NYSE,2024-02-16T21:45:00.000Z,Neutral,Neutral,Fisker Inc. (NYSE: FSR) received notice from the NYSE regarding non-compliance with the average closing price requirement. The company has a six-month cure period to regain compliance by maintaining a minimum share price. Fisker is considering options like a reverse stock split to meet listing standards.,"Fisker Receives Continued Listing Standard Notice From NYSE Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Fisker Inc. (NYSE: FSR) received notice from the NYSE regarding non-compliance with the average closing price requirement. The company has a six-month cure period to regain compliance by maintaining a minimum share price. Fisker is considering options like a reverse stock split to meet listing standards. Positive None. Negative None. Market Research Analyst The notification received by Fisker Inc. from the NYSE regarding non-compliance with minimum share price requirements is a significant indicator of potential financial distress or investor sentiment issues. A sustained share price below $1 can suggest a lack of confidence from the market, possibly due to underperformance, market conditions, or operational challenges. Analysts and investors typically monitor such developments closely, as they may precede more severe actions like delisting if not remedied.From a market research perspective, the company's consideration of a reverse stock split is a common strategic move to boost share price by reducing the number of shares outstanding, thus increasing the price per share. However, this does not inherently change the company's market capitalization or address the underlying issues that might have caused the share price decline. The effectiveness of this strategy will depend on the company's ability to concurrently improve its financial health and market perception. Financial Analyst Receiving a notice of non-compliance from the NYSE is a critical financial event for Fisker Inc., which can influence both short-term trading activity and long-term investor relations. Short-term implications may include increased volatility in share price as investors react to the news. In the long-term, the company's ability to raise capital could be affected if the share price does not recover, as low share prices can limit the attractiveness to new investors and potentially lead to increased borrowing costs.It is also important to consider that while the notice does not immediately affect the company's listing status, failure to regain compliance within the prescribed timeframe could lead to delisting, which would have more severe consequences for the company's ability to access equity markets and for existing shareholders. Legal Expert The legal implications of a notice from the NYSE for non-compliance with their continued listing standards require careful navigation. Fisker Inc. must adhere to the corrective measures stipulated by the NYSE, such as maintaining a minimum average closing share price, to avoid delisting. The company's intent to notify the NYSE of its plans to regain compliance is a mandatory step in this process.Should the company pursue a reverse stock split as one of its strategies to regain compliance, it will need stockholder approval, typically obtained during an annual meeting. This process involves legal considerations around shareholder communication, voting procedures and adherence to both NYSE rules and federal securities laws. The company's proactive approach to considering all available options to address the issue reflects a legal strategy aimed at maintaining its listing status while minimizing disruption to its operations and shareholder interests. 02/16/2024 - 04:45 PM The Company’s common stock continues to trade on the NYSE under symbol “FSR” LOS ANGELES--(BUSINESS WIRE)-- Fisker Inc. (NYSE: FSR) (“Fisker” or the “Company”), driven by a mission to create the world’s most emotional and sustainable electric vehicles, announced that on February 15, 2024, it received notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. The NYSE notice does not result in the immediate delisting of the Company’s common stock from the NYSE. In accordance with applicable NYSE rules, the Company intends to notify the NYSE within 10 business days of its intent to regain compliance with Rule 802.01C and return to compliance with the applicable NYSE continued listing standards. The Company can regain compliance at any time within a six-month cure period following its receipt of the NYSE notice if, on the last trading day of any calendar month during such cure period, the Company has both: (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of the applicable calendar month. The Company intends to remain listed on the NYSE and is considering all available options to regain compliance with the NYSE’s continued listing standards, including, but not limited to, a reverse stock split, subject to stockholder approval no later than at the Company’s next annual meeting of stockholders. The NYSE notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE during such cure period, subject to the Company’s compliance with other NYSE continued listing standards. Furthermore, the Notice is not anticipated to impact the ongoing business operations of the Company or its reporting requirements with the U.S. Securities and Exchange Commission. About Fisker Inc. California-based Fisker Inc. is revolutionizing the automotive industry by designing and developing individual mobility in alignment with nature. Passionately driven by a vision of a clean future for all, the company is on a mission to create the world’s most sustainable and emotional electric vehicles. To learn more, visit Fiskerinc.com and enjoy exclusive content across Fisker's social media channels: Facebook, Instagram, Twitter, YouTube, and LinkedIn. Download the revolutionary new Fisker mobile app from the App Store or Google Play . Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, express or implied forward-looking statements relating to Fisker’s ability to maintain the listing of its common stock on the NYSE and any potential plans of Fisker to cure the stock price deficiency, including by action that would require a stockholder vote. You are cautioned that such statements are not guarantees of future performance and that Fisker’s actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause Fisker’s actual expectations to differ materially from these forward-looking statements include Fisker’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, Fisker’s ability to continue to comply with applicable listing standards of the NYSE and the other factors under the heading “Risk Factors” set forth in the Company’s Annual Report on Form 10-K, as supplemented by the Company’s quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof. Fisker undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216260335/en/ European Media: Press.europe@fiskerinc.com US Media Fisker@GODRIVEN360.com Customer service: Support@fiskerinc.com Fisker Inc. Communications: Matthew DeBord VP, Communications mdebord@fiskerinc.com Franziska Queling Regional Head of Public Relations, Europe fqueling@fiskerinc.com Investor Relations: Eric Goldstein Head of Investor Relations egoldstein@fiskerinc.com Source: Fisker Inc. Why did Fisker receive a notice from the NYSE? Fisker received a notice from the NYSE because the average closing price of its common stock was less than $1.00 per share over a consecutive 30 trading-day period. What is the consequence of non-compliance with NYSE listing standards? Non-compliance with NYSE listing standards could lead to the delisting of Fisker's common stock from the NYSE. How long is the cure period for Fisker to regain compliance? Fisker has a six-month cure period to regain compliance with NYSE listing standards. What options is Fisker considering to regain compliance? Fisker is considering options like a reverse stock split to meet the NYSE's continued listing standards. Will the NYSE notice impact Fisker's business operations? The NYSE notice is not anticipated to impact the ongoing business operations of Fisker or its reporting requirements with the U.S. Securities and Exchange Commission."
KULR Receives Non-Compliance Notice from NYSE American,2024-02-16T22:15:00.000Z,Low,Neutral,"KULR Technology Group, Inc. received a letter from NYSE American stating that its securities' trading price is below compliance criteria. The Company has until August 12, 2024, to improve its stock price or consider a reverse stock split.","KULR Receives Non-Compliance Notice from NYSE American Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary KULR Technology Group, Inc. received a letter from NYSE American stating that its securities' trading price is below compliance criteria. The Company has until August 12, 2024, to improve its stock price or consider a reverse stock split. Positive None. Negative The Company's securities' performance is below compliance criteria, with a 30-trading day average of less than $0.20 per share, potentially leading to a delisting if not rectified by August 12, 2024. Financial Analyst When a company's stock price falls below exchange requirements, it's a signal to investors that the market may lack confidence in the company's current financial health or future prospects. In the case of KULR Technology Group, the notification from NYSE American LLC indicates that the company's stock price has not met the minimum average trading price, which could lead to delisting if not corrected. This scenario necessitates a closer examination of the company's balance sheet, cash flow and revenue streams to assess liquidity and operational efficiency. It also prompts a review of the company's strategic initiatives aimed at boosting shareholder value and market trust.A potential reverse stock split could be employed to bring the stock price above the minimum threshold. While this does not inherently change the company's valuation, it often results in a reduced number of shares outstanding, which can increase the price per share. However, this can be a double-edged sword; it may temporarily satisfy exchange requirements but also might signal to the market an underlying issue with the company's value proposition. Investors should monitor the company's follow-up actions closely, as they will be indicative of the management's ability to navigate financial challenges and restore investor confidence. Market Research Analyst The warning received by KULR from NYSE American LLC is a critical juncture for the company, as it may affect investor perception and the stock's marketability. A drop below compliance criteria often leads to increased market scrutiny and could influence investor decisions, potentially leading to higher volatility in the stock's trading patterns. It's imperative to analyze the broader market dynamics, including sector performance, technological advancements and competitive positioning, to understand if KULR's situation is company-specific or symptomatic of wider industry challenges.Furthermore, the company's plan to cure the stock price deficiency should be evaluated in the context of its market segment's growth potential and the company's innovation pipeline. Sustainable energy management is a rapidly evolving field with significant investor interest and KULR's ability to articulate a clear and convincing strategy for growth and compliance could mitigate the negative impact of the current stock price situation. Legal Expert From a legal standpoint, KULR's receipt of the non-compliance letter triggers a series of regulatory obligations and potential investor communications. The company must now navigate the intricacies of securities regulations while maintaining transparency with shareholders. The legal team must ensure that all responses to the exchange are timely and that any proposed actions, such as a reverse stock split, comply with both the exchange's rules and federal securities laws. Additionally, they must be mindful of the disclosure requirements to avoid any inadvertent missteps that could lead to regulatory penalties or investor lawsuits.It is also essential for the legal team to work closely with the company's leadership to prepare for any potential outcomes, including the implications of a delisting. Should the company fail to improve its stock price or effect a reverse stock split, it would face delisting procedures that involve specific legal steps and communications with stakeholders. The company's ability to navigate these legal challenges while maintaining operational focus will be crucial in the coming months. 02/16/2024 - 05:15 PM SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the ""Company"" or ""KULR""), a global leader in sustainable energy management, today announced that the Company received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”) stating that the Company’s securities’ performance of trading price is below compliance criteria pursuant to Section 1003(f)(v) of the NYSE American Company Guide, which the Exchange determined to be a 30-trading day average of less than $0.20 per share. The Company’s continued listing is predicated on it demonstrating sustained price improvement within a reasonable period of time, which the Exchange has determined to be no later than August 12, 2024, or otherwise effecting a reverse stock split of its common stock. KULR intends to cure the stock price deficiency and to return to compliance with the Exchange continued listing standards. Receipt of the Letter from the Exchange has no immediate effect on the listing or trading of KULR’s common stock on the Exchange, and does not affect KULR’s business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About KULR Technology Group Inc.KULR Technology Group Inc. (NYSE American: KULR) is a leading energy management platform company offering proven solutions that play a critical role in accelerating the electrification of the circular economy. Leveraging a foundation in developing, manufacturing, and licensing next-generation carbon fiber thermal management technologies for batteries and electronic systems, KULR has evolved its holistic suite of products and services to enable its customers across disciplines to operate with efficiency and sustainability in mind. For more information, please visit www.kulrtechnology.com. Safe Harbor Statement This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on March 28, 2023, as may be amended or supplemented by other reports we filed with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. Investor Relations:KULR Technology Group, Inc.Phone: 858-866-8478 x 847Email: ir@kulrtechnology.com What is the reason behind KULR Technology Group, Inc. receiving a letter from NYSE American? KULR received a letter from NYSE American due to its securities' trading price being below compliance criteria. What is the deadline for KULR to improve its stock price according to the letter? KULR has until August 12, 2024, to demonstrate sustained price improvement or consider a reverse stock split. How will the receipt of the letter impact KULR's common stock listing and trading on the Exchange? The receipt of the letter has no immediate effect on the listing or trading of KULR's common stock on the Exchange. Does the receipt of the letter affect KULR's business operations or reporting requirements with the U.S. Securities and Exchange Commission? The receipt of the letter does not affect KULR's business, operations, or reporting requirements with the U.S. Securities and Exchange Commission."
"Ritchie Bros.'; Largest-Ever Premier Global Auction Event in Orlando to Feature Record-Setting 16,500+ Heavy Equipment Assets and Vehicles",2024-02-16T21:45:00.000Z,Low,Neutral,"RB Global, Inc. (RBA) announces a record-breaking 16,500+ items at Ritchie Bros. Auctioneers' premier global auction event in Orlando. The auction features a substantial increase in lots compared to 2023, including construction equipment, transport trucks, aggregate equipment, cranes, and attachments. Customers can bid in-person, online at rbauction.com, or via the mobile app.","Ritchie Bros.'; Largest-Ever Premier Global Auction Event in Orlando to Feature Record-Setting 16,500+ Heavy Equipment Assets and Vehicles Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary RB Global, Inc. (RBA) announces a record-breaking 16,500+ items at Ritchie Bros. Auctioneers' premier global auction event in Orlando. The auction features a substantial increase in lots compared to 2023, including construction equipment, transport trucks, aggregate equipment, cranes, and attachments. Customers can bid in-person, online at rbauction.com, or via the mobile app. Positive None. Negative None. 02/16/2024 - 04:45 PM ORLANDO, Fla. and WESTCHESTER, Ill., Feb. 16, 2024 /PRNewswire/ - RB Global, Inc. (NYSE: RBA) (TSX: RBA), the trusted global marketplace for insights, services and transaction solutions for commercial assets and vehicles, today announced that Ritchie Bros. Auctioneers' Feb. 19-23 premier global auction event in Orlando will feature a record-setting 16,500+ items – over 20% more lots than its 2023 auction. Equipment highlights in the Orlando auction include 3,700+ construction equipment lots, 1,200+ transport trucks, 250+ units of aggregate equipment, 60+ cranes, thousands of attachments, and so much more. Bids in the auction can be made in-person, online in real time at rbauction.com, or via Ritchie Bros.' mobile app. ""We are so excited to welcome customers to our 40th premier global auction event in Orlando, with 200 acres full of heavy industrial equipment and transportation assets ready to be purchased and taken home by new owners,"" said Jeff Jeter, Chief Revenue Officer for RB Global. ""Check out the equipment on our website rbauction.com with high-resolution photos and videos and/or visit our Orlando site in person to inspect and test equipment. At Ritchie Bros., we want our buyers to have all the information they need to bid with confidence."" About RB GlobalRB Global, Inc. (NYSE: RBA) (TSX: RBA) is a leading, omnichannel marketplace that provides value-added insights, services and transaction solutions for buyers and sellers of commercial assets and vehicles worldwide. Through its auction sites in 14 countries and digital platform, RB Global serves customers in more than 170 countries across a variety of asset classes, including automotive, commercial transportation, construction, government surplus, lifting and material handling, energy, mining and agriculture. The company's marketplace brands include Ritchie Bros., the world's largest auctioneer of commercial assets and vehicles offering online bidding, and IAA, a leading global digital marketplace connecting vehicle buyers and sellers. RB Global's portfolio of brands also includes Rouse Services, which provides a complete end-to-end asset management, data-driven intelligence and performance benchmarking system; SmartEquip, an innovative technology platform that supports customers' management of the equipment lifecycle and integrates parts procurement with both OEMs and dealers; Xcira, a leader in live simulcast auction technologies; and VeriTread, an online marketplace for heavy haul transport. Forward-Looking StatementsCertain statements contained in this release contain include forward-looking information within the meaning of Canadian securities legislation and forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (collectively, ""forward-looking statements""). Forward-looking statements may include statements relating to future events and anticipated results of operations, business strategies, the expected timing and associated benefits with respect to the February 2024 Orlando Auction Event and other subjects of this release on our business and plans regarding our growth strategies, and to our customers and company generally, and other aspects of RBA's or IAA's respective businesses, operations, financial condition or operating results and other statements that are not historical facts. Words such as ""should,"" ""may,"" ""will,"" ""anticipates,"" ""expects,"" ""intends,"" ""plans,"" ""believes,"" ""seeks,"" ""estimates"" ""could,"" ""can,"" ""intends,"" ""target,"" ""goal,"" ""projects,"" ""contemplates,"" ""believes,"" ""predicts,"" ""potential,"" ""continue,"" ""foresees,"" ""forecasts,"" ""estimates,"" ""opportunity"" and similar expressions identify forward- looking statements. It is uncertain whether any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what impact they will have on the results of operations and financial condition of the combined companies or the price of RBA's common shares. Therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. While RBA's management believe the assumptions underlying the forward-looking statements are reasonable, these forward-looking statements involve certain risks and uncertainties, many of which are beyond RBA's control, that could cause actual results to differ materially from those indicated in such forward-looking statements, including but not limited to: the effects of the business combination of RBA and IAA, including the combined company's future financial condition, results of operations, strategy and plans; potential adverse reactions or changes to business or employee relationships, including those resulting from the completion of the merger; the diversion of management time on transaction-related issues; the response of competitors to the merger; the ultimate difficulty, timing, cost and results of integrating the operations of RBA and IAA; the fact that operating costs and business disruption may be greater than expected following the consummation of the merger; the effect of the consummation of the merger on the trading price of RBA's common shares; the ability of RBA to retain and hire key personnel and employees; the significant costs associated with the merger; the outcome of any legal proceedings that could be instituted against RBA; the ability of the combined company to realize anticipated synergies in the amount, manner or timeframe expected or at all; the failure of the combined company to realize potential revenue, EBITDA, growth, operational enhancement, expansion or other value creation opportunities from the sources or in the amount, manner or timeframe expected or at all; the failure of the trading multiple of the combined company to normalize or re-rate and other fluctuations in such trading multiple; changes in capital markets and the ability of the combined company to generate cash flow and/or finance operations in the manner expected or to de-lever in the timeframe expected; the failure of RBA or the combined company to meet financial forecasts and/or KPI targets; legislative, regulatory and economic developments affecting the business of RBA; general economic and market developments and conditions; the evolving legal, regulatory and tax regimes under which RBA operates; unpredictability and severity of catastrophic events, including, but not limited to, pandemics, acts of terrorism or outbreak of war or hostilities, as well as RBA's response to any of the aforementioned factors. Other risks that could cause actual results to differ materially from those described in the forward-looking statements are included in RBA's periodic reports and other filings with the Securities and Exchange Commission (""SEC"") and/or applicable Canadian securities regulatory authorities, including the risk factors identified under Item 1A ""Risk Factors"" and the section titled ""Summary of Risk Factors"" in RBA's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and IAA's periodic reports and other filings with the SEC, including the risk factors identified under Item 1A ""Risk Factors"" and the section titled ""Summary of Risks Affecting our Business"" in IAA's most recent Annual Report on Form 10-K for the fiscal year ended January 1, 2023. The forward-looking statements included in this release are made only as of the date hereof. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Many of these risk factors are outside of our control, and as such, they involve risks which are not currently known that could cause actual results to differ materially from those discussed or implied herein. RBA does not undertake any obligation to update any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made, except as required by law. View original content:https://www.prnewswire.com/news-releases/ritchie-bros-largest-ever-premier-global-auction-event-in-orlando-to-feature-record-setting-16-500-heavy-equipment-assets-and-vehicles-302064442.html SOURCE RB Global How many items will be featured at Ritchie Bros. Auctioneers' premier global auction event in Orlando? The auction will feature a record-setting 16,500+ items, over 20% more lots than the 2023 auction. What type of equipment highlights can be found at the Orlando auction? The Orlando auction includes 3,700+ construction equipment lots, 1,200+ transport trucks, 250+ units of aggregate equipment, 60+ cranes, and various attachments. Where can bids be made for the auction? Bids for the auction can be made in-person, online in real time at rbauction.com, or through Ritchie Bros.' mobile app. Who is the Chief Revenue Officer for RB Global? Jeff Jeter is the Chief Revenue Officer for RB Global, welcoming customers to the 40th premier global auction event in Orlando. How can buyers access information about the equipment for sale? Buyers can view high-resolution photos and videos of the equipment on rbauction.com or visit the Orlando site in person to inspect and test the equipment before bidding."
"JPMorgan Chase Files Form 10-K for the Fiscal Year Ended December 31, 2023",2024-02-16T21:31:00.000Z,Low,Neutral,"JPMorgan Chase & Co. (NYSE: JPM) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, showcasing $3.9 trillion in assets and $328 billion in stockholders' equity. The firm is a key player in investment banking, consumer financial services, commercial banking, financial transaction processing, and asset management, serving millions of customers globally.","JPMorgan Chase Files Form 10-K for the Fiscal Year Ended December 31, 2023 Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary JPMorgan Chase & Co. (NYSE: JPM) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, showcasing $3.9 trillion in assets and $328 billion in stockholders' equity. The firm is a key player in investment banking, consumer financial services, commercial banking, financial transaction processing, and asset management, serving millions of customers globally. Positive None. Negative None. Financial Analyst JPMorgan Chase's annual report filing is a critical document for stakeholders as it provides a comprehensive overview of the company's financial health and strategic direction. With $3.9 trillion in assets and $328 billion in stockholders' equity, the firm's financial position appears robust. The asset size indicates significant market influence and a strong capacity for liquidity management, which is essential for maintaining operations during economic fluctuations. Stockholders' equity reflects the firm's underlying value and financial resilience, which is particularly relevant in the context of rising interest rates and potential economic headwinds.As a leader in various financial sectors, JPMorgan Chase's performance is often seen as a barometer for the broader industry. Their success in investment banking and asset management suggests a favorable environment for these services, potentially signaling growth opportunities for similar firms. However, investors should also consider the competitive landscape and regulatory changes that could impact the firm's market share and profitability. Market Research Analyst The disclosed financial figures provide insights into consumer and business trends. JPMorgan Chase's role in financial services for consumers and small businesses indicates its exposure to consumer confidence and spending patterns. A strong performance in these areas could suggest economic vitality and a healthy spending climate. Conversely, any downturns could reflect broader economic challenges that may affect consumer-facing businesses and the stock market.Additionally, JPMorgan Chase's global operations imply its sensitivity to international markets and geopolitical events. The firm's ability to navigate these complexities speaks to its operational expertise and risk management strategies. Market participants should monitor global economic indicators and foreign policy developments, as these can have material effects on the firm's international segments. Legal Expert From a legal standpoint, the annual report filing with the SEC is a mandatory disclosure that ensures transparency and compliance with regulatory standards. It is critical for investors to review such documents for any legal proceedings or regulatory issues that could affect the firm's operations and financial outcomes. Any significant legal risks disclosed in the report could have implications for investor confidence and the firm's stock price.Furthermore, as a financial institution, JPMorgan Chase operates under strict regulatory scrutiny. Changes in financial regulations or enforcement actions can have significant operational and financial consequences. Stakeholders should be aware of the current regulatory climate and any pending legislation that could influence the firm's strategic decisions and market performance. 02/16/2024 - 04:31 PM NEW YORK--(BUSINESS WIRE)-- JPMorgan Chase & Co. (NYSE: JPM) (“JPMorgan Chase” or the “Firm”) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the SEC. The report is available on the SEC's website at https://www.sec.gov and will be available on the Firm's Investor Relations website at https://www.jpmorganchase.com/ir under SEC Filings & Other Disclosures. JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. JPMorgan Chase had $3.9 trillion in assets and $328 billion in stockholders’ equity as of December 31, 2023. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216962787/en/ Investor Contact: Mikael Grubb 212-270-2479 Media Contact: Joseph Evangelisti 212-270-7438 Source: JPMorgan Chase & Co. What is the ticker symbol for JPMorgan Chase & Co.? The ticker symbol for JPMorgan Chase & Co. is JPM. What was the total assets value of JPMorgan Chase & Co. as of December 31, 2023? JPMorgan Chase & Co. had $3.9 trillion in assets as of December 31, 2023. Where can I find JPMorgan Chase & Co.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2023? You can find JPMorgan Chase & Co.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 on the SEC's website at https://www.sec.gov and on the Firm's Investor Relations website at https://www.jpmorganchase.com/ir under SEC Filings & Other Disclosures. What are the main areas of business for JPMorgan Chase & Co.? JPMorgan Chase & Co. is involved in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. How many customers does JPMorgan Chase & Co. serve globally? JPMorgan Chase & Co. serves millions of customers globally."
Granite REIT Declares Distribution for February 2024,2024-02-16T22:00:00.000Z,Low,Very Negative,"Granite Real Estate Investment Trust (GRT.UN / GRP.U) declared a distribution of CDN $0.275 per stapled unit for February 2024, to be paid on March 15, 2024. The distribution does not constitute effectively connected income for U.S. federal tax purposes.","Granite REIT Declares Distribution for February 2024 Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Negative) Tags Rhea-AI Summary Granite Real Estate Investment Trust (GRT.UN / GRP.U) declared a distribution of CDN $0.275 per stapled unit for February 2024, to be paid on March 15, 2024. The distribution does not constitute effectively connected income for U.S. federal tax purposes. Positive None. Negative None. Financial Analyst The declaration of a distribution by Granite Real Estate Investment Trust is a tangible reflection of the company's current financial health and operational efficiency. The distribution amount of CDN $0.275 per stapled unit is a critical figure for investors as it directly impacts their return on investment. This figure should be compared against historical distribution amounts and yields, as well as the average yield of the REIT sector to gauge its competitiveness.Furthermore, the confirmation that the distribution does not constitute effectively connected income for U.S. federal tax purposes is beneficial for U.S. investors, as it simplifies the tax implications and potentially enhances the after-tax yield of their investment. It is important to analyze the sustainability of these distributions by assessing the REIT's payout ratio, which is the proportion of earnings paid out as distributions to unitholders and comparing it with industry norms. Tax Expert The aspect of the distribution not being 'effectively connected income' for U.S. federal tax purposes is a significant detail for cross-border investors. This classification means that the income is not subject to U.S. income tax filing requirements for non-resident aliens, which can be an administrative relief and a financial incentive for U.S. investors. The forthcoming notice to the Depository Trust & Clearing Corporation, as per United States Treasury Regulation Section 1.1446-4, indicates Granite's compliance with tax regulations and the transparency of the distribution's sources. It is essential for stakeholders to understand the tax treatment of these distributions to accurately assess the net benefit of their investment. Market Research Analyst The regularity and size of distributions made by a REIT like Granite are indicative of its performance in the real estate market and its ability to generate consistent rental income. The distribution announcement can influence investor sentiment and the REIT's stock market performance. Tracking the historical distribution growth rate and stability can provide insights into the REIT's asset management capabilities and the underlying property market conditions. It is also valuable to consider the impact of broader economic factors such as interest rates and inflation on the real estate sector, as these can affect property values and rental income, thereby influencing future distributions. 02/16/2024 - 05:00 PM TORONTO--(BUSINESS WIRE)-- Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.275 per stapled unit for the month of February 2024. The distribution will be paid by Granite on Friday, March 15, 2024 to stapled unitholders of record at the close of trading on Thursday, February 29, 2024. Granite confirms that no portion of the distribution constitutes effectively connected income for U.S. federal tax purposes. A qualified notice providing the breakdown of the sources of the distribution will be issued to the Depository Trust & Clearing Corporation subsequent to the record date of February 29, 2024, pursuant to United States Treasury Regulation Section 1.1446-4. ABOUT GRANITE Granite is a Canadian-based REIT engaged in the acquisition, development, ownership and management of logistics, warehouse and industrial properties in North America and Europe. Granite owns 143 investment properties representing approximately 62.9 million square feet of leasable area. OTHER INFORMATION Copies of financial data and other publicly filed documents about Granite are available through the internet on the Canadian Securities Administrators’ System for Electronic Data Analysis and Retrieval +(SEDAR+) which can be accessed at www.sedarplus.ca and on the United States Securities and Exchange Commission’s Electronic Data Gathering, Analysis and Retrieval System (EDGAR) which can be accessed at www.sec.gov. For further information, please see our website at www.granitereit.com or contact Teresa Neto, Chief Financial Officer, at 647-925-7560 or Andrea Sanelli, Associate Director, Legal & Investor Services, at 647-925-7504. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216030854/en/ Teresa Neto Chief Financial Officer 647-925-7560 Andrea Sanelli Associate Director, Legal & Investor Services 647-925-7504 Source: Granite Real Estate Investment Trust What distribution amount did Granite Real Estate Investment Trust declare for February 2024? Granite declared a distribution of CDN $0.275 per stapled unit for February 2024. When will the distribution be paid by Granite Real Estate Investment Trust? The distribution will be paid on March 15, 2024. Is the distribution considered effectively connected income for U.S. federal tax purposes? No, the distribution does not constitute effectively connected income for U.S. federal tax purposes."
FLJ Group Limited Files Annual Report on Form 20-F for Fiscal Year 2023,2024-02-16T22:00:00.000Z,Neutral,Neutral,FLJ Group Limited (NASDAQ: FLJ) filed its annual report for the fiscal year 2023 with the SEC. Shareholders can access the report online or request a hard copy for free.,"FLJ Group Limited Files Annual Report on Form 20-F for Fiscal Year 2023 Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary FLJ Group Limited (NASDAQ: FLJ) filed its annual report for the fiscal year 2023 with the SEC. Shareholders can access the report online or request a hard copy for free. Positive None. Negative None. Financial Analyst The filing of an annual report on Form 20-F by FLJ Group Limited represents a critical disclosure of the company's financial health and operational achievements over the past fiscal year. Investors and analysts scrutinize such documents to assess the company's performance, profitability and strategic direction. The report includes audited financial statements, which provide a reliable basis for evaluating the company's financial position and any growth or contraction in key financial metrics such as revenue, net income and earnings per share.From a financial analysis perspective, the growth trends and margin analysis within this report can signal the company's operational efficiency and market position. If FLJ Group Limited has surpassed industry benchmarks in key performance indicators, it would suggest competitive strength and could positively influence investor sentiment. Conversely, any signs of underperformance might raise concerns about the company's future prospects.Furthermore, the report's disclosures on risks, management discussion and analysis (MD&A) offer insights into management's perspective on the business and future outlook. Such qualitative information is invaluable for investors seeking to understand the company's strategic initiatives and risk management strategies. Market Research Analyst FLJ Group Limited's annual report also provides context for market research analysis, particularly in understanding the company's position within its industry and competitive landscape. Market analysts can extract data on market share, customer acquisition and retention rates, as well as insights into new markets the company may be exploring. Analysis of the company's performance in relation to industry trends and economic conditions can also highlight the company's adaptability and resilience.Strategic moves such as mergers, acquisitions, or divestitures, if any, will be detailed in the report, offering a comprehensive view of the company's market strategy. This information helps in forecasting future market trends and in making educated predictions about the company's growth trajectory. Additionally, the report's revelations about supply chain management, production capabilities and technological advancements contribute to a holistic understanding of the company's market position and potential for innovation. Economist An economist might evaluate the annual report from a macroeconomic standpoint, considering how FLJ Group Limited's financial results correlate with broader economic indicators. For instance, the company's revenue growth can be juxtaposed with GDP growth rates to determine if the company is growing in line with or outpacing the economy. Additionally, the economist might assess the impact of inflation rates on the company's cost structures and pricing strategies.International companies like FLJ Group Limited may also contend with exchange rate fluctuations, which can significantly affect financial performance. The annual report's financials will reflect how well the company has managed such external economic factors. Economists can further analyze the company's capital structure, debt levels and investment activities to infer the company's financial stability and its ability to withstand economic downturns. 02/16/2024 - 05:00 PM SHANGHAI, China, Feb. 16, 2024 (GLOBE NEWSWIRE) -- FLJ Group Limited (NASDAQ: FLJ) (the “Company”), today announced that it filed its annual report on Form 20-F for the fiscal year ended September 30, 2023 with the Securities and Exchange Commission (""SEC"") on February 9, 2024. The annual report can be accessed on the Company's investor relations website at ir.fenglinju.cn as well as the SEC's website at http://www.sec.gov. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company's IR Department at ir@qk365.com. About FLJ Group Limited FLJ Group Limited, through its subsidiaries and consolidated variable interest entities, operates insurance agency and insurance technology business. The insurance agency is PRC-licensed and operates nationwide in the PRC with a wide range of insurance products underwritten by major insurance companies, including industry leading and/or state-owned property and casualty insurance companies as well as certain regional property and casualty insurance companies in China. The insurance technology business is focused on operating and developing insurance technology in the PRC, including developing SaaS platform to connect consumers and underwriting support. For investor and media inquiries, please contact: FLJ Group Limited E-mail: ir@qk365.com ChristensenIn ChinaMr. Rene VanguestainePhone: +86-10-59001548E-mail: rene.vanguestaine@christensencomms.com In the U.S.Ms. Linda BergkampPhone: +1-480-6143004Email: linda.bergkamp@christensencomms.com FLJ Group Limited Where can I access FLJ Group Limited's annual report for the fiscal year 2023? FLJ Group Limited's annual report for the fiscal year 2023 can be accessed on the Company's investor relations website at ir.fenglinju.cn and the SEC's website at http://www.sec.gov. How can shareholders obtain a hard copy of FLJ Group Limited's annual report? Shareholders can request a hard copy of FLJ Group Limited's annual report containing audited financial statements free of charge by contacting the Company's IR Department at ir@qk365.com."
Tenet Calls for Full Redemption of 4.875% Senior Secured First Lien Notes due 2026,2024-02-16T22:00:00.000Z,Low,Very Negative,"Tenet Healthcare Corporation (THC) announces the redemption of all $2.1 billion outstanding 4.875% Senior Secured First Lien Notes due 2026. The redemption will be executed on March 5, 2024, with cash on hand, at a redemption price of 100% of the principal amount plus accrued interest.","Tenet Calls for Full Redemption of 4.875% Senior Secured First Lien Notes due 2026 Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Negative) Tags Rhea-AI Summary Tenet Healthcare Corporation (THC) announces the redemption of all $2.1 billion outstanding 4.875% Senior Secured First Lien Notes due 2026. The redemption will be executed on March 5, 2024, with cash on hand, at a redemption price of 100% of the principal amount plus accrued interest. Positive None. Negative None. Financial Analyst Tenet Healthcare Corporation's redemption of its 4.875% Senior Secured First Lien Notes is a significant financial move, indicating a strategic approach to debt management. By redeeming these notes with cash on hand, the company is likely aiming to reduce interest expenses and improve its balance sheet. This action could signal to investors that the company is generating sufficient cash flow to manage its debt obligations without resorting to further borrowing. The redemption price at 100% of the principal amount, along with accrued interest, suggests a neutral impact on bondholders since they are being compensated fully for their investment.From a credit perspective, this move may be viewed positively by rating agencies, potentially leading to improved credit ratings. This, in turn, could lower the cost of future borrowing for Tenet Healthcare. However, it is important to analyze the company's overall debt structure to assess the impact on its leverage ratios and interest coverage metrics. Investors should watch for any changes in these financial indicators in the company's subsequent earnings reports and SEC filings. Market Research Analyst The redemption of the notes by Tenet Healthcare might have implications for the healthcare sector, especially if other companies follow suit in optimizing their capital structures. It reflects a broader trend where healthcare companies are scrutinizing their debt levels to maintain agility in a dynamic market environment. An important aspect to consider is how this redemption aligns with Tenet's strategic initiatives, such as investments in technology, facility upgrades, or mergers and acquisitions.Investors should evaluate how these capital allocation decisions might influence Tenet's competitive position in the healthcare industry. For instance, freeing up capital from debt servicing could allow for more aggressive growth strategies or operational improvements. This could potentially lead to market share gains or improved operational efficiency, which may be reflected in the company's stock performance over time. Legal Expert The redemption of the notes is governed by the terms set out in the Base Indenture and the Thirty-Second Supplemental Indenture. It is crucial for investors to understand the legal implications of such a redemption, particularly any rights or covenants that may be affected. The legal framework of the indenture agreements often includes specific provisions regarding redemption, such as notice periods, redemption prices and the application of funds.Ensuring compliance with these provisions is essential to avoid any potential legal disputes or breaches of contract. For bondholders, the terms of the indenture dictate the return on their investment and for the company, adherence to these terms is critical to maintain trust and credibility in the capital markets. Investors might consider the legal expertise involved in structuring these agreements as indicative of the company's diligence and risk management practices. 02/16/2024 - 05:00 PM DALLAS--(BUSINESS WIRE)-- Tenet Healthcare Corporation (NYSE: THC) today called for the redemption of all $2,100 million outstanding of its 4.875% Senior Secured First Lien Notes due 2026 (the “Notes”), which were issued pursuant to the Indenture, dated as of November 6, 2001 (the “Base Indenture”), by and between Tenet and The Bank of New York, as predecessor to The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the Thirty-Second Supplemental Indenture, dated as of August 26, 2019 (the “Thirty-Second Supplemental Indenture” and, the Base Indenture, as amended and supplemented by the Thirty-Second Supplemental Indenture, the “Indenture”). The Notes will be redeemed on March 5, 2024 (the “Redemption Date”), with cash on hand, at a redemption price equal to 100% of the principal amount of the Notes being redeemed together with accrued and unpaid interest up to, but not including, the Redemption Date. This press release shall not constitute a notice of redemption of the Notes. Cautionary Statement This release contains “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements often address Tenet’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause Tenet’s actual results to be materially different than those expressed in Tenet’s forward-looking statements include, but are not limited to, the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K and other filings with the Securities and Exchange Commission. About Tenet Healthcare Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 480 ambulatory surgery centers and surgical hospitals. We also operate 58 acute care and specialty hospitals, approximately 160 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240215947062/en/ Investor Contact: Will McDowell 469-893-2387 william.mcdowell@tenethealth.com Media Contact: Robert Dyer 469-893-2640 mediarelations@tenethealth.com Source: Tenet Healthcare Corporation What is the total amount of Tenet Healthcare Corporation's (THC) outstanding Senior Secured First Lien Notes due 2026 being redeemed? Tenet Healthcare Corporation (THC) is redeeming all $2,100 million outstanding of its 4.875% Senior Secured First Lien Notes due 2026. When will the redemption of Tenet Healthcare Corporation's (THC) Senior Secured First Lien Notes take place? The redemption of Tenet Healthcare Corporation's (THC) Senior Secured First Lien Notes will occur on March 5, 2024. What is the redemption price for Tenet Healthcare Corporation's (THC) Senior Secured First Lien Notes? The redemption price for Tenet Healthcare Corporation's (THC) Senior Secured First Lien Notes is equal to 100% of the principal amount of the Notes being redeemed plus accrued and unpaid interest up to, but not including, the Redemption Date."
Mon Power and Potomac Edison Reach Settlement to Adjust Energy Metering Credits,2024-02-16T21:28:00.000Z,Low,Very Positive,"FirstEnergy Corp. subsidiaries Mon Power and Potomac Edison file a settlement agreement with the PSC of West Virginia to address net energy metering. The agreement aims to adjust credit amounts for new net energy metering customers starting Jan. 1, 2025, while existing customers retain current rates for 25 years.","Mon Power and Potomac Edison Reach Settlement to Adjust Energy Metering Credits Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary FirstEnergy Corp. subsidiaries Mon Power and Potomac Edison file a settlement agreement with the PSC of West Virginia to address net energy metering. The agreement aims to adjust credit amounts for new net energy metering customers starting Jan. 1, 2025, while existing customers retain current rates for 25 years. Positive None. Negative None. Energy Policy Analyst The settlement agreement filed by Mon Power and Potomac Edison addresses a critical aspect of energy policy that affects both the business model of utilities and the financial incentives for consumers adopting renewable energy technologies. The adjustment in credit amount for new net energy metering customers can influence the pace of renewable energy adoption. By requiring these customers to pay a larger share of fixed costs, the utilities are ensuring revenue stability and cost fairness among all customers. However, this could potentially slow down the rate at which new customers adopt renewable energy solutions, as the financial returns on their investments may decrease.Moreover, the protection of existing customers' rates for 25 years provides a level of certainty for those who have already invested in renewable energy, which is a positive signal for long-term investment in the sector. It's important to note that the long-term impact on the utility's revenue and energy grid management will depend on how the new credit rates are perceived by potential new customers and how this influences their decision to invest in on-site renewable energy generation. Financial Analyst From a financial perspective, the settlement agreement is significant for FirstEnergy Corp. and its subsidiaries as it directly impacts their revenue model. The agreement's approval could lead to increased predictability in revenue streams, which is crucial for financial planning and stability. Investors and analysts will be closely monitoring the Public Service Commission's decision, as it will have implications for FirstEnergy's profitability and stock performance.It's essential to consider the balance between maintaining utility revenues and encouraging the adoption of renewable energy. If the new rates are set too low, it could discourage new customers from adopting renewable technologies, potentially affecting the utility's long-term strategy and the region's renewable energy goals. Conversely, if managed correctly, this could strengthen FirstEnergy's position by demonstrating proactive management of the evolving energy landscape. Market Research Analyst The reaction of the market to this settlement will depend on the perceived impact on the adoption of renewable energy technologies in West Virginia. The agreement could be seen as a strategic move by FirstEnergy to adapt to the changing energy market, where distributed generation is becoming more prevalent. The decision to grandfather existing customers at the current retail rate could be interpreted as a compromise to mitigate backlash from the renewable energy community and maintain a positive public image.Understanding consumer sentiment towards these changes is essential for predicting market trends. If the new net energy metering customers perceive the credit adjustment as a significant deterrent, it may affect not only the adoption rates but also the public perception of FirstEnergy and its commitment to renewable energy. Such perceptions could influence customer loyalty and the company's market share in the long run. 02/16/2024 - 04:28 PM FAIRMONT, W.V., Feb. 16, 2024 /PRNewswire/ -- Mon Power and Potomac Edison, subsidiaries of FirstEnergy Corp. (NYSE: FE), have filed a settlement agreement with the Public Service Commission (PSC) of West Virginia to resolve the outstanding net energy metering portion of its base rate review. The agreement helps ensure that new net energy metering customers – those who offset their power needs with wind, rooftop solar or other forms of on-site energy – pay a portion of the fixed costs related to the distribution, transmission and capacity facilities they use by adjusting the credit amount that new net energy metering customers receive for the energy they generate beginning Jan. 1, 2025. If the agreement is approved by the PSC, existing net energy metering customers will continue to receive the current retail rate offset for 25 years. Beginning Jan. 1, 2025, any new residential net energy metering customers would receive a credit rate of about 9 cents per kilowatt hour. The settlement also establishes new net energy metering credit rates for non-residential customers, which can be found in the settlement filing. Parties to the newly filed settlement include staff of the PSC, the Consumer Advocate Division of the Commission, West Virginia Citizen Action Group, Solar United Neighbors, Energy Efficient West Virginia, Solar Holler LLC and Mon Power/Potomac Edison. Mon Power serves about 395,000 customers in 34 West Virginia counties. Follow Mon Power at mon-power.com, on X, formerly known as Twitter, @MonPowerWV, and on Facebook at facebook.com/MonPowerWV. Potomac Edison serves about 285,000 customers in seven counties in Maryland and 155,000 customers in the Eastern Panhandle of West Virginia. Follow Potomac Edison at potomacedison.com, on X @PotomacEdison and on Facebook at facebook.com/PotomacEdison. FirstEnergy is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation's largest investor-owned electric systems, serving more than six million customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. The company's transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy online at firstenergycorp.com and on X, @firstenergycorp. View original content to download multimedia:https://www.prnewswire.com/news-releases/mon-power-and-potomac-edison-reach-settlement-to-adjust-energy-metering-credits-302064445.html SOURCE FirstEnergy Corp. What is the settlement agreement filed by FirstEnergy Corp. subsidiaries Mon Power and Potomac Edison related to? The settlement agreement is related to resolving the outstanding net energy metering portion of the base rate review with the Public Service Commission (PSC) of West Virginia. When will the adjustment in credit amounts for new net energy metering customers begin? The adjustment in credit amounts for new net energy metering customers will start on Jan. 1, 2025. What will happen to existing net energy metering customers if the agreement is approved by the PSC? Existing net energy metering customers will continue to receive the current retail rate offset for 25 years if the agreement is approved by the PSC. What credit rate will new residential net energy metering customers receive starting Jan. 1, 2025? Starting Jan. 1, 2025, new residential net energy metering customers would receive a credit rate adjusted as per the agreement."
"Harley-Davidson, Inc. Declares Dividend",2024-02-16T21:30:00.000Z,Low,Neutral,"Harley-Davidson, Inc. (HOG) declares a cash dividend of $0.1725 per share for the first quarter of 2024, payable on March 20, 2024. The dividend is approved by the Board of Directors and will benefit the shareholders of record as of March 4, 2024.","Harley-Davidson, Inc. Declares Dividend Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags dividends Rhea-AI Summary Harley-Davidson, Inc. (HOG) declares a cash dividend of $0.1725 per share for the first quarter of 2024, payable on March 20, 2024. The dividend is approved by the Board of Directors and will benefit the shareholders of record as of March 4, 2024. Positive None. Negative None. Financial Analyst The announcement of a cash dividend by Harley-Davidson represents a direct return on investment for shareholders, signaling the company's current liquidity and profitability status. Dividends are often a reflection of a company's confidence in its financial stability and future earnings. The specific dividend of $0.1725 per share must be evaluated in the context of the company's dividend history, payout ratio and yield. A comparison with industry peers would also provide insights into the company's relative performance and shareholder value proposition.Investors typically look at dividend announcements as indicators of a company's financial health. A consistent or increasing dividend payout can attract income-focused investors and support the stock price by providing a tangible return. Conversely, if this dividend represents a decrease from previous payouts, it could be a warning sign of possible financial distress or a strategic shift towards retaining more capital for internal investments.It's also important to note the ex-dividend date, which is the cutoff date to be eligible for the dividend payment. Investors must own the stock before this date to receive the dividend. This date often influences trading behavior, as some investors may purchase shares just to capture the dividend, potentially affecting the stock's volatility around this period. Market Research Analyst From a market perspective, Harley-Davidson's dividend declaration can be seen as a message to the market about its performance and strategic priorities. The automotive industry, especially companies like Harley-Davidson that are iconic in the motorcycle segment, is facing multiple challenges, including changing consumer preferences, regulatory pressures for cleaner energy and competition from electric vehicle manufacturers.Analysing the dividend in the context of these market trends provides insights into how well Harley-Davidson is navigating these challenges. A steady or increased dividend might suggest that the company is adapting effectively, possibly through diversification of its product line, cost management and innovation in new market segments like electric motorcycles.Furthermore, the response of the stock market to the dividend announcement can serve as a barometer of investor sentiment towards the company. A positive reaction could indicate market approval of the company's financial practices and future outlook, while a negative reaction might reflect concerns about the sustainability of such dividends or the company's growth trajectory. 02/16/2024 - 04:30 PM MILWAUKEE, Feb. 16, 2024 /PRNewswire/ -- The Harley-Davidson, Inc. (NYSE: HOG) Board of Directors has approved a cash dividend of $0.1725 per share for the first quarter of 2024. The dividend is payable March 20, 2024 to the shareholders of record of the Company's common stock as of March 4, 2024. Harley-Davidson, Inc. is the parent company of Harley-Davidson Motor Company and Harley-Davidson Financial Services. ### (HOG-DIVIDEND) View original content to download multimedia:https://www.prnewswire.com/news-releases/harley-davidson-inc-declares-dividend-302064355.html SOURCE Harley-Davidson, Inc. What is the dividend amount declared by Harley-Davidson, Inc. (HOG) for the first quarter of 2024? Harley-Davidson, Inc. (HOG) has declared a cash dividend of $0.1725 per share for the first quarter of 2024. When will the dividend be payable to the shareholders of Harley-Davidson, Inc. (HOG)? The dividend declared by Harley-Davidson, Inc. (HOG) for the first quarter of 2024 will be payable on March 20, 2024. Who approved the cash dividend for Harley-Davidson, Inc. (HOG) for the first quarter of 2024? The Board of Directors of Harley-Davidson, Inc. (HOG) approved the cash dividend of $0.1725 per share for the first quarter of 2024. What is the record date for the shareholders of Harley-Davidson, Inc. (HOG) to receive the dividend? The shareholders of record of Harley-Davidson, Inc. (HOG) common stock as of March 4, 2024, will receive the declared dividend."
Tiidal Announces Shares for Debt Settlement,2024-02-16T22:01:00.000Z,Neutral,Neutral,"Tiidal Gaming Group Corp. announces a Debt Settlement with its Chief Executive Officer and a consultant, issuing 800,000 common shares at $0.05 per share to clear a $40,000 debt. The transaction falls under a related party transaction but is exempt from certain valuation and shareholder approval requirements. The issued securities will be under a hold period of four months and one day.","Tiidal Announces Shares for Debt Settlement Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Tiidal Gaming Group Corp. announces a Debt Settlement with its Chief Executive Officer and a consultant, issuing 800,000 common shares at $0.05 per share to clear a $40,000 debt. The transaction falls under a related party transaction but is exempt from certain valuation and shareholder approval requirements. The issued securities will be under a hold period of four months and one day. Positive None. Negative None. 02/16/2024 - 05:01 PM Toronto, Ontario--(Newsfile Corp. - February 16, 2024) - Tiidal Gaming Group Corp. (CSE: TIDL) (the ""Company"" or ""Tiidal"") announces that it has agreed to issue an aggregate of 800,000 common shares (each, a ""Share"") at a deemed price of $0.05 per Share as full and final payment of debt in the aggregate amount of $40,000 (the ""Debt Settlement"") for certain unpaid remuneration for services performed by Tiidal's Chief Executive Officer (the ""Insider"") and a consultant of the Company.The Debt Settlement with the Insider constituted a ""related party transaction"" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (""MI 61-101""). The issuance of the Shares to the Insider, however, was exempt from the valuation requirement of MI 61-101 by the virtue of the exemption contained in section 5.5(b) as the Company's Shares are not listed on a specified market and from the minority shareholder approval requirements of MI 61-101 by virtue of the exemption contained in Section 5.7(1)(a) as the value of the Shares issued under the Debt Settlement did not exceed 25% of the Company's market capitalization.All securities issued in connection with the Debt Settlement will be subject to a statutory hold period expiring four months and one day after the date of issuance.ABOUT TIIDAL GAMINGTiidal Gaming is a reporting issuer in the Provinces of Ontario, British Columbia and Alberta and its Shares are listed for trading on the Canadian Securities Exchange under the symbol ""TIDL"". Carlo Rigillo Chief Executive Officere: carlo.rigillo@gmail.comt: 647-400-4794 Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.Cautionary StatementsThis news release contains ""forward-looking information"" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as ""may"", ""will"", ""expect"", ""likely"", ""should"", ""would"", ""plan"", ""anticipate"", ""intend"", ""potential"", ""proposed"", ""estimate"", ""believe"" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions ""may"" or ""will"" happen, or by discussions of strategy. Forward-looking information is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management's perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. Any such forward-looking information is based on information currently available to Tiidal and is based on assumptions and analyses made in light of Tiidal's experience and perception of historical trends and current conditions. While the Company considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. Readers are cautioned that actual results may vary from the forward-looking information, and undue reliance should not be placed on such forward-looking information.By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Additional risk factors can also be found in Tiidal's financial statements and management's discussion and analysis, which are available under Tiidal's profile on SEDAR+ at www.sedarplus.ca.Unless otherwise indicated, the forward-looking statements in this news release are based on the Company's expectations at the date of this news release. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. Tiidal undertakes no obligation to update or revise such forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, except as required by applicable law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198200 What is the Debt Settlement announced by Tiidal Gaming Group Corp.? Tiidal Gaming Group Corp. has agreed to issue 800,000 common shares at $0.05 per share to clear a $40,000 debt for certain unpaid remuneration for services performed by its Chief Executive Officer and a consultant. Why is the Debt Settlement considered a related party transaction? The Debt Settlement with the Chief Executive Officer is considered a related party transaction as per the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. What exemptions apply to the issuance of shares under the Debt Settlement? The issuance of shares to the Insider is exempt from the valuation requirement of MI 61-101 under section 5.5(b) and from the minority shareholder approval requirements under Section 5.7(1)(a) as the value of the shares issued did not exceed 25% of the Company's market capitalization. What is the hold period for the securities issued in connection with the Debt Settlement? All securities issued in connection with the Debt Settlement will be subject to a statutory hold period expiring four months and one day after the date of issuance."
AgriFORCE Granted Further Patent from the USPTO Related to its FORCEGH+ Facilities,2024-02-16T22:00:00.000Z,High,Positive,"AgriFORCE Growing Systems Ltd. receives a new US patent for its innovative FORCEGH+ facility design, enhancing its IP portfolio and expanding the Company's capabilities in sustainable crop growth.","AgriFORCE Granted Further Patent from the USPTO Related to its FORCEGH+ Facilities Rhea-AI Impact (High) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary AgriFORCE Growing Systems Ltd. receives a new US patent for its innovative FORCEGH+ facility design, enhancing its IP portfolio and expanding the Company's capabilities in sustainable crop growth. Positive None. Negative None. Intellectual Property (IP) Legal Expert The granting of Patent No. 11,895,958 to AgriFORCE Growing Systems Ltd. represents a significant strengthening of the company's intellectual property portfolio in the AgTech sector. The protection of their FORCEGH+ facility design is crucial, as it encompasses a range of innovative features that differentiate the company's offerings in the market. The integration with automated systems and the ability to operate in extreme macro climates are particularly notable, as they suggest a competitive edge in sustainable agriculture technology.From a legal standpoint, the extension of IP coverage can deter competitors from infringing on these technologies and can also provide leverage in potential licensing deals or partnerships. The patent's duration also ensures long-term exclusivity, which could be factored into the company's valuation by investors. Moreover, the patent's pharma-grade GMP equivalent standards indicate a crossover potential into more regulated industries, which could open additional revenue streams. Agricultural Technology Analyst The FORCEGH+ technology underlines a significant advancement in controlled-environment agriculture. Its emphasis on sustainability, high-efficiency building envelopes and advanced hydroponics positions AgriFORCE at the forefront of the industry. By maximizing crop yields and eliminating the need for harmful chemicals, the company is not only addressing consumer demand for cleaner produce but also potentially reducing operational costs associated with traditional farming methods.Investors should note the potential market growth driven by these innovations, as the AgTech industry is rapidly expanding due to global food security concerns and environmental sustainability initiatives. The ability of FORCEGH+ facilities to be deployed in a variety of ecosystems could allow AgriFORCE to tap into new markets and diversify its geographical presence, which is a strong indicator of scalability and resilience in the face of climate change. Market Research Analyst The announcement by AgriFORCE may have implications for the company's market position and investor perceptions. The patent grant not only secures the company's technology but also serves as a signal to the market of AgriFORCE's commitment to innovation and growth. The potential for increased market share and entry into new markets could positively impact the company's financial performance.Furthermore, the focus on sustainability and the elimination of pesticides aligns with increasing consumer and regulatory pressures for environmentally friendly practices. This alignment with market trends could enhance the company's brand and product desirability, potentially leading to increased sales and a stronger competitive position. Investors often look for companies that are well-positioned to capitalize on market trends and AgriFORCE's recent patent achievement could be an indicator of such positioning. 02/16/2024 - 05:00 PM VANCOUVER, British Columbia, Feb. 16, 2024 (GLOBE NEWSWIRE) -- AgriFORCE Growing Systems Ltd. (“the Company”) (NASDAQ: AGRI; AGRIW), an intellectual property (IP) focused AgTech company, today announced that on February 13, 2024, the USPTO granted Patent No. 11,895,958 entitled ""STRUCTURES FOR GROWING PLANTS (TO GENERATE MICRO-ENVIRONMENT CONDITIONS)"" to the Company. This continuation patent covers the innovative FORCEGH+ facility design, including its ability to integrate with different automated systems. This patent expands on the Company’s previously announced patent related to its FORCEGH+ facilities. FORCEGH+ is the Company’s proprietary grow facility design, a sustainable methodology and environment, including in extreme macro climates, for growing optimized crops through Good Manufacturing Practices (GMP) equivalent pharma-grade standards. FORCEGH+ facilities are designed as advanced AgTech, high efficiency building envelopes developed through proprietary engineering and materials. FORCEGH+ advantages include facility designs that harness solar power; advanced hydroponics providing precise and consistent high yield crop growth cycles; and the ability to be deployed in a variety of ecosystems. The Company has developed FORCEGH+ with the intent to optimize crop yields to as near maximize genetic potential, while eliminating the need for pesticides, fungicides, and herbicides, thereby providing customers with the next-generation of controlled-environment agriculture. “We see the benefits of adding another key U.S. patent around our FORCEGH+ technology, which significantly expands the scope of coverage and extends the timeline around our IP,” commented Richard Wong, Chief Financial Officer of AgriFORCE. ABOUT AGRIFORCE AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI; AGRIW) is an AgTech company focused on building an integrated AgTech platform that combines the best technology, intellectual property, and knowledge to solve an urgent problem – providing the best solutions to help drive sustainable crops and nutritious food for people around the world. The AgriFORCE vision is to be a global leader in delivering plant-based foods and products through an advanced and sustainable AgTech platform that makes positive change in the world—from seed to table. Additional information about AgriFORCE is available at: www.agriforcegs.com. Follow AgriFORCE on Twitter: @agriforcegsFollow AgriFORCE on Facebook: AgriFORCE Growing Systems Ltd.Connect with AgriFORCE on LinkedIn: AgriFORCE Growing Systems Ltd. This press release contains forward-looking statements within the meaning of the ""safe harbor"" provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission and elsewhere. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the issuer. Any offer to sell or solicitation of an offer to buy securities of the issuer may only be made pursuant to a valid prospectus pursuant to an effective registration statement or pursuant to a valid exemption from registration under the Securities Act of 1933, as amended and the rules and regulations promulgated thereunder. Investor Relations: Mauro Pennella, President Brands and CGO, mpennella@agriforcegs.com What patent was granted to AgriFORCE Growing Systems Ltd.? The USPTO granted Patent No. 11,895,958 entitled 'STRUCTURES FOR GROWING PLANTS (TO GENERATE MICRO-ENVIRONMENT CONDITIONS)' to the Company. What is the key feature covered by the new patent? The new patent covers the innovative FORCEGH+ facility design, including its integration with different automated systems. What are the advantages of FORCEGH+ facilities? FORCEGH+ facilities offer high efficiency building envelopes, harness solar power, utilize advanced hydroponics for precise crop growth, and can be deployed in various ecosystems. Who commented on the new patent grant? Richard Wong, the Chief Financial Officer of AgriFORCE, commented on the new patent grant. What is the goal of developing FORCEGH+ technology? The intent behind developing FORCEGH+ technology is to optimize crop yields to near maximize genetic potential while eliminating the need for pesticides, fungicides, and herbicides."
Clover Health Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4),2024-02-16T21:30:00.000Z,Low,Very Positive,"Clover Health Investments, Corp. (CLOV) granted a restricted stock unit award to a newly hired employee under the 2022 Inducement Award Plan. The employee has the right to receive 902,061 shares of the Company's Class A Common Stock, with vesting over a four-year period. This award aims to attract new talent to the company.","Clover Health Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Clover Health Investments, Corp. (CLOV) granted a restricted stock unit award to a newly hired employee under the 2022 Inducement Award Plan. The employee has the right to receive 902,061 shares of the Company's Class A Common Stock, with vesting over a four-year period. This award aims to attract new talent to the company. Positive None. Negative None. 02/16/2024 - 04:30 PM FRANKLIN, Tenn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”) announced today that effective February 16, 2024, the Talent and Compensation Committee of the Company’s Board of Directors granted a restricted stock unit award (the “RSUs”) to a newly hired employee. The RSUs were granted under the Company’s 2022 Inducement Award Plan (the “Inducement Plan”) and otherwise will be subject to the terms and conditions of restricted stock unit award agreements under the Inducement Plan. The RSUs represent the employee’s right to receive 902,061 shares of the Company's Class A Common Stock, subject to such award’s applicable vesting schedule. 25% of the RSUs will vest on the first anniversary of February 16, 2024, with the remaining RSUs vesting in equal quarterly installments over the subsequent three years, subject to continued service of the employee at each such vesting date. The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Clover, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). About Clover Health:Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. Visit: www.cloverhealth.com Press Contact:Andrew Still-Baxterpress@cloverhealth.com Investor Relations Contact:Ryan Schmidtinvestors@cloverhealth.com What award did Clover Health Investments, Corp. (CLOV) grant to a newly hired employee? Clover Health Investments, Corp. granted a restricted stock unit award (RSUs) to a newly hired employee. How many shares of the Company's Class A Common Stock does the employee have the right to receive? The employee has the right to receive 902,061 shares of the Company's Class A Common Stock. What is the vesting schedule for the RSUs granted to the employee? 25% of the RSUs will vest on the first anniversary of February 16, 2024, with the remaining RSUs vesting in equal quarterly installments over the subsequent three years, subject to continued service of the employee. What is the purpose of the Inducement Plan mentioned in the press release? The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Clover, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company."
Ohmyhome Announces Closing of Upsized $4.8 Million Public Offering of Ordinary Shares,2024-02-16T21:45:00.000Z,Low,Neutral,"Ohmyhome Ltd. (OMH) successfully closed an upsized public offering of 3,555,555 ordinary shares at $1.35 per share, raising approximately $4.8 million. Maxim Group LLC served as the placement agent. The offering was made under a registration statement declared effective by the SEC on February 13, 2024.","Ohmyhome Announces Closing of Upsized $4.8 Million Public Offering of Ordinary Shares Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags offering Rhea-AI Summary Ohmyhome Ltd. (OMH) successfully closed an upsized public offering of 3,555,555 ordinary shares at $1.35 per share, raising approximately $4.8 million. Maxim Group LLC served as the placement agent. The offering was made under a registration statement declared effective by the SEC on February 13, 2024. Positive None. Negative None. Financial Analyst The completion of Ohmyhome Ltd.'s upsized public offering represents a significant capital infusion for the company, with gross proceeds of approximately $4.8 million. This capital raise through the issuance of 3,555,555 ordinary shares at $1.35 per share is an important strategic move for Ohmyhome. It indicates a potentially bullish sentiment from investors, given the upsized nature of the offering. The fresh capital could be indicative of plans for expansion, technological upgrades, or other strategic investments that could enhance Ohmyhome's competitive edge in the property technology sector.It is crucial to assess the company's valuation metrics and the offering's pricing strategy. The offering price of $1.35 per share will influence the earnings per share (EPS) metric and investors should monitor the impact on Ohmyhome's price-to-earnings (P/E) ratio. Additionally, the dilution effect on existing shareholders must be considered, as the increase in the number of shares outstanding can affect share price performance. The role of Maxim Group LLC as the sole placement agent could also be a factor in the success of the offering, as their reputation and distribution network can affect investor confidence and the distribution of the newly issued shares. Market Research Analyst Ohmyhome's position within the property technology, or 'proptech', market is potentially strengthened by the successful public offering. Proptech is a rapidly evolving industry that leverages technology to innovate real estate markets. The capital raised may enable Ohmyhome to invest in new technologies, expand its service offerings, or increase market penetration in Singapore and potentially beyond. The proptech sector is characterized by high competition and innovation; thus, Ohmyhome's ability to scale its operations and continuously innovate is crucial for maintaining a competitive advantage.Market trends, such as the increasing demand for digital and remote real estate transactions, especially in a post-pandemic world, could favor platforms like Ohmyhome. However, the company must navigate regulatory challenges, market saturation and the ever-changing technological landscape. The use of proceeds from the offering should be monitored to evaluate the effectiveness of their deployment in creating shareholder value. Legal Expert The announcement highlights the compliance with regulatory requirements by Ohmyhome, specifically mentioning the effective registration statement on Form F-1 with the SEC. The effectiveness of the Registration Statement is a critical legal step that allows the company to proceed with the public offering. This adherence to securities laws is essential for maintaining investor trust and for the legitimacy of the offering.It is also important to note the legal disclaimer stating that the press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described. Such language is standard and serves to protect the company from potential legal repercussions related to the offering. Investors should be aware that the availability of the final prospectus is key to understanding the full details and risks associated with the investment. 02/16/2024 - 04:45 PM Singapore, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Ohmyhome Ltd. (NASDAQ: OMH, “Ohmyhome”), a one-stop-shop property technology platform providing end-to-end property solutions and services to buy, sell, rent, and renovate homes, as well as property management services for condominiums in Singapore, today announced the closing of its upsized public offering of 3,555,555 ordinary shares at a public offering price of $1.35 per ordinary share. Gross proceeds, before deducting placement agent fees and other offering expenses, were approximately $4.8 million. Maxim Group LLC acted as sole placement agent in connection with this offering. The securities described above were offered pursuant to a registration statement on Form F-1, as amended (File No. 333-275987) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the ""SEC"") on February 13, 2024. The offering was made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering has been filed with the SEC. Copies may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Ohmyhome Ohmyhome is a one-stop-shop property technology platform in Singapore that provides end-to-end property solutions and services to buy, sell, rent, and renovate homes, as well as property management services for condominiums in Singapore. Since its launch in 2016, Ohmyhome has transacted over 14,500 properties, and has over 5,800 units under management as of June 30, 2023. It is also the highest-rated property transaction platform, with more than 8,000 genuine reviews, and an average rating of 4.9 out of 5 stars. Ohmyhome is dedicated to bringing speed, ease, and reliability to property-related services and to becoming the most trusted and comprehensive property solution for everyone. For more information, visit: https://ohmyhome.com/en-sg/ Safe Harbor Statement This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Contactir@ohmyhome.com What is the ticker symbol for Ohmyhome Ltd.? The ticker symbol for Ohmyhome Ltd. is OMH. How many ordinary shares were offered in the public offering? Ohmyhome Ltd. offered 3,555,555 ordinary shares in the public offering. At what price were the ordinary shares offered? The ordinary shares were offered at a price of $1.35 per share. How much was raised in the public offering? The public offering raised approximately $4.8 million. Who acted as the sole placement agent in connection with the offering? Maxim Group LLC served as the sole placement agent in connection with the offering. When was the registration statement declared effective by the SEC? The registration statement was declared effective by the SEC on February 13, 2024. Where can copies of the final prospectus be obtained? Copies of the final prospectus can be obtained from Maxim Group LLC in New York."
Ault Disruptive Technologies Announces Offer of Reverse Redemptions in Connection with Vote to Extend Period to Consummate its Initial Business Combination,2024-02-16T21:30:00.000Z,Low,Neutral,"Ault Disruptive Technologies Corporation announces the extension of the merger completion deadline and the option for shareholders to reverse redemption requests. The company received requests to redeem 121,695 shares, with a per-share pro rata trust account portion of $11.72. There are 2,942,180 non-redeemed shares remaining.","Ault Disruptive Technologies Announces Offer of Reverse Redemptions in Connection with Vote to Extend Period to Consummate its Initial Business Combination Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Ault Disruptive Technologies Corporation announces the extension of the merger completion deadline and the option for shareholders to reverse redemption requests. The company received requests to redeem 121,695 shares, with a per-share pro rata trust account portion of $11.72. There are 2,942,180 non-redeemed shares remaining. Positive None. Negative None. Financial Analyst The approval of the Extension Amendment Proposal by Ault Disruptive Technologies Corporation indicates a strategic maneuver to provide the company with additional time to identify and complete a business combination. This is a common practice among special purpose acquisition companies (SPACs) to avoid liquidation if they cannot meet the initially proposed deadlines. The extension to December 20, 2024, suggests that the company is still in the process of negotiating a deal or has yet to find a suitable target.From a financial perspective, the redemption option offered to shareholders is significant. It implies that the company is seeking to maintain its cash trust, which is key for the completion of a future transaction. The mention of 121,695 shares being requested for redemption and the remaining 2,942,180 non-redeemed shares provides an insight into shareholder sentiment, potentially indicating a lack of confidence or a desire for liquidity among a portion of the investors. The pro-rata share of the trust account at $11.72 also suggests a valuation metric that investors may consider when deciding on redemption. Legal Expert The legal implications of the Extension Amendment Proposal are centered around corporate governance and shareholder rights. The company's ability to extend the deadline for a business combination is typically pre-determined in the SPAC's charter documents, subject to shareholder approval. The successful approval reflects adherence to due process and the engagement of stockholders in critical decisions.Moreover, the provision allowing shareholders to reverse their redemption requests is an example of corporate flexibility and responsiveness to investor needs. This action must be managed carefully to ensure compliance with securities regulations and to maintain the integrity of the redemption process. The fact that this option is being provided could indicate an effort by the company to retain its shareholder base in anticipation of a future business combination that requires their support. Market Research Analyst The SPAC market has seen fluctuations in investor sentiment and regulatory scrutiny. The decision by Ault Disruptive Technologies Corporation to extend the deadline for completing a business combination is reflective of the challenges SPACs face in a competitive acquisition environment. The market for SPAC mergers can be influenced by various factors including market conditions, availability of suitable targets and investor appetite for risk.The redemption rate and the subsequent offer to reverse redemptions provide a metric for gauging market confidence in the SPAC's potential to secure a valuable merger. It also offers insights into the company's current standing and the perceived value of its future prospects. The fact that the bulk of non-redeemed shares are held by the company’s sponsor may be indicative of the sponsor's confidence in the SPAC's strategy or a strategic move to maintain control over the company's direction. 02/16/2024 - 04:30 PM LAS VEGAS--(BUSINESS WIRE)-- Ault Disruptive Technologies Corporation, a special purpose acquisition company (the “Company”), today announced that it will allow those holders of shares of the Company's common stock originally sold as part of the units issued in its initial public offering that elected by 5:00 p.m. Eastern Time on February 13, 2024 to redeem their common stock in connection with the special meeting of stockholders held yesterday at 12:00 p.m. Eastern time (the “Special Meeting”), to reverse their redemption requests by sending a DTC DWAC (Deposit/Withdrawal At Custodian) request to the Company's transfer agent, Continental Stock & Transfer Company by 4:15 p.m. Eastern Time, Tuesday, February 20, 2024. The Company proposed yesterday at the Special Meeting, to amend the Company's amended and restated certificate of incorporation to extend the date by which the Company must complete a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination involving the Company and one or more businesses from February 20, 2024 to December 20, 2024 (the “Extension Amendment Proposal”). The Extension Amendment Proposal was approved. In connection with the Special Meeting, the Company received requests to redeem 121,695 shares from its public stockholders. The per-share pro rata portion of the trust account on February 15, 2024 was approximately $11.72, excluding any taxes due or paid but not yet reimbursed by the trust. There are 2,942,180 non-redeemed shares remaining at the time of this press release, of which 2,875,000 are held by the Company’s sponsor Ault Disruptive Technologies Company, LLC. About Ault Disruptive Technologies Corporation Ault Disruptive Technologies Corporation, a Delaware corporation, is a blank check company incorporated in February 2021 whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to as our initial business combination. While we may pursue an initial business combination opportunity in any business, industry, sector or geographical location, we intend to focus on opportunities to acquire companies with innovative and emerging technologies, products or services that have the potential to transform major industries and radically impact society. We intend to acquire a target business or businesses with disruptive technologies that our management team believes can achieve mainstream adoption and create opportunities for long-term appreciation in value. Forward-Looking Statements This press release contains statements that constitute ""forward-looking statements."" Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's annual report on Form 10-K filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216978762/en/ Redemption Contact Continental Stock & Transfer Company SPAC Redemption Team spacredemptions@continentalstock.com Ault Disruptive Technologies Corporation ir@aultdisruptive.com Source: Ault Disruptive Technologies Corporation What is the purpose of the Extension Amendment Proposal announced by ADRT? The Extension Amendment Proposal aims to extend the deadline for completing a merger, share exchange, or similar business combination involving ADRT and other businesses from February 20, 2024, to December 20, 2024. How can shareholders reverse their redemption requests for ADRT? Shareholders who originally sold their common stock as part of the units in ADRT's initial public offering have until February 20, 2024, to send a DTC DWAC request to the Company's transfer agent, Continental Stock & Transfer Company, to reverse their redemption requests. What was the total number of shares redeemed by public stockholders at the Special Meeting for ADRT? At the Special Meeting, ADRT received redemption requests for 121,695 shares from its public stockholders. How many non-redeemed shares are left at the time of the press release for ADRT? As per the press release, there are 2,942,180 non-redeemed shares remaining, with 2,875,000 of these held by ADRT's sponsor, Ault Disruptive Technologies Company, LLC."
The New York Times Company Announces Nominations for Board of Directors,2024-02-16T21:30:00.000Z,Low,Neutral,"The New York Times Company announces the nomination of Margot Golden Tishler as a director for the 2024 annual meeting, with Hays N. Golden stepping down. A.G. Sulzberger praises Tishler's family legacy and business insight, thanking Golden for his service. Tishler, chair of the Ochs-Sulzberger Trust, is a graphic designer with an associate degree from Pratt Institute.","The New York Times Company Announces Nominations for Board of Directors Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags management Rhea-AI Summary The New York Times Company announces the nomination of Margot Golden Tishler as a director for the 2024 annual meeting, with Hays N. Golden stepping down. A.G. Sulzberger praises Tishler's family legacy and business insight, thanking Golden for his service. Tishler, chair of the Ochs-Sulzberger Trust, is a graphic designer with an associate degree from Pratt Institute. Positive None. Negative None. 02/16/2024 - 04:30 PM NEW YORK--(BUSINESS WIRE)-- The New York Times Company announced today that its Board of Directors has nominated Margot Golden Tishler to stand for election as a director at its 2024 annual meeting of stockholders on April 24. All current directors are expected to stand for re-election with the exception of Hays N. Golden, a director since 2017, who is stepping down. ""I am delighted to have Margot nominated to serve on our Board,"" said A.G. Sulzberger, chairman of The New York Times Company. ""As a fifth-generation member of the Ochs/Sulzberger family, she brings a deep understanding of our Company's mission and business objectives. I am very grateful to Hays for his seven years of service to our Board. He’s served during a period of challenge and transformation for The Times, and we’ve been so lucky to have his wisdom, sharp intellect and steadfastness in tackling tough questions and navigating difficult moments. Through it all, he’s shown a deep commitment to The Times and our mission.” Ms. Tishler, 47, serves as the chair of the Ochs-Sulzberger Trust. She is a freelance graphic designer and manages a company that sells accessories for children’s clothing. She holds an associate degree in graphic design from Pratt Institute. Dr. Golden joined the Board in 2017 and has served on the Finance Committee for his full tenure. About The New York Times Company The New York Times Company (NYSE: NYT) is a trusted source of quality, independent journalism whose mission is to seek the truth and help people understand the world. With more than 10 million subscribers across a diverse array of print and digital products — from news to cooking to games to sports — The Times has evolved from a local and regional news leader into a diversified media company with curious readers, listeners and viewers around the globe. Follow news about the company at NYTCo.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216360509/en/ Investors: Anthony DiClemente, 212-556-7661, anthony.diclemente@nytimes.com Media: Danielle Rhoades Ha, 212-556-8719, danielle.rhoades-ha@nytimes.com Source: The New York Times Company Who has The New York Times Company nominated as a director for the 2024 annual meeting? Margot Golden Tishler When is the 2024 annual meeting of The New York Times Company stockholders? April 24 Who is stepping down from The New York Times Company Board of Directors? Hays N. Golden What is Margot Golden Tishler's role at The New York Times Company? Nominee for director, chair of the Ochs-Sulzberger Trust What is Margot Golden Tishler's background? Freelance graphic designer with an associate degree in graphic design from Pratt Institute"
Cue Health Announces Appointment of Rishi Reddy to Board of Directors,2024-02-16T22:00:00.000Z,Low,Very Positive,Cue Health (HLTH) partners with Tarsadia Investments and appoints Rishi Reddy to its Board of Directors. The company aims to enhance shareholder value and improve operational efficiency.,"Cue Health Announces Appointment of Rishi Reddy to Board of Directors Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags management Rhea-AI Summary Cue Health (HLTH) partners with Tarsadia Investments and appoints Rishi Reddy to its Board of Directors. The company aims to enhance shareholder value and improve operational efficiency. Positive None. Negative None. 02/16/2024 - 05:00 PM SAN DIEGO--(BUSINESS WIRE)-- Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the “Cooperation Agreement”) with Tarsadia Investments (“Tarsadia”), and appointed Rishi Reddy to its board of directors (the “Board”), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm’s venture and growth equity strategy. He was previously an Observer on Cue’s Board of Directors from April 2018 to September 2021. In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board. “Cue remains focused on creating value for all of its stakeholders,” said Ayub Khattak, Chairman and CEO of Cue. “We look forward to Rishi’s contributions as a director and to continuing our collaborative relationship.” “Cue’s industry-leading technology has the potential to transform how acute and chronic conditions are diagnosed and managed,” said Mr. Reddy. “Tarsadia is Cue’s largest shareholder, and I am joining the Board because I believe there is an opportunity to create significant value for shareholders. I am looking forward to working with the Board and supporting the management team as they execute on initiatives to improve its cost structure and drive greater operational efficiency.” With the appointment of Mr. Reddy, Cue’s Board will expand to eight directors. The complete Cooperation Agreement between Cue and Tarsadia will be included as an exhibit to a Current Report on Form 8-K, which will be filed by Cue with the Securities and Exchange Commission. About Rishi Reddy Mr. Reddy is a Managing Director at Tarsadia Investments, where he focuses on partnering with durable, transformative companies across the healthtech and fintech ecosystems. Prior to Tarsadia, Mr. Reddy was the founder and CEO of DigiPath Solutions, an early innovator in the digital anatomic pathology space. After joining Tarsadia, he helped build the venture and growth practice. Mr. Reddy currently serves on the Boards of AvantStay, Phil, Chronus Health, Fathom, Continental Hospitals, and Envisics, and is a board observer at BoltTech, YieldStreet and Petal. He received a B.S. in Management from Babson College and an M.B.A. from the University of Pennsylvania’s Wharton School. About Cue Health Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive this FDA approval. Cue also received Emergency Use Authorization from the FDA for its molecular mpox test at the point-of-care. To further expand its test menu, Cue has made other submissions that are now under review by the FDA, including for the Cue® Flu + COVID-19 Molecular Test and the Cue® RSV Molecular Test, both of which are designed for at-home and point-of-care use. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216313644/en/ Investor Relations ir@cuehealth.com Media Relations press@cuehealth.com FGS Global CueHealth@fgsglobal.com Source: Cue Health Inc. What is the recent cooperation agreement announced by Cue Health (HLTH)? Cue Health (HLTH) entered into a cooperation agreement with Tarsadia Investments and appointed Rishi Reddy to its Board of Directors. Who is Rishi Reddy and what role does he play in Cue Health (HLTH)? Rishi Reddy, a Managing Director at Tarsadia Investments, joins Cue Health (HLTH) Board of Directors to contribute to creating value for shareholders. How many directors will Cue Health (HLTH) have on its Board with the appointment of Mr. Reddy? With the appointment of Mr. Reddy, Cue Health's Board will expand to eight directors. What is the goal of Cue Health (HLTH) with the new appointment and cooperation agreement? Cue Health (HLTH) aims to enhance shareholder value, improve operational efficiency, and transform how acute and chronic conditions are diagnosed and managed."
,,,,,
,,,,,
,,,,,
,,,,,
Westlake Corporation Declares Quarterly Dividend,2024-02-16T21:15:00.000Z,Low,Neutral,"Westlake Corporation (WLK) declares a dividend of $0.50 per share for the fourth quarter of 2024, payable on March 14, 2024. This marks the 78th consecutive quarterly dividend since the company's IPO in 2004.","Westlake Corporation Declares Quarterly Dividend Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags dividends Rhea-AI Summary Westlake Corporation (WLK) declares a dividend of $0.50 per share for the fourth quarter of 2024, payable on March 14, 2024. This marks the 78th consecutive quarterly dividend since the company's IPO in 2004. Positive None. Negative None. Financial Analyst The announcement of a $0.50 per share dividend by Westlake Corporation is a tangible return to shareholders and can be indicative of the company's financial health and confidence in its cash flow stability. Dividends are a critical aspect of the total return on investment for shareholders and can influence the company's stock price. The fact that this is the 78th successive quarterly dividend suggests a consistent return to shareholders, which can be appealing to income-focused investors. It is also a sign of financial discipline and a shareholder-friendly capital allocation policy.From a financial analysis standpoint, it is important to assess the dividend yield, which is the dividend per share divided by the stock price. This yield is compared against industry benchmarks and historical company levels to evaluate attractiveness. Furthermore, the payout ratio, which is the proportion of earnings paid out as dividends, should be sustainable over the long term without compromising the company's growth prospects or financial stability. Market Research Analyst Regular dividends can be a signal to the market about the company's current performance and future outlook. The consistent history of dividend payments by Westlake Corporation may be interpreted as a positive indicator by the market, potentially leading to increased investor confidence and demand for the stock. However, it is also essential to consider market conditions and investor sentiment, as these factors can significantly impact how the news is received and the subsequent effect on the stock price.Analysts would also consider the company's position within the industry and compare its dividend policy to its peers. A higher or more stable dividend can differentiate Westlake Corporation from its competitors, potentially making it a more attractive investment in the eyes of dividend-seeking shareholders. Economist Dividend declarations can also be reflective of broader economic conditions. In a stable or growing economy, companies may have more confidence in maintaining or increasing dividends. Conversely, during economic downturns, dividend cuts or suspensions are more common as companies conserve cash. The ability of Westlake Corporation to sustain dividends over multiple quarters, including periods of economic uncertainty, can be a testament to its resilience and strategic financial management.It is also pertinent to analyze the potential impact of such distributions on the company's capital structure and investment in growth opportunities. While dividends are beneficial for shareholders, they represent cash outflows that could otherwise be used for reinvestment in the business. An optimal balance is crucial to ensure long-term value creation. 02/16/2024 - 04:15 PM $0.50 per share dividend declared payable on March 14, 2024 HOUSTON--(BUSINESS WIRE)-- The Board of Directors of Westlake Corporation (NYSE: WLK) today declared a regular dividend distribution of 50 cents per share for the fourth quarter of 2024. This dividend will be payable on March 14, 2024, to stockholders of record on February 28, 2024. This is the 78th successive quarterly dividend that Westlake has declared since completing its initial public offering in August 2004. The statements in this release that are not historical facts, including statements regarding future repurchases of common stock, are forward-looking statements. These forward-looking statements are subject to significant risks and uncertainties. Actual results could differ materially, based on factors including, but not limited to, the ultimate timing, outcome and results of integrating the operations of recent acquisitions; general economic and business conditions; the cyclical nature of the chemical and building products industries; availability, cost and volatility of raw materials and utilities; uncertainties associated with the United States, European and worldwide economies, including those due to political tensions and unrest; uncertainties associated with pandemic infectious diseases; and other risk factors. For more detailed information about the factors that could cause actual results to differ materially, please refer to Westlake’s Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC in February 2023, and Westlake’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023, which were filed with the SEC in May and August 2023, respectively. About Westlake Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the Company's web site at www.westlake.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216973873/en/ Media Inquiries: Westlake Corp. Ben Ederington, 713-960-9111 or Investor Inquiries: Westlake Corp. Steve Bender, 713-960-9111 Source: Westlake Corporation When will Westlake Corporation (WLK) pay the dividend for the fourth quarter of 2024? Westlake Corporation (WLK) will pay the dividend of $0.50 per share for the fourth quarter of 2024 on March 14, 2024. How much is the dividend per share declared by Westlake Corporation (WLK) for the fourth quarter of 2024? Westlake Corporation (WLK) has declared a dividend of 50 cents per share for the fourth quarter of 2024. How many consecutive quarterly dividends has Westlake Corporation (WLK) declared since its IPO in 2004? Westlake Corporation (WLK) has declared 78 successive quarterly dividends since its initial public offering in August 2004."
"General American Investors Files Certified Shareholder Report for Year Ended December 31, 2023",2024-02-16T21:25:00.000Z,Low,Neutral,"General American Investors Company, Inc. (GAM) filed its Certified Shareholder Report with the SEC, revealing financial data for 2023. The report shows an increase in Net Assets Applicable to Common Stock, Net Investment Income, and Dividends to Common Shareholders compared to 2022. The Company also repurchased shares and disclosed its top stock holdings.","General American Investors Files Certified Shareholder Report for Year Ended December 31, 2023 Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary General American Investors Company, Inc. (GAM) filed its Certified Shareholder Report with the SEC, revealing financial data for 2023. The report shows an increase in Net Assets Applicable to Common Stock, Net Investment Income, and Dividends to Common Shareholders compared to 2022. The Company also repurchased shares and disclosed its top stock holdings. Positive Increase in Net Assets Applicable to Common Stock from $1,041,159,645 in 2022 to $1,233,031,938 in 2023. Net Investment Income rose from $5,508,597 in 2022 to $10,577,329 in 2023. Dividends to Common Shareholders increased from $36,099,231 in 2022 to $61,945,377 in 2023. Repurchased 776,220 shares of outstanding common stock in 2023. Top stock holdings include Republic Services, Microsoft Corporation, Alphabet Inc., Apple Inc., and Berkshire Hathaway, Inc. Negative None. Financial Analyst The recent filing by General American Investors Company, Inc. of its Certified Shareholder Report (Form N-CSR) for the year ended December 31, 2023, presents a substantial increase in net assets applicable to common stock, rising from approximately $1.04 billion in 2022 to $1.23 billion in 2023. This represents a noteworthy growth in shareholder equity, which is a critical indicator of the company's financial health and can affect investor confidence. The report also disclosed a significant improvement in net investment income, which doubled from $5.5 million in 2022 to $10.6 million in 2023, reflecting the company's ability to generate earnings from its investment portfolio.Moreover, the shift from a net loss on investments in 2022 to a net gain in 2023 is indicative of a successful investment strategy, especially during a period that has been volatile for the markets. The net gain on investments of approximately $262.8 million, compared to a net loss of $182.8 million the previous year, could suggest a strong recovery and effective portfolio management. Additionally, the company's strategy to repurchase shares when trading at a significant discount could potentially lead to accretion in shareholder value, as it may indicate management's confidence in the intrinsic value of the stock. Market Research Analyst The composition of General American Investors Company's portfolio, particularly the inclusion of large-cap stocks like Republic Services, Microsoft Corporation, Alphabet Inc., Apple Inc. and Berkshire Hathaway, Inc., is a strategic choice that may provide stability and growth. These companies are known for their robust market positions and have historically shown resilience in various market conditions. The emphasis on such blue-chip stocks could be appealing to conservative investors seeking long-term capital appreciation with potentially lower volatility.Furthermore, the company's long history since 1927 and its consistent public trading since its inception, contribute to its reputation and may instill a sense of reliability among investors. The authorization to repurchase preferred shares when trading below their liquidation value also suggests a proactive approach to capital management, which could be reassuring to preferred shareholders concerned about the preservation of capital. Economist General American Investors Company's performance, as indicated by the increase in net assets and net investment income, must be contextualized within the broader economic landscape of 2023. The reported financials suggest that the company navigated the economic conditions effectively, which may include fluctuating interest rates, inflationary pressures, or other macroeconomic factors. The ability to achieve capital appreciation in such an environment could be indicative of a robust investment strategy and a well-diversified portfolio.Additionally, the company's policy of repurchasing common shares at a discount greater than 8% could be seen as a strategic use of capital, particularly in a market that might be undervaluing the company's shares. This move could not only signal management's confidence to the market but also serve as a mechanism to support the stock price during periods of market undervaluation. 02/16/2024 - 04:25 PM NEW YORK--(BUSINESS WIRE)-- General American Investors Company, Inc., a closed-end investment company listed on the New York Stock Exchange (GAM), filed with the U.S. Securities and Exchange Commission (SEC) its Certified Shareholder Report (Form N-CSR) for the year ended December 31, 2023. The Form N-CSR, which contains the Company’s 2023 Annual Report, is available at the SEC’s website: www.sec.gov and the Company’s website: www.generalamericaninvestors.com. The 2023 Annual Report and the Proxy Statement, pertaining to the Company’s Annual Meeting of Stockholders to be held on April 24, 2024, are also available on the website. The Annual Report indicates that as of and for the year ended: 2023 2022 Net Assets Applicable to Common Stock $1,233,031,938 $1,041,159,645 Per Common Share $51.96* $43.42** Net Investment Income $10,577,329 $5,508,597 Per Common Share $0.44 $0.22 Net Gain (Loss) on Investments $262,826,469 ($182,783,273) Per Common Share $11.18 ($7.38) Common Shares Outstanding 23,732,324 23,979,022 Dividends and Distributions to Common Shareholders $61,945,377 $36,099,231 Per Common Share $2.65 $1.50 Dividends and Distributions to Preferred Shareholders $11,310,806 $11,311,972 Per Common Share $0.48 $0.47 * After dividends and distributions of $2.65 per share paid in December 2023. ** After dividends and distributions of $1.00 per share paid in December 2022 and $0.50 per share paid in February 2022. The Company also reported that it purchased 776,220 shares of its outstanding common stock in the open market during 2023. The Board of Directors has authorized repurchasing common shares when they are trading at a discount in excess of 8%. The Company is also authorized to repurchase up to a remaining 1,601,553 shares of its 5.95% Cumulative Preferred Stock, Series B (symbol GAM Pr B on NYSE) when they are trading at less than $25 per share. The aggregate liquidation value of the preferred stock is $190.0 million. The five largest stock holdings in the Company’s portfolio at December 31, 2023 included: Republic Services, Microsoft Corporation, Alphabet Inc., Apple Inc., and Berkshire Hathaway, Inc. General American Investors was founded in 1927, has been publicly traded since its inception and has been listed on the NYSE since 1930. The objective of the Company is long-term capital appreciation through investment in companies with above average growth potential. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216612325/en/ Eugene S. Stark Vice-President, Administration (212) 916-8447 Source: General American Investors Company, Inc. What is the Net Assets Applicable to Common Stock for General American Investors in 2023? General American Investors' Net Assets Applicable to Common Stock for 2023 is $1,233,031,938. How much did General American Investors' Net Investment Income increase by from 2022 to 2023? General American Investors' Net Investment Income increased from $5,508,597 in 2022 to $10,577,329 in 2023. What was the total Dividends and Distributions to Common Shareholders in 2023 for General American Investors? General American Investors paid $61,945,377 in Dividends and Distributions to Common Shareholders in 2023. How many shares of its outstanding common stock did General American Investors repurchase in 2023? General American Investors repurchased 776,220 shares of its outstanding common stock in 2023. What are the top five stock holdings in General American Investors' portfolio as of December 31, 2023? The top five stock holdings in General American Investors' portfolio as of December 31, 2023, include Republic Services, Microsoft Corporation, Alphabet Inc., Apple Inc., and Berkshire Hathaway, Inc."
Finance of America Receives Continued Listing Standard Notice from the NYSE,2024-02-16T21:23:00.000Z,Moderate,Neutral,Finance of America Companies Inc. (FOA) received a notice from the NYSE stating non-compliance with the average closing price requirement. The company has a six-month cure period to meet the $1.00 per share threshold. FOA plans to notify the NYSE of its intention to regain compliance and explore available options.,"Finance of America Receives Continued Listing Standard Notice from the NYSE Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Finance of America Companies Inc. (FOA) received a notice from the NYSE stating non-compliance with the average closing price requirement. The company has a six-month cure period to meet the $1.00 per share threshold. FOA plans to notify the NYSE of its intention to regain compliance and explore available options. Positive None. Negative None. Financial Analyst When a company's stock price falls below the NYSE's minimum average closing price requirement, it signifies potential financial instability or a lack of investor confidence. This situation often leads to increased market scrutiny and can impact investor perception. Stakeholders should monitor the company's financial performance and management's strategic initiatives to address this issue. The company must take corrective actions, such as financial restructuring, cost optimization, or strategic partnerships, to improve its stock performance and regain compliance.However, these actions could come with risks such as dilution of existing shares if the company opts for a reverse stock split or additional equity financing. Stakeholders should evaluate the company's long-term value proposition and the effectiveness of its turnaround strategies. It is also crucial to assess the broader market conditions and sector performance, as these can influence the stock's recovery prospects. Market Research Analyst The NYSE's compliance notice serves as a market signal that can influence investor sentiment and the company's reputation. Competitors might leverage this opportunity to position themselves more favorably in the market. It is essential to analyze industry trends and the competitive landscape to understand how this development could affect the company's market share and growth prospects.Consumer confidence and partner relations may also be impacted, potentially affecting the company's operations and revenue streams. The company's ability to regain compliance within the six-month cure period is critical to maintaining its listing status and avoiding further negative market perception. The effectiveness of the company's communication strategy in addressing these concerns and articulating a clear path to compliance will be key to stabilizing its stock price. Legal Expert The legal implications of a NYSE compliance notice require careful navigation. The company must adhere to strict regulatory timelines and procedures to regain compliance, failing which could lead to delisting. Delisting can have severe consequences, including reduced liquidity and access to capital markets, which could hamper the company's growth and operational capabilities.Furthermore, the company's governance practices may come under scrutiny as it seeks shareholder approval for any measures that may be necessary to address the price condition. This process must be transparent and comply with SEC regulations to maintain shareholder trust and avoid legal complications. The company's legal team must ensure adherence to all regulatory requirements during this period to minimize the risk of further regulatory sanctions or shareholder litigation. 02/16/2024 - 04:23 PM PLANO, Texas--(BUSINESS WIRE)-- The New York Stock Exchange (the “NYSE”) requires that companies with shares listed on the NYSE comply with the NYSE’s continued listed standards. The NYSE’s continued listing standards include the requirement set forth in Section 802.01C of the NYSE Listed Company Manual that the average closing price of a security is not less than $1.00 over a consecutive 30 trading-day period. If the average closing price of a security is less than $1.00 over a consecutive 30 trading-day period, then Section 802.01C of the NYSE Listed Company Manual provides for a six month cure period to regain compliance. Compliance can be achieved if on the last trading day of any calendar month during the cure period (or the last trading day of the cure period), the security has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the prior 30 trading-day period. Further, if a company determines that, if necessary, it will cure the price condition by taking an action that will require approval of its shareholders, it must so inform the NYSE, obtain the shareholder approval by no later than its next annual meeting and implement the action promptly thereafter. In such circumstances, the price condition will be deemed cured if the price of the security promptly exceeds $1.00 per share and the price remains above the level for at least the following 30 trading days. On February 12, 2024, Finance of America Companies Inc. (“Finance of America” or the “Company”) (NYSE: FOA) received a notice (the “Notice”) from the NYSE, indicating the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because as of February 9, 2024, the average closing price of the Company’s Class A Common Stock was less than $1.00 over a consecutive 30 trading-day period. The Notice has no immediate effect on the listing of the Class A Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements. Furthermore, the Notice is not anticipated to impact the ongoing business operations of the Company or its reporting requirements with the U.S. Securities and Exchange Commission (the “SEC”). Finance of America plans to notify the NYSE within ten business days of its receipt of the Notice that it intends to bring the Company into compliance with this listing standard within the six month cure period. Finance of America intends to remain listed on the NYSE and is considering all available options to regain compliance with the NYSE’s continued listing standards. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the Company’s ability to regain compliance with the NYSE’s continued listing standards. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only management’s beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These statements are subject to risks, uncertainties, assumptions, and other important factors. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements can be found in the section entitled “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 16, 2023, as such factors may be amended and updated from time to time in the Company’s subsequent periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. Finance of America assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216095649/en/ For Finance of America Media: pr@financeofamerica.com For Finance of America Investor Relations: ir@financeofamerica.com Source: Finance of America Companies Inc. What notice did Finance of America (FOA) receive from the NYSE? Finance of America received a notice from the NYSE stating non-compliance with Section 802.01C of the NYSE Listed Company Manual due to the average closing price of its Class A Common Stock being less than $1.00 over a consecutive 30 trading-day period. What is the consequence of not meeting the average closing price requirement on the NYSE? Non-compliance with the average closing price requirement may lead to a delisting of the stock from the NYSE, subject to the company's ability to regain compliance within the specified cure period. How long is the cure period given by the NYSE for non-compliance with the average closing price requirement? The NYSE provides a six-month cure period for companies to meet the $1.00 per share threshold if their average closing price falls below that level over a consecutive 30 trading-day period. What action must Finance of America take if shareholder approval is required to cure the price condition? If shareholder approval is needed to cure the price condition, Finance of America must inform the NYSE, obtain shareholder approval by the next annual meeting, and promptly implement the action to regain compliance. Is Finance of America (FOA) at risk of delisting from the NYSE? While non-compliance with the average closing price requirement poses a risk of delisting, Finance of America plans to notify the NYSE of its intention to bring the company into compliance within the cure period."
"CF Industries Holdings, Inc. to Participate in Upcoming Investor Conferences",2024-02-16T21:30:00.000Z,Low,Very Positive,"CF Industries Holdings, Inc. (NYSE: CF) will be presenting at several upcoming investor conferences in February 2024, providing an opportunity for investors to gain insights into the company's operations and future prospects.","CF Industries Holdings, Inc. to Participate in Upcoming Investor Conferences Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags conferences Rhea-AI Summary CF Industries Holdings, Inc. (NYSE: CF) will be presenting at several upcoming investor conferences in February 2024, providing an opportunity for investors to gain insights into the company's operations and future prospects. Positive None. Negative None. 02/16/2024 - 04:30 PM NORTHBROOK, Ill.--(BUSINESS WIRE)-- CF Industries Holdings, Inc. (NYSE: CF) today announced that the Company will present at the following upcoming investor conferences: Citi’s 2024 Global Industrial Tech and Mobility Conference at 11:20 am ET on Wednesday, February 21, 2024. Barclays Industrial Select Conference at 8:00 am ET on Thursday, February 22, 2024. BofA Global Agriculture and Materials Conference 2024 at 9:50 am ET on Thursday, February 29, 2024. Investors who wish to access the live conference webcasts should visit the Investor Relations section of the company’s website at www.cfindustries.com. A replay of the webcasts will be available on the CF Industries Holdings, Inc. website for 180 days following the events. About CF Industries Holdings, Inc. At CF Industries, our mission is to provide clean energy to feed and fuel the world sustainably. With our employees focused on safe and reliable operations, environmental stewardship, and disciplined capital and corporate management, we are on a path to decarbonize our ammonia production network – the world’s largest – to enable green and blue hydrogen and nitrogen products for energy, fertilizer, emissions abatement and other industrial activities. Our manufacturing complexes in the United States, Canada, and the United Kingdom, an unparalleled storage, transportation and distribution network in North America, and logistics capabilities enabling a global reach underpin our strategy to leverage our unique capabilities to accelerate the world’s transition to clean energy. CF Industries routinely posts investor announcements and additional information on the Company’s website at www.cfindustries.com and encourages those interested in the Company to check there frequently. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216461961/en/ Media Chris Close Senior Director, Corporate Communications 847-405-2542 – cclose@cfindustries.com Investors Darla Rivera Director, Investor Relations 847-405-2045 – darla.rivera@cfindustries.com Source: CF Industries Holdings, Inc When will CF Industries Holdings, Inc. present at Citi’s Global Industrial Tech and Mobility Conference? CF Industries Holdings, Inc. will present at Citi’s Global Industrial Tech and Mobility Conference at 11:20 am ET on Wednesday, February 21, 2024. What time is CF Industries Holdings, Inc. scheduled to present at Barclays Industrial Select Conference? CF Industries Holdings, Inc. is scheduled to present at Barclays Industrial Select Conference at 8:00 am ET on Thursday, February 22, 2024. Where can investors access the live conference webcasts of CF Industries Holdings, Inc.? Investors can access the live conference webcasts of CF Industries Holdings, Inc. by visiting the Investor Relations section of the company’s website at www.cfindustries.com. How long will the replay of the webcasts be available on CF Industries Holdings, Inc. website? The replay of the webcasts will be available on the CF Industries Holdings, Inc. website for 180 days following the events."
"Globalstar, Inc. Earnings Release and Call Notice",2024-02-16T21:53:00.000Z,Low,Positive,"Globalstar, Inc. (GSAT) will announce its Q4 and annual 2023 financial results on February 28, 2024. A conference call will be held to discuss the results.","Globalstar, Inc. Earnings Release and Call Notice Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags earnings Rhea-AI Summary Globalstar, Inc. (GSAT) will announce its Q4 and annual 2023 financial results on February 28, 2024. A conference call will be held to discuss the results. Positive None. Negative None. 02/16/2024 - 04:53 PM COVINGTON, La.--(BUSINESS WIRE)-- Globalstar, Inc. (NYSE American: GSAT) will announce its fourth quarter and annual 2023 financial and operating results on Wednesday, February 28, 2024 before the market opens. The release will be available over the wire and from the Globalstar, Inc. website at www.globalstar.com. The Company will also conduct a conference call on Wednesday, February 28, 2024 at 9:00 a.m. Eastern Time (ET) to discuss these results. Details are as follows: Earnings Call: The earnings call will be available via webcast from the following link. Webcast Link: https://edge.media-server.com/mmc/p/wmykc7an To participate in the earnings call via teleconference, participants should register at the following link to receive an email containing the dial-in number and unique passcode. Participant Teleconference Registration Link: https://register.vevent.com/register/BI4278f818741f4629a5509ede176b0a4d Audio Replay: For those unable to participate in the live call, a replay of the webcast will be available in the Investor Relations section of our website. About Globalstar, Inc. Globalstar empowers its customers to connect, transmit, and communicate in smarter ways – easily, quickly, securely, and affordably – offering reliable satellite and terrestrial connectivity services as an international telecom infrastructure provider. The Company’s LEO satellite constellation assures secure data transmission for connecting and protecting assets, transmitting critical operational data, and saving lives for consumers, businesses, and government agencies across the globe. Globalstar’s terrestrial spectrum, Band 53, and its 5G variant, n53, offers carriers, cable companies, and system integrators a versatile, fully licensed channel for private networks with a growing ecosystem to improve customer wireless connectivity, while Globalstar’s XCOM RAN product offers significant capacity gains in dense wireless deployments. In addition to SPOT GPS messengers, Globalstar offers next-generation IoT hardware and software products for efficiently tracking and monitoring assets, processing smart data at the edge, and managing analytics with cloud-based telematics solutions to drive safety, productivity, and profitability. Note that all SPOT products described in this press release are the products of SPOT LLC, which is not affiliated in any manner with Spot Image of Toulouse, France or Spot Image Corporation of Chantilly, Virginia. For more information, visit www.globalstar.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216630226/en/ Investor Contact Information: investorrelations@globalstar.com Source: Globalstar, Inc. When will Globalstar, Inc. announce its Q4 and annual 2023 financial results? Globalstar, Inc. (GSAT) will announce its fourth quarter and annual 2023 financial and operating results on Wednesday, February 28, 2024 before the market opens. What is the ticker symbol for Globalstar, Inc.? The ticker symbol for Globalstar, Inc. is GSAT. How can I access the earnings call webcast? The earnings call webcast will be available via the following link: https://edge.media-server.com/mmc/p/wmykc7an When is the earnings call scheduled to take place? The earnings call is scheduled for Wednesday, February 28, 2024 at 9:00 a.m. Eastern Time (ET). Where can I find the audio replay of the earnings call? For those unable to participate in the live call, a replay of the webcast will be available in the Investor Relations section of Globalstar, Inc.'s website."
,,,,,
CNX Resources Corporation Announces Pricing Terms of Cash Tender Offer for its 7.250% Senior Notes due 2027,2024-02-16T21:15:00.000Z,Neutral,Neutral,"CNX Resources Corporation announces pricing terms for cash tender offer of 7.250% Senior Notes due 2027, offering Purchase Price and accrued interest. The Tender Offer is conditioned on a new notes offering. CNX also issues conditional notice for Redemption of unsold Notes.","CNX Resources Corporation Announces Pricing Terms of Cash Tender Offer for its 7.250% Senior Notes due 2027 Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary CNX Resources Corporation announces pricing terms for cash tender offer of 7.250% Senior Notes due 2027, offering Purchase Price and accrued interest. The Tender Offer is conditioned on a new notes offering. CNX also issues conditional notice for Redemption of unsold Notes. Positive None. Negative None. Financial Analyst The tender offer announced by CNX Resources Corporation for its 7.250% Senior Notes due 2027 represents a strategic financial maneuver aimed at managing the company's debt profile. The repurchase of these notes at a premium, set by a fixed spread plus the yield of a reference U.S. Treasury security, is a common practice known as a 'yield to worst' calculation. The fixed spread of 0 basis points indicates that CNX is offering to buy back the notes at the yield equivalent to the reference Treasury rate. This could imply that the company is confident about its liquidity position and the success of its concurrent new notes offering.From a financial perspective, this transaction could be beneficial for CNX as it may result in interest cost savings if the new notes offering has a lower interest rate compared to the existing 7.250% notes. Additionally, the tender offer may also be seen as a signal to the market that CNX is proactive in managing its debt and could potentially improve its credit rating over time. However, the timing and success of the tender offer and subsequent redemption are contingent upon the completion of the new notes offering, which introduces a degree of uncertainty for investors and the company alike. Market Research Analyst The natural gas sector, where CNX Resources Corporation operates, is subject to volatile market conditions influenced by a myriad of factors including geopolitical events, regulatory changes and shifts in supply and demand dynamics. CNX's decision to repurchase its outstanding senior notes could be interpreted as an effort to optimize its capital structure amidst such volatility. This move might also be indicative of the company's broader strategy to maintain financial flexibility, which is crucial in the energy industry where companies must swiftly adapt to changing market conditions.Moreover, the announcement of this tender offer and potential redemption could have an impact on CNX's stock market performance. Investors typically view such financial strategies as positive when they lead to a stronger balance sheet and reduced interest expense. However, the market will also consider the terms of the new notes offering and the company's future debt servicing capabilities. It is important for current and potential investors to monitor these developments closely as they could influence CNX's financial health and stock valuation. Legal Expert The tender offer and subsequent redemption of notes are governed by complex legal documents and securities regulations. CNX Resources Corporation must adhere to the covenants outlined in the indenture agreement of the 7.250% Senior Notes due 2027. The company's ability to issue a conditional notice of redemption is contingent upon the fulfillment of specific conditions, including the successful closing of the new notes offering and the receipt of sufficient net proceeds. Failure to meet these conditions could result in the termination of the redemption and rescission of the notice, which would have legal implications for CNX and its investors.Additionally, the press release's cautionary statements highlight the regulatory compliance aspect of such transactions, emphasizing that the tender offer is not a solicitation for sales or purchases in jurisdictions where it would be unlawful without appropriate registration or exemptions. It is crucial for CNX to navigate these legal intricacies carefully to avoid potential regulatory issues and to ensure the successful completion of their financial restructuring activities. 02/16/2024 - 04:15 PM PITTSBURGH, Feb. 16, 2024 /PRNewswire/ -- CNX Resources Corporation (NYSE: CNX) (""CNX"") today announced the pricing terms of the previously announced cash tender offer to purchase (the ""Tender Offer"") any and all of its outstanding 7.250% Senior Notes due 2027 (the ""Notes""). The ""Purchase Price"" for each $1,000 principal amount of the Notes validly tendered, and not validly withdrawn, and accepted for purchase pursuant to the Tender Offer will be determined in the manner described in the Offer to Purchase by reference to the fixed spread specified below plus the yield based on the bid-side price of the U.S. Treasury Reference Security specified below as of 2:00 p.m. New York City time today, the date on which the Tender Offer is currently scheduled to expire. The Purchase Price is based on a yield to March 14, 2024, the date of the next specified redemption price reduction under the indenture governing the Notes, and assuming the Notes are redeemed on March 14, 2024, at the specified redemption price for such date of 101.813% of the principal amount, as described in the Offer to Purchase. Title of Security CUSIP Principal AmountOutstanding U.S. Treasury Reference Security Bloomberg ReferencePage Reference Yield Fixed Spread (basis points) PurchasePrice 7.250% Senior Notes due 2027 144A (12653CAC2) Reg S (U1749LAB0) $350,000,000 0.250% U.S. Treasury due March 15, 2024 FIT3 5.536 % 0 $1,018.97 In addition to the Purchase Price, holders whose Notes are purchased pursuant to the Tender Offer will also receive accrued and unpaid interest thereon from the last interest payment date up to, but not including, the initial date on which CNX makes payment for such Notes, which date is currently expected to be February 23, 2024, assuming that the Tender Offer is not extended or earlier terminated. The Tender Offer is being made pursuant to the terms and conditions contained in the Offer to Purchase and Notice of Guaranteed Delivery, copies of which may be obtained from Global Bondholder Services Corporation, the tender agent and information agent for the Tender Offer, by calling (855) 654-2015 (toll free) or, for banks and brokers, (212) 430-3774 or by email at contact@gbsc-usa.com. The Tender Offer will expire at 5:00 p.m. New York City Time today, unless extended or earlier terminated (such time and date as the same may be extended, the ""Expiration Time""). Tendered Notes may be withdrawn at any time before the Expiration Time. Holders of Notes must validly tender and not validly withdraw their Notes (or comply with the procedures for guaranteed delivery) before the Expiration Time to be eligible to receive the Purchase Price for their Notes. The Tender Offer is conditioned upon the satisfaction of certain conditions, including the completion of a contemporaneous notes offering by CNX (the ""new notes offering"") on terms and conditions (including, but not limited to, the amount of proceeds raised in such offering) satisfactory to CNX. The Tender Offer is not conditioned upon any minimum amount of Notes being tendered and the Tender Offer may be amended, extended, terminated or withdrawn, subject to applicable law. Concurrently with the commencement of the Tender Offer, CNX issued a conditional notice, pursuant to the indenture governing the Notes, to redeem (the ""Redemption"") all Notes not purchased in the Tender Offer, at a redemption price of 101.813% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date of March 14, 2024 (the ""redemption date""). The Redemption is conditioned on the closing of CNX's new notes offering and its receipt of net proceeds from such offering, and there can be no assurance the Redemption will be completed. The Redemption may be terminated and the redemption notice may be rescinded in the event such conditions shall not have been satisfied by the redemption date. CNX has retained J.P. Morgan Securities LLC to serve as the Lead Dealer Manager and TD Securities (USA) LLC to serve as the Dealer Manager for the Tender Offer. Questions regarding the terms of the Tender Offer may be directed to J.P. Morgan Securities LLC, Liability Management Group, at (866) 834-4666 (U.S. toll free) or (212) 834-4087 (collect). CNX Resources Corporation (NYSE: CNX) is a premier, ultra-low carbon intensive natural gas development, production, midstream, and technology company centered in Appalachia, one of the most energy abundant regions in the world. With the benefit of a 160-year regional legacy, substantial asset base, leading core operational competencies, technology development and innovation, and astute capital allocation methodologies, we responsibly develop our resources and deploy free cash flow to create long-term per share value for our shareholders, employees, and the communities where we operate. As of December 31, 2023, CNX had 8.74 trillion cubic feet equivalent of proved natural gas reserves. Cautionary Statements: This press release does not constitute an offer to purchase or the solicitation of an offer to sell any Notes in the Tender Offer, nor does it constitute a notice of redemption under the indenture governing the 2027 Notes . In addition, this press release is not an offer to sell or the solicitation of an offer to buy any securities issued in connection with any contemporaneous notes offering, nor shall there be any sale of the securities issued in such offering in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Various statements in this release, including those that express a belief, expectation or intention, may be considered forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) that involve risks and uncertainties that could cause actual results to differ materially from projected results. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. The forward-looking statements may include projections and estimates concerning the timing and success of specific projects and our future production, revenues, income and capital spending. When we use the words ""believe,"" ""intend,"" ""expect,"" ""may,"" ""should,"" ""anticipate,"" ""could,"" ""estimate,"" ""plan,"" ""predict,"" ""project,"" ""will,"" or their negatives, or other similar expressions, the statements which include those words are usually forward-looking statements. When we describe strategy that involves risks or uncertainties, we are making forward-looking statements. The forward-looking statements in this press release, including those relating to the offer, the new notes offering and the Redemption, speak only as of the date of this press release; we disclaim any obligation to update these statements. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. These risks, contingencies and uncertainties relate to, among other matters, the factors discussed in our 2023 Annual Report on Form 10-K under ""Risk Factors,"" which is on file at the U.S. Securities and Exchange Commission. View original content to download multimedia:https://www.prnewswire.com/news-releases/cnx-resources-corporation-announces-pricing-terms-of-cash-tender-offer-for-its-7-250-senior-notes-due-2027--302064430.html SOURCE CNX Resources Corporation What are the details of CNX's cash tender offer for 7.250% Senior Notes due 2027? CNX announced the pricing terms for the Tender Offer, including the Purchase Price based on a fixed spread and yield, with a reference to the U.S. Treasury Reference Security. What is the Purchase Price for each $1,000 principal amount of Notes tendered? The Purchase Price for each $1,000 principal amount of Notes validly tendered is $1,018.97. What additional benefits do holders receive if their Notes are purchased through the Tender Offer? Holders will also receive accrued and unpaid interest from the last interest payment date up to the initial payment date by CNX. What is the deadline for the Tender Offer to expire? The Tender Offer will expire at 5:00 p.m. New York City Time today unless extended or earlier terminated. What is the condition for the Redemption of unsold Notes? The Redemption of unsold Notes is conditioned on the closing of CNX's new notes offering and its receipt of net proceeds from such offering."
iAnthus Announces Restatement of Third Quarter 2023 Financial Results,2024-02-16T21:45:00.000Z,Low,Negative,"iAnthus Capital Holdings, Inc. announces errors in financial reporting process leading to overstatement of inventory in previously issued unaudited interim financial statements. The company will amend its Quarterly Report on Form 10-Q filed with the SEC and restated financial statements by February 29, 2024.","iAnthus Announces Restatement of Third Quarter 2023 Financial Results Rhea-AI Impact (Low) Rhea-AI Sentiment (Negative) Tags earnings Rhea-AI Summary iAnthus Capital Holdings, Inc. announces errors in financial reporting process leading to overstatement of inventory in previously issued unaudited interim financial statements. The company will amend its Quarterly Report on Form 10-Q filed with the SEC and restated financial statements by February 29, 2024. Positive None. Negative Material misstatement in Third Quarter 2023 Interim Financial Statements due to errors in financial reporting process Overstatement of 'inventories, net' and 'accrued and other current liabilities' on balance sheet as of September 30, 2023 Overstatement of 'income tax expense' and understatement of 'cost and expenses applicable to revenues' on statements of operations for the three and nine months ended September 30, 2023 02/16/2024 - 04:45 PM NEW YORK and TORONTO, Feb. 16, 2024 /PRNewswire/ - February 16, 2024 – iAnthus Capital Holdings, Inc. (""iAnthus"" or the ""Company"") (CSE: IAN) (OTCQB: ITHUF), which owns, operates and partners with regulated cannabis operations across the United States, announces that, in connection with the preparation by the Company of its consolidated financial statements for the fiscal year ended December 31, 2023, the Company's management identified an error related to its financial reporting process in connection with an intercompany consolidation of two wholly-owned subsidiaries and in the valuation of inventory, both resulting in an overstatement of inventory in its previously issued unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2023, as contained in the Company's Quarterly Report on Form 10-Q for its fiscal quarter ended September 30, 2023 filed with the Securities and Exchange Commission (the ""SEC"") on November 9, 2023 and its corresponding management's discussion and analysis filed publicly on the System or Electronic Document Analysis and Retrieval (SEDAR+). (collectively, the ""Third Quarter 2023 Interim Financial Statements""). This error resulted in an overstatement of 'inventories, net' and 'accrued and other current liabilities' on the unaudited interim condensed consolidated balance sheet as of September 30, 2023, and an overstatement of 'income tax expense', and an understatement of 'cost and expenses applicable to revenues', on its unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2023. This error has no impact on the cash balance as of September 30, 2023, and results in no net change in cash flows for the nine months ended September 30, 2023. On February 13, 2024, the Audit Committee of the Company's Board of Directors concluded, after discussion with the Company's management and its advisors, that the Third Quarter 2023 Interim Financial Statements were materially misstated due to this error. As a result, the Third Quarter 2023 Interim Financial Statements and accompanying earnings release should no longer be relied upon. The Company anticipates making the appropriate adjustments in an amendment to its Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023, which will include restated unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2023, and any other appropriate revisions no later than February 29, 2024. The Restated Third Quarter 2023 Interim Financial Statements will also be publicly available on the Company's SEDAR+ profile. The Company will report these errors as material weaknesses and its intended remediation efforts within Item 4. Controls and Procedures in the amended Form 10Q for its fiscal quarter ended September 30, 2023. The Company's management and Audit Committee have discussed the matters disclosed in this release with its independent registered public accounting firm, PKF O'Connor Davies, LLP. About iAnthus iAnthus owns and operates licensed cannabis cultivation, processing and dispensary facilities throughout the United States. For more information, visit www.iAnthus.com. Forward Looking StatementsStatements in this news release contain forward-looking statements. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Company's reports that it files from time to time with the SEC and the Canadian securities regulators which you should review including, but not limited to, the Company's Annual Report on Form 10-K filed with the SEC. When used in this news release, words such as ""will,"" could,"" plan,"" estimate,"" expect,"" intend,"" may,"" potential,"" believe, ""should"" and similar expressions, are forward-looking statements. Forward-looking statements may include, without limitation, statements relating to the Company's financial performance, filing of financial statements, business development and results of operations. These forward-looking statements should not be relied upon as predictions of future events, and the Company cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward- looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by the Company or any other person that it will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this news release or to reflect the occurrence of unanticipated events, except as required by law. Neither the Canadian Securities Exchange nor the United States Securities and Exchange Commission has reviewed, approved or disapproved the content of this news release. View original content to download multimedia:https://www.prnewswire.com/news-releases/ianthus-announces-restatement-of-third-quarter-2023-financial-results-302064452.html SOURCE iAnthus Capital Holdings, Inc. What errors were identified by iAnthus Capital Holdings, Inc. in its financial reporting process? iAnthus identified errors related to intercompany consolidation of two wholly-owned subsidiaries and valuation of inventory, resulting in overstatement of inventory in its previously issued unaudited interim financial statements. When will iAnthus Capital Holdings, Inc. make the appropriate adjustments to its financial statements? The company anticipates making the appropriate adjustments in an amendment to its Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023, and restated financial statements by February 29, 2024. Who concluded that the Third Quarter 2023 Interim Financial Statements were materially misstated? The Audit Committee of the Company's Board of Directors concluded, after discussion with the Company's management and its advisors, that the Third Quarter 2023 Interim Financial Statements were materially misstated. What impact did the errors have on iAnthus Capital Holdings, Inc.'s cash balance as of September 30, 2023? The errors had no impact on the cash balance as of September 30, 2023, and resulted in no net change in cash flows for the nine months ended September 30, 2023. Which accounting firm did the Company's management and Audit Committee discuss the matters disclosed in the release with? The company discussed the matters with its independent registered public accounting firm, PKF O'Connor Davies, LLP."
,,,,,
Permianville Royalty Trust Announces Monthly Operational Update,2024-02-16T21:15:00.000Z,Low,Negative,"Permianville Royalty Trust (PVL) announces no monthly distribution for March 2024 due to $1.25 million shortfall from capital expenditures exceeding cash receipts. Oil and gas sales volumes, prices, and cash receipts declined month-over-month, with total accrued operating expenses at $2.8 million and capital expenditures increasing to $2.0 million.","Permianville Royalty Trust Announces Monthly Operational Update Rhea-AI Impact (Low) Rhea-AI Sentiment (Negative) Tags Rhea-AI Summary Permianville Royalty Trust (PVL) announces no monthly distribution for March 2024 due to $1.25 million shortfall from capital expenditures exceeding cash receipts. Oil and gas sales volumes, prices, and cash receipts declined month-over-month, with total accrued operating expenses at $2.8 million and capital expenditures increasing to $2.0 million. Positive Reported net profits interest calculation for February 2024 revealed a $1.25 million shortfall, leading to no monthly distribution for March 2024. Oil and gas sales volumes, prices, and cash receipts declined in the current month compared to the prior month. Total accrued operating expenses for the period were $2.8 million, with capital expenditures increasing to $2.0 million. Elevated capital expenditures led to direct operating and development expenses exceeding cash receipts, impacting the Trust's ability to make distributions to unitholders. The Trust anticipates a return to positive net profits later in 2024 based on current commodity prices. Negative No monthly distribution will be paid in March 2024 due to a $1.25 million shortfall from elevated capital expenditures. Oil and gas sales volumes, prices, and cash receipts declined month-over-month, indicating a negative trend in revenue generation. The Trust's total accrued operating expenses were $2.8 million, with an increase in capital expenditures to $2.0 million, potentially straining financial resources. If the Trust's cash on hand is insufficient to cover expenses, no further distributions will be made to unitholders until borrowed funds are repaid. Financial Analyst The announcement from Permianville Royalty Trust regarding its net profits interest calculation for February 2024 reveals significant financial metrics that can influence investor sentiment. The shortfall of approximately $1.25 million and the subsequent suspension of the March 2024 distribution to unitholders is a critical development. This situation stems from capital expenditures outpacing cash receipts, a scenario that may raise concerns about the Trust's near-term liquidity and cash flow management.Analysis of the reported sales volumes and prices indicates a decrease in oil production and a reduction in realized wellhead prices for oil and natural gas compared to the previous month. Such fluctuations in commodity prices and production volumes are inherent risks in the energy sector and can materially impact revenues. The decline in oil cash receipts is particularly noteworthy, as it suggests potential volatility in the Trust's revenue streams.Moreover, the increase in capital expenditures, primarily due to projects outlined in the Trust's Quarterly Report, reflects ongoing investment in the Underlying Properties. While such investments could potentially enhance future production and profitability, they currently contribute to the net profits shortfall. Investors should monitor the Trust's ability to manage these expenditures and the impact on future distributions. Energy Sector Analyst From an energy sector perspective, the details provided by Permianville Royalty Trust about its operational and financial performance are indicative of the challenges faced in the oil and gas industry. The Trust's reliance on the performance of its Underlying Properties and the volatility of oil and natural gas prices underscore the sector's sensitivity to market conditions.The reported decrease in average received wellhead prices for both oil and natural gas reflects broader market trends, which can be attributed to various factors including supply and demand dynamics, geopolitical events and macroeconomic factors. The Trust's exposure to these risks is evident in the reported month-over-month decline in revenue.It is also important to note the Trust's statement regarding the anticipated return to generating positive net profits later in 2024, based on current commodity prices. This forward-looking statement provides a glimpse into the management's expectations but should be taken with caution by investors, as commodity price forecasts are inherently uncertain and subject to change. Market Research Analyst Examining the impact of Permianville Royalty Trust's recent announcement on the broader market, it is clear that the Trust's financial health is closely tied to the performance of the energy sector. The shortfall and halted distribution might be interpreted as a negative signal, potentially affecting investor confidence not only in the Trust but also in similar entities within the market.Investors often look at distribution payments as a sign of a trust's financial stability and the health of its cash flow. The suspension of payments may lead to a reassessment of the Trust's valuation by the market. Additionally, the Trust's ability to cover ordinary course administrative expenses and the mention of possible borrowing or advances from the Sponsor to cover these expenses, could be seen as a red flag, indicating potential liquidity constraints.It is also worth considering the Trust's long-term prospects. While the short-term challenges are evident, the Trust's management anticipates a positive shift in net profits. This outlook may influence long-term investors who are willing to endure the current volatility in anticipation of future gains. However, such optimism must be balanced with a realistic assessment of the risks involved, including continued volatility in commodity prices and operational performance. 02/16/2024 - 04:15 PM HOUSTON--(BUSINESS WIRE)-- Permianville Royalty Trust (NYSE: PVL, the “Trust”) today announced the net profits interest calculation for February 2024. The net profits interest calculation represents reported oil production for the month of November 2023 and reported natural gas production during October 2023. The calculation includes accrued costs incurred in December 2023. As a result of the elevated capital expenditures recorded this month as described below, for which timing is not always ratable month-to-month, direct operating and development expenses exceeded cash receipts, leading to a shortfall of approximately $1.25 million this month. As a result, no monthly distribution will be paid in March 2024 to the Trust’s unitholders of record on February 29, 2024. The following table displays reported underlying oil and natural gas sales volumes and average received wellhead prices attributable to the current and prior month recorded net profits interest calculations. Underlying Sales Volumes Average Price Oil Natural Gas Oil Natural Gas Bbls Bbls/D Mcf Mcf/D (per Bbl) (per Mcf) Current Month 34,461 1,149 240,007 7,742 $ 78.56 $ 2.24 Prior Month 48,594 1,568 221,020 7,367 $ 86.50 $ 2.51 Recorded oil cash receipts from the oil and gas properties underlying the Trust (the “Underlying Properties”) totaled $2.7 million for the current month on realized wellhead prices of $78.56/Bbl, down $1.5 million from the prior month’s oil cash receipts. Oil production and oil cash receipts declined month-over-month partly because the prior month included the initial revenues from eight new Permian wells turned to sales, which also reflected revenues attributable to prior periods, resulting in elevated cash receipts from those wells last month. Recorded natural gas cash receipts from the Underlying Properties totaled $0.5 million for the current month on realized wellhead prices of $2.24/Mcf, down $0.1 million from the prior month. Total accrued operating expenses for the period were $2.8 million, a $0.1 million decrease month-over-month. Capital expenditures increased $1.4 million from the prior period to $2.0 million. The increase in capital expenditures was predominately related to multiple projects listed in the Trust’s Quarterly Report on Form 10-Q filed on November 14, 2023 (pertaining to the entity identified as Large Cap E&P 1 in the table presented under “Overview—Capital Drilling Activity Update” in Part I, Item 2 of the report). The cumulative shortfall in net profits for the current month will be deducted from any net profits in next month’s net profits interest calculation. The Trust will not receive proceeds pursuant to its net profits interest until the cumulative net profits shortfall is eliminated. In addition, if the Trust’s cash on hand is not sufficient to pay ordinary course administrative expenses and the Trust borrows funds or draws on the letter of credit that has been provided to the Trust, or if COERT Holdings 1, LLC (the “Sponsor”) advances funds to the Trust to pay such expenses, no further distributions will be made to Trust unitholders until such amounts borrowed or drawn, or advanced to the Trust, are repaid. At this time based on current commodity prices, the Sponsor anticipates that the Underlying Properties will return to generating positive net profits later in 2024. About Permianville Royalty Trust Permianville Royalty Trust is a Delaware statutory trust formed to own a net profits interest representing the right to receive 80% of the net profits from the sale of oil and natural gas production from certain, predominantly non-operated, oil and gas properties in the states of Texas, Louisiana and New Mexico. As described in the Trust’s filings with the Securities and Exchange Commission (the “SEC”), the amount of the periodic distributions is expected to fluctuate, depending on the proceeds received by the Trust as a result of actual production volumes, oil and gas prices, the amount and timing of capital expenditures, and the Trust’s administrative expenses, among other factors. Future distributions are expected to be made on a monthly basis. For additional information on the Trust, please visit www.permianvilleroyaltytrust.com. Forward-Looking Statements and Cautionary Statements This press release contains statements that are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release, other than statements of historical facts, are “forward-looking statements” for purposes of these provisions. These forward-looking statements include the amount and date of any anticipated distribution to unitholders and expectations regarding the future generation of net profits from the Underlying Properties. The anticipated distribution is based, in large part, on the amount of cash received or expected to be received by the Trust from the Sponsor with respect to the relevant period. The amount of such cash received or expected to be received by the Trust (and its ability to pay distributions) has been and will continue to be directly affected by the volatility in commodity prices, which can fluctuate significantly as a result of a variety of factors that are beyond the control of the Trust and the Sponsor. Low oil and natural gas prices will reduce profits to which the Trust is entitled, which will reduce the amount of cash available for distribution to unitholders and in certain periods could result in no distributions to unitholders. Other important factors that could cause actual results to differ materially include expenses of the Trust, reserves for anticipated future expenses, and public health concerns, such as the COVID‑19 pandemic. In addition, future monthly capital expenditures may exceed the average levels experienced in 2023 and prior periods, which could reduce the amount of cash available for distribution to unitholders and in certain periods could result in no distributions to unitholders. Statements made in this press release are qualified by the cautionary statements made in this press release. Neither the Sponsor nor the Trustee intends, and neither assumes any obligation, to update any of the statements included in this press release. An investment in units issued by the Trust is subject to the risks described in the Trust’s filings with the SEC, including the risks described in the Trust’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. The Trust’s quarterly and other filed reports are or will be available over the Internet at the SEC’s website at http://www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216207740/en/ Permianville Royalty Trust Sarah Newell 1 (512) 236-6555 Source: Permianville Royalty Trust Why is Permianville Royalty Trust (PVL) not paying a monthly distribution in March 2024? The Trust experienced a $1.25 million shortfall due to elevated capital expenditures exceeding cash receipts. What were the reported oil and natural gas sales volumes and prices for the current month? Oil sales volumes were 34,461 Bbls, natural gas sales volumes were 240,007 Mcf, with average prices of $78.56 per Bbl and $2.24 per Mcf. How did the oil and gas sales volumes and prices compare to the prior month? Oil and gas sales volumes and prices declined in the current month compared to the prior month. What were the total accrued operating expenses for the period? Total accrued operating expenses for the period were $2.8 million. What was the increase in capital expenditures from the prior period? Capital expenditures increased by $1.4 million to $2.0 million from the prior period."
"United Community Banks, Inc. Announces Quarterly Cash Dividends on Preferred Stock",2024-02-16T21:15:00.000Z,No impact,Very Positive,"United Community Banks, Inc. (UCBI) announced a quarterly cash dividend of $429.6875 per share on its 6.875% Non-Cumulative Perpetual Preferred Stock, Series I. The dividend, equivalent to $0.4296875 per depositary share, will be paid on March 15, 2024, to shareholders of record on February 29, 2024.","United Community Banks, Inc. Announces Quarterly Cash Dividends on Preferred Stock Rhea-AI Impact (No impact) Rhea-AI Sentiment (Very Positive) Tags dividends Rhea-AI Summary United Community Banks, Inc. (UCBI) announced a quarterly cash dividend of $429.6875 per share on its 6.875% Non-Cumulative Perpetual Preferred Stock, Series I. The dividend, equivalent to $0.4296875 per depositary share, will be paid on March 15, 2024, to shareholders of record on February 29, 2024. Positive None. Negative None. 02/16/2024 - 04:15 PM GREENVILLE, S.C., Feb. 16, 2024 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NASDAQ: UCBI) (“United”), reported that its Board of Directors approved a quarterly cash dividend of $429.6875 per share (equivalent to $0.4296875 per depositary share or 1/1000th interest per share) on the Company’s 6.875% Non-Cumulative Perpetual Preferred Stock, Series I (NASDAQ: UCBIO). The dividend is payable March 15, 2024 to shareholders of record on February 29, 2024. About United Community Banks, Inc.United Community Banks, Inc. (NASDAQ: UCBI) is the financial holding company for United Community, a top 100 US financial institution that is committed to improving the financial health and well-being of its customers and ultimately the communities it serves. United Community provides a full range of banking, wealth management, and mortgage services. As of December 31, 2023, United Community had $27.2 billion in assets and 207 offices across Alabama, Florida, Georgia, North Carolina, South Carolina, and Tennessee, as well as a national SBA lending franchise and a national equipment financing subsidiary. United Community has been recognized nationally as a leader in customer service, financial performance, and workplace environment. Among the accolades, United Community is a nine-time winner of the J.D. Power award that ranked the bank #1 in customer satisfaction with consumer banking in the Southeast and was recognized in 2023 by Forbes as one of the World’s Best Banks and one of America’s Best Banks. United Community was also recognized by Newsweek in 2023 as one of the Most Trusted Companies in America, is a multi-award recipient of the Greenwich Excellence Awards and was named by American Banker as one of the ""Best Banks to Work For"" in 2023 for the seventh consecutive year. Additional information about United Community can be found at ucbi.com. For more information:Jefferson HarralsonChief Financial Officer(864) 240-6208Jefferson_Harralson@ucbi.com What dividend did United Community Banks, Inc. (UCBI) declare? United Community Banks, Inc. (UCBI) declared a quarterly cash dividend of $429.6875 per share on its 6.875% Non-Cumulative Perpetual Preferred Stock, Series I. When will the dividend be paid? The dividend of $429.6875 per share will be paid on March 15, 2024. Who are the shareholders eligible to receive the dividend? Shareholders of record on February 29, 2024, are eligible to receive the dividend."
,,,,,
Athene Holding Ltd. Declares First Quarter 2024 Preferred Stock Dividends,2024-02-16T21:15:00.000Z,Low,Very Positive,"Athene Holding Ltd. declared preferred stock dividends on various series of non-cumulative preferred stock, with quarterly dividends ranging from $304.6875 to $484.375 per share, payable on April 1, 2024. The depositary shares for each series are listed on the NYSE under ticker symbols ATHPrA, ATHPrB, ATHPrC, ATHPrD, and ATHPrE.","Athene Holding Ltd. Declares First Quarter 2024 Preferred Stock Dividends Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags dividends earnings Rhea-AI Summary Athene Holding Ltd. declared preferred stock dividends on various series of non-cumulative preferred stock, with quarterly dividends ranging from $304.6875 to $484.375 per share, payable on April 1, 2024. The depositary shares for each series are listed on the NYSE under ticker symbols ATHPrA, ATHPrB, ATHPrC, ATHPrD, and ATHPrE. Positive None. Negative None. 02/16/2024 - 04:15 PM WEST DES MOINES, Iowa, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) announced that it has declared the following preferred stock dividends on its non-cumulative preferred stock (represented by depositary shares, each representing a 1/1,000th interest in a share of preferred stock), payable on April 1, 2024 to holders of record as of March 15, 2024. Quarterly dividend of $396.875 per share on the company’s 6.35% Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock, Series A (the “Series A Preferred Stock”); holders of depositary shares will receive $0.396875 per depositary share.Quarterly dividend of $351.5625 per share on the company’s 5.625% Fixed-Rate Perpetual Non-Cumulative Preferred Stock, Series B (the “Series B Preferred Stock”); holders of depositary shares will receive $0.3515625 per depositary share.Quarterly dividend of $398.4375 per share on the company’s 6.375% Fixed-Rate Reset Perpetual Non-Cumulative Preferred Stock, Series C (the “Series C Preferred Stock”); holders of depositary shares will receive $0.3984375 per depositary share.Quarterly dividend of $304.6875 per share on the company’s 4.875% Fixed-Rate Perpetual Non-Cumulative Preferred Stock, Series D (the “Series D Preferred Stock”); holders of depositary shares will receive $0.3046875 per depositary share.Quarterly dividend of $484.375 per share on the company’s 7.750% Fixed-Rate Reset Perpetual Non-Cumulative Preferred Stock, Series E (the “Series E Preferred Stock”); holders of depositary shares will receive $0.484375 per depositary share. Depositary shares for the Series A Preferred Stock are listed on the New York Stock Exchange (“NYSE”) under the ticker symbol “ATHPrA,” depositary shares for the Series B Preferred Stock are listed on the NYSE under the ticker symbol “ATHPrB,” depositary shares for the Series C Preferred Stock are listed on the NYSE under the ticker symbol “ATHPrC,” depositary shares for the Series D Preferred Stock are listed on the NYSE under the ticker symbol “ATHPrD,” and depositary shares for the Series E Preferred Stock are listed on the NYSE under the ticker symbol “ATHPrE.” About AtheneAthene is a leading retirement services company with $300 billion of total assets as of December 31, 2023, and operations in the United States, Bermuda, Canada, and Japan. Athene is focused on providing financial security to individuals by offering an attractive suite of retirement income and savings products and also serves as a solutions provider to corporations. For more information, please visit www.athene.com. Contact Jeanne Hess VP, External Relations +1 646 768 7319 jeanne.hess@athene.com What are the quarterly dividends declared by Athene Holding Ltd. on its preferred stock? Athene Holding Ltd. declared quarterly dividends ranging from $304.6875 to $484.375 per share on its non-cumulative preferred stock. When are the dividends payable to the holders of Athene Holding Ltd.'s preferred stock? The dividends declared by Athene Holding Ltd. on its preferred stock are payable on April 1, 2024. What is the ticker symbol for the depositary shares of Athene Holding Ltd.'s Series A Preferred Stock? The ticker symbol for the depositary shares of Athene Holding Ltd.'s Series A Preferred Stock is ATHPrA. Where are the depositary shares of Athene Holding Ltd.'s Series D Preferred Stock listed? The depositary shares for Athene Holding Ltd.'s Series D Preferred Stock are listed on the NYSE."
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2024-02-16T21:30:00.000Z,Low,Very Positive,"Esperion (ESPR) granted 66 new employees 204,900 restricted stock units (RSUs) under the 2017 Inducement Equity Incentive Plan. Each RSU will vest over time, subject to continued employment. Esperion focuses on developing medicines for cardiovascular diseases, aiming to improve patient outcomes by lowering LDL-cholesterol levels.","Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary Esperion (ESPR) granted 66 new employees 204,900 restricted stock units (RSUs) under the 2017 Inducement Equity Incentive Plan. Each RSU will vest over time, subject to continued employment. Esperion focuses on developing medicines for cardiovascular diseases, aiming to improve patient outcomes by lowering LDL-cholesterol levels. Positive None. Negative None. 02/16/2024 - 04:30 PM ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant. Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc. Esperion Contact Information:Investors:Alexis Callahaninvestorrelations@esperion.com(406) 539-1762 Media:Tiffany Aldrichcorporateteam@esperion.com(616) 443-8438 How many new employees were granted RSUs by Esperion? Esperion granted 66 new employees 204,900 restricted stock units (RSUs) under the 2017 Inducement Equity Incentive Plan. What is the vesting schedule for the RSUs? Each RSU will vest as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest as to the remaining 75 percent in twelve equal quarterly installments. What is the focus of Esperion's work? Esperion focuses on discovering, developing, and commercializing medicines for cardiovascular and cardiometabolic diseases, aiming to improve patient outcomes by lowering LDL-cholesterol levels."
HII Employees Honored At 38th Annual Black Engineer of the Year Award (BEYA) STEM Conference,2024-02-16T21:30:00.000Z,Low,Positive,"HII employees recognized at the 38th annual Black Engineer of the Year Award STEM Conference for their achievements in science, technology, engineering, and math fields. Victor Deal received the Technical Sales & Marketing award, while six others received the Modern-Day Technology Leader award, and three others received the Science Spectrum Trailblazer award. Paul C. Harris, HII's executive VP, emphasized the crucial role these employees play in HII's mission to protect peace and freedom worldwide.","HII Employees Honored At 38th Annual Black Engineer of the Year Award (BEYA) STEM Conference Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary HII employees recognized at the 38th annual Black Engineer of the Year Award STEM Conference for their achievements in science, technology, engineering, and math fields. Victor Deal received the Technical Sales & Marketing award, while six others received the Modern-Day Technology Leader award, and three others received the Science Spectrum Trailblazer award. Paul C. Harris, HII's executive VP, emphasized the crucial role these employees play in HII's mission to protect peace and freedom worldwide. Positive None. Negative None. 02/16/2024 - 04:30 PM BALTIMORE, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Global all-domain defense provider HII (NYSE: HII) announced today that 10 employees from its Newport News Shipbuilding, Ingalls Shipbuilding and Mission Technologies divisions were recognized for achievements in the science, technology, engineering and math fields during the 38th annual Black Engineer of the Year Award (BEYA) STEM Conference. The conference is taking place this weekend at the Convention Center in Baltimore, Maryland. “I am extremely proud of our awardees that represent some of our best talent across all three of our company’s divisions,” said Edmond Hughes, HII’s executive vice president and chief human resources officer, who attended the conference. “These awardees are helping to build a culture of innovation within HII and represent the value that HII’s engineering team brings to making our company stronger in support of national security missions. Thank you and congratulations to all our winners!” One employee receiving special recognition at this year’s conference received the Technical Sales & Marketing award, which recognizes efforts in the development of product lines and marketing plans on a national scale. This employee’s efforts revolutionized federal acquisitions, fostering a new generation of innovation in the defense sector. He is: Victor Deal, account director and program manager, Mission Technologies Images accompanying this release are available at: https://hii.com/news/hii-black-engineers-beya-honored-2024/. Six other HII employees received the Modern-Day Technology Leader award, which recognizes efforts in shaping the future of engineering, science and technology. They are: Seth Fitch, ship design manager, Newport News Shipbuilding Scott Moses, designer, Newport News Shipbuilding Nathan Riles, IT software engineer, Newport News Shipbuilding Walter Williams, program production director, Newport News Shipbuilding Marques Moulds, logistics engineer, Ingalls Shipbuilding Terance Neal, nuclear engineer, Mission Technologies Three other employees received the Science Spectrum Trailblazer award, which recognizes efforts in creating new paths for others in science, research, technology and development. They are: Anthony Snow, test engineer manager, Ingalls Shipbuilding Mar’Quis Bryant-Morgan, nuclear engineer, Mission Technologies Harry Johnson, IS technology director, Mission Technologies Paul C. Harris, executive vice president and chief sustainability and compliance officer at HII, was a speaker during the awards presentation. Harris shared that these employees are exceptional leaders who play a crucial role in HII’s mission to protect peace and freedom worldwide. “It's an honor to be here among the next generation of STEM leaders, embracing diversity and recognizing those who have shaped the STEM landscape,” Harris said. “These individuals not only embody ethics, integrity, and responsibility but also excel in their challenging roles at HII. Congratulations to all the honorees, whose dedication and innovation inspire us to reach new heights in the ever-evolving world of technology.” About HII HII is a global, all-domain defense provider. HII’s mission is to deliver the world’s most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world. As the nation’s largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII’s workforce is 44,000 strong. For more information, visit: HII on the web: https://www.HII.com/HII on Facebook: https://www.facebook.com/TeamHIIHII on Twitter: https://www.twitter.com/WeAreHIIHII on Instagram: https://www.instagram.com/WeAreHII Contact: Danny HernandezDanny.J.Hernandez@hii-co.com(202) 264-7143 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6524ac8d-cf6e-45f2-bdbe-a91d2871b79e Who received the Technical Sales & Marketing award at the Black Engineer of the Year Award STEM Conference? Victor Deal, account director and program manager at Mission Technologies, received the Technical Sales & Marketing award. How many HII employees received the Modern-Day Technology Leader award at the conference? Six HII employees received the Modern-Day Technology Leader award. Which HII executive emphasized the crucial role of the honored employees in the company's mission? Paul C. Harris, HII's executive vice president, emphasized the crucial role of the honored employees in the company's mission."
Corporación América Airports S.A. Reports January 2024 Passenger Traffic,2024-02-16T21:31:00.000Z,Low,Neutral,"Corporación América Airports S.A. (NYSE: CAAP) reports a 2.0% YoY increase in passenger traffic in January 2024, reaching 91.7% of January 2019 levels. International passenger traffic is 0.3% above pre-pandemic levels. The company showcases growth in cargo volume and aircraft movements, with varying performances across different regions.","Corporación América Airports S.A. Reports January 2024 Passenger Traffic Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Corporación América Airports S.A. (NYSE: CAAP) reports a 2.0% YoY increase in passenger traffic in January 2024, reaching 91.7% of January 2019 levels. International passenger traffic is 0.3% above pre-pandemic levels. The company showcases growth in cargo volume and aircraft movements, with varying performances across different regions. Positive None. Negative None. Market Research Analyst The reported increase in passenger traffic for Corporación América Airports S.A. (CAAP) is a positive indicator for the aviation sector, suggesting a continued recovery trajectory towards pre-pandemic levels. The data shows a nuanced recovery, with international passenger traffic slightly exceeding pre-pandemic levels, which could signal a shift in consumer behavior favoring international travel or a rebound in global business activities. However, the mixed performance across various countries, such as the notable recovery in Armenia and the decline in Brazil, points to uneven economic recovery and possibly differing levels of consumer confidence or restrictions related to travel.For investors, the regional variances in traffic recovery could influence strategic decisions on asset allocation within the aviation industry. The increased cargo volume, particularly in Argentina, Ecuador and Uruguay, also reflects broader economic activity and could be a leading indicator for trade and commerce health in these regions. The long-term implication for stakeholders includes potential infrastructure investments to accommodate the changing patterns of passenger and cargo traffic. Financial Analyst An 8.4% year-over-year increase in cargo volume is a strong performance metric, especially considering the overall cargo volume has not yet reached pre-pandemic levels. This growth may reflect an increase in trade activity or an optimization of cargo operations by CAAP. The financial health of the company could benefit from this uptick in cargo volume, as cargo operations often provide a stable revenue stream, less susceptible to the volatility seen in passenger traffic.However, the overall passenger traffic still being below pre-pandemic levels by 8.3% indicates that while there is growth, the company has not fully recovered from the pandemic's impact. This could affect the company's short-term revenue and profitability. The detailed breakdown of passenger traffic growth in key markets like Argentina and Italy, versus the decline in markets like Brazil, provides a more granular understanding of regional performance, which is critical for investors assessing the company's growth prospects and risk factors. Economist The reported figures could be indicative of broader economic trends, such as the resurgence of international trade and tourism. The differential recovery rates among domestic and international passengers could reflect varying degrees of economic resilience and public health strategies in response to the pandemic. For instance, the significant YoY increase in international traffic in Italy might be associated with the country's appeal as a tourist destination and its economic ties within the European Union.Conversely, the financial and aircraft constraints impacting Brazil's passenger traffic suggest underlying economic challenges that extend beyond the aviation sector. These challenges could have broader implications for regional economic stability and growth prospects. The data provided by CAAP could therefore serve as an economic barometer for the regions in which it operates, offering insights into the post-pandemic economic recovery and the resilience of the aviation industry as a whole. 02/16/2024 - 04:31 PM Total passenger traffic up 2.0% YoY, reaching 91.7% of January 2019 levels International passenger traffic 0.3% above pre-pandemic LUXEMBOURG--(BUSINESS WIRE)-- Corporación América Airports S.A. (NYSE: CAAP), (“CAAP” or the “Company”), one of the leading private airport operators in the world, reported today a 2.0% year-on-year (YoY) increase in passenger traffic in January 2024, reaching 91.7% of January 2019 levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216193710/en/2-Year Passenger Traffic Monthly Performance (vs. 2019) (Graphic: Business Wire) Passenger Traffic, Cargo Volume and Aircraft Movements Highlights (2024 vs. 2023) Statistics Jan'24 Jan'23 % Var. Domestic Passengers (thousands) 3,610 3,639 -0.8% International Passengers (thousands) 2,387 2,136 11.7% Transit Passengers (thousands) 643 732 -12.1% Total Passengers (thousands) 6,640 6,507 2.0% Cargo Volume (thousand tons) 28.6 26.3 8.4% Total Aircraft Movements (thousands) 69.8 69.1 0.9% Passenger Traffic, Cargo Volume and Aircraft Movements Highlights (2024 vs. 2019) Statistics Jan'24 Jan'19 % Var. Domestic Passengers (thousands) 3,610 4,010 -10.0% International Passengers (thousands) 2,387 2,380 0.3% Transit Passengers (thousands) 643 850 -24.3% Total Passengers (thousands) 6,640 7,240 -8.3% Cargo Volume (thousand tons) 28.6 33.0 -13.5% Total Aircraft Movements (thousands) 69.8 74.7 -6.6% (1) Note that preliminary passenger traffic figures for 2019, as well as January 2020 for Ezeiza Airport, in Argentina, were adjusted to include additional inbound passengers not accounted for in the initial count, for an average of approximately 5% of total passenger traffic at Ezeiza Airport and 1% of total traffic at CAAP, during that period. Importantly, inbound traffic does not affect revenues, as tariffs are applicable on departure passengers. (2) Cargo volumes in Uruguay were rectified from January 2019 to June 2020, to reflect all cargo passing through the cargo terminal, instead of air cargo only. Passenger Traffic Overview Total passenger traffic grew 2.0% compared to the same month of 2023, reaching 91.7% of January 2019 levels. International passenger traffic surpassed pre-pandemic levels by 0.3%, while domestic traffic stood at 90.0% of January 2019 levels. In Argentina, total passenger traffic continued to recover in January, increasing by 4.3% year-over-year (YoY) and reaching 97.0% of pre-pandemic volumes. Domestic traffic was 1.7% higher than the levels in January 2019, while International traffic reached 88.0% of pre-pandemic levels, down from the 97.7% recorded in December, mainly as a result of a tough comparison due to a particularly strong January 2019. In Italy, passenger traffic grew by 8.6% compared to the same month in 2023, reaching 99.8% of January 2019 levels, up from the 95.0% recorded in December. International passenger traffic, which accounted for over 75% of the total traffic, was 4.4% higher than January 2019 levels, while domestic passenger traffic was 12.3% below pre-pandemic levels. Although total traffic is still below pre-pandemic levels, Florence airport exceeded January 2019 traffic volumes. In Brazil, total passenger traffic decreased by 5.9% YoY, reaching 80.2% of January 2019 levels, down from the 84.4% recorded in December. Domestic traffic, which accounted for over 60% of the total traffic, reached 85.5% of pre-pandemic levels, while transit passengers stood at 68.9% of January 2019 levels, a decrease from the 78.1% recorded in December. Traffic in Brazil remained heavily impacted by financial and aircraft constraints in some of the local airlines. In Uruguay, total passenger traffic, which is largely international, continued to recover and increased 26.3% YoY, reaching 93.9% of pre-pandemic levels of January 2019. However, passenger traffic increased sequentially on an absolute basis. In Ecuador, passenger traffic decreased 4.3% YoY and stood at 97.8% of pre-pandemic volumes. While international passenger traffic exceeded pre-pandemic levels by 6.3%, domestic traffic reached 90.1% of January 2019 levels, impacted by the exit of the local airline Equair. In Armenia, passenger traffic continued its solid recovery trend, increasing by 1.5% YoY and surpassing the pre-pandemic levels of January 2019 by 73.5%. Cargo Volume and Aircraft Movements Cargo volume increased 8.4% YoY and reached 86.5% of January 2019 levels, or 87.5% when adjusting for the discontinuation of operations in Peru. Cargo volumes in Armenia and Italy were above pre-pandemic levels, whereas Argentina stood at 82.1%, Uruguay at 95.3%, Ecuador at 79.1%, and Brazil at 77.0%. Around 70% of cargo volume originated in Argentina, Ecuador and Uruguay. Aircraft movements increased 0.9% YoY, reaching 93.4% of January 2019 levels, or 96.2% when adjusting for the discontinuation of operations in Peru. Aircraft movements were above pre-pandemic levels in Armenia, while it stood at 98.0% in Argentina, 97.3% in Uruguay, 93.9% in Italy, 86.3% in Brazil, and 92.2% in Ecuador. Summary Passenger Traffic, Cargo Volume and Aircraft Movements (2024 vs. 2023) Jan'24 Jan'23 % Var. Passenger Traffic (thousands) Argentina(1) 3,738 3,585 4.3% Italy 459 423 8.6% Brazil 1,497 1,592 -5.9% Uruguay 232 183 26.3% Ecuador 345 361 -4.3% Armenia 368 363 1.5% TOTAL 6,640 6,507 2.0% (1) See Footnote 1 in previous table. (2) See Footnote 2 in previous table. Cargo Volume (tons) Argentina 15,471 13,359 15.8% Italy 1,029 1,052 -2.2% Brazil 4,653 4,958 -6.1% Uruguay(2) 2,022 1,985 1.9% Ecuador 2,953 2,747 7.5% Armenia 2,429 2,248 8.1% TOTAL 28,557 26,348 8.4% Aircraft Movements Argentina 39,352 37,642 4.5% Italy 4,359 4,113 6.0% Brazil 12,665 13,602 -6.9% Uruguay 3,835 3,767 1.8% Ecuador 6,594 6,631 -0.6% Armenia 2,961 3,380 -12.4% TOTAL 69,766 69,135 0.9% Summary Passenger Traffic, Cargo Volume and Aircraft Movements (2024 vs. 2019) Jan'24 Jan'19 % Var. Passenger Traffic (thousands) Argentina(1) 3,738 3,853 -3.0% Italy 459 460 -0.2% Brazil 1,497 1,866 -19.8% Uruguay 232 247 -6.1% Ecuador 345 353 -2.2% Armenia 368 212 73.5% Peru 249 - TOTAL 6,640 7,240 -8.3% (1) See Footnote 1 in previous table. (2) See Footnote 2 in previous table. Cargo Volume (tons) Argentina 15,471 18,845 -17.9% Italy 1,029 1,027 0.1% Brazil 4,653 6,042 -23.0% Uruguay(2) 2,022 2,121 -4.7% Ecuador 2,953 3,733 -20.9% Armenia 2,429 859 182.9% Peru - 370 - TOTAL 28,557 32,996 -13.5% Aircraft Movements Argentina 39,352 40,140 -2.0% Italy 4,359 4,644 -6.1% Brazil 12,665 14,670 -13.7% Uruguay 3,835 3,941 -2.7% Ecuador 6,594 7,154 -7.8% Armenia 2,961 1,948 52.0% Peru - 2,164 - TOTAL 69,766 74,661 -6.6% About Corporación América Airports Corporación América Airports acquires, develops and operates airport concessions. Currently, the Company operates 53 airports in 6 countries across Latin America and Europe (Argentina, Brazil, Uruguay, Ecuador, Armenia and Italy). In 2023, Corporación América Airports served 81.1 million passengers, 23.7% above the 65.6 million passengers served in 2022 and 3.6% below the 84.2 million served in 2019. The Company is listed on the New York Stock Exchange where it trades under the ticker “CAAP”. For more information, visit http://investors.corporacionamericaairports.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216193710/en/ Investor Relations Contact Patricio Iñaki Esnaola Email: patricio.esnaola@caairports.com Phone: +5411 4899-6716 Source: Corporación América Airports What is the YoY increase in passenger traffic reported by Corporación América Airports S.A. (NYSE: CAAP) in January 2024? Corporación América Airports S.A. (NYSE: CAAP) reported a 2.0% year-on-year (YoY) increase in passenger traffic in January 2024. How does the international passenger traffic of Corporación América Airports S.A. (NYSE: CAAP) compare to pre-pandemic levels in January 2024? International passenger traffic of Corporación América Airports S.A. (NYSE: CAAP) is 0.3% above pre-pandemic levels in January 2024. What was the percentage change in cargo volume for Corporación América Airports S.A. (NYSE: CAAP) in January 2024 compared to 2023? Corporación América Airports S.A. (NYSE: CAAP) saw an 8.4% increase in cargo volume in January 2024 compared to 2023. How did the total aircraft movements change for Corporación América Airports S.A. (NYSE: CAAP) in January 2024 compared to 2023? Corporación América Airports S.A. (NYSE: CAAP) experienced a 0.9% increase in total aircraft movements in January 2024 compared to 2023. What was the total passenger traffic percentage change for Corporación América Airports S.A. (NYSE: CAAP) in January 2024 compared to 2019? Corporación América Airports S.A. (NYSE: CAAP) had a total passenger traffic decrease of 8.3% in January 2024 compared to 2019."
LIBERTY LATIN AMERICA SCHEDULES INVESTOR CALL FOR FULL-YEAR 2023 RESULTS,2024-02-16T21:30:00.000Z,Low,Neutral,"Liberty Latin America Ltd. announces plans to release full-year 2023 results on February 22, 2024, followed by an investor call the next day. Management will discuss results, business, and provide forward-looking information.","LIBERTY LATIN AMERICA SCHEDULES INVESTOR CALL FOR FULL-YEAR 2023 RESULTS Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary Liberty Latin America Ltd. announces plans to release full-year 2023 results on February 22, 2024, followed by an investor call the next day. Management will discuss results, business, and provide forward-looking information. Positive None. Negative None. 02/16/2024 - 04:30 PM DENVER, Colorado--(BUSINESS WIRE)-- Liberty Latin America Ltd. (“Liberty Latin America” or the “Company”) (NASDAQ: LILA and LILAK, OTC Link: LILAB) today announced plans to release its full-year 2023 results on Thursday, February 22, 2024 after NASDAQ market close. You are invited to participate in its investor call, which will begin the following day at 8:30 a.m. (Eastern Time) on Friday, February 23, 2024. During the call, management will discuss the Company’s results and business, and may provide other forward-looking information. A webcast and investor presentation will be available within the Investor Relations section of the Liberty Latin America website at https://investors.lla.com/events-and-presentations/events/. The webcast will be archived in the Investor Relations section of the Company’s website for at least 75 days. ABOUT LIBERTY LATIN AMERICA Liberty Latin America is a leading communications company operating in over 20 countries across Latin America and the Caribbean under the consumer brands BTC, Flow, Liberty and Más Móvil, and through ClaroVTR, our joint venture in Chile. The communications and entertainment services that we offer to our residential and business customers in the region include digital video, broadband internet, telephony and mobile services. Our business products and services include enterprise-grade connectivity, data center, hosting and managed solutions, as well as information technology solutions with customers ranging from small and medium enterprises to international companies and governmental agencies. In addition, Liberty Latin America operates a subsea and terrestrial fiber optic cable network that connects approximately 40 markets in the region. Liberty Latin America has three separate classes of common shares, which are traded on the NASDAQ Global Select Market under the symbols “LILA” (Class A) and “LILAK” (Class C), and on the OTC link under the symbol “LILAB” (Class B). For more information, please visit www.lla.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240215151598/en/ Investor Relations: Kunal Patel ir@lla.com Media Relations: Kim Larson llacommunications@lla.com Source: Liberty Latin America Ltd. When will Liberty Latin America Ltd. release its full-year 2023 results? Liberty Latin America Ltd. will release its full-year 2023 results on Thursday, February 22, 2024 after NASDAQ market close. When is the investor call scheduled for Liberty Latin America Ltd.? The investor call for Liberty Latin America Ltd. is scheduled for 8:30 a.m. (Eastern Time) on Friday, February 23, 2024. Where can I find the webcast and investor presentation for Liberty Latin America Ltd.? The webcast and investor presentation for Liberty Latin America Ltd. will be available in the Investor Relations section of the company's website at https://investors.lla.com/events-and-presentations/events/."
The L.S. Starrett Company Announces Fiscal 2024 Second Quarter Results,2024-02-16T21:15:00.000Z,Neutral,Neutral,"The L.S. Starrett Company (NYSE: SCX) reported a decline in net sales for the quarter ended December 31, 2023, with challenges in labor availability and lower factory utilization affecting measuring tools production. International sales improved, but gross margin decreased due to product mix. Operating income and net income were negatively impacted, leading to a net loss for the quarter. The Company focused on reducing debt and inventory, strengthening its financial position.","The L.S. Starrett Company Announces Fiscal 2024 Second Quarter Results Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary The L.S. Starrett Company (NYSE: SCX) reported a decline in net sales for the quarter ended December 31, 2023, with challenges in labor availability and lower factory utilization affecting measuring tools production. International sales improved, but gross margin decreased due to product mix. Operating income and net income were negatively impacted, leading to a net loss for the quarter. The Company focused on reducing debt and inventory, strengthening its financial position. Positive International sales growth compared to the prior year Reduction of debt by $5.7 million during the second quarter Improved operating cash flow due to inventory reductions Stabilization of demand for industrial products Focus on growth initiatives and reducing debt levels Negative Decline in net sales compared to the prior year Decrease in gross margin from 32.3% to 30.5% Operating income dropped from 8.9% to 4.0% Net loss for the quarter of $0.4 million Negative impact on net income due to an unfavorable tax adjustment Financial Analyst The decline in net sales by 7.0% and the currency neutral net sales by 9.2% for The L.S. Starrett Company reflects a contraction in revenue streams that could concern investors regarding the company's growth trajectory. The factors contributing to this decline, such as labor availability and lower factory utilization, are indicative of operational challenges that may persist if not addressed. The decrease in sales of high-margin products and the impact of customer consolidation and capital expenditure delay in the automotive sector are reflections of market and industry-specific headwinds. The increase in SG&A expenses, partly attributed to currency translation, signals cost management issues that might affect profitability margins.From a balance sheet perspective, the reduction of debt to its lowest level in over a decade is a positive sign of financial prudence. However, the net loss of $0.4 million, compared to a net income in the previous year, alongside an unfavorable tax adjustment, is a notable concern for the financial health of the company. Investors should consider the potential for a rebound in profitability as the company invests in growth initiatives and continues to manage its inventory and expenses effectively. Market Research Analyst The performance of The L.S. Starrett Company within the precision measuring tools and metrology solutions market is reflective of broader economic conditions, including labor market tightness and capital expenditure cycles. The company's focus on high precision granite measuring products and the noted international sales improvement suggest a strategic pivot towards areas of growth and diversification. However, the downturn in the North American industrial markets, particularly the automotive sector, underscores the importance of market diversification and the potential volatility associated with dependency on specific industries.Investors should monitor the company's ability to adapt to the changing market demands and to capitalize on international growth opportunities. The reported stabilization of demand for industrial products internationally may provide a buffer against domestic market fluctuations. Additionally, the strategic reduction of inventory and debt could enhance operational efficiency and financial flexibility, potentially leading to improved shareholder value in the long term. Economist The L.S. Starrett Company's financial results are occurring against a backdrop of macroeconomic factors such as labor shortages, currency fluctuations and sector-specific issues like the automotive workers' strikes. These factors can have a ripple effect throughout the economy, affecting both supply chains and consumer demand. The company's international sales performance may reflect global economic resilience or targeted growth strategies in less volatile markets.Moreover, the use of non-U.S. GAAP financial measures like 'currency-neutral net sales' can offer a more nuanced view of the company's performance by isolating the impact of currency exchange rate fluctuations. This analytical approach provides insights into the company's core operating performance, which is crucial for stakeholders seeking to understand the fundamental health of the business amidst external economic pressures. 02/16/2024 - 04:15 PM ATHOL, Mass.--(BUSINESS WIRE)-- The L.S. Starrett Company (NYSE: SCX) (“Starrett” or “the Company”) a global innovator, manufacturer and marketer of precision measuring tools, cutting tools and equipment, and high-end metrology solutions for industrial, professional, and consumer markets, today announced operating results for the quarter ended December 31, 2023. Financial results include non-U.S. GAAP financial measures. These non-U.S. GAAP measures are more fully described and are reconciled from the respective measures determined under U.S. GAAP in the section titled “Use of Non-U.S. GAAP Financial Measures” and the attached tables. Fiscal 2024 Second Quarter Financial Highlights Net sales for the quarter of $62.1 million were 7.0% lower compared to the second quarter of the prior year, while currency neutral net sales of $60.7 million declined 9.2% compared to the second quarter of fiscal 2023. The decline in net sales compared to the comparative period was primarily driven by continued challenges with labor availability and resulting lower factory utilization in the Company’s measuring tools plant, and a decline in sales of the Company’s in-line laser measuring systems, which was attributed to customer consolidation and capital expenditure delay in that sector, and the recent automotive workers’ strikes, which also paused sector capital spending. International sales continued to improve compared to the prior year, and sales of the Company’s high precision granite measuring products continued to grow. Gross margin for the quarter was 30.5%, a decline of 180 basis points from 32.3% in the second quarter of the prior year. This was partially a result of the forementioned labor headwinds in our measuring tool production facility, and partially due to product mix, as net sales of the Company’s higher margin in-line laser measuring systems declined disproportionately relative to other products compared to the prior year quarter. Second quarter operating income was 4.0%, compared to 8.9% in the second quarter of the prior year. In addition, selling general and administrative expenses increased as a percentage of net sales compared to the prior year quarter. Approximately one-third of the increase was due to the translation of foreign currencies, particularly the Brazilian Real, into U.S. Dollars. In addition, the Company has continued to reinvest in growth initiatives, and incurred additional consulting costs during the quarter. The Company continues its efforts to reduce inventory, resulting in improved operating cash flow and the retirement of $5.7 million of debt during the second quarter. By quarter end, debt was at its lowest level in over 10 years. Net loss for the quarter was $0.4 million, compared to net income of $3.1 million in the comparative quarter. Net income was impacted by an unfavorable tax adjustment of $2.0 million related to IRS Notice 2023-80 released in December 2023. Second quarter diluted earnings per share was a loss of $0.05, compared to a gain of $0.42 for the second quarter in the prior fiscal year. “I am pleased to see the continued profitable growth of our high precision granite measuring products and a stabilization of demand of our industrial products internationally. This helped offset challenges in our North American industrial markets, particularly in the automotive sector, impacting both industrial distribution and capital equipment demand over the past couple of quarters. Our team continued to drive inventory reductions, allowing us to reduce debt to its lowest level in more than a decade. We remain committed to strengthening our financial position, giving us increased flexibility to invest in our business to drive long-term growth and shareholder value creation.” remarked Douglas A. Starrett, President and CEO. Use of Non- U.S. GAAP Financial Measures The Company uses the following non-U.S. GAAP financial measures: “currency-neutral net sales,” which are sales calculated using actual exchange rates in use during the comparative prior year period to enhance the visibility of the underlying business trends excluding the impact of translation arising from foreign currency exchange rate fluctuations. The Company discusses these non-U.S. GAAP financial measures because management believes they assist investors in comparing the Company’s performance across reporting periods on a consistent basis by eliminating items that the Company does not believe are indicative of its core operating performance. Such non-U.S. GAAP financial measures assist investors in understanding the ongoing operating performance of the Company by presenting financial results between periods on a more comparable basis. Such measures should be considered in addition to, and not in lieu of, the financial measures calculated and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). References to currency-neutral net sales should not be considered in isolation or as a substitute for other financial measures calculated and presented in accordance with U.S. GAAP, and may not be comparable to similarly titled non-U.S. GAAP financial measures used by other companies. In evaluating these non-U.S. GAAP financial measures, investors should be aware that in the future the Company may incur expenses or be involved in transactions that are the same as or similar to some of the adjustments in this press release. The Company’s discussion of non-U.S. GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Non-U.S. GAAP financial measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. About The L.S. Starrett Company: Founded in 1880 by Laroy S. Starrett and incorporated in 1929, The L.S. Starrett Company is a leading manufacturer of high-end precision tools, cutting equipment, and metrology systems for industrial, professional and consumer markets and is engaged in the business of manufacturing over 5,000 different products for industrial, professional and consumer markets. The Company has a long history of global manufacturing experience and currently operates three major global manufacturing plants. All subsidiaries principally serve the global manufacturing industrial base with concentration in the metalworking, construction, machinery, equipment, aerospace and automotive markets. The Company offers its broad array of measuring and cutting products to the market through multiple channels of distribution throughout the world. Starrett is a brand recognized around the world for precision, quality and innovation. For more information, please visit: https://www.starrett.com. Forward-Looking Statements: This press release may contain forward-looking statements concerning the Company’s expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, as amended, which was filed with the Securities and Exchange Commission on September 27, 2023 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements. L.S. Starrett Company Summary of Operations Quarter and Six Months Ended December 31, 2023 TABLE 1 Quarter Ended 12/31/2023 Comparison to Quarter Ended 12/31/2022 Fiscal 2024 YTD 12/31/2023 Comparison Fiscal 2023 YTD 12/31/2022 (Amounts in Thousands, except income per share) 12/31/2022 $ Change % Change 12/31/2022 $ Change % Change Net sales $ 62,076 $ 66,775 (4,699) -7.0 % $ 122,712 $ 127,236 (4,524) -3.6 % Gross Profit 18,964 21,576 -2,612 -12.1 % 38,500 41,776 -3,276 0 as % of Net Sales 30.5 % 32.3 % 31.4 % 32.8 % Selling, general, and administrative expenses 16,470 15,561 +909 5.8 % 33,548 31,855 +1,693 5.3 % as % of Net Sales 26.5 % 23.3 % 27.3 % 25.0 % Restructuring charges - 54 (54) -100.0 % - 244 (244) -100.0 % Operating income 2,494 5,961 (3,467) -58.2 % 4,952 9,677 (4,725) -48.8 % as % of Net Sales 4.0 % 8.9 % 4.0 % 7.6 % Other expense (526 ) (1,121 ) +595 -53.1 % (890 ) (1,797 ) +907 -50.5 % Income before income taxes 1,968 4,840 (2,872) -59.3 % 4,062 7,880 (3,818) -48.5 % Income tax expense 2,362 1,709 +653 38.2 % 2,537 2,693 (156) -5.8 % Net (loss) income $ (394 ) $ 3,131 (3,525) -112.6 % $ 1,525 $ 5,187 (3,662) 70.6 % Basic net income per share $ (0.05 ) $ 0.42 $ (0.47) -111.9 % $ 0.20 $ 0.71 $ (0.51) -71.8 % Diluted net income per share $ (0.05 ) $ 0.42 $ (0.47) -111.9 % $ 0.20 $ 0.69 $ (0.49) -71.0 % L.S. Starrett Company Consolidated, Condensed Balance Sheet December 31, 2023 TABLE 2 ASSETS 12/31/2023 6/30/2023 Cash $ 5,684 $ 10,454 Accounts receivable 34,826 36,611 Inventories, net 61,284 65,414 Prepaid expenses and other current assets 10,950 9,723 Total current assets 112,744 122,202 Property, plant and equipment, net 44,852 39,375 Other long-term assets 29,466 31,225 Deferred tax assets, net 15,667 19,073 Intangible assets, net 4,829 4,888 Goodwill 1,015 1,015 Total assets $ 187,062 $ 192,802 LIABILITIES AND STOCKHOLDERS’ EQUITY 12/31/2023 6/30/2023 Notes payable and current maturities of long-term debt $ 4,403 $ 4,961 Current lease liability 1,604 1,650 Accounts payable 13,487 15,047 Other current liabilities 18,379 19,555 Accrued compensation 4,613 8,040 Total current liabilities 36,269 39,563 Other long term liabilities 2,899 2,884 Long-term lease liability 2,966 3,423 Long-term debt, net of current portion 3,103 5,273 Postretirement benefit and pension obligations 10,699 12,192 Total Liabilities 55,936 63,335 Stockholders' Equity 131,126 129,467 Total liabilities and stockholders' equity $ 187,062 $ 192,802 L.S. Starrett Company Reconciliation of Net Sales to Currency Neutral Net Sales Quarter and Six Months Ended December 31, 2023 TABLE 3 Quarter Ended 12/31/2023 Comparison to Quarter Ended 12/31/2022 Fiscal 2024 YTD 12/31/2023 Comparison Fiscal 2023 YTD 12/31/2022 (Amounts in Thousands) 12/31/2022 $ Change % Change 12/31/2022 $ Change % Change Net sales, as reported 62,076 66,775 (4,699 ) -7.0 % 122,712 127,236 (4,524 ) -3.6 % *Currency Impact (1,412 ) - (1,412 ) -2.1 % (2,986 ) - (2,986 ) -2.35 % Currency neutral net sales $ 60,664 $ 66,775 (6,111 ) -9.2 % $ 119,726 $ 127,236 (7,510 ) -5.9 % *Change when converting FY24 sales in non USD functional currencies at the same exchange rates used in the comparison period View source version on businesswire.com: https://www.businesswire.com/news/home/20240216508949/en/ John C. Tripp Chief Financial Officer (978) 249-3551 jtripp@starrett.com Source: The L.S. Starrett Company What were the net sales for the quarter ended December 31, 2023? Net sales were $62.1 million, a 7.0% decrease compared to the prior year. How did the international sales perform compared to the prior year? International sales continued to improve compared to the prior year. What was the gross margin for the quarter? The gross margin was 30.5%, a decline of 180 basis points from the prior year. What impacted the decline in net sales? Challenges in labor availability, lower factory utilization, and decline in sales of in-line laser measuring systems contributed to the decline in net sales. Why did the net income decrease? Net income was impacted by an unfavorable tax adjustment of $2.0 million related to IRS Notice 2023-80 released in December 2023. How did the Company focus on improving its financial position? The Company reduced debt by $5.7 million during the second quarter and continued efforts to reduce inventory. What was the impact on diluted earnings per share? Second quarter diluted earnings per share was a loss of $0.05, compared to a gain of $0.42 for the second quarter in the prior fiscal year."
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2024-02-16T21:15:00.000Z,Low,Very Positive,"Scholar Rock (SRRK) grants inducement equity awards to new employees, totaling 131,688 shares of common stock, including stock options and restricted stock units. The awards are part of the 2022 Inducement Equity Plan, with options priced at $15.75 and vesting over time.","Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Rhea-AI Impact (Low) Rhea-AI Sentiment (Very Positive) Tags management Rhea-AI Summary Scholar Rock (SRRK) grants inducement equity awards to new employees, totaling 131,688 shares of common stock, including stock options and restricted stock units. The awards are part of the 2022 Inducement Equity Plan, with options priced at $15.75 and vesting over time. Positive None. Negative None. 02/16/2024 - 04:15 PM CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK; “The Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 131,688 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 75,250 shares of common stock and inducement restricted stock units (“RSUs”), covering an aggregate of 56,438 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (“The Plan”) and the award agreements thereunder. The Plan, which was adopted by the Company’s board of directors on June 16, 2022, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $15.75, which is equal to the closing price of Scholar Rock’s common stock on February 12, 2024. The stock option award will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of each employee’s start date, and the remaining 75% of the shares of common stock underlying the Stock Option Award will vest in 12 equal quarterly installments thereafter. Vesting for RSUs will be in four equal annual installments. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date. About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. Scholar Rock® is a registered trademark of Scholar Rock, Inc. Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216694867/en/ Scholar Rock: Investors Rushmie Nofsinger Scholar Rock rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573 Media Molly MacLeod Scholar Rock mmacleod@scholarrock.com media@scholarrock.com 802-579-5995 Source: Scholar Rock How many shares of common stock were granted in the inducement equity awards by Scholar Rock? Scholar Rock granted a total of 131,688 shares of its common stock to four newly hired employees. What types of equity awards were included in the grants? The equity awards consisted of stock options to purchase 75,250 shares of common stock and restricted stock units (RSUs) covering 56,438 shares of common stock. What is the exercise price of the stock options granted? The stock options have an exercise price of $15.75, equivalent to the closing price of Scholar Rock's common stock on February 12, 2024. How will the stock options vest? The stock option award will vest with 25% of the shares on the first anniversary of each employee's start date, with the remaining 75% vesting in 12 equal quarterly installments thereafter. What is the vesting schedule for the RSUs? The RSUs will vest in four equal annual installments."
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares,2024-02-16T21:20:00.000Z,Low,Negative,"Larimar Therapeutics, Inc. successfully closed a public offering of 19,736,842 shares of common stock, raising approximately $172.5 million. The proceeds will support the development of nomlabofusp (CTI-1601) and other pipeline candidates, as well as general corporate purposes.","Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Rhea-AI Impact (Low) Rhea-AI Sentiment (Negative) Tags offering Rhea-AI Summary Larimar Therapeutics, Inc. successfully closed a public offering of 19,736,842 shares of common stock, raising approximately $172.5 million. The proceeds will support the development of nomlabofusp (CTI-1601) and other pipeline candidates, as well as general corporate purposes. Positive None. Negative None. Financial Analyst The completion of Larimar Therapeutics' underwritten public offering, resulting in gross proceeds of approximately $172.5 million, is a significant financial event for the company. The capital raised through the sale of nearly 20 million shares at $8.74 each provides Larimar with a substantial cash infusion. This funding is critical for the company's ongoing research and development efforts, particularly for their lead candidate nomlabofusp (CTI-1601), which targets complex rare diseases. The full exercise of the underwriters' option to purchase additional shares indicates strong investor confidence in Larimar's potential and its pipeline.From a financial perspective, the influx of capital will likely extend Larimar's operational runway, allowing them to progress through expensive clinical trials without the immediate need for further fundraising. This is particularly important in the biotechnology sector, where cash burn rates are high due to the cost-intensive nature of drug development. However, investors should monitor how efficiently the company utilizes these funds to advance its pipeline and create shareholder value. Medical Research Analyst The successful funding round is a pivotal development for Larimar Therapeutics, as it secures the necessary capital to advance the clinical trials of nomlabofusp (CTI-1601). Nomlabofusp represents a potential breakthrough treatment for Friedreich's ataxia, a debilitating and rare genetic disease that currently lacks effective treatments. The ability to fund these trials is crucial, as clinical development is a lengthy and uncertain process, often taking years and requiring significant resources to reach pivotal trials and, eventually, regulatory approval.Investors and stakeholders should note that the success of these trials could have a profound impact on the company's valuation and stock performance. Positive trial results could lead to increased investor interest and potentially partnerships or buyout offers from larger pharmaceutical companies. Conversely, any setbacks in clinical development could adversely affect the company's financial position and stock price. Therefore, the allocation of the raised funds toward the development of nomlabofusp and other pipeline candidates will be closely scrutinized by the market. Market Research Analyst In the context of the broader biotechnology sector, Larimar Therapeutics' successful capital raise is indicative of the market's appetite for investment in innovative therapies for rare diseases. The sector often sees significant volatility based on clinical trial outcomes and regulatory news. The fact that Larimar has secured a substantial amount of funding suggests that the market perceives its scientific approach and pipeline as promising. This could reflect a broader trend of increased investment in rare disease therapies, which often command high prices and can benefit from regulatory incentives such as orphan drug designation.Looking at the market dynamics, it is important to consider that while the capital raise may dilute existing shares, the potential for long-term growth could offset this effect if Larimar successfully brings its treatments to market. The involvement of reputable financial institutions as bookrunners and managers in the offering also lends credibility to the transaction, which may positively influence investor perception and the stock's liquidity. 02/16/2024 - 04:20 PM BALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 19,736,842 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,574,370 additional shares, at the public offering price of $8.74 per share, the closing price of its common stock on February 13, 2024. The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million. Leerink Partners, Citigroup and Guggenheim Securities acted as joint bookrunning managers for the offering. LifeSci Capital acted as lead manager for the offering. Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp (CTI-1601) and other pipeline candidates, and for working capital and general corporate purposes, including research and development expenses. The shares were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-268312) that was declared effective by the Securities and Exchange Commission (“SEC”) on November 21, 2022. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on February 14, 2024 and is available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105 or by email at syndicate@leerink.com; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (800) 831-9146; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017 by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. About Larimar Therapeutics, Inc. Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Larimar’s management. Such forward-looking statements include, without limitation, statements relating to the use of proceeds from the public offering of common stock. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others, the risks and uncertainties set forth in the “Risk Factors” section and elsewhere in the prospectus supplement related to the public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at www.sec.gov, including but not limited to Larimar’s periodic reports, including Larimar’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Larimar assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor Contact:Joyce AllaireLifeSci Advisorsjallaire@lifesciadvisors.com (212) 915-2569 Company Contact:Michael CelanoChief Financial Officermcelano@larimartx.com(484) 414-2715 What is the ticker symbol for Larimar Therapeutics, Inc.? The ticker symbol for Larimar Therapeutics, Inc. is LRMR. How many shares of common stock were offered in the public offering? Larimar Therapeutics, Inc. offered 19,736,842 shares of common stock in the public offering. What was the public offering price per share? The public offering price per share was $8.74. What is the intended use of the net proceeds from the offering? The net proceeds from the offering will be used to support the development of nomlabofusp (CTI-1601) and other pipeline candidates, as well as for working capital and general corporate purposes. Who were the joint bookrunning managers for the offering? Leerink Partners, Citigroup, and Guggenheim Securities acted as joint bookrunning managers for the offering. When was the shelf registration statement declared effective by the SEC? The shelf registration statement on Form S-3 (File No. 333-268312) was declared effective by the SEC on November 21, 2022. Where can the final prospectus supplement and accompanying prospectus be obtained? Copies of the final prospectus supplement and accompanying prospectus can be obtained from Leerink Partners LLC, Citigroup, and Guggenheim Securities, as detailed in the press release. Does this press release constitute an offer to sell securities? No, this press release does not constitute an offer to sell securities. What is the purpose of the public offering? The purpose of the public offering was to raise funds to support the development of Larimar Therapeutics, Inc.'s pipeline candidates and for general corporate purposes."
Gray Announces Closing and Upsizing of Revolving Credit Facility Refinancing  and Announces Update on Term Loan and BMI Sale Proceeds,2024-02-16T21:15:00.000Z,Neutral,Neutral,"Gray Television, Inc. (GTN) closes refinancing and upsizing of revolving credit facility, postpones term loan refinancing, and receives $110 million in pre-tax cash proceeds from the sale of Broadcast Music, Inc. Gray upsized its revolving credit facilities to $625 million due to strong demand.","Gray Announces Closing and Upsizing of Revolving Credit Facility Refinancing and Announces Update on Term Loan and BMI Sale Proceeds Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary Gray Television, Inc. (GTN) closes refinancing and upsizing of revolving credit facility, postpones term loan refinancing, and receives $110 million in pre-tax cash proceeds from the sale of Broadcast Music, Inc. Gray upsized its revolving credit facilities to $625 million due to strong demand. Positive None. Negative None. Financial Analyst The refinancing and upsizing of Gray Television's revolving credit facility is a strategic financial maneuver that indicates the company's proactive approach to capital management. The increase from $500 million to $625 million provides Gray with a larger liquidity buffer, which can be critical in navigating uncertain market conditions. This move also suggests a vote of confidence from the banking group, which has agreed to the amendment and extension of the facility's maturity dates. It's important to note that the postponement of the term loan refinancing could signal a cautious approach in the face of less favorable borrowing terms or market volatility. Investors should consider how these changes affect the company's interest expenses and debt covenants, as well as their overall financial flexibility. Market Research Analyst Gray Television's sale of Broadcast Music, Inc. for $110 million in pre-tax cash proceeds represents a significant liquidity event for the company. It is essential to understand the context within which this divestiture occurs. The media industry is experiencing consolidation and transformation, driven by changing consumer behaviors and technological advancements. This sale could be a strategic move to streamline operations and focus on core competencies. From a market perspective, the injection of cash might be utilized for further investment in growth areas or to reduce existing debt, thereby potentially improving the company's risk profile and attractiveness to investors. Debt Market Expert The postponement of the opportunistic refinancing of Gray's $1.19 billion term loan suggests a response to unfavorable market conditions, possibly higher interest rates or reduced investor appetite for corporate debt. This decision highlights the importance of timing and market sentiment in the debt refinancing process. For stakeholders, it's critical to monitor the company's future moves regarding this term loan, as the terms of refinancing could significantly impact Gray's interest obligations and overall financial health. The upsizing of the revolving credit facility may offset some immediate concerns, but the long-term implications of the term loan's current status warrant close observation. 02/16/2024 - 04:15 PM ATLANTA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Gray Television, Inc. (“Gray,” “we,” “us” or “our”) (NYSE: GTN) announced today that it has closed a refinancing and upsizing of its revolving credit facility and has postponed its planned opportunistic refinancing of its $1.19 billion term loan due in 2026, due to recent market conditions. In addition, Gray announced today that, on February 8, 2024, Gray received approximately $110 million in pre-tax cash proceeds from the closing of the previously announced sale of Broadcast Music, Inc. (“BMI”) to a shareholder group led by New Mountain Capital, LLC. On January 30, 2024, Gray launched a process, subject to market and other conditions, to refinance a portion of its existing senior credit facilities. Subsequent developments in the capital markets led Gray to postpone the process through which it intended to amend certain terms and extend the maturity of its $1.19 billion term loan. Despite such developments, Gray’s banking group continued to support the company in amending and extending its $500 million revolving credit facility. In fact, due to strong demand, Gray upsized its revolving credit facilities to $625 million, which includes a new $552.5 million revolving credit facility maturing on December 31, 2027 and $72.5 million facility maturing on December 1, 2026. Gray paid transaction fees and expenses in cash at closing. We currently have no amounts drawn on our revolving credit facilities. About Gray: Gray Television, Inc. is a multimedia company headquartered in Atlanta, Georgia. Gray is the nation’s largest owner of top-rated local television stations and digital assets in the United States. Its television stations serve 113 television markets that collectively reach approximately 36 percent of US television households. This portfolio includes 80 markets with the top-rated television station and 102 markets with the first and/or second highest rated television station. Gray also owns video program companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, as well as the studio production facilities Assembly Atlanta and Third Rail Studios. Gray owns a majority interest in Swirl Films. For more information, please visit www.gray.tv. Cautionary Statements for Purposes of the “Safe Harbor” Provisions of the Private Securities Litigation Reform Act This press release contains certain forward-looking statements that are based largely on Gray’s current expectations and reflect various estimates and assumptions by Gray. These statements are statements other than those of historical fact, and may be identified by words such as “estimates,” “expect,” “anticipate,” “will,” “implied,” “assume” and similar expressions. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such forward-looking statements. Such risks, trends and uncertainties, which in some instances are beyond Gray’s control. Gray is subject to additional risks and uncertainties described in Gray’s quarterly and annual reports filed with the Securities and Exchange Commission from time to time, including in the “Risk Factors,” and management’s discussion and analysis of financial condition and results of operations sections contained therein, which reports are made publicly available via its website, www.gray.tv. Any forward-looking statements in this communication should be evaluated in light of these important risk factors. This press release reflects management’s views as of the date hereof. Except to the extent required by applicable law, Gray undertakes no obligation to update or revise any information contained in this communication beyond the date hereof, whether as a result of new information, future events or otherwise. Gray Contacts: Jim Ryan, Executive Vice President and Chief Financial Officer, 404-504-9828Kevin P. Latek, Executive Vice President, Chief Legal and Development Officer, 404-266-8333 What did Gray Television, Inc. announce regarding its credit facilities? Gray Television, Inc. announced the closing of a refinancing and upsizing of its revolving credit facility and postponed its planned opportunistic refinancing of its $1.19 billion term loan due to recent market conditions. How much pre-tax cash proceeds did Gray receive from the sale of Broadcast Music, Inc.? Gray received approximately $110 million in pre-tax cash proceeds from the closing of the sale of Broadcast Music, Inc. to a shareholder group led by New Mountain Capital, LLC. What led Gray to postpone the refinancing process of its term loan? Subsequent developments in the capital markets led Gray to postpone the process through which it intended to amend certain terms and extend the maturity of its $1.19 billion term loan. How much did Gray upsize its revolving credit facilities to? Gray upsized its revolving credit facilities to $625 million, which includes a new $552.5 million revolving credit facility maturing on December 31, 2027 and $72.5 million facility maturing on December 1, 2026. Are there any amounts currently drawn on Gray's revolving credit facilities? Gray currently has no amounts drawn on its revolving credit facilities."
SL Green Realty Corp. Announces Common Stock Dividend,2024-02-16T21:05:00.000Z,Low,Neutral,"SL Green Realty Corp. declares a monthly dividend of $0.25 per share, equivalent to an annualized dividend of $3.00 per share, payable on March 15, 2024.","SL Green Realty Corp. Announces Common Stock Dividend Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags dividends Rhea-AI Summary SL Green Realty Corp. declares a monthly dividend of $0.25 per share, equivalent to an annualized dividend of $3.00 per share, payable on March 15, 2024. Positive None. Negative None. Financial Analyst The recent declaration of a monthly ordinary dividend by SL Green Realty Corp. reflects the company's financial health and commitment to returning value to its shareholders. A dividend of $0.25 per share translates to a yield that should be compared against the sector's average and the company's historical payouts. Investors will be interested in the sustainability of this dividend, which hinges on the company's operational cash flow, payout ratio and debt levels.It's essential to scrutinize the company's earnings reports and cash flow statements to assess whether the current dividend is supported by earnings or if it might be financed through debt, which could be a red flag. Additionally, the real estate market's current trends, especially in Manhattan, should be considered, as they will directly impact SL Green's operational success and, consequently, its ability to maintain or grow dividends. Real Estate Market Analyst SL Green Realty's dividend announcement must be contextualized within the broader real estate market dynamics. The Manhattan office space market has unique drivers, such as occupancy rates, average rent per square foot and the influx of new developments. The stability of a REIT's (Real Estate Investment Trust) dividend often correlates with the health of the property portfolio it holds.Given the cyclical nature of real estate, it's important to analyze current economic indicators, such as job growth, corporate expansions, or contractions in Manhattan and how these may influence commercial real estate demand. A detailed look at SL Green's tenant diversification and lease expiration profiles can provide further insights into the company's risk exposure and potential for stable future earnings. Economist From an economic standpoint, the dividend policy of a firm like SL Green Realty can be influenced by macroeconomic factors, including interest rates, inflation and economic growth. These factors can affect both the company's operational costs and the attractiveness of its dividends. For instance, in a low-interest-rate environment, REIT dividends can be more appealing to income-focused investors as an alternative to bonds.However, if interest rates rise, the cost of borrowing for companies like SL Green could increase, potentially impacting their profit margins and ability to sustain dividends. Inflation trends are also crucial as they can affect property values and rental income. Analyzing these macroeconomic conditions provides a backdrop against which the company's dividend policy can be evaluated. 02/16/2024 - 04:05 PM NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.25 per share of common stock, which is the equivalent of an annualized dividend of $3.00 per share. The dividend is payable in cash on March 15, 2024 to shareholders of record at the close of business on February 29, 2024. About SL Green Realty Corp. SL Green Realty Corp., Manhattan's largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of December 31, 2023, SL Green held interests in 58 buildings totaling 32.5 million square feet. This included ownership interests in 28.8 million square feet of Manhattan buildings and 2.8 million square feet securing debt and preferred equity investments. Forward Looking Statement This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, are forward-looking statements. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “continue,” or the negative of these words, or other similar words or terms. Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include the risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise. SLG – DIV PRESS CONTACTslgreen@berlinrosen.com What dividend has SL Green Realty Corp. declared? SL Green Realty Corp. has declared a monthly ordinary dividend of $0.25 per share of common stock. When is the dividend payable? The dividend is payable in cash on March 15, 2024. What is the annualized dividend per share? The annualized dividend per share is $3.00."
Simplify Announces an ETF Closure,2024-02-16T21:15:00.000Z,Neutral,Negative,Simplify Exchange Traded Funds to liquidate the Simplify Tail Risk Strategy ETF following the recommendation by Simplify Asset Management Inc. The liquidation payment to shareholders is expected soon.,"Simplify Announces an ETF Closure Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Negative) Tags Rhea-AI Summary Simplify Exchange Traded Funds to liquidate the Simplify Tail Risk Strategy ETF following the recommendation by Simplify Asset Management Inc. The liquidation payment to shareholders is expected soon. Positive None. Negative None. 02/16/2024 - 04:15 PM NEW YORK--(BUSINESS WIRE)-- The Board of Trustees (the “Board”) of Simplify Exchange Traded Funds (the “Trust”) has determined that it is in the best interests of shareholders to liquidate the Simplify Tail Risk Strategy ETF (the “Fund”), a series of the Trust, following a recommendation by the Fund’s investment adviser, Simplify Asset Management Inc. The Board has determined to liquidate the Fund with the liquidation payment to its shareholders expected to take place on or about March 14, 2024 (“Liquidation Date”). After the close of business on March 7, 2024, the Fund will no longer accept creation orders. The last day of trading in the Fund on the NYSE Arca, Inc. will be March 7, 2024. Shareholders who do not sell their shares of the Fund before market close on March 7, 2024 will receive cash equal to the amount of the net asset value of their shares in their brokerage accounts, on or about the Liquidation Date. As calculated on the Liquidation Date, the Fund’s net asset value will reflect any costs of closing the Fund. Once the distributions are complete, the Fund will terminate. ABOUT SIMPLIFY ASSET MANAGEMENT INC Simplify Asset Management Inc. is a Registered Investment Adviser founded in 2020 to help advisors tackle the most pressing portfolio challenges with an innovative set of options-based strategies. By accounting for real-world investor needs and market behavior, along with the non-linear power of options, our strategies allow for the tailored portfolio outcomes for which clients are looking. For more information, visit www.simplify.us. Investors should carefully consider the investment objectives, risks, charges, and expenses of Exchange Traded Funds (ETFs) before investing. To obtain an ETF's prospectus containing this and other important information, please call (855) 772-8488, or visit SimplifyETFs.com. Please read the prospectus carefully before you invest. Simplify ETFs are distributed by Foreside Financial Services, LLC. © 2024 Simplify ETFs. All rights reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216872234/en/ MEDIA CONTACT: Chris Sullivan Craft & Capital chris@craftandcapital.com Source: Simplify Asset Management Inc. Why is Simplify Exchange Traded Funds liquidating the Simplify Tail Risk Strategy ETF? The Board of Trustees has decided to liquidate the Fund following a recommendation by Simplify Asset Management Inc. When will the liquidation payment to shareholders take place? The liquidation payment to shareholders is expected to take place soon."
Bowman Consulting Group Announces Earnings Release Schedule and Preliminary 2023 Financial Results,2024-02-16T21:05:00.000Z,Low,Neutral,"Bowman Consulting Group Ltd. (NASDAQ: BWMN) announced the scheduling of its 2023 earnings release and investor conference call. Preliminary results for fiscal 2023 Net Service Billing and Adjusted EBITDA were shared, with expectations of approximately $303 million in Net Service Billing and $44.5 to $46.0 million in Adjusted EBITDA. The Company highlighted a larger seasonal impact on utilization in December across its core and acquired operations.","Bowman Consulting Group Announces Earnings Release Schedule and Preliminary 2023 Financial Results Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags earnings Rhea-AI Summary Bowman Consulting Group Ltd. (NASDAQ: BWMN) announced the scheduling of its 2023 earnings release and investor conference call. Preliminary results for fiscal 2023 Net Service Billing and Adjusted EBITDA were shared, with expectations of approximately $303 million in Net Service Billing and $44.5 to $46.0 million in Adjusted EBITDA. The Company highlighted a larger seasonal impact on utilization in December across its core and acquired operations. Positive None. Negative None. 02/16/2024 - 04:05 PM RESTON, Va.--(BUSINESS WIRE)-- Bowman Consulting Group Ltd. (“Bowman” or the “Company”) (NASDAQ: BWMN), today announced the scheduling of its 2023 earnings release and investor conference call along with preliminary results for fiscal 2023 Net Service Billing and Adjusted EBITDA, both non-GAAP financial measures. The Company will release its financial results for the fourth quarter and full year 2023 after the U.S. financial markets close on Monday, March 11, 2024. The Company will host a webcast to discuss its fourth quarter and full year results at 9:00 a.m. ET on Tuesday, March 12, 2024. Bowman Chairman and CEO, Gary Bowman and Chief Financial Officer, Bruce Labovitz will host the call followed by a question-and-answer session. Links to the live webcast of the event and subsequent replay of the event will be available on the Bowman Investor Relations website at investors.bowman.com. Based on preliminary, unaudited results, the Company expects to report full year 2023 Net Service Billing of approximately $303 million and Adjusted EBITDA in the range of $44.5 to $46.0 million1. The Company noted that results were affected by a larger than anticipated seasonal impact to utilization in December throughout the Company’s core and acquired operations. The preliminary financial results described herein are based upon unaudited results and are subject to adjustment based on the completion of the Company’s year-end financial closing procedures. The Company will release audited results and reconciled non-GAAP financial metrics and address 2024 guidance in connection with its upcoming earnings release and conference call. 1 Non-GAAP financial metrics. See “Non-GAAP Financial Measures” below for additional information. About Bowman Consulting Group Ltd. Headquartered in Reston, Virginia, Bowman is a national engineering services firm delivering infrastructure solutions to customers who own, develop, and maintain the built environment. With over 2,000 employees and more than 90 offices throughout the United States, Bowman provides a variety of planning, engineering, geospatial, construction management, commissioning, environmental consulting, land procurement and other technical services to customers operating in a diverse set of regulated end markets. Bowman trades on the Nasdaq under the symbol BWMN. For more information, visit bowman.com or investors.bowman.com. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, including statements regarding our future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements and represent our views as of the date of this press release. The words “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intend”, “may”, “will”, “goal” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs, These forward-looking statements are subject to several assumptions and risks and uncertainties, many of which involve factors or circumstances that are beyond our control that could affect our financial results. The Company cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained in this news release. Such factors include: (a) changes in demand from the local and state government and private clients that we serve; (b) general economic conditions, nationally and globally, and their effect on the market for our services; (c) competitive pressures and trends in our industry and our ability to successfully compete with our competitors; (d) changes in laws, regulations, or policies; and (e) the “Risk Factors” set forth in the Company’s most recent SEC filings. Considering these risks, uncertainties and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipates or implied in any forward-looking statements. Except as required by law, we are under no obligation to update these forward-looking statements after the date of this press release, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements. Non-GAAP Financial Measures We supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, with certain non-GAAP financial measures, to help represent, explain, and understand our operating performance. These non-GAAP financial measures may be different than similarly referenced measures used by other companies. The non-GAAP measures are intended to enhance investors’ overall understanding and evaluation of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We present these non-GAAP financial measures to assist investors in seeing our financial performance in a manner more aligned with management’s view and believe these measures provide additional tools by which investors can evaluate our core financial performance over multiple periods relative to other companies in our industry. We only provide guidance on a non-GAAP basis. We do not provide reconciliations of forward-looking Net Service Billing or Adjusted EBITDA to the most directly comparable GAAP financial measures, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. We will provide reconciliations of the final calculations of these non-GAAP financial measures to the most directly comparable GAAP financial measures when we report our audited 2023 financial results. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216973058/en/ Investor Relations Contacts: Bruce Labovitz ir@bowman.com Larry Clark lclark@bowman.com Source: Bowman Consulting Group When will Bowman release its financial results for the fourth quarter and full year 2023? Bowman will release its financial results for the fourth quarter and full year 2023 after the U.S. financial markets close on Monday, March 11, 2024. What are the expected figures for full year 2023 Net Service Billing and Adjusted EBITDA? The Company expects to report approximately $303 million in Net Service Billing and $44.5 to $46.0 million in Adjusted EBITDA for full year 2023. Who will host the webcast to discuss the fourth quarter and full year results? Bowman Chairman and CEO, Gary Bowman, and Chief Financial Officer, Bruce Labovitz, will host the webcast to discuss the fourth quarter and full year results. Where can investors access the live webcast and replay of the event? Investors can access the live webcast and replay of the event on the Bowman Investor Relations website at investors.bowman.com. What impacted the Company's results for fiscal 2023? The results for fiscal 2023 were affected by a larger than anticipated seasonal impact to utilization in December across the Company's core and acquired operations."
"Open Lending to Announce Fourth Quarter and Full Year 2023 Results on February 27, 2024",2024-02-16T21:05:00.000Z,Low,Positive,"Open Lending Corporation (LPRO) to host a conference call to discuss Q4 and full year 2023 financial results on February 27, 2024. Webcast and dial-in details provided.","Open Lending to Announce Fourth Quarter and Full Year 2023 Results on February 27, 2024 Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags earnings Rhea-AI Summary Open Lending Corporation (LPRO) to host a conference call to discuss Q4 and full year 2023 financial results on February 27, 2024. Webcast and dial-in details provided. Positive None. Negative None. 02/16/2024 - 04:05 PM AUSTIN, Texas, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Open Lending Corporation (NASDAQ: LPRO) (“Open Lending” or “the Company”), an industry trailblazer in automotive lending enablement and risk analytics solutions for financial institutions, today announced that the Company will host a conference call to discuss fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024 at 5:00pm ET. A press release with fourth quarter and full year 2023 financial results will be issued after the market closes that same day. The conference call will be webcast live from the Company's investor relations website at https://investors.openlending.com/ under the “Events” section. The conference call can also be accessed live over the phone by dialing (877) 407-4018, or for international callers (201) 689-8471; the conference ID is 13743278. An archive of the webcast will be available at the same location on the website shortly after the call has concluded. About Open LendingOpen Lending (NASDAQ: LPRO) provides loan analytics, risk-based pricing, risk modeling, and default insurance to auto lenders throughout the United States. For over 20 years we have been empowering financial institutions to create profitable auto loan portfolios with less risk and more reward. For more information, please visit www.openlending.com. Contact information: Investor Relations Inquiries: openlending@icrinc.com Source: Open Lending Corporation When will Open Lending Corporation host a conference call to discuss Q4 and full year 2023 financial results? Open Lending Corporation will host a conference call on February 27, 2024, at 5:00pm ET. Where can I access the webcast of the conference call? The webcast will be available on Open Lending Corporation's investor relations website at https://investors.openlending.com/ under the 'Events' section. How can I listen to the conference call live over the phone? You can dial (877) 407-4018 for domestic callers or (201) 689-8471 for international callers. The conference ID is 13743278. Will there be an archive of the webcast available after the call? Yes, an archive of the webcast will be available at the same location on the website shortly after the call has concluded."
Bruker Announces Quarterly Dividend,2024-02-16T21:05:00.000Z,Low,Positive,"Bruker Corporation (BRKR) declares a quarterly cash dividend of $0.05 per share on its common stock, payable on March 15, 2024, to stockholders of record as of March 1, 2024.","Bruker Announces Quarterly Dividend Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags dividends Rhea-AI Summary Bruker Corporation (BRKR) declares a quarterly cash dividend of $0.05 per share on its common stock, payable on March 15, 2024, to stockholders of record as of March 1, 2024. Positive None. Negative None. Financial Analyst The declaration of a quarterly cash dividend by Bruker Corporation signifies a distribution of earnings back to shareholders, which is a positive signal of the company's financial health and stability. This action demonstrates the management's confidence in the company's steady cash flow and profitability. Dividends are often seen as a sign of a mature company that has a consistent revenue stream and is less likely to reinvest all profits back into the company for growth.It is important to consider the dividend yield, which is calculated by dividing the annual dividends per share by the stock's price per share. While a $0.05 dividend might seem small in absolute terms, the yield is what matters to investors seeking income. If Bruker's stock price is relatively high, the yield may be low, which could impact investor perception, especially those looking for income-generating investments.Investors should also be aware of the ex-dividend date, which is the cutoff date to be eligible for the dividend payment. In this case, shareholders must own the stock before March 1, 2024, to receive the dividend. This can sometimes lead to a short-term increase in stock purchases as investors look to capture the dividend, potentially affecting the stock price. Market Research Analyst From a market perspective, Bruker Corporation's dividend payment can be compared with industry standards to gauge its competitiveness. Companies in the same sector may offer higher dividends and thus could be more attractive to dividend-seeking investors. However, a lower dividend could also indicate that Bruker is reinvesting more into its operations for future growth, which could attract a different type of investor interested in capital gains.Additionally, the frequency and consistency of dividend payments are key indicators of a company's reliability. A company that can maintain or increase its dividend over time is generally perceived as stable and well-managed. Investors often look at the payout ratio, the percentage of earnings paid to shareholders in dividends, to assess whether a company is overextending itself or if the dividends are sustainable. 02/16/2024 - 04:05 PM BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com. Forward-Looking Statements Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding expected quarterly cash dividends in 2024. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2022, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216236003/en/ Justin Ward Sr. Director, Investor Relations & Corporate Development Bruker Corporation T: +1 (978) 313-5800 E: Investor.Relations@bruker.com Source: Bruker Corporation What is the dividend amount declared by Bruker Corporation (BRKR)? Bruker Corporation (BRKR) has declared a quarterly cash dividend of $0.05 per share on its common stock. When will the dividend be paid by Bruker Corporation (BRKR)? The dividend declared by Bruker Corporation (BRKR) will be paid on March 15, 2024. Who is eligible to receive the dividend from Bruker Corporation (BRKR)? Stockholders of record as of March 1, 2024, are eligible to receive the dividend from Bruker Corporation (BRKR)."
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
OutKick Sees Most Growth in Unique Visitors Amongst Competitive Set,2024-02-16T17:28:00.000Z,Neutral,Very Positive,"OutKick, a leading sports platform, experienced significant growth in total unique visitors, views, and engagement in January 2024 compared to the previous month. The platform's founder, Clay Travis, highlighted the commitment to providing engaging content and driving conversations.","OutKick Sees Most Growth in Unique Visitors Amongst Competitive Set Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Very Positive) Tags Rhea-AI Summary OutKick, a leading sports platform, experienced significant growth in total unique visitors, views, and engagement in January 2024 compared to the previous month. The platform's founder, Clay Travis, highlighted the commitment to providing engaging content and driving conversations. Positive None. Negative None. Market Research Analyst The substantial increase in unique visitors and views reported by OutKick signifies a notable expansion in its digital footprint within the sports media landscape. The reported 22% rise in unique visitors and 29% increase in multiplatform views month-over-month indicate a successful engagement strategy, likely driven by content that resonates with its audience. This growth trajectory, if sustained, could lead to increased advertising revenue and partnership opportunities, given that higher traffic and engagement metrics are key selling points for digital platforms when negotiating with advertisers.Furthermore, the impressive 93% increase in social actions suggests that OutKick's content is not only being consumed but is also prompting significant interaction on social media platforms. This level of engagement can be a precursor to a loyal and active community, which can further drive organic growth through word-of-mouth and social sharing. The potential for monetizing such an engaged user base through targeted marketing campaigns and sponsorships is considerable. Financial Analyst From a financial perspective, OutKick's pronounced growth metrics could be indicative of an upward trajectory in terms of valuation and attractiveness to investors. The platform's ability to consistently increase its audience and engagement month-over-month demonstrates a scalable business model, which is a critical factor for investors seeking growth opportunities. Moreover, the platform's focus on 'common-sense reporting' and outspoken talent might be carving out a niche that differentiates it from competitors, potentially translating into a strong brand identity and customer loyalty.It's important to consider the long-term sustainability of this growth. If OutKick can maintain its momentum, it may result in increased market share and possibly attract strategic partnerships or acquisition interest. However, it is crucial to monitor whether these growth figures reflect a short-term spike or a stable trend. Investors will be particularly interested in the platform's strategies to retain the expanded audience and leverage the increased traffic to boost monetization through diversified revenue streams. Digital Media Strategist The strategies employed by OutKick to achieve such growth are of interest to digital media strategists. The platform's reported increases suggest effective content strategies and marketing tactics that resonate with their target demographic. The emphasis on 'talent that’s unafraid to speak their minds' may be appealing to a segment of the audience seeking alternative viewpoints, which can be a differentiating factor in the crowded digital sports media market. The ability to create and distribute content that drives both consumption and interaction is a key competency in today's digital ecosystem.OutKick's performance on social media platforms, with a 141% year-over-year increase in social actions, indicates a strong command of content virality and audience engagement techniques. This success on social media can amplify content reach and drive traffic back to the main platform, creating a virtuous cycle of growth and engagement. Understanding the content types, posting frequencies and audience interactions that led to these results can provide valuable insights for other media companies looking to enhance their digital strategies. 02/16/2024 - 12:28 PM The Platform Delivers Increases Month-Over-Month Across Every Category NEW YORK--(BUSINESS WIRE)-- OutKick, the fastest growing national multimedia sports platform, saw the most growth in total multiplatform unique visitors amongst its custom competitive set with 7.1 million in January 2024, up 22% versus December 2023, according to Comscore. The platform also delivered 33 million total multiplatform views in January 2024, up 29% versus December 23 and saw 33 million total multiplatform minutes, up 27% versus the prior month, according the Comscore. In commenting on the digital performance, OutKick founder Clay Travis said, “We kick off the year once again with numbers that not only speak to the platform’s growth but our commitment to providing engaging content to our audience. OutKick is the only destination for common-sense reporting with talent that’s unafraid to speak their minds on any topic. I’m looking forward to an exciting year and continuing to drive the conversation.” On Facebook, X (formerly Twitter), and Instagram, OutKick saw over 2.3 million total social actions in January 2023, up 93% versus the prior month and up 141% versus January 2023. The platform also saw over 16.5 million video views on Facebook, X, and YouTube which is up 12% versus January 2023, according to Shareablee. *Source: Comscore Media Metrix® Multi-Platform, Desktop & Mobile, Total Audience, Custom-Defined List Including CBS Sports, ESPN.com, Yahoo Sports-NBC Sports Network, BLEACHERREPORT.com, DEADSPIN.com, BARSTOOLSPORTS.com, and NY Post Sports, January 2023 – January 2024 U.S. **Source: Comscore Social, Metrics & Trends, Facebook, X YouTube, January 2023, Report Date: 02/15/2024. About OutKick OutKick is one of the fastest growing national multimedia platforms that produces and distributes engaging content at the intersection of sports, sports culture, pop culture and news. OutKick’s industry recognized stable of reporters, hosts and contributors are accessible on www.OutKick.com as well as across video livestreams, social media, podcasts, and radio, reaching tens of millions of fans each month. Owned by FOX Corporation, OutKick was originally founded by Clay Travis. For more information, please visit www.OutKick.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216360688/en/ OutKick Press Contact: Brian Karpas 212-301-9966 brian.karpas@outkick.com Source: OutKick How many total multiplatform unique visitors did OutKick have in January 2024? OutKick had 7.1 million total multiplatform unique visitors in January 2024. What percentage increase did OutKick see in total multiplatform views in January 2024 compared to December 2023? OutKick experienced a 29% increase in total multiplatform views in January 2024 versus December 2023. Who commented on OutKick's digital performance? Clay Travis, the founder of OutKick, commented on the platform's digital performance. How many total social actions did OutKick receive on Facebook, X, and Instagram in January 2023? OutKick received over 2.3 million total social actions on Facebook, X, and Instagram in January 2023. What was the percentage increase in total video views on Facebook, X, and YouTube for OutKick in January 2024 compared to January 2023? OutKick saw a 12% increase in total video views on Facebook, X, and YouTube in January 2024 versus January 2023."
"KORE Named a Leader by Gartner in the Magic Quadrant for Managed IoT Connectivity Services, Worldwide, for Fifth Consecutive Time",2024-02-16T16:42:00.000Z,Low,Neutral,"KORE, a leading IoT solutions provider, has been recognized as a Leader in the 2024 Gartner Magic Quadrant for Managed IoT Connectivity Services for the fifth consecutive year. The company's commitment to delivering innovative IoT solutions has been praised by Gartner, highlighting KORE's ability to provide global connectivity solutions tailored for diverse markets and use cases.","KORE Named a Leader by Gartner in the Magic Quadrant for Managed IoT Connectivity Services, Worldwide, for Fifth Consecutive Time Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags Rhea-AI Summary KORE, a leading IoT solutions provider, has been recognized as a Leader in the 2024 Gartner Magic Quadrant for Managed IoT Connectivity Services for the fifth consecutive year. The company's commitment to delivering innovative IoT solutions has been praised by Gartner, highlighting KORE's ability to provide global connectivity solutions tailored for diverse markets and use cases. Positive None. Negative None. Market Research Analyst The recognition of KORE as a Leader in the Gartner Magic Quadrant for Managed IoT Connectivity Services for the fifth consecutive time underscores the company's robust position in the IoT market. This distinction is indicative of KORE's strong ability to execute and a complete vision, which are critical parameters for assessing the potential and stability of a company in a highly competitive and rapidly evolving industry like IoT.From an investment standpoint, this consistent recognition may signal to stakeholders that KORE has a sustainable competitive advantage and is likely to maintain, if not increase, its market share. This can translate into potential long-term revenue growth, which is an essential factor for investors. Additionally, KORE's emphasis on a unified platform and diverse suite of offerings aligns with the increasing demand for integrated IoT solutions, which can lead to new customer acquisitions and retention.It is important to note that while such recognitions can enhance a company's reputation, they should not be the sole basis for investment decisions. Investors should consider a range of factors, including financial performance, market trends and competitive dynamics. Financial Analyst The announcement by KORE could be seen as a positive signal to the market, potentially impacting the company's stock performance. Recognition by a reputable entity like Gartner often serves as a third-party validation of a company's strategic direction, operational efficiency and market leadership. Such validation can contribute to investor confidence and might be reflected in the stock's valuation.However, it's essential to analyze this news in the context of KORE's financial health, including revenue growth, profit margins and cash flow. Furthermore, investors should assess the IoT sector's overall growth trajectory and how KORE's offerings are positioned relative to emerging market needs and competitor advancements.While the Gartner Magic Quadrant is a respected assessment, it is one of many factors that informed investors should weigh. It is also crucial to monitor how KORE capitalizes on this recognition to expand its market presence and whether it can convert the increased visibility into tangible financial results. Technology Industry Analyst KORE's positioning as a Leader in the Gartner Magic Quadrant reflects its strategic initiatives in the IoT space, particularly in managed connectivity services. The IoT market is characterized by a need for seamless integration of various technologies and the ability to manage complex ecosystems. KORE's focus on providing comprehensive coverage and a unified management platform is highly relevant as businesses increasingly seek to deploy IoT solutions at scale.Given the technical nature of IoT services, KORE's expertise and recognition could lead to partnerships or collaborations with other industry players looking to leverage its capabilities. This could potentially open up new revenue streams and drive innovation. Additionally, KORE's commitment to multi-technology, multi-carrier connectivity solutions is a significant differentiator in the IoT market, where flexibility and reliability are paramount.Investors should monitor how KORE continues to evolve its technology offerings and stay ahead of industry trends, as this will be critical to maintaining its leadership position and driving long-term growth in the dynamic IoT sector. 02/16/2024 - 11:42 AM Evaluation Based on Completeness of Vision and Ability to Execute ATLANTA, Feb. 16, 2024 /PRNewswire/ -- KORE, a global leader in Internet of Things (""IoT"") Solutions and pioneering IoT hyperscaler, and provider of IoT Connectivity, Solutions and Analytics, announced today its fifth consecutive recognition as a Leader in the 2024 Gartner® Magic Quadrant for Managed IoT Connectivity Services, worldwide. Romil Bahl, President, and CEO of KORE, expressed gratitude for the consecutive recognition by Gartner, emphasizing the company's commitment to delivering swift and resilient IoT connectivity solutions. ""Our customers are the cornerstone of our business, which is why KORE is dedicated to a clear vision and strategy to build a diverse suite of offerings that guarantee multi-technology, multi-carrier, global connectivity, regardless of location. The fact that we are recognized by Gartner is particularly satisfying.""KORE transforms intricate and fragmented IoT offerings into seamless, scalable solutions. The company provides comprehensive global coverage plans managed through a single, unified platform, a spectrum of compatible hardware and device options and robust IoT managed services designed to simplify the complexities inherent in the complete IoT lifecycle. KORE stands as a global leader in bringing together the complex puzzle of IoT needs, offering one-stop solutions tailored for local markets and diverse use cases. Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables you to get the most from market analysis in alignment with your unique business and technology needs. To view a complimentary copy of the Magic Quadrant report, and learn more about KORE's offerings, click here. Gartner disclaimerGARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner, Magic Quadrant for Managed IoT Connectivity Services, Worldwide, By Pablo Arriandiaga, Kameron Chao, Jon Dressel, 12 February 2024 Gartner does not endorse any vendor, product, or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About KOREKORE is a pioneer, leader, and trusted advisor delivering mission critical IoT solutions and services. We empower organizations of all sizes to improve operational and business results by simplifying the complexity of IoT. Our deep IoT knowledge and experience, global reach, purpose-built solutions, and deployment agility accelerate and materially impact our customers' business outcomes. For more information, visit korewireless.com. KORE Media ContactStephen Bell Marketing ManagerEmail: sbell@korewireless.com+1-440-622-9352 View original content to download multimedia:https://www.prnewswire.com/news-releases/kore-named-a-leader-by-gartner-in-the-magic-quadrant-for-managed-iot-connectivity-services-worldwide-for-fifth-consecutive-time-302064217.html SOURCE KORE Wireless What recognition did KORE receive in the 2024 Gartner Magic Quadrant report? KORE was recognized as a Leader in the 2024 Gartner Magic Quadrant for Managed IoT Connectivity Services. Who is the President and CEO of KORE? Romil Bahl is the President and CEO of KORE. What does KORE specialize in? KORE specializes in providing IoT Connectivity, Solutions, and Analytics globally. What does the Gartner Magic Quadrant report assess? The Gartner Magic Quadrant report assesses providers in specific markets based on rigorous research to determine their positions. What are the four quadrants in the Gartner Magic Quadrant report? The four quadrants are Leaders, Challengers, Visionaries, and Niche Players."
Capital Increase Reserved for Employees of TotalEnergies in 2024,2024-02-16T17:00:00.000Z,Low,Positive,"TotalEnergies SE announces an annual capital increase reserved for employees and former employees to enhance employee shareholding. The Board of Directors authorized a new share capital increase in 2024, offering 18 million shares, valued at €45 million, with immediate dividend rights.","Capital Increase Reserved for Employees of TotalEnergies in 2024 Rhea-AI Impact (Low) Rhea-AI Sentiment (Positive) Tags Rhea-AI Summary TotalEnergies SE announces an annual capital increase reserved for employees and former employees to enhance employee shareholding. The Board of Directors authorized a new share capital increase in 2024, offering 18 million shares, valued at €45 million, with immediate dividend rights. Positive None. Negative None. Market Research Analyst The announcement by TotalEnergies SE regarding its annual capital increase reserved for employees represents a strategic initiative aimed at fostering employee loyalty and aligning their interests with those of the company. By offering shares at a 30% discount, TotalEnergies incentivizes employees to invest in the company, potentially boosting morale and productivity. From a market research perspective, this move can enhance the company's reputation as an employer, which could be beneficial in attracting and retaining talent.However, the dilution effect of a capital increase on existing shareholders is an important consideration. The issuance of 18 million new shares, which equates to 0.72% of the share capital, is relatively modest and unlikely to cause significant dilution. It's also worth noting that employee share ownership at 7.4% is substantial, indicating a strong culture of employee investment in the company. Financial Analyst From a financial standpoint, the capital increase of €45 million through employee stock ownership is a non-dilutive financing option that can strengthen TotalEnergies SE's balance sheet. The operation's impact on earnings per share (EPS) will be minimal given the small percentage of the capital increase relative to the total share capital. Furthermore, the immediate dividend rights of the newly issued shares suggest that employees will benefit directly from the company's financial performance, which could align their efforts with shareholder value creation.Investors should monitor the subscription rate of this offering, as a high take-up would demonstrate confidence in the company's future prospects from those with insider perspectives. Moreover, the share subscription price determination method, based on the average closing prices with a significant discount, could offer insights into market sentiment about the stock's value around the subscription period. Legal Expert Legally, TotalEnergies SE is leveraging French commercial and labor code provisions that facilitate employee share ownership. This move underscores the company's compliance with regulatory frameworks designed to promote employee participation in corporate growth. It is also indicative of TotalEnergies SE's adherence to corporate governance practices that recognize the value of employee stakeholders.The decision by the Board to execute this capital increase within the authority granted by the shareholders' meeting reflects a transparent governance process. The legal stipulations, including the maximum period of 26 months and the cap of 1.5% of share capital for such operations, ensure that the Board's actions are within predetermined boundaries, safeguarding shareholder interests. 02/16/2024 - 12:00 PM PARIS--(BUSINESS WIRE)-- Regulatory News: In accordance with its policy in favor of employee shareholding, TotalEnergies SE (the “Corporation”) (Paris:TTE) (LSE:TTE) (NYSE:TTE) is implementing its annual capital increase reserved for employees and former employees of the TotalEnergies company (the “Company”). Through this operation, TotalEnergies SE intends to continue involving its employees in the Company’s growth. Employee shareholders, within the meaning of Article L. 225-102 of the French Commercial Code and article 11 par. 6 of the Articles of Association of TotalEnergies SE, held 7.4% of TotalEnergies SE’s share capital as of December 31, 2023. The sixteenth resolution of the Shareholders’ Meeting held on May 26, 2023 granted the Board of Directors (the “Board”) the authority to decide, within a maximum period of 26 months, to carry out one or more capital increases of ordinary shares without preferential subscription rights, not to exceed 1.5% of the share capital at the date of the Board meeting deciding on the operation and reserved to members of a savings plan pursuant to the provisions of Articles L. 225-129 et seq., L. 225-138 and L. 225-138-1 of the French Commercial Code and Articles L. 3332-1 to L. 3332-9 and L. 3332-18 to L. 3332-24 of the French Labor Code. The Board, pursuant to the above-mentioned authorization, decided during its meeting on September 21, 2023, to carry out, in 2024, a new share capital increase reserved for employees and former employees of the Company pursuant to the following conditions: Maximum number of shares to be offered and total amount of the offer: 18 million shares with a nominal value of €2.50 each, representing a total nominal amount of €45 million, which is the equivalent of 0.72% of the share capital as of the date of the Board’s decision. Description of the newly issued shares: same category as existing TotalEnergies shares with immediate dividend rights. The rights attached to the newly issued shares are the same as the rights attached to the existing shares of the Corporation, and are described in the Articles of Association of TotalEnergies SE. Listing of the newly issued shares on Euronext: on the same line as existing TotalEnergies shares (ISIN code FR0000120271), from their issuance. American Depositary Receipts admitted to trading on the New York Stock Exchange may be issued in exchange for the new shares. Share subscription price: equal to price corresponding to the average of the closing prices of the TotalEnergies shares on Euronext over the 20 trading sessions preceding the date of the decision setting the opening date for the subscription period, reduced by a 30% discount, and rounded off to the highest tenth of a euro. The subscription price will be definitively fixed before the beginning of the subscription period. Indicative timeline (subject to the Chairman and CEO’s decision): - Determination of the subscription price: April 25, 2024; - Subscription period: from April 29, 2024 to May 14, 2024 (included). Please refer to the appendix to this press release for further information on this operation. ____ About TotalEnergies TotalEnergies is a global multi-energy company that produces and markets energies: oil and biofuels, natural gas and green gases, renewables and electricity. Our more than 100,000 employees are committed to energy that is ever more affordable, more sustainable, more reliable and accessible to as many people as possible. Active in nearly 130 countries, TotalEnergies puts sustainable development in all its dimensions at the heart of its projects and operations to contribute to the well-being of people. @TotalEnergies - TotalEnergies - TotalEnergies - TotalEnergies Cautionary Note The program, reserved to eligible employees and retirees of the Company, will be implemented in France as well as in certain foreign countries, including the United States, where the shares offered in the United States will be registered with the Securities and Exchange Commission (SEC). Shares and FCPE units offered outside the United States will not be registered with the SEC. In particular, the units of the below-mentioned FCPEs cannot be offered or sold in the United States directly or indirectly (or in its territories or possessions), or for the benefit of a ""U.S. Person"", as defined in American regulations. Persons wishing to subscribe to units in these FCPEs, will have to certify, when subscribing, that they are not ""U.S. Persons"". The definition of ""U.S. Person"" is available on the FCPE Management Company's website (www.amundi.com). This press release is produced for information purposes only and does not constitute an offer for the sale or the subscription of securities. Moreover, this press release should not be distributed in the countries where the offering remains subject to approval of the local authorities. The offer will be issued only in the countries where the local administrative and regulatory procedures have been implemented (in particular, the registration procedures, notification, granting of authorizations and/or applicable exemptions and the information or the consultation of the representatives of the employees). This press release represents the document required to qualify for the exemption from the requirement to publish a prospectus as defined in Articles 1 4°i) and 5°h) of the Regulation (UE) 2017/1129 of June 14, 2017. Appendix to the press release on February 16, 2024 Issuer: TotalEnergies SE Information related to TotalEnergies SE is available on its website (www.totalenergies.com) and more specifically in its 2020 Universal Registration Document, the French version of which was filed with the Autorité des marchés financiers (“AMF”) on March 24, 2023 under the registration number D. 23-0144 and is also available free of charge at the head office of TotalEnergies SE. Scope of the reserved offering: corporations and Beneficiaries Approximately 115,000 beneficiaries are eligible to participate in the 2024 capital increase. Subject to compliance with regulations and required administrative approvals being obtained in the different countries, this capital increase will be reserved to employees and former employees of the Corporation and its French and non-French subsidiaries, the capital or voting rights of which, as of the opening date for the subscription period, are directly or indirectly held at more than 50% by TotalEnergies SE (the “Subsidiaries”), members of the PEG-A: - employees of TotalEnergies SE and its Subsidiaries: who have at least 3 months of employment with the Company as of the last day of the subscription period; and - former employees of TotalEnergies SE or the Subsidiaries, if they: have left the Company due to retirement or early retirement; had made at least one payment in the PEG-A before termination of their employment; still have assets invested in the PEG-A, and, thus, are members of the plan. Matching contribution Employees subscribing to the offering will benefit from a matching contribution in the form of a free allotment of additional shares, determined based on the amount of the personal contribution and within the limits of ten free shares per employee and within the maximum amount of the offering set by the Board at its meeting on September 21, 2023. Subscription terms and conditions The beneficiaries will have the opportunity to subscribe via employee shareholding funds (“FCPEs”) created for the needs of this offering and which have been approved by the AMF. In the countries where this option is not available the shares will be directly subscribed. Voting rights attached to the shares subscribed through an FCPE will be exercised by the Supervisory Board of such FCPE. With respect to the shares subscribed directly by employees, the voting rights will be exercised by the subscribers individually. Maximum subscription Pursuant to Article L. 3332-10 of the French Labor Code, the amount of the payments made each year by an employee as part of a savings plan (excluding matching contribution and profit-sharing schemes, i.e., intéressement and participation) cannot exceed one quarter of the employee’s gross annual salary. Lock-up period for the units or shares Pursuant to Article L. 3332-25 of the French Labor Code, shares or FCPE units subscribed in this offering must be held during a lock-up period of five years, except for certain early release cases provided for by Articles L. 3324-10 et R. 3324-22 of the French Labor Code. For beneficiaries who are not French tax residents, the list of early release cases may be adapted due to legal provisions applicable locally. Rule for reduction of subscription requests The capital increase will be fulfilled by the total number of shares subscribed directly by employees and via the FCPEs. If the total number of subscribed shares exceeds the maximum number of shares offered by the Board of Directors at its meeting on September 21, 2023 (18 million shares, including shares allotted as an immediate employer contribution), the subscriptions will be cut back in the following manner: - all subscription undertakings will be fully honored up to the subscription average, defined as the quotient between the maximum number of shares offered by the Board and the number of subscribers, - subscriptions undertakings that exceed the subscription average will be fulfilled in proportion to the number of subscription undertakings not yet fulfilled with the reduction being made as follows: the reduction will be carried out on a pro rata basis according to the subscription undertakings; and the reduction will be carried out first on the portion of the offer paid in cash, then on the portion paid with salary advance and then, when applicable, on the portion paid with profit-sharing schemes. View source version on businesswire.com: https://www.businesswire.com/news/home/20240216347292/en/ TotalEnergies Media Relations: +33 (0)1 47 44 46 99 l presse@totalenergies.com l @TotalEnergiesPR Investor Relations: +33 (0)1 47 44 46 46 l ir@totalenergies.com Source: TOTALENERGIES SE What is TotalEnergies SE implementing for its employees? TotalEnergies SE is implementing an annual capital increase reserved for employees and former employees to enhance employee shareholding. How many shares are being offered in the new share capital increase? TotalEnergies SE is offering 18 million shares with a nominal value of €2.50 each, totaling €45 million. What is the subscription price for the new shares? The subscription price for the new shares is determined by the average closing prices of TotalEnergies shares on Euronext over the 20 trading sessions preceding the subscription period, with a 30% discount. When is the subscription period for the new shares? The subscription period for the new shares is from April 29, 2024, to May 14, 2024."
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
